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  animals	  at	  the	  8	  months	  time	  point.	  
Table	  13	  –	  Biomechanical	  parameters	  of	  the	  proximal	  tibia	  in	  Sham	  and	  Ovx	  animals	  at	  
month	  3.	  
Table	  14	  –	  Biomechanical	  parameters	  of	  femurs	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3.	  
Table	   15	   –	   Densitometry	   analyses	   of	   calvarial	   bones	   of	   Sham	   and	   Ovx	   animals,	   at	  
month	  3	  and	  5.	  
Table	  16	  –	  Densitometry	  analyses	  of	  vertebras	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  
and	  5.	  
Table	  17	  –	  Densitometry	  analyses	  of	  maxilla	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  
5.	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Table	  18	  –Microstructural	  analysis	  of	  maxilla	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  
5.	  
Table	  19	  –Densitometry	  analyses	  of	  the	  mandible	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  
and	  5.	  
Table	  20	  –Microstructural	  analyses	  of	  mandible	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  
and	  5.	  
Table	  21	  –	  Morphometric	  analysis	  of	  histological	  samples.	  Histomorphometric	  analysis	  
of	   the	  bone	  regeneration	  process	   in	  Sham	  and	  Ovx	  animals,	   throughout	  6	  months	  of	  
healing	  following	  craniotomy.	  
Table	  22	  –	  Densitometry	  of	  mandibular	  bone	  defects	  of	   Sham	  and	  Ovx	  animals,	   at	  1	  
month.	  
Table	  23	  –	  Densitometry	  of	  mandibular	  bone	  defects	  of	   Sham	  and	  Ovx	  animals,	   at	  3	  
month.	  
Table	   24	   –Microstructural	   analyses	   of	   mandibular	   defect	   in	   the	  Membrane	   (M)	   and	  
Membrane	  and	  Biomaterial	  (MB)	  groups	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  1	  and	  3.	  
Table	  25	  –	  Morphometric	  analysis	  of	  histological	  samples.	  Histomorphometric	  analysis	  
of	   the	  bone	  regeneration	  process	   in	  Sham	  and	  Ovx	  animals,	   throughout	  3	  months	  of	  
healing	  following	  mandibular	  bone	  defect.	  
	  
	  
	   	  
	  	  
MODULATION	  OF	  THE	  BONE	  REGENERATION	  PROCESS	  IN	  SYSTEMIC	  IMPAIRED	  CONDITIONS	   XVII	  
ABBREVIATION	  LIST	  
AP40	  –	  Bioactive	  Silica-­‐Phosphate	  Glasses	  
ACTH	  –	  Adrenocorticotropic	  Hormone	  
ALB	  -­‐	  Albumin	  
ALP	  -­‐	  Alkaline	  Phosphatase	  
AU	  –	  Arbitrary	  Unit	  
BMC	  -­‐	  Bone	  Mineral	  Content	  
BMD	  –	  Bone	  Mineral	  Density	  
BMP	  -­‐	  Bone	  Morphogenetic	  Proteins	  
BMU	  –	  Basic	  Multicellular	  Unit	  
BPs	  –	  Bisphosphonates	  
BSAP	  -­‐	  Bone-­‐specific	  Alkaline	  Phosphatase	  
BSV/TV	  -­‐	  Bone	  Substitute	  Volume	  per	  Tissue	  Volume	  
β-­‐TCP	  -­‐	  Beta-­‐tricalcium	  phosphate	  
BV/TV	  -­‐	  Bone	  Volume	  per	  Total	  Volume	  
C	  –	  Control	  
Ca	  -­‐	  Calcium	  
CD	  -­‐	  Connective	  Density	  
Col	  I	  –	  Collagen	  type	  I	  
CK	  -­‐	  Creatine	  kinase	  
CSD	  –	  Critical	  Size	  Defect	  
CT	  –	  Quantitative	  Computed	  Tomography	  
DXA	  –	  Dual-­‐Energy	  X-­‐ray	  Absorptiometry	  
ECM	  -­‐	  Extracellular	  Matrix	  	  
EMP	  –	  Enamel	  Matrix	  Proteins	  
e-­‐PTFE	  –	  Polytetrafluoroethylene	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ER-­‐a	  -­‐	  Estrogen	  Receptor-­‐alpha	  
ER-­‐b	  -­‐	  Estrogen	  Receptor-­‐beta	  
FDA	  -­‐	  Food	  and	  Drug	  Administration	  
FMDUP	  –	  Faculdade	  de	  Medicina	  Dentária	  da	  Universidade	  do	  Porto	  
FRAX	  	  -­‐	  Fracture	  Risk	  
FSH	  -­‐	  Follicle-­‐stimulating	  hormone	  
GAPDH	  -­‐	  Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  
GBR	  -­‐	  Guided	  Bone	  Regeneration	  
GH	  -­‐	  Growth	  Hormone	  
GnRH	  -­‐	  Gonadotropin-­‐releasing	  Hormone	  
GTR	  -­‐	  Guided	  Tissue	  Regeneration	  
HA	  –	  Hydroxyapatite	  
HPG	  –	  Hypothalamic	  Pituitary	  Gonadal	  
HRT	  –	  Hormone	  Replacement	  Therapy	  
ICSI	  –	  Institute	  for	  Clinical	  Systems	  Improvement	  
IGF	  I	  -­‐	  Insulin-­‐like	  Growth	  Factor-­‐I	  	  
IOF	  -­‐	  International	  Osteoporosis	  Foundation	  	  
IL-­‐1	  –	  Interleukin-­‐1	  	  
IL-­‐6	  –	  Interleukin-­‐6	  
IP	  –	  Intraperitonial	  
LF	  -­‐	  Luteinizing	  Hormone	  	  
M-­‐	  Membrane	  group	  
MB	  –	  Membrane	  and	  Biomaterial	  group	  
M-­‐CSF	  -­‐	  Macrophage	  Colony-­‐stimulating	  Factor	  
Mpa	  –	  Megapascals	  
MSCs	  -­‐	  Mesenchymal	  Stem	  Cells	  
NF-­‐κB	  -­‐	  Transcription	  Factor	  Nuclear	  kappa	  B	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OC	  -­‐	  Osteocalcin	  
OPG	  –	  Osteoprotegerin	  
Ovx	  –	  Ovariectomy	  
P	  -­‐	  Phosphorous	  
PDGF	  –	  Platelet-­‐Derived	  Growth	  Factor	  
PGAs	  -­‐	  Polyglycolides	  	  
PLAs	  	  -­‐	  Polylactides	  
pQCT	  -­‐	  Peripheral	  Quantitative	  Computed	  Tomography	  	  
PCR	  –	  Polymerase	  chain	  reaction	  
PPAR-­‐g	  -­‐	  Peroxisome	  Proliferator-­‐activated	  Receptor	  Gamma	  
PTH	  –	  Parathyroid	  Hormone	  
QCT	  	  -­‐	  Quantitative	  Computed	  Tomography	  
QUS	  –	  Quantitative	  Ultrasound	  
RA	  -­‐	  Radiographic	  absorptiometry	  
RANKL	  –	  RANK	  Ligand	  
ROI	  –	  Region	  Of	  Interest	  
RUNX2	  -­‐	  Runt-­‐related	  transcription	  factor	  2	  
RUTH	  -­‐	  Raloxifene	  Use	  for	  The	  Heart	  
SD	  –	  Standard	  deviations	  
SERMs	  	  -­‐	  Selective	  Estrogen	  Receptor	  Modulators	  
Sham	  –	  Control	  
SPA	  –	  Single-­‐Photon	  Absorptiometry	  
SPSS	  –	  Statistical	  Package	  for	  Social	  Sciences	  
Tb.N	  -­‐	  Trabecular	  Number	  
Tb.Sp	  -­‐	  Trabecular	  Separation	  
Tb.Th	  –	  Trabecular	  Thickness	  
TG	  -­‐	  Triglyceride
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TGF	  –	  Transforming	  Growth	  Factor	  
Ti	  –	  Titanium	  
TNF	  –	  Tumor	  Necrosis	  Factor	  
TP	  –	  Total	  protein	  
WHO	  –	  World	  Health	  Organization	  
VOI	  -­‐	  Volume	  Of	  Interest	  
ZrO2	  –	  Zirconia	  
μCT	  -­‐	  Microcomputed	  Tomography	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Osteoporosis	   is	   characterized	   by	   a	   reduction	   in	   bone	  mass	   and	   disruption	   of	  
bone	   architecture,	   resulting	   in	   increased	   bone	   fragility	   and	   fracture	   risk.	   These	  
fractures	  are	  widely	   recognized	  as	  a	  major	  health	  problem	   in	   the	  elderly	  population.	  
Osteoporosis	  is	  of	  additional	  relevance	  in	  women	  entering	  the	  menopause,	  due	  to	  the	  
lack	   of	   estrogen	   production.	   Hormonal	   disequilibrium	   is	   known	   to	   favour	   bone	  
resorption,	   which	   in	   turn	   leads	   to	   skeletal	   fragility	   and	   increased	   risk	   of	   fracture.	  
Additionally,	   preliminary	   data	   reports	   that	   the	   bone	   regeneration	   process,	   in	  
osteoporotic	   conditions,	  may	  be	   somewhat	   limited	  mainly	  due	   to	  a	  decrease	  of	  new	  
bone	  formation,	  nevertheless	  specific	  mechanisms	  have	  not	  been	  stated.	  	  
In	   this	   way,	   this	   experimental	   work	   aims	   to	   address	   the	   bone	   regeneration	  
process	   in	   an	   animal	   model	   of	   osteoporosis	   mediated	   by	   a	   biomaterial	   in	   two	  
experimental	   designs:	   in	   the	   absence	   of	   biomechanical	   load	   (implementation	   in	   the	  
calvarial	   bone),	   and	   in	   the	   presence	   of	   biomechanical	   load	   (implementation	   in	   the	  
mandibular	  bone).	  
The	  ovariectomized	  rat	  model,	  known	  to	  represent	  the	  most	  important	  clinical	  
features	   of	   post-­‐menopausal	   osteoporosis,	   was	   established	   and	   thoroughly	  
characterized.	  	  
The	  bone	  regeneration	  process	  was	  evaluated	  by	  routine	  radiographic,	  micro-­‐
tomography	  and	  histological	  evaluations	  were	  conducted	  at	  adequate	  time	  points.	  	  
Reported	   data	   converge	   to	   substantiate	   a	   detrimental	   effect	   of	   the	  
osteoporotic	   condition	   in	   the	   process	   the	   biological	   response	   to	   biomaterial’s	  
implantation,	  and	  the	  guided	  bone	  regeneration	  process,	  in	  the	  assayed	  animal	  model,	  
in	  the	  absence	  and	  presence	  of	  a	  biomechanical	  load.	  
The	  stated	  biological	  hindrances	  and	  the	  data	  trend	  substantiating	  the	  impaired	  
biomaterial-­‐mediated	   bone	   regeneration	   process	   in	   osteoporotic	   conditions	   suggest	  
that	   care	   should	   be	   taken	   on	   pre-­‐operative	   preparation	   and	   a	   selective	   choice	   of	  
biomaterials	   should	   be	   undertaken	   when	   facing	   bone	   regeneration	   in	   osteoporotic-­‐
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compromised	   conditions.	   Moreover,	   there	   is	   an	   imperative	   need	   for	   new	   and	  
optimized	   clinical	   interventions	   for	   the	   treatment	   of	   bone-­‐related	   conditions,	   in	  
osteoporotic	  patients.	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RESUMO	  
	  
A	  osteoporose	  é	  uma	  patologia	  caracterizada	  por	  uma	  redução	  da	  massa	  óssea	  
e	   perda	   da	   sua	   arquitectura,	   resultando	   num	   aumento	   da	   fragilidade	   e	   risco	   de	  
fractura	  óssea.	  Estas	  fracturas	  são	  vastamente	  reconhecidas	  como	  um	  grave	  problema	  
de	  saúde	  na	  população	  idosa.	  A	  osteoporose	  tem	  maior	  impacto	  nas	  mulheres	  na	  pós-­‐
menopausa	   devido	   à	   falta	   de	   produção	   de	   estrogénio.	   O	   desequilíbrio	   hormonal	   é	  
conhecido	  por	   favorecer	   a	   reabsorção	  óssea,	   o	   que	   leva	   à	   fragilidade	   e	   aumento	  do	  
risco	   de	   fractura.	   Adicionalmente	   há	   estudos	   que	   sugerem	   que	   o	   processo	   de	  
regeneração	  óssea,	  em	  condições	  osteoporóticas,	  possa	  estar	  alterado	  devido	  a	  uma	  
diminuição	   do	   processo	   de	   formação	   óssea.	   No	   entanto,	   os	  mecanismos	   específicos	  
associados	  a	  esta	  condição	  não	  estão	  totalmente	  esclarecidos.	  
Desta	   forma,	   este	   trabalho	   experimental	   tem	   como	   objectivo	   o	   estudo	   do	  
processo	   de	   regeneração	   óssea	   mediada	   por	   um	   biomaterial	   num	   modelo	   animal	  
osteoporótico	   em	   duas	   condições	   experimentais:	   na	   ausência	   de	   carga	   biomecânica	  
funcional	   (implantação	   na	   calote	   craniana),	   e	   na	   presença	   de	   carga	   biomecânica	  
funcional	  (implantação	  na	  mandíbula).	  
O	  modelo	  do	  rato	  ovarectomizado,	  conhecido	  por	  apresentar	  as	  características	  
clínicas	   mais	   preponderantes	   da	   osteoporose	   pós-­‐menopausa,	   foi	   estabelecido	   e	  
detalhadamente	  caracterizado.	  	  
O	   processo	   de	   regeneração	   foi	   avaliado	   através	   de	   técnicas	   imagiológicas,	  
micro-­‐tomográficas	  e	  histológicas,	  nos	  tempos	  estipulados.	  
Os	   resultados	   obtidos	   demonstram	   um	   efeito	   negativo	   da	   osteoporose	   no	  
processo	   de	   regeneração	   óssea,	   guiada	   por	   biomateriais,	   no	   modelo	   animal	  
estabelecido.	   Verificou-­‐se	   um	   atraso	   no	   processo	   regenerativo	   dos	   animais	  
osteoporóticos,	  na	  ausência	  e	  na	  presença	  de	  carga	  biomecânica	  funcional.	  	  	  	  	  
As	   alterações	   biológicas	   observadas	   na	   regeneração	   óssea	   em	   condições	  
osteoporóticas	   sugerem	   que	   a	   preparação	   pré-­‐operatória	   cuidada	   e	   a	   selecção	  
criteriosa	   dos	   biomateriais	   a	   utilizar	   devem	   ser	   consideradas	   no	   planeamento	   de	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procedimentos	  ósseos	  regenerativos	  em	  pacientes	  osteoporóticos.	  De	  forma	  adicional,	  
é	   essencial	   o	   desenvolvimento	   de	   novas	   terapêuticas	   regenerativas	   dirigidas	   a	  
pacientes	   afectados	   por	   condições	   sistémicas	   que	   interfiram	   com	   o	   processo	   de	  
regeneração	  óssea.	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FOREWORD	  	  
	  
Systemic	   impaired	   conditions	   may	   affect	   the	   homeostasis	   of	   oral	   tissues,	  
increase	   their	   susceptibility	   to	  other	  diseases,	   interfere	  with	  healing	  and	   in	  addition,	  
may	  be	  treated	  with	  drugs	  and/or	  other	  therapeutic	  interventions	  that	  can	  potentially	  
affect	  tissue	  remodeling	  and	  healing.	  The	  increase	  in	  life	  expectancy,	  raise	  the	  number	  
of	  patients	  submitted	  to	  surgical	  interventions	  of	  osteosynthesis	  and	  joint	  replacement	  
affected	   by	   age	   related,	   post	   menopausal	   and	   other	   secondary	   osteoporosis	   and	  
systemic	   diseases.	   This	   is	   of	   particularly	   importance	   due	   to	   demand	   of	   surgical	  
interventions	  with	  the	  requirement	  of	  biomaterials	  to	  enhance	  the	  outcome	  of	  the	  life	  
expectancy	   and	   life	   quality.	   The	   systemic	   impaired	   conditions	   may	   affect	   the	   bone	  
tissue	  and	  modify	  the	  bone	  regeneration	  process.	  
Since	  the	  beginning	  of	  oral	  implant	  surgery,	  some	  therapeutic	  approaches	  have	  
been	   contraindicated	   for	   certain	   patients	  with	   systemic	   impaired	   conditions,	   namely	  
those	  including	  bone	  regeneration	  procedures.	  
Several	   factors	   have	   been	   described	   to	   inhibit	   the	   osseointegration.	   These	  
include:	   osteoporosis[1,	   2],	   rheumatoid	   arthritis[3],	   radiation	   therapy[4,	   5],	   smoking,	  
advanced	   age,	   nutritional	   deficiency	   and	   renal	   insufficiency,	   pharmacological	   agents	  
such	  as	  cyclosporine	  A[6],	  methotrexate	  and	  cis-­‐platinum[7].	  
Osteoporosis	  is	  of	  major	  concern	  due	  to	  its	  high	  prevalence,	  being	  an	  important	  
health	   problem,	   reporting	   an	   elevated	   rate	   of	   mortality	   and	   morbidity,	   in	   several	  
countries.	  Global	  epidemiological	  data	  report	  that	  1	  in	  every	  3	  women	  and	  1	  in	  every	  
50	   men	   over	   the	   age	   of	   50	   years	   old	   have	   osteoporosis.[8]	   In	   Europe	   alone,	   it	   is	  
estimated	  that	  179,000	  men	  and	  611,000	  women	  will	  suffer	  a	  hip	   fracture	  each	  year	  
and	  that	  the	  cost	  of	  all	  osteoporotic	  fractures	  in	  Europe	  is	  provisionally	  €25	  billion.[9]	  
National	   indexes	   vary	   but	   reported	   data	   from	   the	   International	   Osteoporosis	  
Foundation	   (IOF)	   show	   that	   in	   2003,	   7.8	  million	  Germans	   (6.5	  million	  women)	  were	  
affected	   by	   osteoporosis[10],	   while	   in	   Denmark,	   the	   estimated	   prevalence	   of	  
osteoporosis	  in	  persons	  aged	  50	  years	  or	  more	  was	  about	  41%	  among	  women	  and	  18%	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among	  men,	   in	  2005.[11]	   In	  Spain,	  approximately	  2	  million	  women	  have	  been	  shown	  
to	  report	  osteoporosis	  and	  its	  prevalence	  was	  shown	  to	  be	  26.1%	  of	  women	  who	  are	  
50	  years	  of	  age	  and	  older.[12]	  	  
In	  Portugal,	  the	  prevalence	  of	  osteoporosis	  was	  established	  to	  be	  around	  5%,	  in	  
2003.[13]	   The	   prevalence	   increased	   with	   age,	   and	   has	   been	   shown	   to	   be	   higher	   in	  
women.	   Another	   report,	   based	   on	   the	   reevaluation	   of	   the	   population-­‐based	   cohort	  
EPIPorto	   (2003-­‐2005)	   revealed	   that	   3,3%	   men	   and	   28,1%	   women	   had	   the	   medical	  
diagnosis	  of	  osteoporosis[14],	  while	  a	  telephone-­‐based	  enquiry,	  randomly	  assigned	  to	  
1800	   women	   resident	   in	   Portugal,	   in	   2004,	   revealed	   that	   15.4%	   declared	   to	   have	  
osteoporosis,	  of	  whom	  96.8%	  referred	  to	  have	  an	  exam	  confirming	  the	  diagnosis.[15]	  	  	  	  	  
In	   the	   population	   attending	   the	   appointment	   of	   Oral	   Surgery,	   at	   Faculty	   of	  
Dental	  Medicine,	  University	   of	   Porto	   (FMDUP),	  we	  performed	  a	   5-­‐year	   retrospective	  
study	  (between	  September	  2003	  and	  July	  2008)	  of	  all	  patients	  who	  underwent	  surgical	  
consultation.	  The	  sample	   included	  1423	  patients,	  of	  whom	  773	  were	  women	  (54.3%)	  
and	   650	   were	  men	   (45.7%).	  We	   documented	   that	   2.7%	   of	   patients	   above	   50	   years	  
reported	  to	  have	  osteoporosis.	  The	  major	  percentages	  of	   those	  were	   female	   (83.3%)	  
and	  only	  16.7%	  were	  male	  patients.	  
	  	  The	  appraisal	  of	  the	  osteoporotic	  condition	   in	  the	  Dental	  Medicine	  field	   is	  of	  
particular	  relevance	  and	  broadly	  disregarded,	  mainly	  due	  to	  the	  reported	  influence	  of	  
the	  disease	  in	  the	  alveolar	  bone	  metabolism.[16]	  In	  fact	  osteoporosis	  has	  been	  found	  
to	   be	   associated	   with	   periodontal	   bone	   loss	   and	   temporomandibular	   joint	   bone	  
loss.[17]	  	  
Some	  data	  suggest	  that	  osteoporosis	  negatively	  influences	  the	  healing	  process	  
after	   a	   fracture.[18,	   19]	   This	   is	   of	   the	   utmost	   relevance	   since	   the	   oral/maxillofacial	  
bone	   tissue	   is	   the	   ground	   support	   for	   therapeutic	   and	   restorative	   approaches	   in	  
dentistry,	  supporting	  roughly	  the	  vast	  majority	  of	  oral	  rehabilitation	  procedures.	  	  
The	   osteointegration	   rate	   of	   prosthetic	   implants	   also	   appears	   to	   be	   impaired	  
and	   clinical	   studies	   substantiate	   a	   partial	   degree	   of	   success	   in	   the	   establishment	   of	  
bone-­‐related	  procedures	  and	  oral	  implant	  placement	  in	  osteoporotic	  patients.[20,	  21]	  
Nonetheless,	  the	  detailed	  biological	  issues	  of	  the	  bone	  regenerative	  process	  in	  
osteoporotic	  conditions	  have	  not	  been	  adequately	  disclosed.	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AIMS	  
	  
Osteoporosis	   is	  a	  major	  health	  problem	  in	  the	  elderly	  population	  and	  is	  known	  
to	   increased	   bone	   fragility	   and	   fracture	   risk.	   Bone	   regeneration	   process,	   in	  
osteoporotic	  conditions,	  may	  be	   further	   limited	  essentially	  due	  to	  a	  decrease	  of	  new	  
bone	  formation,	  nevertheless	  specific	  mechanisms	  have	  not	  been	  stated.	  	  
Thereby,	  this	  experimental	  work	  aimed	  the	  establish	  and	  characterization	  of	  a	  
representative	   animal	   model	   of	   the	   human	   condition	   of	   osteoporosis,	   i.e.,the	  
ovariectomized	  rat,	  due	  to	  functional	  similarity	  to	  the	  osteoporotic	  condition.	  Further,	  
the	   biomaterial-­‐mediated	   bone	   regeneration	   process	   was	   evaluated	   in	   two	  
experimental	  models:	  in	  the	  calvarial	  bone	  (in	  the	  absence	  of	  functional	  biomechanical	  
loading)	  and	  in	  the	  mandibular	  (in	  the	  presence	  of	  functional	  biomechanical	   loading).	  
In	   each	   bone,	   a	   critical	   size	   bone	   defect	  was	   established	   and	   following	   filled	  with	   a	  
biomaterial	  of	  known	  biocompatibility.	  The	  bone	  regeneration	  process	  was	  adequately	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BONE	  TISSUE	  STRUCTURE	  
	  
Bone	  is	  a	  living	  and	  dynamic	  tissue	  that	  is	  able	  to	  provide	  strength	  and	  stiffness	  
to	   the	   skeleton	   and	   yet	   be	   flexible	   enough	   to	   absorb	   energy	   and	   therefore	   reduce	  
fracture	  risks.	  	  It	  is	  only	  able	  to	  perform	  in	  such	  a	  remarkable	  way	  due	  to	  its	  structural	  
and	  compositional	  properties.[22]	  Bone	  is	  a	  highly	  vascular	  and	  mineralized	  connective	  
tissue,	  which	  comprises	  several	  specialized	  cells	  in	  a	  fibrous	  organic	  matrix,	  permeated	  
by	  inorganic	  constituents.	  	  
	  Mature	   bone	   may	   be	   classified	   into	   cortical	   or	   compact	   (Figure	   1),	   and	  
trabecular	   or	   cancellous	   (Figure	   2).[23]	   Cortical	   bone	   is	   found	  on	   the	  outer	   surface	  of	  
individual	   bones	   and	   surrounds	   the	   trabecular	   bone.	   Approximately	   80%	   of	   the	  
skeleton	   corresponds	   to	   cortical	   bone.	   The	   architecture	   and	   relative	   amount	   of	   the	  
cortical	   tissue,	   at	   any	   given	   anatomical	   location,	   are	   related	   to	   its	   function	   at	   that	  
specific	  area.	  Cortical	  bone	   is	  porous,	  but	   its	  density	   is	  considerably	  higher	   than	  that	  
reported	   for	   trabecular	   bone	   –	   around	   80%	   against	   20%,	   respectively.[24]	   Cortical	  
bone	   is	   composed	   of	   Haversian	   canals,	   which	   are	   a	   collection	   of	   cylindrical	   units	  
oriented	  parallel	  to	  the	  length	  of	  the	  bone	  and	  enclose	  a	  neurovascular	  bundle.	  Each	  
canal	   is	  surrounded	  by	  concentric	   lamellae	  containing	  small	  voids	  designated	   lacunae	  
in	   which	   osteocytes	  may	   be	   found.	   The	   canaliculi	   are	   small	   channels	   that	   allow	   for	  
nutritional	   support	   and	   oxygenation	   to	   the	   cellular	   constituents	   of	   the	   lacunae.[23]	  
They	   are	   also	   responsible	   for	   the	   removal	   of	   the	   waste	   products	   originated	   from	  
metabolic	   actions.	   The	   canaliculi	   connect	   to	   the	   Haversian	   systems	   which,	   in	   turn,	  
anastomose	   with	   obliquely	   orientated	   vascular	   branches,	   designated	   Volkmann’s	  
canals,	   which	   establish	   communication	   between	   the	   periosteum	   and	   the	  
endosteum.[24]	  The	  gaps	  between	  the	  Haversian	  systems	  are	  made	  up	  of	   interstitial	  
bone,	   which	   consists	   of	   similar	   tissue	   elements,	   but	   in	   a	   less	   organized	   pattern.	  
Haversian	  systems	  are	  separated	  from	  one	  another	  by	  cement	  lines	  which	  are	  strongly	  












Figure	  1	  –	  Structure	  and	  organization	  of	  compact	  bone.	  [25]	  
	  
	  
Trabecular	   bone	   is	   predominant	   in	   vertebrae,	   pelvis,	   and	  other	   flat	   bones,	   as	  
well	   as	   at	   the	   epiphyses	   of	   long	   bones.	   It	   is	   essentially	   constituted	   by	   calcified	  
trabeculae,	  which	  result	  from	  the	  fragmentation	  of	  Haversian	  systems.	  The	  void	  spaces	  
between	   trabeculae	   -­‐	   lacunae	   -­‐	   are	   filled	   with	   active	   bone	  marrow,	   responsible	   for	  
nutritional	   support.[24]	   Reports	   indicate	   that	   trabecular	   bone	   has	   a	   high	   area-­‐to-­‐
volume	  ratio	  and	  the	  capacity	  to	  respond	  quicker	  than	  cortical	  bone	  to	  biomechanical	  
inputs.	  Moreover,	  it	  presents	  a	  high	  metabolic	  rate,	  in	  fact	  significantly	  greater	  that	  of	  
cortical	  bone.[23]	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Figure	  2	  –	  Structure	  and	  organization	  of	  trabecular	  bone.[25]	  
	  
Two	   distinct	   mechanisms	   determine	   how	   the	   bone	   tissue	   is	   formed	   during	  
development,	   either	   by	   endochondral	   or	   intramembranous	   ossification.	  Most	   of	   the	  
skeleton	   is	   crafted	   by	   endochondral	   ossification,	   a	   process	   that	   occurs	   via	   an	  
intermediate	  step	  of	  cartilage,	  and	  involves	  a	  coordinated	  set	  of	  interactions	  requiring	  
the	   transient	   expression	   of	   specific	   genes	   and	   various	   cell	   –	   cell	   and	   cell	   –	   matrix	  
interactions,	   which	   results	   in	   the	   eventual	   replacement	   of	   cartilage	   with	   bone.	  
Alternatively,	   new	   bone	   formation	   can	   occur	   via	   intramembranous	   ossification,	   in	  
which	   de	   novo	   synthesis	   occurs.	   Mesenchymal	   cells	   migrate	   and	   condensate	   into	  
clusters	   within	   the	   fibrous	   tissue,	   and	   differentiate	   directly	   into	   osteoblasts.	   Such	   a	  
cluster	  is	  known	  as	  an	  ossification	  center,	  and	  the	  osteoblasts	  start	  to	  secrete	  matrix,	  
which	  subsequently	  mineralize.[26]	  	  
In	  both	  processes,	  the	  bone	  tissue	  initially	  formed	  is	  characterized	  as	  primary	  or	  
woven.	   Primary	   bone	   is	   a	   temporary	   tissue,	   soon	   to	   be	   replaced	   by	   the	   definitive	  
lamellar	  or	  secondary	  bone	  and	  it	  may	  also	  be	  found	  during	  tissue	  healing.	  This	  tissue	  
has	   an	   increased	  metabolic	   activity	   and	   is	   characterized	  by	   a	   scattered	  and	   irregular	  
structure,	   while	   secondary	   bone	   portrays	   an	   ordered	   arrangement	   of	   cells	   and	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matrix.[27]	   These	   mechanisms	   of	   developmental	   bone	   growth	   and	   modeling	   cease	  
with	   the	   completion	   of	   adolescent	   growth	   and	   mark	   a	   transition	   to	   adult	   bone	  
remodeling,	  characterized	  by	  the	  focusing	  on	  maintenance	  and	  repair.[26]	  
	  
BONE	  TISSUE	  REMODELING	  	  
	  
Bone	   remodeling	   is	   the	   process	   by	  which	   bone	   is	   renewed	   to	  maintain	   bone	  
strength	  and	  mineral	  homeostasis.	  The	  main	  recognized	  functions	  of	  bone	  remodeling	  
include	  preservation	  of	  bone	  mechanical	  strength	  by	  replacing	  older,	  micro	  damaged	  
bone	  with	  newer,	  healthier	  bone	  and	  calcium	  and	  phosphate	  homeostasis.	  
Bone	   surfaces	   may	   be	   undergoing	   formation	   or	   resorption,	   or	   they	   may	   be	  
inactive.	  These	  processes	  occur	   throughout	   life	   in	  both	  cortical	   and	   trabecular	  bone.	  
Bone	   remodeling	   is	   a	   surface	   phenomenon,	   and	   it	   occurs	   on	   periosteal,	   endosteal,	  
Haversian	  canal,	  and	  trabecular	  surfaces.	  The	  rate	  of	  cortical	  bone	  remodeling,	  which	  
may	  be	  as	  high	  as	  50%	  per	  year	  in	  the	  midshaft	  of	  the	  femur	  during	  the	  first	  2	  years	  of	  
life,	  eventually	  declines	  to	  a	  rate	  of	  2–5%	  per	  year	  in	  the	  elderly.	  Rates	  of	  remodeling	  
in	  trabecular	  bone	  are	  proportionally	  higher	  throughout	  life	  and	  may	  normally	  be	  5–10	  
times	  higher	  than	  cortical	  bone	  remodeling	  rates	  in	  the	  adult.	  [28]	  
Resorption	  and	  formation	  are	  closely	  linked	  by	  temporary	  anatomic	  structures	  
called	  basic	  multicellular	  units	  (BMU).[29]	  The	  BMU	  of	  bone	  comprises	  the	  osteocytes,	  
osteoclasts,	  bone	   lining	  cells	  and	  osteoblasts,	   this	  activity	   is	   regulated	  by	  mechanical	  
forces,	   bone	   cell	   turnover,	   hormones	   (e.g.	   parathyroid	   hormone	   (PTH),	   growth	  
hormone	   (GH)),	   cytokines	   and	   local	   factors.	   The	  osteocytes	  detect	  mechanical	   stress	  
and	  respond	  to	  mechanical	  stimuli	  taking	  apart	  for	  the	  activation	  process.[30]	  	  
The	  cellular	  cycle	  of	  such	  units	  begins	  with	  the	  recruitment	  of	  precursors	  from	  
osteoclasts,	   their	   differentiation	   and	   activation.	   Following,	   mature	   multinucleated	  
osteoclasts	  are	  responsible	  for	  the	  resorption	  of	  the	  anatomical	  location	  on	  the	  surface	  
of	  trabecular	  bone,	  creating	  the	  Howship's	  lacunae,	  or	  cutting	  cones,	  in	  cortical	  bone.	  
These	  are	  identical	  processes	  -­‐	   in	  trabecular	  bone	  the	  BMU	  may	  be	  looked	  upon	  as	  a	  
sagittal	   section	   of	   a	   cortical	   BMU.	   Resorption	   is	   then	   followed	   by	   a	   reversal	   phase,	  
during	  which	  a	  cement	   line	  is	  deposited.	  Subsequently,	  osteoblast	  precursor	  cells	  are	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recruited	  and,	  following	  differentiation	  and	  activation,	  fill	  the	  cavity	  with	  a	  volume	  of	  
new	  bone	  that	  undergoes	  rapid	  primary,	  and	  then	  slower	  secondary	  mineralization.	  	  
The	   rate	   of	   trabecular	   bone	   turnover	   is	   higher,	   more	   than	   required	   for	  
maintenance	  of	  mechanical	  strength,	  indicating	  that	  trabecular	  bone	  turnover	  is	  more	  
important	  for	  mineral	  metabolism.	  Increased	  demand	  for	  calcium	  or	  phosphorus	  may	  
require	  increased	  bone	  remodeling	  units,	  but,	  in	  many	  cases,	  this	  demand	  may	  be	  met	  
by	  increased	  activity	  of	  existing	  osteoclasts.	  Increased	  demand	  for	  skeletal	  calcium	  and	  
phosphorus	   is	  met	   partially	   by	   osteoclastic	   resorption	   and	   partly	   by	   nonosteoclastic	  
calcium	   influx	   and	   efflux.	   Ongoing	   bone	   remodeling	   activity	   ensures	   a	   continuous	  
supply	   of	   newly	   formed	   bone	   that	   has	   relatively	   low	  mineral	   content	   and	   is	   able	   to	  
exchange	  ions	  more	  easily	  with	  the	  extracellular	  fluid.	  Bone	  remodeling	  units	  seem	  to	  
be	   mostly	   randomly	   distributed	   throughout	   the	   skeleton	   but	   may	   be	   triggered	   by	  
microcrack	   formation	  or	  osteocyte	  apoptosis.	  The	  bone	  remodeling	  space	  represents	  
the	  sum	  of	  all	  of	  the	  active	  bone	  remodeling	  units	  in	  the	  skeleton	  at	  a	  given	  time.[31]	  
The	  volume	  of	  bone	  resorbed	  and	  produced	  within	  each	  focal	  remodeling	  unit	  










Figure	  3	  –	  Mechanism	  of	  bone	  remodeling.[32]	  
	  	  
Proper	   bone	   remodeling	   relies	   on	   a	   regulated	   balance	   between	   the	   four	  
principal	   cells	  which	   constitute	   the	   bone	   tissue:	   osteoblasts,	   osteocytes,	   bone	   lining	  
cells	  and	  osteoclasts	  (Figure	  3).[26]	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BONE	  TISSUE	  CELLULAR	  COMPOSITION	  
	  
Osteoblasts	  
These	  cells	  derive	  from	  undifferentiated	  mesenchymal	  cells	  and	  are	  responsible	  
for	  the	  deposition	  of	  the	  extracellular	  matrix	  (ECM)	  and	  its	  subsequent	  mineralization.	  
They	  are	  highly	  differentiated	  columnar	  shaped	  cells	   (20–30	  µm	  in	  diameter),	  usually	  
found	   in	   a	   single	   cell	   layer,	   intimately	   apposed	   to	   areas	   of	   bone	   formation	   or	  
remodeling	   (Figure	   4).	   They	   are	   metabolically	   active	   secretory	   cells	   that	   are	  
characterized	  for	  having	  a	  round	  nucleus	  opposing	  the	  bone	  surface,	  small	  amounts	  of	  
basophilic	  cytoplasm,	  and	  the	  presence	  of	  prominent	  Golgi	  complex	  and	  endoplasmic	  
reticulum.	   They	   secrete	   proteins	   of	   the	   extracellular	   matrix,	   such	   as	   alkaline	  
phosphatase,	   osteocalcin,	   osteopontin,	   osteonectin	   and	   proteoglycans,	   as	   well	   as	  
soluble	   signaling	   factors	   (e.g.,	   bone	   morphogenetic	   proteins	   (BMPs),	   transforming	  
growth	   factor-­‐β	   (TGF-­‐β),	   insulin-­‐like	   growth	   factor-­‐I	   (IGF	   I),	   IGF-­‐II,	   interleukin-­‐1	   (IL-­‐1)	  
and	  platelet-­‐derived	  growth	  factor	  (PGDF)).[33]	  	  
Populations	   of	   osteoblasts	   are	   heterogeneous,	   with	   different	   osteoblasts	  
expressing	  different	  gene	  repertoires	  that	  may	  explain	  the	  heterogeneity	  of	  trabecular	  
microarchitecture	   at	   different	   skeletal	   sites,	   anatomic	   site-­‐specific	   differences	   in	  
disease	  states,	  and	  regional	  variation	  in	  the	  ability	  of	  osteoblasts	  to	  respond	  to	  agents	  
used	  to	  treat	  bone	  disease.[31]	  
In	  due	  course,	  osteoblasts,	  following	  their	  biological	  role,	  can	  commit	  to	  one	  of	  
three	   pathways:	   remain	   metabolically	   active	   cells;	   become	   entrenched	   by	   the	  
mineralized	   extracellular	   matrix	   and	   turn	   into	   osteocytes;	   or,	   become	   relatively	  
inactive	  and	  originate	  bone	  lining	  cells.[34]	  	  
	  
Osteocytes	  
Osteocytes	  comprise	  the	  vast	  majority	  of	  bone	  cells	  of	  the	  adult	  skeleton.	  They	  
are	  the	  result	  of	  osteoblasts	  entrapment	  by	  their	  own	  bone	  matrix-­‐secreting	  activity.	  
As	   they	   become	  more	   isolated	   from	   the	   bone-­‐forming	   surface,	   osteocytes’	   protein-­‐
synthesizing	   activity	   declines,	   the	   size	   of	   the	   endoplasmic	   reticulum	   and	   Golgi	  
apparatus	   decreases,	   and	   the	   mitochondrial	   content	   falls.[35]	   Osteocytes	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communicate	  with	  each	  other	   via	   cytoplasmic	  processes	   that	  pass	   through	   the	  bone	  
canaliculi.	   This	   network	   is	   also	   considered	   to	   substantiate	   metabolic	   exchange	   and	  
coordinate	   the	   response	   of	   bone	   to	   biomechanical	   challenges.[23]	   Osteocytes	   are	  
involved	   in	   the	   biomechanical	   regulation	   of	   bone	   mass	   and	   structure,	   probably	   by	  
sensing	   bone	   deformation,	   pressure,	   fluid	   flows	   and	   streaming	   potentials,	   which	  
consequently	  affects	  the	  release	  of	  signaling	  molecules	  and	  growth	  factors	  that	  seem	  
to	  regulate	  cell	  proliferation	  and	  differentiation.[36]	  
Osteocytes	   do	   not	   divide	   and	   their	   turnover	   is	   only	   assured	   through	   the	  
remodeling	  process.	  	  
	  
Bone	  lining	  cells	  
While	   several	   osteoblasts	   are	   active	   in	   bone	   formation,	   flatter	   and	   more	  
inactive	   cells	   are	   found	   in	   the	   bone	   surface	   of	   the	  mature	   skeleton,	   i.e.	   bone	   lining	  
cells.	  They	  are	  closely	  associated	  with	  each	  other	  via	  cellular	  adhesion	  complexes,	  and	  
in	  contact	  with	  the	  osteocytes	  network.[23]	  They	  present	   less	  cytoplasmic	  organelles	  
than	  osteoblasts	  and	  their	  biological	  function	  has	  not	  been	  definitely	  established:	  they	  
seem	   to	  be	   responsible	   for	   removing	   the	   thin	   layer	  of	  osteoid	  which	   coats	   the	  bone	  
surface,	  thus	  exposing	  the	  bone	  for	  osteoclastic	  resorption;	  and	  also	  enroll	  osteoblast-­‐
like	  functions	  following	  proper	  activation.[34]	  	  	  	  
	  
Osteoclasts	  
Osteoclasts	   are	   derived	   from	   the	   fusion	   of	  mononuclear	   hematopoietic	   stem	  
cells.	  These	  multinucleated	  giant	  cells	  are	  responsible	  for	  bone	  resorption	  and	  seem	  to	  
attach	   to	   the	   bone	   surface,	   secreting	   hydrolytic	   enzymes	   in	   a	   acidic	  
microenvironment.[26]	  They	  are	   typically	   large	  cells	  and	  are	  characterized	   for	  having	  
an	   average	   of	   10	   to	   12	   nuclei	   (Figure	   4).	   These	   cells	   show	   cellular	   polarity,	   and	  
resorption	  occurs	  along	  the	  folds	  and	  finger-­‐like	  projections	  of	  the	  plasma	  membrane,	  
characterized	  as	  a	  “ruffled	  border”,	  along	  the	  bone	  surface.	  The	  cytoplasm	  adjacent	  to	  
this	   surface	   is	   devoid	   of	   organelles,	   but	   is	   rich	   in	   actin	   filaments	   and	   other	  
microfilament-­‐associated	  proteins,	  suggesting	  that	  this	  area	  supports	  the	  osteoclastic	  
bone	   adhesion.[23]	   These	   cells	   mediate	   the	   resorption	   process	   via	   the	   release	   of	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powerful	  lysosomal	  enzymes	  and	  acids	  which	  digest	  protein	  and	  mineral	  components	  
of	   the	   bone	  matrix.[37]	   The	   key	   family	   of	   proteinases	   involved	   in	   osteoclastic	   bone	  
















Figure	  4	  –	  Cellular	  composition	  of	  the	  bone	  tissue.	  (A-­‐	  osteoclasts;	  B-­‐	  osteoblasts;	  in	  the	  middle	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OSTEOBLASTS-­‐OSTEOCLASTS	  INTERACTION	  
	  
Central	   to	   the	   bone	   remodeling	   activity,	   namely	   in	   which	   refers	   to	   the	  
interaction	   between	   osteoblasts	   and	   osteoclasts,	   is	   the	   recognition	   that	   novel	  
members	   of	   the	   tumor	   necrosis	   factor	   receptor	   family	   influence	   directly	   osteoclast	  
function	  (Figure	  5).[40]	  RANKL,	  the	  ligand	  of	  the	  receptor	  activator	  for	  nuclear	  factor	  κB,	  
activates	   the	   NFκB	   transcriptional	   pathway	   on	   cells	   that	   bear	   RANK;	   such	   RANK-­‐
expressing	   cells	   include	   cells	   of	   the	   monocyte/macrophage	   lineage,	   and	   thus,	  
osteoclasts.[38]	  	  
RANKL	  is	  synthesized	  and	  expressed	  by	  bone	  stromal	  cells	  and	  osteoblasts,	  that	  
also	  produce	  macrophage	  colony-­‐stimulating	  factor	  (M-­‐CSF)	  that	  attaches	  to	  a	  distinct	  
macrophage	   cell	   surface	   receptor.[38]	   Together,	   RANKL	   and	   M-­‐CSF	   converge	   to	  
differentiate/activate	  osteoclasts-­‐precursor	  cells	  into	  their	  functional	  effector	  cells.[24]	  
RANK	   activation	   is	   therefore	   a	  major	   stimulus	   for	   bone	   resorption.	   Osteoblasts	   also	  
produce	   and	   secrete	   osteoprotegerin	   (OPG),	   a	   decoy	   for	   the	   receptor	   activator	   of	  
nuclear	   factor	   kappa	   B	   ligand	   (RANKL).	   By	   binding	   RANKL,	   OPG	   inhibits	   the	  
transcription	  factor	  nuclear	  kappa	  B	  (NF-­‐κB).[41]	  In	  which	  relates	  to	  bone	  metabolism,	  
OPG	   can	   reduce	   the	   production	   of	   osteoclasts	   by	   inhibiting	   the	   differentiation	   of	  
osteoclast	   precursors	   into	   osteoclasts	   and	   also	   regulating	   the	   resorptive	   activity	   of	  
osteoclasts.[38]	  OPG	   levels	   increase	  with	  age,	  and	   it	   is	  possible	   that	  OPG	  production	  
rises	  as	  a	  homeostatic	  response	  to	  limit	  the	  bone	  loss	  that	  occurs	  with	  an	  increase	  in	  


















Figure	  5	  -­‐	  Paracrine	  mechanisms	  regulating	  osteoclast	  formation	  and	  function.[44]	  
	  
	  
REGULATION	  OF	  BONE	  CELLS	  ACTIVITY	  
	  
Overall,	   bone	   metabolism	   is	   under	   constant	   control	   by	   three	   main	   systemic	  
hormonal	   systems	   i.e.,	   calcitonin,	   vitamin	   D,	   and	   parathyroid	   hormone	   (PTH),	   that	  
adjust	  calcium	  homeostasis.	  Briefly,	  the	  principal	  action	  of	  calcitonin,	  which	  is	  secreted	  
by	   the	   thyroid	  gland	   in	  answer	   to	  an	   increasing	  of	   calcium	  plasma	   level,	   is	   to	   inhibit	  
bone	   resorption.[24]	  Parathyroid	  hormone	  produces	  changes	   in	   the	  calcium	  pool,	  by	  
favoring	   osteoclastic	   bone	   resorption	   and	   inducing	   calcium	   resorption	   by	   the	  
kidneys.[45]	  1,25-­‐dihydroxyvitamin	  D3,	  the	  active	  form	  of	  vitamin	  D,	  seems	  to	  have	  an	  
effect	   both	   on	   osteoblasts	   –	   it	   increases	   the	   production	   of	   osteocalcin	   and	   alkaline	  
phosphatase	  by	  these	  cells	  –	  and	  osteoclasts	  –	  it	  stimulates	  osteoclastic	  differentiation	  
and	  multinucleation,	  depending	  on	  the	  stage	  of	  the	  remodeling	  cycle	  it	  acts	  on.[38]	  	  	  
Additional	   hormones	   can	   also	   influence	   bone	   cell	   function	   and	   bone	  
metabolism.	   For	   instance,	   estrogen	   has	   an	   important	   action	   in	   preserving	   bone.	  
Estrogen	  deficiency	   increases	   the	   rate	  of	  bone	   remodeling,	  as	  well	  as	   the	  amount	  of	  
bone	   loss	  within	  each	   remodeling	   cycle.	   Experimental	   reports	   suggest	   that	   there	  are	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multiple	  sites	   for	  estrogen	  action,	  not	  only	  on	  the	  cells	  of	   the	  bone	  remodeling	  unit,	  
but	   also	   on	   other	   marrow	   cells.	   The	   mechanism	   of	   action	   is	   not	   yet	   known,	   but	  
potential	   modulatory	   actions	   include	   effects	   on	   T	   cell	   cytokine	   production,	   on	   the	  
RANKL	  and	  OPG	  production	  by	  stromal	  or	  osteoblastic	  cells,	  inhibition	  of	  differentiated	  
osteoclasts,	   and	  on	   the	   enhancement	   of	   bone	   formation,	   in	   response	   to	  mechanical	  
forces	  sensed	  by	  osteoblasts	  or	  osteocytes.[46]	  
	  
BONE	  TISSUE	  EXTRACELLULAR	  MATRIX	  
	  
The	   extracellular	   mineralized	   matrix	   consists	   of	   around	   35%	   of	   organic	   and	  
around	  65%	  of	   inorganic	  content.	  The	  principal	  organic	  component	   is	  type	  I	  collagen,	  
which	  comprises	  80–90%	  of	  the	  organic	  matrix,	  although	  others	  types	  of	  collagen	  are	  
present	   in	   small	   amounts,	   i.e.,	   type	   V,	   VI,	   VIII	   and	   XII.	   	   Collagen	   type	   I	   is	   a	  
heteropolymer	  of	   two	  α1	  chains	  and	  one	  α2	  chain,	  wound	   together	   in	  a	   triple	  helix.	  	  
Several	   non-­‐collagenous	   proteins	   are	   also	   present,	   such	   as	   alkaline	   phosphatase,	  
osteocalcin,	  osteonectin,	  osteopontin,	  and	  several	  proteoglycans.[24]	  	  
Serum	   osteocalcin	   synthesized	   by	   osteoblasts	   was	   previously	   thought	   to	  
function	   as	   a	   promoter	   or	   initiator	   of	   calcium	   deposition	   at	   the	   nidus	   between	   the	  
ends	   of	   collagen	   fibrils	   and	   therefore	   regarded	   as	   a	  marker	   of	   bone	   formation.	   The	  
observation	   that	   the	   osteocalcin	   knockout	  mouse	   has	   a	   high	   bone	  mass	   phenotype	  
suggests	  that	  osteocalcin	  normally	  inhibits	  bone	  formation.	  Because	  serum	  osteocalcin	  
is	  derived	  from	  both	  matrix	  releases	  by	  osteoclast	  activity	  and	  osteoblast	  synthesis,	  it	  
is	   currently	   regarded	   as	   a	  marker	   of	   bone	   turnover	   rather	   than	   a	   specific	  marker	   of	  
bone	   formation.	   The	   main	   glycosylated	   protein	   present	   in	   bone	   is	   alkaline	  
phosphatase,	  this	  is	  bound	  to	  osteoblast	  cell	  surfaces	  via	  a	  phosphoinositol	  linkage	  and	  
also	   is	   found	   free	   within	   mineralized	   matrix.	   Alkaline	   phosphatase	   plays	   an	   as-­‐yet-­‐
undefined	   role	   in	   mineralization	   of	   bone.[47]	   The	   most	   prevalent	   noncollagenous	  
protein	   in	   bone	   is	   osteonectin,	   accounting	   for	   approximately	   2%	   of	   total	   protein	   in	  
developing	   bone.	   Osteonectin	   is	   thought	   to	   affect	   osteoblast	   growth	   and/or	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The	   inorganic	   matrix	   contains	   important	   ionic	   components	   such	   as	   calcium,	  
phosphate,	  magnesium,	  carbonate,	  hydroxyl,	  fluoride,	  citrate,	  and	  chloride.	  The	  most	  
important	  crystalline	  component	  of	  bone	  is	  hydroxyapatite	  -­‐	  Ca10(PO4)6(OH)2,	  found	  as	  
needle-­‐shaped	  crystals	  with	  20–40	  nm	  in	   length	  and	  3–6	  nm	  in	  width,	  generally	   lying	  
with	   their	   long	   axes	   parallel	   to	   the	   collagen	   fibers.[24]	  Other	   bone	  mineral	   ions	   are	  
found	   in	   association	   with	   the	   surface	   of	   the	   hydroxyapatite	   crystals,	   or	   they	   may	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BONE	  TISSUE	  HEALING	  
	  
Fracture	  healing	  is	  a	  unique	  response	  to	  bone	  injury,	  which	  in	  contrast	  to	  repair	  
of	  many	  other	  types	  of	  tissues,	  aims	  to	  restore	  the	  anatomy,	  structure	  and	  function	  of	  
the	  tissue,	  to	  its	  original	  characteristics.	  In	  general,	  fracture	  healing	  is	  completed	  in	  6	  
to	   8	   weeks	   after	   initial	   injury.	   Fracture	   healing	   may	   occur	   both	   through	   direct	  
(intramembranous)	  or	  indirect	  (endochondral)	  bone	  formation.	  
Fracture	   healing	   can	   be	   divided	   in	   four	   more	   or	   less	   overlapping	   stages	  
(inflammation,	   soft	   callus,	  hard	   callus	  and	  bone	   remodeling)(Figure	   6).	   	  At	   the	   cellular	  
level,	  inflammatory	  cells,	  vascular	  cells,	  osteochondral	  progenitors,	  and	  osteoclasts	  are	  
key	  players	  in	  the	  repair	  process.	  At	  the	  molecular	  level,	  fracture	  repair	  is	  driven	  by	  the	  
3	   main	   classes	   of	   factors:	   pro-­‐inflammatory	   cytokines	   and	   growth	   factors,	   pro-­‐
osteogenic	   factors,	   and	   angiogenic	   factors,	   recruiting	   cells	   and	   stimulating	   growth	  
and/or	   differentiation.	   Thereafter,	   the	   damaged	   soft	   tissues	   are	   repaired	   and	   the	  
fracture	   is	   bridged	   by	   soft	   callus	   and	   later	   hard	   callus.	   The	   bridging	   hard	   callus	   is	  
eventually	   remodeled	   to	   re-­‐establish	   the	   original	   anatomy	   and	   function	   of	   the	  
fractured	  bone.	  
This	   process	   begins	   with	   the	   formation	   of	   a	   hematoma	   at	   the	   fracture	   site,	  
through	  the	  release	  of	  cytokines	  and	  recruitment	  of	  inflammatory	  cells	  (granulocytes,	  
lymphocytes	   and	   monocytes),	   which	   secrete	   cytokines/growth	   factors	   and	   advance	  
formation	  of	   a	   stable	   fibrinous	   clot,	   along	  with	   fibroblasts,	   pericytes	   and	  endothelial	  
cells.	   Subsequently	   the	   clot	   is	   reorganized	   into	   granulation	   tissue	   with	   extensive	  
ingrowth	   of	   capillaries,	   allowing	   macrophages	   and	   other	   phagocytic	   cells	   to	   clear	  
degenerated	   cells	   and	   debris.	   These	   factors	   contribute	   to	   further	   attraction	   of	  
inflammatory	   cells,	   as	  well	   as	  multipotent	  mesenchymal	   stem	   cells.[48]	  Hypoxia	   and	  
vascular	  disruption	  at	  the	  fracture	  site	  are	  also	  stimuli	  for	  cell	  recruitment.	  These	  cells	  
initiate	   the	   deposition	   of	   extracellular	  matrix	   rich	   in	   fibronectin	   and	   collagen,	  which	  
results	   in	   the	   formation	   of	   granulation	   tissue.	   Following,	   fibrous-­‐vascular	   tissue	   is	  
deposited	   in	   the	   areas	   in	   which	   the	   hematoma	   is	   being	   resorbed.	   Simultaneously,	  
recruited	  osteoblasts	  and	  chondrocytes	  initiate	  the	  deposition	  of	  osteoid	  and	  cartilage,	  
respectively,	  contributing	  to	  soft	  callus	  formation.	  Hard	  callus	  formation	  (primary	  bone	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formation) 	  represents	  the	  most	  active	  period	  of	  osteogenesis,	  with	  intense	  osteoblast	  
activity	   and	   formation	   of	   mineralized	   bone	   matrix,	   which	   arises	   directly	   in	   the	  
peripheral	   callus	   in	   areas	   of	   stability	   bridging	   the	   bone	   fragments.	   The	   soft	   callus	   is	  
replaced	  with	  woven	   bone,	   which	   becomes	   revascularized.	   Sufficient	   vascularization	  
yielding	   increased	  local	  oxygen	  tension	  and	  thus	  promoting	  osteoblast	  differentiation	  
is	  critical	  to	  formation	  of	  hard	  callus.	  
The	   woven	   bone	   is	   remodeled	   over	   time	   to	   originate	   lamellar	   bone	   with	  























Figure	  6	  –	  Representative	  stages	  of	  bone	  healing.[49]	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BONE	  MECHANICS	  
	  
Bone	   provides	   mechanical	   support	   related	   to	   protection	   and	   locomotion	   it	  
functions	   as	   a	   system	   of	   complex	   metabolic	   mineral	   homeostasis	   and	   shows	  
mechanical	   properties	   of	   anisotropy,	   nonlinearity,	   and	   viscoelasticity.	   These	  
properties,	   along	   with	   its	   ability	   to	   respond	   to	   changes	   in	   its	   physiological	   and	  
mechanical	   environment,	   make	   it	   more	   difficult	   to	   establish	   universal	   constants	  
related	  to	  the	  physical	  properties	  of	  bone.[24]	  
Based	  on	  biomechanical	  principles,	  bone	  responds	  to	  forces	  in	  nature,	  including	  
gravity,	  ground	  reaction,	  and	  muscle	  contraction.	  When	  a	  force	  or	  a	  load	  is	  applied	  to	  
bone,	  an	  internal	  resistance	  develops	  (i.e.,	  stress).	  Stress	  is	  the	  force	  per	  unit	  area	  and	  
is	   equal	   in	   magnitude	   but	   opposite	   in	   direction	   to	   the	   applied	   load.	   Stress	   can	   be	  
categorized	  as	  tensile,	  when	  too	  forces	  act	  along	  a	  straight	  line	  in	  opposite	  directions;	  
compressive,	  when	  too	  forces	  act	  along	  a	  straight	  line	  in	  the	  same	  direction;	  or	  shear,	  
when	  too	  forces	  are	  acting	  parallel	  to	  each	  other	  but	  not	  in	  the	  same	  line.	  Most	  forces	  
applied	   to	   bone	   are	   a	   combination	   of	   the	   three	   stresses,	   resulting	   in	   a	   bending	   or	  
torsion.	   The	   resulting	   deformation	   of	   the	   applied	   force	   is	   known	   as	   strain,	   which	   is	  
equal	  to	  the	  change	  in	  length	  divided	  by	  the	  original	  length.[50]	  
At	   low	   levels	   of	   stress,	   a	   linear	   relationship	   exists	   between	   stress	   and	   strain.	  
The	   ratio	  of	   the	   stress	  divided	  by	   the	   strain	   is	   known	  as	   the	  modulus	  of	  elasticity	  or	  
Young’s	  modulus.	  This	  relationship	  or	  modulus	  relates	  to	  the	  overall	  stiffness	  or	  rigidity	  
of	   bone.	   The	   linear	   portion	  of	   the	   stress-­‐strain	   curve	   is	   known	   as	   the	   elastic	   region,	  
where	  removal	  of	  the	  load	  results	  in	  no	  permanent	  strain	  or	  deformation.	  The	  point	  at	  
which	   the	   curve	   becomes	   nonlinear,	   the	   plastic	   region,	   a	   permanent	   deformation	  
occurs	  even	  after	   the	   load	   is	   removed.	  This	  occurs	  at	   the	  elastic	   limit	  or	   yield	  point.	  
Stressing	  a	  bone	  beyond	  the	  plastic	  region	  will	  result	  in	  failure,	  such	  as	  a	  fracture.	  The	  
ultimate	   strength	  of	   a	  bone	   is	  determined	  by	   calculating	   the	  maximum	  stress	   at	   the	  
point	  of	  failure	  (Figure	  7).[50]	  
Bone,	   like	   many	   other	   biological	   tissues,	   demonstrates	   the	   property	   of	  
anisotropy;	   it	   responds	   differently	   depending	   on	   the	   type	   of	   load	   applied.	   Cortical	  
bone	   has	   been	   shown	   to	   resist	   compressive	   forces	   better	   than	   tensile	   forces.	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found in the body. The physiological functions related
to nerve conduction and muscle contraction depend on
this inorganic matrix in order to maintain appropriate
extracellular fluid ion concentrations.
Bone mineral crystals, previously thought to be classified
as pure hydroxyapatite,9 are now regarded as apatite due
to unique acid-phosphate groups. The mechanical and
physiological roles of bone mineral crystals appear to
depend on the amount of crystal present as well as on
the age of the crystal. Both of these factors are important
when dealing with bone diseases and fracture healing1
and will be discussed later in this perspective.
Mineralization
During initial bone formation, the mineralization pro-
cess is complex and well regulated, and it occurs quickly
once initiated. At least 60% of the process occurs within
hours, while the remaining mineralization gradually
increases the density and strength of bone. Exactly how the
process is controlled is still under investigation, but it is
believed that a variety of mechanisms related to the minor
organic components of the matrix and their precursors,
rather than the collagen itself, are responsible.10
Calcium phosphate granules are found within an osteo-
blast’s mitochondria and matrix vesicles, which are
membrane-bound extracellular structures formed from
the plasma membrane of osteoblasts. In the case of
mineralization of the epiphyseal plate, they are formed
from the plasma membrane of the chondrocyte. The
minerals are deposited within and between adjacent
collagen fibrils, and the crystals are aligned in a parallel
fashion. As this process proceeds, the amount of water
and noncollagenous proteins decrease. Although the
concentration of minerals increases, the organization
and amount of collagen remains the same. This corre-
lates with the increasing strength and stiffness of bone.1,2
Resorption
As relevant research is being published, especially in the
area of osteoporosis, the process of bone resorption is
becoming better understood. The process is initiated by
the proliferation of osteoclast precursors, their differen-
tiation into osteoclasts, followed by the degradation
process of the bone matrix. Initially, the inorganic
matrix dissolves through acidication (HCl) of the extra-
cellular environment, which causes a decrease in pH.
Following this, cathepsin K, a lysosomal protease,
degrades the organic component. By-products of this
process are then transported to the opposite side of the
osteoclast where they are released. Following the degra-
dation of the bony matrix, a “resorptive lacuna” is left
behind. The osteoclast will detach from the site and move
on potentially to a new site of resorption. Osteoblasts will
then come into the area and replace the resorbed bone.11
During the adolescent years, bone density increases
rapidly, reaching a maximum approximately 10 years
after the completion of skeletal growth. In the aging
person, the balance between resorption and deposition
becomes negative, because the amount of resorption
exceeds the deposition. In the 10 years following meno-
pause, women lose close to half of their cancellous bone
and one third of their cortical bone mass because of
accelerated bone loss from estrogen depletion. In con-
trast, men lose approximately 30% less bone mass during
their lifetime. Once this imbalance has become clinically
significant, a person is diagnosed with osteoporosis.12
Bone Structure
The overall structure of bone can be divided into cortical
(compact) versus cancellous (spongy) (Fig. 3). Within
these classifications, cortical and cancellous bone can
consist of either woven (primary) or lamellar (second-
ary) bone. Comparison of cortical and cancellous bone
demonstrates a similar matrix structure and composi-
tion, but vastly different masses, with cortical bone
having a greater mass-to-volume ratio.1
Cortical bone surrounds the marrow cavity and the
trabecular plates of the cancellous bone. It accounts for
80% of the mature skeleton and forms the diaphysis, or
shaft, of long bones. The metaphysis and epiphysis of
long bones have thinner cortical walls, with the epiphysis
forming a bulbous end surrounding the inner cancel-
lous bone. Short bones (eg, the tarsals and carpals), the
vertebrae, skull, and pelvic bones also tend to have
thinner cortical walls but contain a greater percentage of
cancellous bone compared with long bones.1,13
Figure 2.
A standard stress/strain curve of bone loaded in bending. Reproduced
with permission of Springer-Verlag from: Einhorn TA. Bone strength: the
bottom line. Calcif Tissue Int. 1992;51:333–339. Copyright 1992.
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Compared	  with	  cortical	  bone,	  cancellous	  bone	  has	  a	  lower	  modulus	  of	  elasticity	  due	  to	  
its	   greater	   porosity.	   Cancellous	   bone	   demonstrates	   the	   greatest	   strength	   when	   a	  
compressive	  force	  is	  applied	  parallel	  to	  the	  trabecular	  system,	  such	  as	  a	  vertical	  force	  
to	   a	   vertebral	   bone.	   Therefore,	   the	   strength	   and	   rigidity	   of	   bone	  are	   greatest	   in	   the	  
direction	   of	   normal	   loading.	   Bone	   also	   demonstrates	   the	   property	   of	   viscoelasticity,	  
which	   indicates	   that	  materials	  will	  demonstrate	  different	  properties	  according	   to	   the	  
rate	  of	  force	  application.	  At	  low	  rates	  of	  loading,	  bone	  demonstrates	  a	  lower	  modulus	  
of	   elasticity,	   and	   behaves	   like	   a	   viscous	   material.	   At	   higher	   rates	   of	   loading,	   bone	  
behaves	  as	  a	  brittle	  material.[24]	  
Mechanical	  loads	  applied	  to	  bone	  are	  thought	  to	  be	  communicated	  through	  the	  
bone	  by	  way	  of	  a	  mechanical	  signal	  detected	  by	  either	  bone	  lining	  cells	  or	  osteocytes,	  
or	  both.	  It	  is	  believed	  that	  these	  mechanical	  signals	  lead	  to	  the	  generation	  of	  chemical	  
signals	   involved	  in	  the	  regulation	  of	  bone	  formation	  and	  remodeling.	  The	  osteocytes,	  
in	  particular,	  have	  received	  much	  attention	  in	  this	  regard.	  Osteocytes	  are	  connected	  to	  
each	   other	   and	   to	   osteoblasts	   by	  way	   of	   cellular	   processes	  within	   canaliculi	   and	   are	  
linked	  by	  gap	  junctions.	  This	  network	  allows	  for	  the	  possibility	  of	  electrical	  coupling	  as	  well	  













Figure	  7	  –	  A	  standard	  stress/strain	  curve	  of	  bone	  loaded	  in	  bending.	  [52]	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Osteoporosis	   is	   by	   far	   the	   most	   common	   bone	   disease.	   Osteoporosis	   is	   a	  
skeletal	   disorder	   characterized	   by	   compromised	   bone	   strength,	   predisposing	   to	   an	  
increased	   risk	   of	   fracture.[24]	   The	   composition	   of	   the	   mineral	   and	   matrix,	   the	   fine	  
structure	  of	  the	  trabecular	  bone,	  the	  porosity	  of	  the	  cortical	  bone,	  and	  the	  presence	  of	  
micro-­‐fractures	  and	  other	   forms	  of	  damage	   in	  bone	  are	  all	   important	   in	  determining	  
bone	  strength.	  Changes	  in	  the	  fine	  structure	  or	  micro-­‐architecture	  of	  trabecular	  bone	  
are	  particularly	   important	  since	   the	  most	  common	  fractures	   in	  osteoporosis	  occur	  at	  
sites	  where	  trabecular	  bone	  predominates.	  
Osteoporosis	   is	   classified	   as	   primary	   and	   secondary.	   Primary	  osteoporosis,	   by	  
far	   the	   most	   common	   variety,	   has	   been	   also	   designated	   as	   postmenopausal,	  
involutional,	   senile,	   and	   idiopathic	   osteoporosis,	   and	   seems	   to	   involve	   multiple	  
pathogenic	   mechanisms,	   many	   of	   which	   have	   not	   yet	   been	   adequately	   defined.	   In	  
addition,	   there	   are	  many	   disorders	   that	   can	   lead	   to	   skeletal	   fragility	   with	   a	   defined	  
cause	   -­‐	   secondary	   osteoporosis	   -­‐	   including	   genetic	   disorders	   (e.g.,	   osteogenesis	  
imperfecta	   and	   osteoporosis-­‐pseudoglioma	   syndrome);	   endocrine	   disorders	   (e.g.,	  
Cushing	   syndrome,	   hyperparathyroidism,	   hyperthyroidism	   and	   hypogonadism);	   and	  
inflammatory	  and	  nutritional	  disorders	  (e.g.,	  rheumatoid	  arthritis,	  Crohn’s	  disease	  and	  




Osteoporosis	   reports	   a	   high	   rate	   of	   mortality	   and	  morbidity,	   not	   only	   in	   the	  
Western	  countries,	  but	  also	  in	  Asia,	  Latin	  America,	  the	  Middle	  East,	  and	  Africa.	   It	  has	  
been	  estimated	   that	   these	   regions	  will	   account	   for	  more	   than	  70%	  of	   the	  estimated	  
6.26	  million	  bone	  fractures,	  expected	  by	  the	  year	  2050.[53]	  Osteoporosis	  affects	  both	  
men	  and	  women,	  nonetheless	   the	  cumulative	   lifetime	   risk	  of	  having	  an	  osteoporotic	  
fracture	  is	  2–4	  times	  greater	  in	  women.[23]	  
An	  estimated	  40%	  of	  women	  and	  13%	  of	  men	  aged	  50	  years	  old	  and	  older	  will	  
sustain	   an	   osteoporotic	   fracture	   in	   their	   lifetime.[54]	   Taking	   into	   account	   future	  
mortality	  trends,	  these	  figures	  rise	  to	  47%	  for	  women	  and	  22%	  for	  men.[55]	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The	   three	  most	   common	   sites	   for	   osteoporotic	   fracture	   are	   the	   distal	   radius,	  
the	  vertebral	  body	  and	  the	  upper	  femur.[23]	  Nonetheless,	  other	  bones	  are	  affected	  by	  
osteoporosis,	   and	   yield	   a	   particular	   relevance	   regarding	   osteoporosis-­‐associated	  
morbidity	   and	   mortality.	   For	   instance,	   hip	   bone	   is	   of	   particular	   clinical	   relevance.	  
Approximately	  20–27%	  of	  women	  who	  sustain	  hip	  fracture,	  are	  expected	  to	  die	  within	  
a	  year.[56]	  About	  half	  of	  the	  women	  who	  have	  had	  a	  hip	  fracture	  will	  experience	  long-­‐
term	   pain	   and	   disability,[57]	   and	   20%	   will	   be	   expected	   to	   have	   severely	   impaired	  
mobility	  within	  a	  year.[56]	  
In	   2010,	   the	  number	  of	   deaths	   causally	   related	   to	  osteoporotic	   fractures	  was	  
estimated	   at	   43.000	   in	   the	   European	   Union.	   Approximately	   50%	   of	   fracture-­‐related	  






In	   adults	   and	   in	   physiological	   conditions,	   there	   is	   equilibrium	   between	   bone	  
formation	   and	   resorption,	   in	   a	   dynamic	   process	   of	   bone	   remodeling.	   Osteoporosis	  
occurs	  when	  the	  balance	  is	  disrupted	  and	  tilts	  in	  favor	  of	  resorption.	  Osteoporosis	  is	  a	  
multifactorial	   disorder	   and	   any	   model	   for	   pathogenesis	   has	   to	   recognize	   that	   a	  
different	   set	   of	   mechanisms	   may	   be	   operative	   in	   any	   given	   individual.	   Although	   a	  
complete	  understanding	  of	  the	  underlying	  control	  mechanisms	  is	  not	  yet	  known,	  there	  
are	   a	   number	   of	   features	   that	   have	   been	   reported	   to	   be	   associated	   with	   the	  
development	  of	  skeletal	  fragility.	  
	  
• Age-­‐related	   changes.	   With	   the	   increase	   of	   age,	   osteoblasts	   replicate	   and	  
synthesize	   extracellular	   matrix	   with	   progressively	   reestablished	   defects.	   The	  
various	   growth	   factors	   deposited	   within	   the	   ECM	   also	   tend	   to	   become	   less	  
effective	  with	   time.[59]	  Unfortunately,	  while	   new	  bone	   synthesis	  wanes	  with	  




MODULATION	  OF	  THE	  BONE	  REGENERATION	  PROCESS	  IN	  SYSTEMIC	  IMPAIRED	  CONDITIONS	   53	  
• Hormonal	   influences.	   The	   decline	   in	   estrogen	   levels	   associated	   with	  
menopause	  correlates	  to	  an	  annual	  decline	  of	  as	  much	  as	  2%	  of	  cortical	  bone	  
and	  9%	  of	   cancellous	   bone.[60]	   This	   can	   add	  up	   to	   35%	  of	   cortical	   bone	   and	  
50%	  of	   trabecular	  bone	  within	  30-­‐40	  years.	   It	   is	   therefore	  not	   surprising	   that	  
roughly	   half	   of	   post-­‐menopausal	   women	   are	   expected	   to	   suffer	   an	  
osteoporosis-­‐associated	   fractures,	  compared	  to	  2-­‐3%	  of	  men	  of	   the	  same	  age	  
group.[60]	  
Bone	   loss	   accelerates	   in	   women	   at	   menopause	   because	   estrogen	  
withdrawal	  increases	  the	  rate	  of	  bone	  remodeling,	  creating	  many	  foci	  of	  bone	  
resorption	  on	  the	  endosteal	  surfaces.	  Estrogen	  deficiency	  increases	  the	  activity	  
of	  osteoclasts,	  probably	  by	  suppressing	  their	  apoptosis.[42]	  The	  hypoestrogenic	  
effects	   are	   attributable	   in	   part	   to	   augmented	   cytokine	   production	   (especially	  
interleukin-­‐1	  and	  tumour	  necrosis	   factor).	  Moreover,	  estrogen	  regulates	  bone	  
resorption	   by	   limiting	   the	   release	   of	   RANKL	   from	   osteoblasts,	   among	   other	  
cells.[61]	   Loss	   of	   estrogen	   leads	   to	   significantly	   increased	   RANKL	   expression,	  
which	   in	  turn	  result	   in	  excess	  formation	  and	  activity	  of	  osteoclasts.[62]	  At	  the	  
same	  time,	  OPG	  levels	  increase	  with	  age,	  and	  it	  is	  possible	  that	  OPG	  production	  
rises	   as	   a	   homeostatic	   response	   to	   limit	   the	   bone	   loss	   that	   occurs	   with	   an	  
increase	   in	   other	   bone-­‐resorbing	   factors.[42]	   Nonetheless,	   despite	   some	  
simultaneous	  compensatory	  osteoblastic	  activity,	  the	  anabolic	  response	  seems	  
to	   be	   inadequate	   to	   keep	   pace	   with	   the	   higher	   osteoclast-­‐mediated	   bone	  
resorption.[62]	  
Increased	  osteoclastic	   activity	   induces	  an	  augmented	  depth	  of	  erosion	  
of	   bone	   by	   these	   cells,	   contributing	   to	   the	   trabecular	   penetration	   and	  
disruption	   of	   bone	   architecture.[59]	   In	   each	   remodeling	   site,	   more	   bone	   is	  
resorbed	   than	   replaced,	   producing	   a	  net	  negative	  BMU	  balance,	  which	   is	   the	  
basis	  of	  bone	   loss.	  Moreover,	  estrogen	  deficiency	   increases	   the	  prevalence	  of	  
osteocyte	   apoptosis,	   which	   might	   impair	   the	   ability	   of	   the	   osteocyte	  
mechanosensory	  network	  to	  repair	  microdamage,	  and	  thus	  contribute	  further	  
to	  bone	  fragility.[63]	  The	  initial	  rapid	  fall	   in	  bone	  mineral	  density	  (BMD)	  is	  the	  
result	   of	   the	   increase	   in	   bone	   porosity	   of	  many	   BMUs,	   as	   remodeling	  moves	  
LITERATURE	  OVERVIEW	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  54	  
from	   a	   low	   rate	   before	  menopause	   to	   a	   high	   rate	   after	  menopause.[42]	   The	  
rapid	   fall	   in	   BMD	   is	   the	   result	   of	   the	   normal	   delay	   in	   initiation	   of	   bone	  
formation	  and	  its	  slower	  completion,	  within	  the	  many	  resorption	  cavities.	  The	  
microarchitectural	  deterioration	  probably	  reflects	  the	  intensity	  and	  duration	  of	  
osteoclast	  activity	  as	  well	  as	  the	  number	  of	  osteoclasts	  formed.[64]	  
The	   increased	   remodeling	   and	   negative	   bone	   balance	   produce	   bone	  
loss,	   trabecular	   thinning	   and	   loss	   of	   connectivity,	   cortical	   thinning,	   and	  
porosity.[59]	   Older,	   more	   mineralized	   interstitial	   bone,	   distant	   from	   surface	  
remodeling,	   accumulates	   microdamage,	   whereas	   more	   superficial	   bone	   is	  
replaced	  with	  younger	  and	  less	  mineralized	  bone,	  reducing	  stiffness.[65]	  Bone	  
modeling	   by	   periosteal	   apposition	   reduces	   compressive	   stress	   by	   distributing	  
loads	  on	  a	  larger	  area,	  and	  partly	  maintains	  bending	  strength.[66]	  Moreover,	  it	  
may	   be	   impaired	   due	   to	   abnormalities	   in	   periosteal	   osteoblast	   function	   or	  
osteocyte	  signaling.[59]	  
	  
• Lifestyle.	   Smoking	   is	   associated	   with	   a	   reduced	   peak	   bone	   mass,[67]	   earlier	  
menopause	  [68]	  and	  thinness[69],	  all	  of	  which	  are	  risk	  factors	  for	  osteoporotic	  
fracture.	  Smoking	  appears	  to	  reduce	  bone	  mineral	  density	  by	  a	  mechanism	  that	  
is	  independent	  of	  its	  effect	  on	  weight	  or	  estrogen	  metabolism,	  and	  may	  act	  by	  
reducing	  calcium	  absorption.[70]	  	  
	  Framingham	   cohort	   demonstrated	   that	   an	   alcohol	   intake,	   at	   around	  
200	  ml	   or	  more	   per	   week,	   is	   a	   risk	   factor	   for	   bone	   loss,	   but	   concluded	   that	  
weight,	   estrogen	  use,	   and	   cigarette	   smoking	   are	   also	   important	   predictors	   of	  
bone	  health.[71]	  It	  is	  not	  known	  whether	  the	  lower	  bone	  mineral	  density	  found	  
in	   alcoholics	   is	   mainly	   due	   to	   inadequate	   dietary	   intake,	   poor	   exercise,	   or	   a	  
direct	  effect	  of	  alcohol	  in	  reducing	  osteoblastic	  activity;[23]	  however	  it	  is	  likely	  
to	  be	  a	  combination	  of	  these	  factors.	  
Because	  mechanical	  forces	  stimulate	  bone	  remodeling,	  reduced	  physical	  
activity	   increases	   bone	   loss.[72]	   This	   effect	   is	   usually	   observed	   in	   an	  
immobilized	   limb,	   but	   also	   occurs	   diffusely	   in	   a	   gravity-­‐free	   environment.[73]	  
Decreased	   physical	   activity	   in	   older	   individuals	   also	   contributes	   to	   senile	  
LITERATURE	  OVERVIEW	  
	  
MODULATION	  OF	  THE	  BONE	  REGENERATION	  PROCESS	  IN	  SYSTEMIC	  IMPAIRED	  CONDITIONS	   55	  
osteoporosis.[72]	   Because	   the	  magnitude	   of	   skeletal	   loading	   influences	   bone	  
density	  more	   than	   the	   number	   of	   load	   cycles,	   the	   type	   of	   physical	   activity	   is	  
important.[74]	  
	  
• Genetic	  factors.	  Several	  population	  and	  genetic-­‐based	  variations	  seem	  to	  play	  a	  
role	   in	  peak	  bone	  mass	  and	  BMD	  variations.	   For	   instance,	  peak	  bone	  mass	   is	  
greater	  in	  men	  than	  in	  women,	  and	  in	  Blacks	  than	  in	  Whites	  or	  Asians.[23]	  Also	  
there	   is	   a	   higher	   concordance	   of	   peak	   bone	   mass	   in	   monozygotic	   than	   in	  
dizygotic	   twins.[22]	   Moreover,	   women	   of	   reproductive	   age,	   whose	   mothers	  
have	  postmenopausal	  osteoporosis,	  exhibit	  a	  lower	  BMD	  than	  do	  women	  of	  the	  
general	  population.[59]	  	  
In	   fact,	   genetic	   variations	   explain	   high	   percentage	   of	   the	   variance	   in	  
BMD.[23]	   Vitamin	   D	   receptor	   polymorphisms	  may	   account	   for	   approximately	  
75%	   of	   variation	   in	   the	   maximal	   peak	   bone	   mass	   achieved	   in	   any	   given	  
individual.[44]	  Additional	  genetic	  variables	  can	  influence	  calcium	  uptake	  or	  PTH	  
synthesis	  and,	  accordingly,	  influence	  related	  biological	  responses.	  
	  
• Calcium	   nutritional	   state.	  Dietary	   calcium	   intake	   can	   majorly	   determine	   the	  
status	   of	   bone	   metabolism.	   It	   is	   of	   particular	   relevance	   in	   worldwide	  
population,	   that	   the	   majority	   of	   adolescent	   girls	   have	   insufficient	   dietary	  
calcium	   intake	   in	   a	   period	   of	   rapid	   bone	   growth.	   As	   a	   result,	   they	   do	   not	  
achieve	   the	  maximal	   peak	   bone	  mass	   that	   could	   be	  otherwise	   expected,	   and	  
are	   therefore	   likely	   to	   develop	   clinically	   significant	   osteoporosis	   at	   an	   earlier	  
age.[23]	  
1,25-­‐Dihydroxyvitamin	   D,	   the	   active	   metabolite	   of	   vitamin	   D,	   has	  
important	   physiologic	   activities,	   including	   the	   absorption	  of	   calcium	   from	   the	  
gastrointestinal	  tract,	  the	  helping	  on	  the	  regulation	  of	  calcium	  handling	   in	  the	  
kidney,	  the	  regulation	  of	  the	  homeostatic	  control	  of	  bone	  remodeling,	  and	  the	  
regulation	  of	   the	  synthesis	  of	   the	  parathyroid	  hormone	  –	   functions	   important	  
to	   the	   homeostatic	   control	   of	   calcium	   metabolism.[46]	   Any	   abnormality	   in	  
vitamin	  D	   formation,	  metabolism	  or	   action	   could	   result	   in	   an	   increased	  bone	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resorption	  and	  consequently	  accelerate	  bone	  loss.[24,	  75]	  Subclinical	  vitamin	  D	  
deficiencies	  have	  been	  verified	  in	  osteoporotic	  women.[76]	  Vitamin	  D	  may	  also	  
have	  a	  direct	  effect	  on	  muscle	  strength	  and	  dexterity.[77]	  There	  appears	  to	  be	  
a	  relationship	  between	  low	  serum	  vitamin	  D	  and	  age-­‐related	  muscle	  weakness,	  
increased	  body	  sway,	  increased	  risk	  of	  fall,	  and	  fall-­‐related	  fractures.[78]	  
	  
Overall,	   the	   reported	   mechanisms	   can	   be	   embraced	   in	   three	   summarizing	  
features:	   1)	   failure	   to	   achieve	   optimal	   peak	   bone	   mass	   and	   strength	   -­‐	   largely	  
determined	  by	  genetic	  background,[79]	  but	  which	  can	  also	  be	  substantially	  affected	  by	  
lifestyle;[46]	  2)	  accelerated	  bone	   loss	  due	   to	   resorption;	  3)	   impaired	  bone	   formation	  
response	   during	   remodeling	   –	   which	   physiologically	   occurs	   shortly	   after	   the	  
achievement	   of	   peak	   bone	   mass,	   but	   may	   be	   greatly	   augmented	   by	   pathologic	  
mechanisms.[80]	  
	  
Osteoporosis	   may	   also	   develop	   in	   association	   with	   many	   other	   conditions	   –	  
secondary	   osteoporosis.	   Causes	   include	   genetic	   disorders,	   hypogonadal	   states,	  
endocrine	  disorders,	  gastrointestinal	  diseases,	  hematological	  disorders,	  rheumatic	  and	  
autoimmune	   diseases,	   immobilization,	   and	   several	   other	   conditions,	   as	   portrayed	   in	  
Table	  1.	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Premature	  ovarian	  failure	  










Inflammatory	  bowel	  disease	  
Malabsorption	  
Celiac	  disease	  
Primary	  biliary	  cirrhosis	  
Hematologic	  Disorders	  
Hemophilia	  
Leukemias	  and	  Lymphomas	  
Multiple	  myeloma	  
Sickle	  cell	  disease	  
Systemic	  mastocytosis	  
Thalassemia	  
Rheumatic	  and	  Auto-­‐immune	  diseases	  




Chronic	  metabolic	  acidosis	  
Congestive	  heart	  failure	  
Depression	  
Emphysema	  











Osteoporosis	   can	   also	   be	   a	   side	   effect	   of	   particular	   medical	   therapies	   as	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Table	  2	  –	  Medications	  associated	  with	  secondary	  osteoporosis.[82]	  	  
Medications	  associated	  with	  secondary	  osteoporosis	  
Glucocorticoids	  (and	  ACTH)	  
Anticoagulants	  (heparin)	  
Anticonvulsants	  
Cyclosporine	  A	  and	  Tacrolimus	  
Cancer	  chemotherapeutic	  drugs	  







Glucocorticoid-­‐Induced	   osteoporosis	   is	   by	   far	   the	   most	   common	   form	   of	  
osteoporosis	   produced	   by	   drug	   treatment.	  While	   it	   has	   been	   known	   for	  many	   years	  
that	  excessive	  production	  of	   the	  adrenal	  hormone	  cortisol	   can	   cause	   thinning	  of	   the	  
bone	  and	  fractures,	  this	  condition,	  a	  form	  of	  Cushing’s	  syndrome,	  remains	  uncommon.	  
With	   the	   increased	   use	   of	   prednisone	   and	   other	   drugs	   that	   act	   like	   cortisol	   for	   the	  
treatment	  of	  many	  inflammatory	  and	  autoimmune	  diseases,	  this	  form	  of	  bone	  loss	  has	  
become	  a	  major	  clinical	  concern.	  The	  concern	   is	  greatest	   for	   those	  diseases	   in	  which	  
the	   inflammation	   itself	   and/	   or	   the	   immobilization	   caused	  by	   the	   illness	   also	   caused	  
increased	  bone	  loss	  and	  fracture	  risk.	  Glucocorticoids,	  which	  are	  used	  to	  treat	  a	  wide	  
variety	   of	   inflammatory	   conditions	   (e.g.,	   rheumatoid	   arthritis,	   asthma,	   emphysema,	  
chronic	  lung	  disease),	  can	  cause	  profound	  reductions	  in	  bone	  formation	  and	  may,	  to	  a	  
lesser	  extent,	  increase	  bone	  resorption,	  leading	  to	  loss	  of	  trabecular	  bone	  at	  the	  spine	  
and	  hip,	  especially	  in	  postmenopausal	  women	  and	  older	  men.[83]	  The	  most	  rapid	  bone	  
loss	  occurs	  early	  in	  the	  course	  of	  treatment,	  and	  even	  small	  doses	  (equivalent	  to	  2.5–
7.5	  mg	  prednisone	  per	  day)	  are	  associated	  with	  an	  increase	  in	  fractures.[84]	  The	  risk	  of	  
fractures	  increases	  rapidly	  in	  patients	  treated	  with	  glucocorticoids,	  even	  before	  much	  
bone	  has	  been	  lost.	  This	  rapid	  increase	  in	  fracture	  risk	  is	  attributed	  to	  damage	  to	  the	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bone	  cells,	  which	  results	  in	  less	  healthy	  bone	  tissue.	  To	  avoid	  this	  problem,	  health	  care	  
providers	  are	  urged	   to	  use	   the	   lowest	  possible	  dose	  of	  glucocorticoids	   for	  as	   short	  a	  
time	   as	   possible.	   For	   some	   diseases,	   providers	   should	   also	   consider	   giving	  
glucocorticoids	   locally	   (e.g.,	  asthma	  patients	  can	   inhale	   them),	  which	  results	   in	  much	  
less	  damage	  to	  the	  bone.	  
Cyclosporine	   A	   and	   tacrolimus	   are	   widely	   used	   in	   conjunction	   with	  
glucocorticoids	   to	   prevent	   rejection	   after	   organ	   transplantation,	   and	   high	   doses	   of	  
these	  drugs	  are	  associated	  with	  a	  particularly	  severe	  form	  of	  osteoporosis.[85]	  	  
Bone	   disease	   has	   also	   been	   reported	   with	   several	   frequently	   prescribed	  
anticonvulsants,	   including	   diphenylhydantoin,	   phenobarbital,	   sodium	   valproate,	   and	  
carbamazepine.[81]	   Patients	   who	   are	   most	   at	   risk	   of	   developing	   this	   type	   of	   bone	  
disease	   include	   those	   on	   long-­‐term	   therapy,	   high	   medication	   doses,	   multiple	  
anticonvulsants,	  and/or	  simultaneous	  therapy	  with	  medications	  that	  raise	  liver	  enzyme	  
levels.	   Low	   vitamin	   D	   intake,	   restricted	   sun	   exposure,	   and	   the	   presence	   of	   other	  
chronic	   illnesses	   increase	   the	   risk,	   particularly	   among	   elderly	   and	   institutionalized	  
individuals.	   In	   contrast,	   high	   intakes	   of	   vitamin	   A	   (retinal)	   may	   increase	   fracture	  
risk.[86]	  
Methotrexate,	   a	   folate	   antagonist	   used	   to	   treat	   malignancies	   and	   (in	   lower	  
doses)	  inflammatory	  diseases	  such	  as	  rheumatoid	  arthritis,	  may	  also	  cause	  bone	  loss,	  
although	  research	  findings	  are	  not	  consistent.	  	  
In	  addition,	  gonadotropin-­‐releasing	  hormone	  (GnRH)	  agonists,	  which	  are	  used	  
to	   treat	  endometriosis	   in	  women	  and	  prostate	   cancer	   in	  men,	   reduce	  both	  estrogen	  
and	   testosterone	   levels,	   which	   may	   cause	   significant	   bone	   loss	   and	   fragility	  
fractures.[87]	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DIAGNOSIS	  
	  
In	   the	   past,	   osteoporosis	   was	   often	   diagnosed	   on	   the	   basis	   of	   radiologic	  
changes	  and	  in	  the	  presence	  of	  a	  low	  trauma	  fracture,	  for	  example	  a	  fall	  from	  standing	  
and	  generally	  in	  postmenopausal	  women	  and	  older	  men.[23]	  More	  recently,	  an	  inverse	  
relationship	  between	  bone	  mineral	  density	  and	  fracture	  risk	  was	  established	  and	  the	  
diagnostic	   start	   to	   be	   based	   on	   BMD	   measurements,	   allowing	   the	   diagnose	   of	  
osteoporosis	  and	  osteopenia	  before	  fractures	  occur,	  as	  well	  as	  the	  confirmation	  of	  the	  
diagnosis	  in	  patients	  with	  fragility	  fractures.[88,	  89]	  
	  
Radiogrammetry	  
Radiogrammetry	  uses	  measurements	  derived	  from	  standard	  x-­‐rays	  of	  the	  hand	  
to	  determine	  an	   index	   that	   compares	   cortical	   thickness	  with	   the	   total	  bone	  width	   in	  
the	  mid-­‐shaft	  of	  at	  least	  two	  metacarpal	  bones.[82]	  
	  This	  techinique	  has	  been	  used	  to	  assess	  bone	  mineral	  density	  of	  the	  peripheral	  
skeleton,	   usually	   at	   the	  metacarpals.	   The	  metacarpal	   cortical	   thickness	  was	  used	   for	  
many	  years	  to	  diagnose	  and	  predict	  the	  risk	  of	  osteoporosis.	  However,	  the	  sensitivity	  
of	  this	  radiographic	  technique	  is	  poor,[90]	  and	  the	  results	  of	  metacarpal	  measurement	  




Radiographic	   absorptiometry	   (RA),	   also	   termed	   photodensitometry,	   uses	   a	  
standard	   x-­‐ray	   of	   the	   hand	   to	  measure	   density	   in	   the	  middle	   bones	   on	   the	   second,	  
third	   and	   fourth	   fingers.	   Specialized	   equipment	   is	   used	   to	   calcite	   bone	   volume	   and	  
bone	  density.	  The	  cortical	  thickness	  of	  the	  bones	  also	  can	  be	  measured.	  [82]	  
	  
Radiographic	   analysis	   reveals	   recognizable	   bone	   loss	   only	   when	   25–30%	   of	  
bone	  density	  has	  been	  lost,	  at	  which	  time	  osteoporosis	  is	  generally	  considered	  to	  have	  
developed.	   Although	   there	   is	   a	   correlation	   between	   bone	   mineral	   density	   in	   the	  
peripheral	   and	   central	   skeleton,[91]	   the	   association	   is	   not	   strong	   enough	   to	   predict	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central	  bone	  mineral	  density	  from	  peripheral	  measurements	  in	  a	  given	  subject.[91,	  92]	  




The	   most	   common	   method	   for	   measuring	   bone	   mass	   is	   Dual-­‐Energy	   X-­‐Ray	  
Absorptiometry	   (DXA).	   Beside	   this	   one,	   Quantitative	   Computed	   Tomography	   (QCT),	  
Peripheral	   Quantitative	   Computed	   Tomography	   (pQCT)	   and	   Quantitative	   Ultrasound	  
(QUS)	  are	  also	  used.	  	  
	  
• Dual-­‐Energy	  X-­‐Ray	  Absorptiometry	  
Dual-­‐energy	   X-­‐ray	   absorptiometry	   (DXA)	   measures	   bone	   mineral	   density	   by	  
determining	   the	   absorption	   of	   two	   beams	   of	   photons	   at	   two	   different	   energies.[93]	  
This	   technique	   is	   accurate	   and	   involves	   low	  doses	   of	   x-­‐rays.	  DXA	   is	   able	   to	  measure	  
bone	  mineral	  density	  (as	  mass/area)	   in	  the	  proximal	  femur	  and	  lumbar	  spine,	  as	  well	  
as	   the	  mineral	   density	   of	   the	   entire	   body.	  However,	   it	   cannot	  differentiate	  between	  
the	   measurement	   of	   the	   cortical	   and	   trabecular	   bone,	   which	   are	   important	  
determinants	   of	   bone	   strength	   and	   loss	   at	   different	   rates.[94]	   The	   cortical-­‐to-­‐
trabecular	  ratio	  is	  1:2	  in	  the	  spine	  and	  3:1	  in	  the	  femoral	  neck.[23]	  
DXA	   enables	   bone	  mineral	   density	   to	   be	  measured	   at	   the	   hip	   or	   spine,	   with	  
greater	  precision	  than	  that	  described	  for	  other	  methods	  (precision	  error:	  0.5–2%).	  The	  
scanning	   time	   is	   around	   5	   min	   at	   each	   site	   and	   the	   radiation	   dose	   is	   low.[95,	   96]	  
Additional	  to	  the	  assessment	  of	  the	  classic	  anatomical	  sites,	  lateral	  views	  can	  now	  be	  
used	   to	   give	   morphometric	   evaluations	   of	   vertebrae,	   to	   determine	   vertebral	  
deformities	  and	  fractures.[23]	  
The	  results	  are	  reported	  as	  a	  density	  measurement	  in	  g/cm2	  and	  T	  and	  Z	  scores.	  
T	  scores	  correspond	  to	  the	  number	  of	  standard	  deviations	  (SDs)	  from	  the	  mean	  bone	  
density	  values	  in	  normal	  sexmatched	  young	  adults.	  This	  is	  used	  to	  make	  a	  diagnosis	  of	  
normal	  bone	  density,	   osteoporosis,	   or	   osteopenia	   in	  postmenopausal	  women	  and	   in	  
men	   age	   50	   years	   and	   older.[97]	   Z	   scores	   represent	   the	   number	   of	   SDs	   from	   the	  
normal	   mean	   value	   for	   age-­‐	   and	   sex-­‐matched	   control	   subjects.	   Z	   scores	   are	   used	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preferentially	  to	  assess	  bone	  loss	  in	  premenopausal	  females	  and	  in	  men	  younger	  than	  
the	  age	  50	  years.	  	  
The	  World	  Health	  Organization	  (WHO)	  defines	  osteoporosis	  as	  a	  result	  on	  BMD	  
assessment,	  2.5	  SDs	  or	  more,	  below	  the	  mean	  value	  for	  young	  adults	  (a	  T	  score	  <	  −2.5),	  
and	  severe	  osteoporosis,	  as	  a	  BMD	  below	  this	  cut-­‐off	  and	  the	  concomitant	  occurrence	  
of	  one	  or	  more	  fragility	  fractures.[89]	  The	  WHO	  defines	  osteopenia	  as	  a	  BMD	  T	  score	  
between	   −1.0	   and	   −2.5.	   It	   should	   be	   remembered	   that	   at	   the	   same	   time	   as	  
osteoporotic	   fracture	   incidence	   is	   highest	   in	   those	   with	   the	   most	   pronounced	  
osteoporosis,	  a	  substantial	  number	  of	  fractures	  occur	  in	  women	  who	  do	  not	  have	  very	  
low	   bone	   density	   measurements.[98]	   A	   new	   algorithm	   from	   the	   WHO,	   for	   the	  
definition	  of	  osteoporosis	   treatment	  thresholds,	  which	   includes	  other	   factors	  such	  as	  
age,	  is	  currently	  awaited.	  
	  
• Quantitative	  Computed	  Tomography	   	  
Quantitative	   computed	   tomography	   (QCT),	   with	   a	   suitable	   software	   package,	  
enables	  the	  determination	  of	  the	  absorption	  of	  different	  calcified	  tissues,	  so	  that	  areas	  
of	   particular	   interest,	   such	   as	   the	   vertebral	   body	   (which	   has	   a	   cortical-­‐to-­‐trabecular	  
ratio	  of	  approximately	  5:95),	  may	  be	  studied.	  The	  technique	  measures	   true	  densities	  
with	  the	  results	  being	  expressed	  in	  g/cm3.[99]	  	  
An	  advantage	  of	  QCT	  is	  that	  trabecular	  bone	  is	  distinguished	  from	  cortical	  bone,	  
and	  extra	  osseous	  calcium,	  which	  artificially	   increases	   the	  bone	  density	  measured	  by	  
DXA,	  is	  readily	  identified.[100]	  Trabecular	  diameter	  and	  intertrabecular	  spaces	  can	  be	  
measured	   using	   high-­‐resolution	   CT,	   and	   abnormal	   trabecular	   architecture	   can	   be	  
identified.	   The	   recent	   development	   of	   three-­‐dimensional	   (3-­‐D)	   CT	   allows	   the	  
assessment	  of	  3-­‐D	  trabecular	  structural	  characteristics	  and	  may	  improve	  the	  ability	  to	  
estimate	  bone	  biomechanical	  properties.[23]	  
Dual-­‐energy	  scanning	  (with	  double	  radiation	  dose)	  may	   improve	  the	  accuracy,	  
but	   worsens	   precision.	  Moreover	   is	  more	   expensive	   and	   involves	   a	   higher	   radiation	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• Peripheral	  Quantitative	  Computed	  Tomography	  
Peripheral	  quantitative	  computed	  tomography	  (pQCT)	  uses	  specialized	  
equipment	  to	  measure	  cortical	  bone	  (the	  outer,	  more	  solid	  shell	  of	  bone)	  and	  
cancellous	  bone	  (the	  inner,	  honeycomb-­‐	  like	  bone)	  in	  the	  forearm.	  This	  technique	  is	  
used	  primarily	  for	  research.[82]	  
	   	  
• Quantitative	  Ultrasound	  	  	  
Quantitative	  ultrasound	  (QUS)	  uses	  sound	  waves	  to	  assess	  bone	  mass	  and	  thus	  
does	   not	   use	   radiation.	   This	   technique	   provides	   some	   information	   on	   the	   structural	  
organization	  of	  bone,	  in	  addition	  to	  bone	  mass.	  The	  attenuation	  of	  ultrasound	  signals	  
during	  their	  passage	  through	  bone	  may	  be	  measured	  by	  determining	  the	  reduction	  in	  
ultrasound	  signal	  amplitude.	  Several	  ultrasound	  parameters	  used	  to	  characterize	  bone	  
have	   been	   proposed,	   including	   broadband	   ultrasound	   attenuation,	   speed	   of	   sound,	  
combined	   index,	   amplitude-­‐dependent	   speed	   of	   sound	   and	   others.[101-­‐103]	   For	  
example	   the	   attenuation	   of	   the	   signal	   may	   reflect	   both	   the	   density	   and	   the	  
architecture	   of	   bone,	   and	   the	   velocity	   of	   the	   signal	   reflects	   the	   density	   as	   the	  
biomechanical	  properties	  (elasticity).	  
Ultrasound	  instruments	  have	  theoretical	  advantages	  over	  DXA	  in	  that	  they	  are	  
radiation-­‐free,	   portable,	   and	   inexpensive.	   However,	   at	   present,	   clinical	   use	   of	  
ultrasound	  is	  difficult	  because	  of	  the	  absence	  of	  clear	  diagnostic	  criteria	  and	  the	  use	  of	  
a	  variety	  of	  instruments.	  Moreover,	  because	  of	  the	  technological	  differences	  between	  
devices,	   results	   cannot	   be	   extrapolated	   from	   one	   device	   to	   another.[104]	   Using	   a	  
combination	   of	   both	   bone	   mineral	   density	   and	   broadband	   ultrasonic	   attenuation	  
measurements,	  one	  may	  prove	  to	  have	  higher	  sensitivity	  and	  specificity	  for	  predicting	  
fracture	  risk	  than	  the	  use	  of	  each	  method	  alone.	  However,	  for	  now	  QUS	  alone	  cannot	  
be	   used	   for	   the	   diagnosis	   of	   osteoporosis	   or	   for	   monitoring	   the	   effects	   of	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BIOCHEMICAL	  MARKERS	  OF	  BONE	  TURNOVER	  
	  
Biochemical	   markers	   of	   bone	   turnover	   have	   been	   used	   widely	   in	   clinical	  
research	   and	   represent	   the	   products	   of	   bone	   formation	   and	   resorption	   that	   are	  
released	  into	  the	  circulation,	  and	  changes	  in	  these	  values	  reflect	  the	  dynamic	  process	  
of	  bone	  metabolism.	  (Table	  3)	  
Markers	   of	   bone-­‐formation	   are	   released	   from	   osteoblasts	   and	   typically	   are	  
measured	   in	   serum.[106]	   Largely	   because	   of	   their	   tissue	   specificity	   and	   assay	  
sensitivity,	  the	  most	  useful	  markers	  are	  bone-­‐specific	  alkaline	  phosphatase	  (BSAP)	  and	  
osteocalcin.[107]	   Although	   type	   I	   collagen	   is	   the	   major	   product	   synthesized	   and	  
secreted	   by	   osteoblasts,	   it	   also	   is	   produced	   by	   other	   tissues	   and	   current	   assays	   lack	  
selectivity	   for	   bone	   derived	   type	   I	   collagen.[108]	   In	   addition,	   current	   assays	   for	  
quantitating	   BSAP	   and	   osteocalcin	   are	   more	   effective	   at	   differentiating	   between	  
normal	  and	  disease	  states	  compared	  with	  those	  for	  type	  I	  collagen.[108]	  
Bone-­‐resorption	  markers	   are	   secreted	  during	  osteoclastic	   activity	   and	   include	  
the	  collagen	  breakdown	  products	  pyridinoline,	  deoxypyridinoline,	  and	  cross-­‐linked	  C-­‐	  
and	   N-­‐telopeptides.	   Multiple	   assays	   are	   now	   available	   that	   can	   measure	   these	  
products	   relatively	   quickly	   and	   inexpensively.	   [108]	   Tartrate-­‐resistant	   acid	  
phosphatase,	  which	   is	  a	   lysosomal	  enzyme	  present	   in	  cells,	  until	   recently	  was	   limited	  
as	  a	  bone-­‐resorption	  marker	  because	  early	  assays	  lacked	  specificity	  for	  the	  osteoclast-­‐
derived	   enzyme	   (TRACP)	   and	   because	   of	   its	   instability	   in	   assay	   samples.[108]	  Newer	  
assays	   are	   now	   available	   that	   are	   selective	   for	   TRACP	   5b,	   the	   osteoclast-­‐specific	  
isoform	   that	   is	   considered	   to	   be	   a	   promising	   marker	   for	   predicting	   vertebral	  
fractures.[109]	   Indeed,	   in	   large	   prospective	   studies,	   biochemical	   markers	   of	   bone	  
resorption	  have	  been	  associated	  with	   increased	  vertebral	  and	  nonvertebral	   fractures	  
independently	   of	   BMD.	   However,	   their	   use	   in	   predicting	   fracture	   risk	   in	   specific	  
patients	  has	  not	  been	  defined	  clearly.	  The	  value	  of	  these	  markers	  in	  the	  assessment	  of	  
fracture	  risk	  therefore	  is	  likely	  to	  be	  in	  combination	  with	  other	  important	  risk	  factors,	  
including	  BMD.[106]	  
Other	   potential	   uses	   of	   turnover	  markers	   include	   the	   ability	   to	  monitor	   drug	  
efficacy,	  to	  predict	  increases	  in	  bone	  mass,	  and	  to	  assist	  in	  the	  selection	  of	  patients	  for	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treatment.	   This	   makes	   them	   more	   suitable	   for	   treatment	   monitoring	   than	   bone	  
density,	  as	  changes	  in	  density	  are	  often	  not	  apparent	  for	  two	  years.	  	  
	  
Table	  3	  –	  Currently	  available	  bone	  turnover	  markers. [108] 
Bone	  formation	  markers	   	  
Serum	  
Bone-­‐specific	  alkaline	  phosphatase	  
Osteocalcin	  
Carboxyterminal	  propeptide	  o	  type	  I	  collagen	  
Aminoterminal	  propeptide	  of	  type	  I	  collagen	  
Bone-­‐resorption	  markers	   	  
Serum	  
Cross-­‐linked	  C-­‐telopeptide	  of	  type	  I	  collagen	  
	  Tartrate-­‐resistant	  acid	  phosphatase	  
N-­‐telopeptide	  of	  collagen	  cross-­‐links	  





	  N-­‐telopeptide	  of	  collagen	  cross-­‐links	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LABORATORY	  TESTING	  FOR	  SECONDARY	  CAUSES	  OF	  OSTEOPOROSIS	  
	  
General	  consensus	  sustain	  that	  a	  minimum	  screening	  laboratory	  profile	  should	  
be	  considered	  for	  all	  patients	  who	  are	  diagnosed	  as	  having	  osteoporosis,	  since	  many	  
diseases	   are	   associated	   with	   bone	   loss,	   being	   secondary	   causes	   of	   osteoporosis.	  
Nonetheless,	  no	  consensus	  exists	  regarding	  which	  tests	  should	  be	  done.[97]	  
Institute	  for	  Clinical	  Systems	  Improvement	  (ICSI)	  proposes	  a	  rationale	  approach	  
for	   the	   biochemical	   assessments	   of	   patients	   with	   newly	   diagnosis	   osteoporosis,	   as	  
reported	  on	  Table	  4.	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Table	  4	  –	  ICSI	  Guidelines	  for	  Laboratory	  testing	  in	  patients	  with	  newly	  diagnosed	  osteoporosis.[97]	  
	  
Laboratory	  Test	   Rationale	  
Serum	  creatinine	   Renal	  failure	  is	  associated	  with	  secondary	  hyperparathyroidism.	  
Liver	  function	  tests	   Intrinsic	  liver	  disease	  and	  cholestatic	  disorders	  are	  associated	  with	  multifactorial	  causes	  of	  increased	  risk	  of	  osteoporosis.	  
Serum	  calcium	   Increased	  in	  patients	  with	  hyperparathyroidism	  and	  decreased	  in	  those	  with	  malabsorption	  or	  vitamin	  D	  deficiency.	  
Alkaline	  phosphatase	   Increased	  in	  patients	  with	  Paget	  disease	  of	  bone,	  prolonged	  immobilization,	  acute	  fractures,	  and	  other	  bone	  diseases.	  
Serum	  phosphorus	   Decreased	  in	  patients	  with	  osteomalacia.	  
Thyroid	  studies	  (thyrotropin	  and	  
thyroxine)	   Hyperthyroidism-­‐associated	  bone	  loss.	  
Sedimentation	  rate	  or	  C-­‐reactive	  
protein	  
May	  indicate	  an	  inflammatory	  process	  or	  monoclonal	  
gammopathy	  associated	  with	  bone	  loss.	  
Complete	  blood	  cell	  count	  
To	  evaluate	  for	  bone	  marrow	  malignancy,	  infiltrative	  processes	  
(anemia,	  low	  white	  blood	  cells,	  or	  low	  platelets),	  or	  
malabsorption	  (anemia,	  microcytosis,	  or	  macrocytosis).	  
Urinary	  calcium	  excretion	  
24-­‐hour	  urinary	  calcium	  excretion	  on	  a	  high	  calcium	  intake	  diet	  
screens	  for	  malabsorption	  and	  hypercalciuria—a	  correctable	  
cause	  of	  bone	  loss;	  low	  24-­‐hour	  urinary	  calcium	  excretion	  
suggests	  vitamin	  D	  deficiency,	  osteomalacia,	  or	  malabsorption	  
due	  to	  small	  bowel	  disease	  such	  as	  celiac	  sprue.	  
Serum	  25-­‐hydroxyvitamin	  D	   To	  identify	  vitamin	  D	  deficiency.	  
Serum	  intact	  (whole-­‐molecule)	  
PTH	   Screening	  for	  hyperparathyroidism.	  
Serum	  testosterone	  (total	  and	  
free)	  
Screening	  for	  hypogonadism	  in	  men;	  if	  abnormal,	  Luteinizing	  
Hormone	  (LH),	  Follicle-­‐stimulating	  hormone	  (FSH),	  and	  
prolactin	  measurements	  may	  be	  indicated	  to	  determine	  the	  
cause	  of	  the	  hypogonadism.	  
Serum	  estradiol	  
Screening	  for	  hypogonadism	  in	  premenopausal	  or	  
perimenopausal	  women;	  if	  abnormal,	  LH,	  FSH,	  and	  prolactin	  
measurements	  may	  be	  indicated	  to	  determine	  the	  cause	  of	  the	  
hypogonadism.	  
Tissue	  transglutaminase	  
antibodies	   If	  gluten	  enteropathy	  is	  suspected	  clinically.	  
24-­‐hour	  urinary	  free	  cortisol	  and	  
overnight	  dexamethasone	  
suppression	  test	  
If	  hypercortisolemia	  is	  suspected.	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FRAX®	  (fracture	  risk)	  is	  a	  computer-­‐based	  algorithm	  that	  calculates	  the	  10-­‐year	  
probability	  of	  a	  major	  fracture	  (hip,	  clinical	  spine,	  humerus	  or	  wrist	  fracture)	  and	  the	  
10-­‐year	   probability	   of	   hip	   fracture.[110]	   	   Fracture	   risk	   is	   calculated	   from	   age,	   body	  
mass	   index	  and	  dichotomized	   risk	   factors	   comprising	  prior	   fragility	   fracture,	  parental	  
history	   of	   hip	   fracture,	   current	   tobacco	   smoking,	   ever	   use	   of	   long-­‐term	   oral	  
glucocorticoids,	   rheumatoid	   arthritis,	   other	   causes	   of	   secondary	   osteoporosis	   and	  
alcohol	  consumption.	  The	  use	  of	  clinical	  risk	  factors	  in	  conjunction	  with	  BMD	  and	  age	  
improves	  sensitivity	  of	  fracture	  prediction	  without	  adverse	  effects	  on	  specificity.	  [110]	  
The	  models	  were	  developed	  from	  large	  population-­‐based	  cohorts	  from	  Europe,	  
North	  America,	  Asia	  and	  Australia.	  FRAX	  is	  a	  better	  risk	  tool	  for	  older	  women	  after	  age	  
60	   years	   who	   are	   at	   risk	   for	   hip	   fractures,	   Spine	   DXA	   cannot	   be	   used	   in	   the	   FRAX	  
analysis	   because	   elderly	   people	   with	   osteoarthritis	   show	   an	   artifactual	   increase	   in	  
spine	  BMD	  by	  10%	  and	  this	   limits	   the	  use	  of	  FRAX	   in	  predicting	  which	  women	   in	  the	  
age	  group	  50–60	  years	  will	  develop	  spine	  osteoporosis	  in	  the	  next	  10–15	  years.[111]	  	  
	  
QFractureTM	  	  
The	   QFractureTM	   tool	   is	   based	   on	   a	   UK	   prospective	   open	   cohort	   study	   of	  
routinely	  collected	  data	  from	  357	  general	  practices	  on	  over	  2	  million	  men	  and	  women	  
aged	  30–85	  years	  (www.qfracture.org).	  Like	  the	  FRAX	  tool,	  it	  takes	  into	  account	  history	  
of	   smoking,	   alcohol,	   corticosteroid	   use,	   parental	   history	   (of	   hip	   fracture	   or	  
osteoporosis)	   and	   several	   secondary	   causes	   of	   osteoporosis.	   Unlike	   FRAX,	   it	   also	  
includes	  a	  history	  of	   falls	   (yes/no	  only	  over	  an	  unspecified	   time	   frame)	  and	  excludes	  
previous	  fracture	  history	  and	  BMD.	  It	  has	  been	  internally	  validated	  (i.e.	  from	  a	  stratum	  
of	  the	  same	  population)	  and	  also	  externally	  validated	  in	  the	  UK.[112]	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 The	  bone	  regeneration	  process	  around	  implanted	  biomaterials	  are	  reported	  as	  
very	  similar	  to	  the	  principle	  mechanism	  occuring	  during	  fracture	  repair	  and	   involve	  a	  
cascade	   of	   cellular	   and	   extracellular	   events.[113]	   	   Bone	   is	   complex	   and	   is	   mainly	  
composed	  by	  cells,	  mineralized	  extracellular	  matrix	  and	  organic	  extracellular	  matrix.	  In	  
the	  organic	  extracellular	  matrix	  are	  local	  factors	  such	  as	  cytokines	  and	  growth	  factors	  
that	   ar	   released	   in	   the	   lesion	   site,	   that	   play	   an	   interessant	   role	   in	   this	   process.	   The	  
further	  studied	  local	  factors	  inclued	  the	  interleukin	  1	  (IL-­‐1),	  interleukin	  6	  (IL-­‐6),	  tumor	  
necrosis	   factor	   alfa	   (TNF-­‐α),	   fibroblast	   growth	   factor	   (FGF),	   platelet	   derived	   growth	  
factor	   (PDGF),	   transforming	   growth	   factor	   beta	   1	   (TGF-­‐β1)	   and	   bone	   morphogenic	  
proteins	   (BMP).	   In	   the	   initial	   phases	   to	   reaction	   to	   trauma	   PDGF	   and	   TGF-­‐1	   are	  
released	   by	   activated	   platelets.	   Then	   macrophages	   and	   other	   inflammatory	   cells	  
release	  FGF,	  PDGF,	  TGF-­‐β1	  and	  IL-­‐1	  and	  IL-­‐6.	  These	  factors	  are	  present	  during	  the	  first	  
hours	   following	   the	   trauma	   to	   achieve	   the	   regeneration	   and	   act	   on	   the	   bone,	  
periosteal,	   medullar	   and	   adjacent	   soft	   tissue	   cells.	   Mesenchymal	   staminal	   cells	   are	  
present	  3	  days	  after	  the	  trauma	  and	  remain	  for	  days,	  playing	  an	  important	  role	  in	  this	  
process.	  	  
	   Osteoporosis	  can	  modify	  cell	  proliferation,	  cell	  synthetic	  activity,	  cell	  reactivity	  
to	   local	  factors	  and	  mesenchymal	  staminal	  cell	  number.	  The	  bone	  multi-­‐cellular	  units	  
are	   also	   important	   for	   the	   remodeling	   of	   bone.	   These	   units	   are	   altered	   on	  
osteoporosis,	   on	   the	   activation	   frequency	   and	   the	   formation	   and	   resorption	   phases.	  
Decreased	   ability	   of	   osteoblasts	   to	   fill	   resorption	   lacunae	   will,	   contribute	   to	  
unbalanced	   remodeling	   and	   loss	   of	   bone,	   but	   this	   component	   varies	  much	   less	   than	  
activation	   frequences	   in	   the	   healthy	   and	   diseased	   skeleton.[114]	   These	   biological	  
differences,	   associated	   with	   the	   biomechanical	   and	   microarchitectural	   bone	  
properties,	   are	   involved	   in	   a	   reported	   increased	   risk	   of	   bone	   remodelling	   in	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It	   is	   considered	   that	   osteoporosis	   could	   be	   the	   cause	   behind	  mineral	   density	  
and	  mass	  reduction	  of	  jawbones,	  due	  to	  the	  influence	  of	  estrogen.	  Some	  studies	  report	  
an	  association	  of	  post-­‐menopausal	   tooth	   loss	  and	  metacarpal	  bone	  mass,	  and	  others	  
consider	  a	  relationship	  between	  general	   low	  skeletal	  bone	  mineral	  densities	  to	  tooth	  
loss.[116,	   117]	   Others	   studies	   sustain	   that	   the	   thickness	   of	   the	   mandibular	   inferior	  
border	   tends	   to	   reduce	   in	   subjects	  with	  osteoporosis.[118,	   119]	  Nonetheless,	   others	  
refute	   this	   association	   and	   have	   found	   no	   relationship	   between	   skeletal	   and	  
mandibular	  BMD.[120-­‐122]	  	  
Alveolar	   bone	   can	   undergo	   the	   same	  metabolic	   changes	   as	   limb	   bones	   since	  
osteoporosis	   is	  a	  systemic	  disease	  that	  affects	  all	   the	  skeletal	  bones.	  Particularly,	   the	  
similarity	   in	   microstructures	   and	   composition	   between	   the	   jawbones	   and	   the	   limb	  
bones	  may	   support	   such	   assumption.	  Although,	   recently,	   it	   has	   been	   suggested	   that	  
the	   embryologic	   origin	   of	   the	   maxillofacial	   bones	   changes	   their	   response	   to	  
osteoporosis.[123]	  Jawbones	  are	  derived	  from	  cells	  of	  the	  anterior	  neural	  crest	  while	  
the	   limb	   bones	   are	   developed	   from	   the	   lateral	   plate	   mesoderm,	   and	   these	  
developmental	   stages	   of	   the	   jaws	   are	   complex	   processes	   being	   coordinated	   by	   a	  
variety	   of	   genes	   and	   transcription	   factors	   not	   yet	   clearly	   understood.[124]	  
Consequently,	  it	  is	  not	  surprising	  to	  know	  that	  limb	  bones	  and	  the	  bones	  of	  oral	  cavity	  
show	  regionally	  different	  gene	  expression	  resulting	   in	  site-­‐specific	  bone	  cell	  behavior	  
and	   activity	   as	   well	   as	   matrix	   composition.	   This	   might	   explain	   why	   jawbones	   can	  
respond	  differently	  to	  osteoporosis.[124]	  
Osteoporosis	   has	   also	   been	   found	   to	   be	   associated	   with	   periodontal	   and	  
alveolar	  bone	   loss	   and	   temporomandibular	   joint	  bone	   loss.	  Osteoporosis	   in	   the	   jaws	  
may	   present	   a	   risk	   for	   alveolar	   bone	   loss	   following	   the	   use	   of	   full	   dentures.[16]	  
Conflicting	  results	  highlight	  the	  controversy	  of	  whether	  a	  causal	  relationship	  between	  
systemic	  bone	  loss	  and	  various	  oral	  conditions	  is	  present	  or	  not.	  
Several	   authors	   report	   the	   association	   of	   osteoporosis	   in	   postmenopausal	  
women	  with	  periodontitis,	   attachment	   loss	  and	  gingival	   recession.	   [125-­‐127]	  Various	  
studies	   have	   indicated	   that	   reduced	   bone	   mineral	   density	   was	   associated	   with	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increased	  clinical	  attachment	  loss.	  [128,	  129]	  Nonetheless,	  others	  have	  found	  weak	  or	  
no	   significant	   associations	   between	   systemic	   bone	   mineral	   density	   and	   clinical	  
attachment	  loss.[130,	  131]	  
As	  far	  as	  dental	  implants	  and	  bone	  grafts	  are	  concerned,	  because	  of	  increasing	  
life	  expectancy	  and	  popularity	  of	  these	  treatments,	  surgeons	  face	  a	   larger	  amount	  of	  
osteoporotic	   patients	   who	   require	   bone	   augmentation	   and	   implant	   placement.	   The	  
main	  concern	  of	  performing	  oral	  surgery	   in	  patients	  with	  osteoporosis	   is	  the	  premise	  
of	   a	  metabolic	   disease	   affecting	   the	  bones	   of	   the	  maxilla	   and	  mandible	   in	   the	   same	  
way	  it	   impairs	  other	  bones,	  reducing	  the	  bone	  mass.[20]	   In	  surgical	  procedures,	  such	  
as	   alveolar	   bone	   augmentation	   or	   implant	   rehabilitation,	   the	   bone	   healing	   and	   the	  
incorporation	   of	   the	   graft	   or	   an	   implant,	   include	   a	   course	   of	   events	   involving	  
osteogenesis,	   osteoclastic	   resorption,	   osteoinduction	   and	   osteoconduction.[132]	   In	  
osteoporosis	   the	   success	   of	   these	   interventions	  may	  be	   altered	  due	   to	   the	   impaired	  
bone	   formation	   and	   resorption	   activity,	   the	   changes	   in	   the	   bone	   density	   and	  micro-­‐
architectural	   of	   the	   patient’s	   bone.[20]	   The	   estimated	   lower	   implant	   fixation	   in	  
osteoporosis	   is	   probable	   due	   to	   the	   structural	   and	   mechanical	   bone	   changes,	  
decreased	   number	   of	   bone	   formation	   (osteoblasts)	   cells,	   increased	   activity	   of	  
osteoclasts	   cells,	   and	   an	   imbalanced	   bone	   remodeling	   at	   the	   site	   of	   attempted	  
osseointegration.[133]	   Some	   authors	   have	   already	   anticipated	   that	   in	   osteoporotic	  
induced	   animal	   models,	   before,	   after	   or	   simultaneously	   with	   the	   placement	   of	  
implants,	   changes	   the	   process	   of	   bone	   regeneration,	   particularly	   in	   trabecular	   bone,	  
and	  causes	  a	  significant	  decrease	  in	  the	  percentage	  of	  bone–implant	  contact	  and	  in	  the	  
mechanical	   strength	   of	   the	   bone-­‐implant	   interfaces.	   [115,	   134]	   The	   suggestion	   that	  
osteoporosis	   is	   a	   risk	   factor	   for	   dental	   implant	   failure	  has	  been	  proposed	  by	   several	  
studies.	  [135-­‐137]	  
However,	   osteoporosis	   does	   not	   imply	   that	   the	   systemic	   bone	   is	   unable	   to	  
achieve	  osseointegration;	  there	  is	  a	  correlation	  between	  systemic	  bone	  loss	  and	  loss	  of	  
density	  and	  quantity	  in	  the	  jaw	  but	  osteoporosis	  is	  not	  an	  absolute	  contraindication	  for	  
bone	   augmentation	   and	   implant	   therapy.	   Though,	   modifiable	   risk	   factors	   for	  
osteoporosis	  should	  be	  eliminated	  before	  surgery.[137-­‐141]	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The	   diagnosis	   of	   jaw	   osteoporosis	   is	   of	   major	   importance.	   It	   requires	  
assessment	   of	   the	   bone	   mineral	   content	   (BMC)/density	   (BMD)	   using	   specially	  
constructed	   jaw	   bone	   scanners	   and	   development	   of	   a	   corresponding	   gender-­‐related	  
set	   of	   normal	   BMC/BMD.	  Nowadays,	   the	   available	   techniques	   for	   in	   vivo	   bone	  mass	  
measurement	  techniques	  in	  the	  craniofacial	  area	  are	  expensive	  and	  not	  cost	  effective	  
to	   screen	   the	   general	   population.[142]	   Recent	   studies	   have	   suggested	   that	   because	  
dental	   panoramic	   radiographs	   are	   frequently	   made	   during	   the	   general	   practice	   of	  
dentistry,	   the	   findings	   on	   such	   exams	   may	   help	   dentists	   to	   identify	   patients	   with	  
undetected	   low	   BMD	   and	   refer	   them	   to	   medical	   professionals	   for	   bone	  
densitometry.[142,	  143]	  	  
Some	   authors	   report	   that	   mandibular	   bone	   density	   may	   be	   indicative	   of	  
systemic	   bone	   mineral	   density	   and,	   in	   most	   cases,	   osteoporosis	   may	   be	   associated	  
with	  a	  severe	  decrease	  in	  BMC	  of	  the	  jaws.[138]	  These	  kind	  of	  analyses	  would	  not	  be	  
used	   as	   a	   diagnostic,	   but	   rather	   to	   refer	   patients	   for	   appropriate	   evaluation	   and	  
treatment	  as	  necessary.[144]	  Adding	  to	  that,	  the	  only	  site	  of	  the	  jaws	  which	  fulfills	  the	  
criteria	  for	  a	  reference	  site	  is	  the	  basal	  area	  of	  the	  mandible,	  posterior	  to	  the	  premolar	  
region.[138]	  
Systemic	   treatment	   involving	   bone	   metabolism	   affects	   BMC/BMD	   in	   the	  
skeleton,	   including	   the	   jaws,	   either	   negatively	   (long-­‐term	   high	   dose	  
glucocorticosteroids)	   or	   positively	   (calcium	   +	   vitamin	   D3,	   estrogen	   replacement	  
therapy).[145]	  Nevertheless,	   it	  still	  remains	  to	  be	  tested	  to	  what	  extent	  this	  effective	  
preventive	  therapy	  against	  general	  osteoporosis	  may	  prevent	  osteoporosis	  in	  the	  jaws.	  
On	  the	  other	  side,	  the	  effect	  of	  bisphosphonates	  on	  the	  jaw	  BMC	  and	  alveolar	  
bone	  loss	  has	  not	  been	  full	  analyzed.	  These	  drugs	  are	  still	  under	  evaluation	  and	  future	  
trials	   ought	   to	   comprise	   analyses	   of	   possible	   adverse	   effects	   of	   arrested	   bone	  
resorption	  in	  relation	  to	  periodontal	  and	  surgical	  diseases	  and	  treatments	  or,	  in	  case	  of	  
abrupt	  changes,	   in	   the	   function	  of	   the	   jaws.	  Further	   studies	  on	   the	  effect	  of	   implant	  
treatment	  with	  and	  without	  bone	  transplantation	  in	  relation	  to	  the	  BMC/BMD	  changes	  
in	  jaws	  and	  the	  systemic	  bone	  metabolic	  changes	  will	  also	  be	  of	  special	  interest.[16]	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BMD	   in	   the	   mandible	   has	   proven,	   in	   a	   number	   of	   studies,	   to	   be	   positively	  
correlated	  with	  that	  in	  lumbar	  spine,	  femoral	  neck,	  and	  forearm,	  which	  are	  important	  
sites	  in	  osteoporosis.[146]	  	  
Another	   indicator	   to	   aid	   in	   the	   diagnosis	   of	   osteoporosis	   and	   osteopenia	  
referred	  by	  Reddy	  et	  al.	  consists	  in	  the	  analysis	  of	  salivary	  parameters	  such	  as calcium,	  
phosphorus	  and	  alkaline	  phosphatase,	  along	  with	  some	  oral	  signs	  like	  periodontitis	  and	  
number	  of	  missing	  teeth.[147]	  The	  authors	  state	  that	  they	  could	  be	  indicators	  to	  aid	  in	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MANAGEMENT	  OF	  OSTEOPOROSIS	  
	  
Several	   non	   pharmacological	   and	   pharmacological	   interventions	   are	  
recommended	   to	   an	   osteoporotic	   condition,	   de	   pending	   on	   the	   fracture	   risk	  
assessment,	  that	  can	  be	  measured	  for	  example	  by	  the	  FRAX	  system.[111]	  
	  
	  
NON-­‐PHARMOLOGICAL	  MANAGEMENT	  	  
Preventive	   treatments	   have	   the	   intention	   to	   increase	   peak	   bone	   mass	   and	  
reduce	  the	  subsequent	  rate	  of	  bone	  loss.	  All	  patients	  with	  osteoporosis	  and	  fractures	  
should	  be	   given	  advice	  on	   lifestyle	  measures	   that	  decrease	  bone	   loss.	   These	   include	  
eating	  a	  balanced	  diet	  rich	  in	  calcium	  and	  vitamin	  D,	  moderating	  tobacco	  and	  alcohol	  
consumption,	  maintaining	  regular	  physical	  activity,	  and	  exposure	  to	  sunlight.	  
	  
• Immobilization	  Vs.	  Exercise	  
Immobilization	  is	  an	  important	  cause	  of	  bone	  loss,	  as	  we	  can	  se	  in	  immobilized	  
patients	   that	   lose	   as	  much	   bone	   in	   a	   week	  when	   confined	   to	   bed	   than	   they	  would	  
otherwise	   lose	   in	   a	   year.	   For	   this	   reason,	   immobility	   should,	   wherever	   possible,	   be	  
avoided.	  [58]	  
A	  regular	  and	  well	  structured	  exercise	  can	  be	  a	  significant	  factor	  in	  osteoporosis	  
prevention,	   as	   it	   increases	   muscle	   mass	   and	   strength,	   improves	   balance	   and	  
coordination	   and	   reports	   a	   reduce	   risk	   of	   falls	   about	   25%,	   in	   elderly	   persons.[148]	  
Weight-­‐bearing	   exercise	   appears	   to	   be	   effective	   in	   maintaining	   or	   increasing	   bone	  
density	  at	  the	  lumbar	  spine	  and	  hip,	  in	  postmenopausal	  women.[149]	  
	  
• Fall	  Prevention	  	  
Elderly	  patients	  have	  high	  risk	  factors	  associated	  with	  fall	  prevention	  that	  were	  
observed	   in	   randomized	   clinical	   trials,	   allowing	   the	   accurate	   measures	   to	   prevent	  
them.[150]	  Risk	  factors	  consist	  of	  visual	  impairment,	  impaired	  cognition,	  poor	  balance,	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muscle	   weakness,	   joint	   deformities	   due	   to	   osteoarthritis,	   postural	   hypotension,	  
multiple	  medications,	  and	  environmental	  hazards.	  	  
The	  following	  measures	  can	  be	  implanted	  to	  reduce	  falls	  risk	  such	  as:	  physical	  
therapy	  to	  improve	  strength	  and	  balance,	  correcting	  decreased	  visual	  acuity,	  reducing	  
consumption	  of	  medication	  that	  alters	  alertness	  and	  balance,	  prevention	  or	  treatment	  
of	  hypotension,	  elimination	  of	  environmental	  hazards	  and	  use	  of	  appropriate	  footwear	  
or	  clothing.[58,	  151]	  
Several	  randomized	  trials	  have	  shown	  that	  wearing	  hip	  protectors	  can	  distinctly	  
reduce	  hip	  fracture	  risk,	  mostly	  in	  the	  elderly	  living	  in	  nursing	  homes.	  However	  a	  meta	  
analysis	  of	   randomized	  controlled	  trials	  has,	  cast	  some	  doubt	  about	   the	  anti-­‐fracture	  
efficacy	  of	  this	  preventive	  measure.[58]	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PHARMACOLOGICAL	  INTERVENTIONS	  	  	  
	  
The	  methods	  of	  pharmacological	   intervention	  of	  osteoporosis	  may	  be	  broadly	  
divided	  into	  antiresorptive	  agents	  that	  prevent	  the	  bone	  resorption	  (such	  as	  hormone	  
replacement	   therapy	   (HRT),	   selective	   estrogen	   receptor	   modulators	   (SERMs),	  
calcitonin,	   bisphosphonates,	   denosumab)	   and	   anabolic	   agents	   that	   stimulate	   bone	  
formation	   (such	   as	   teriparatide	   and	   strontium	   ranelate	   -­‐	   which	   also	   has	   some	  
antiresorptive	  activity).[97,	  111,	  152]	  Antiresorptive	  agents	  decrease	  bone	  resorption	  
and,	  due	  to	  transient	  uncoupling	  of	  bone	  turnover,	  result	  in	  a	  small	  increase	  in	  BMD	  of	  
between	   5	   and	   10%,	   usually	   in	   the	   first	   or	   second	   year	   of	   treatment.	   In	   contrast,	  
anabolic	  agents	   can	   increase	  BMD	  by	  up	   to	  20%.	  Recently,	   combined	   regimens	  have	  
been	  under	  investigation.[97]	  
	  
A.	  Antiresorptive	  agents	  
	  
• Hormone	  replacement	  therapy	  (HRT)	  	  
Estrogens	   reduce	   the	   accelerated	   bone	   turnover	   induced	   by	  menopause	   and	  
prevent	   bone	   loss	   at	   all	   skeletal	   sites	   regardless	   of	   age	   and	   duration	   of	   therapy.	  
Therapeutic	  approach	  may	  consist	  of	  estrogens	  administration	  alone	  or	  in	  combination	  
with	  progestin.	  HRT	  slows	  bone	  turnover	  and	  increases	  BMD	  at	  all	  skeletal	  sites	  in	  early	  
and	   late	   postmenopausal	   women,	   and	   is	   an	   appropriate	   method	   of	   treatment	   and	  
prevention	  of	  osteoporosis	  and	  which	  effects,	  both	  beneficial	  and	  adverse,	  have	  been	  
well	   studied.[57,	   153-­‐155]	   A	  majority	   of	   literature	   reports	   show	   that	   HRT	   decreases	  
fragility	  fracture	  risk	  by	  20	  to	  35%,	  and	  interruption	  of	  the	  HRT	  results	  in	  acceleration	  
of	   bone	   turnover,	   decrease	   in	   BMD	   and	   eventual	   loss	   of	   anti-­‐fracture	   efficacy.	  
Although,	   HRT	   use	   has	   declined	   as	   a	   result	   of	   patient	   concerns	   about	   breast	   and	  
endometrial	   cancer,	   and	   increased	   incidence	   of	   cardiovascular	   events	   (unstable	  
angina,	   thromboembolic	   stroke,	   venous	   thromboembolism),	   and	   also	   as	   a	   slight	  
increase	  in	  the	  risk	  of	  dementia.[155-­‐157]	  
HRT	  should	  remain	  a	  mainstay	  of	  treatment,	  particularly	  for	  prevention	  of	  the	  
disease	  in	  younger	  postmenopausal	  women.	  Some	  countries	  chose	  to	  recommend	  HRT	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only	  for	  climacteric	  symptoms,	  at	  a	  dose	  as	  small	  as	  possible	  and	  for	  a	  limited	  period	  of	  
time.[58]	  
It	   remains	   to	   be	   seen	   whether	   several	   years	   of	   therapy	   around	   the	   time	   of	  
menopause	  can	  result	  in	  future	  fracture	  prevention	  for	  years	  to	  come.[23]	  
	  
• Selective	  estrogen	  receptor	  modulators	  (SERMs)	  
SERMs	   are	   synthetic	   molecules,	   non-­‐steroidal	   agents,	   which	   bind	   to	   the	  
estrogen	  receptor	  and	  act	  as	  estrogen	  agonists	  or	  antagonists,	  depending	  on	  the	  target	  
tissue.	  The	  concept	  of	  SERMs	  was	  triggered	  by	  the	  observation	  that	  tamoxifen,	  which	  
is	   an	   estrogen	   antagonist	   in	   breast	   tissue,	   is	   a	   partial	   agonist	   on	   bone,	   reducing	   the	  
rate	  of	  bone	  loss	  in	  postmenopausal	  women.[58,	  158-­‐160]	  	  	  	  
Ralixofene	  is	  the	  only	  SERM	  broadly	  available	  for	  the	  prevention	  and	  treatment	  
of	  postmenopausal	  osteoporosis.	  Raloxifene	  prevents	  bone	  loss	  and	  reduces	  the	  risk	  of	  
vertebral	   fractures	   by	   30–50	  %	   in	   postmenopausal	  women	  with	   low	  bone	  mass	   and	  
with	   osteoporosis	   with	   or	   without	   prior	   vertebral	   fractures.	   Ralixofene	   reports	   the	  
benefits	   of	   cardiovascular	   prevention,	   although	   its	   common	   adverse	   effects	   include	  
increase	   risk	   of	   venous	   thromboembolism	  and	   increased	   vasomotor	   symptoms.[159]	  
RUTH	  (Raloxifene	  Use	  for	  The	  Heart)	  study[159]	  confirmed	  the	  reduction	   in	  vertebral	  
fractures,	   and	   the	   reduction	   of	   breast	   cancer,	   but	   demonstrated	   conclusively	   that	  
raloxifene	  does	  not	  reduce	  hip	  fracture	  incidence	  therefore	  its	  use	  is	  not	  appropriate	  
for	  women	  who	  are	  at	  high	  risk	  of	  non-­‐vertebral	  fractures.	  [58,	  159,	  161]	  
Lasofoxifene	   is	   another	   third	   generation	   SERM	   with	   excellent	   oral	  
bioavailability.	  It	  has	  a	  high	  affinity	  for	  both	  ERα	  and	  ERβ,	  approximately	  the	  same	  as	  
estradiol,	   and	   about	   10-­‐fold	   higher	   than	   the	   other	   SERMs	   raloxifene,	   tamoxifen	   and	  
droloxifene.	   Two	   doses	   of	   lasofoxifene	   0.25	   and	   0.5mg	   were	   evaluated	   in	   a	  
randomized	  trial	  (PEARL	  study).	  In	  the	  three-­‐year	  analysis	  lasofoxifene	  0.25	  mg	  and	  0.5	  
mg	   daily	   increased	   lumbar	   spine	   BMD	   by	   3.0%	   and	   3.1%	   respectively,	   increased	  
femoral	  neck	  BMD	  by	  2.9%-­‐3.0%	  respectively	  relative	  to	  placebo.	  Lasofoxifene	  0.25	  mg	  
and	  0.5	  mg/d	  reduced	  the	  risk	  of	  vertebral	  fractures	  by	  31%	  and	  42%,	  respectively	  (P	  <	  
0.002),	  while	   nonvertebral	   fractures	  were	   significantly	   reduced	   by	   22%	  with	   the	   0.5	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mg/d	   dose.	   The	   higher	   dose	   of	   lasofoxifene	   reduced	   breast	   cancer	   by	   81%	   and	   the	  
lower	  dose	  by	  49%.	  [162]	  
Bazedoxifene	   is	   a	   selective	   estrogen	   receptor	   modulator	   that	   has	   been	  
approved	  in	  Europe	  but	  is	  only	  available	  in	  Spain	  and	  Germany	  and	  recently	  approved	  
in	   United	   States.	   Bazedoxifene	   was	   shown	   to	   significantly	   reduce	   the	   risk	   of	   new	  
vertebral	   fracture,	   with	   favorable	   effects	   on	   bone	   mineral	   density,	   bone	   turnover	  
markers	   and	   the	   lipid	   profile.[163]	   In	   a	   subgroup	   of	   women	   at	   increased	   risk	   of	  
fracture,	   bazedoxifene	   significantly	  decreased	  non-­‐vertebral	   fracture	   risk.	   In	   contrast	  
to	   raloxifene,	   the	  efficacy	  of	  bazedoxifene	   is	  dependent	  on	   the	   level	  of	   fracture	   risk.	  
However	   like	   with	   raloxifene,	   venous	   thromboembolic	   events,	   primarily	   deep	   vein	  
thrombosis,	   leg	  cramps	  and	  hot	   flushes	  were	  more	   frequently	   reported	   in	   the	  active	  
treatment	  groups	  compared	  with	  the	  placebo	  group.[164]	  
	  
	  
• Bisphosphonates	  (BPs)	  
BPs	  are	  stable	  analogs	  of	  pyrophosphate,	  which	  bind	  to	  the	  bone	  surface	  and	  
inhibit	  osteoclastic	  activity.	  They	  have	  a	  strong	  affinity	  for	  bone	  apatite,	  both	   in	  vitro	  
and	  in	  vivo,	  which	  is	  the	  basis	  for	  their	  clinical	  use.	  They	  are	  potent	  inhibitors	  of	  bone	  
resorption	   and	   produce	   their	   effect	   by	   reducing	   the	   recruitment	   and	   activity	   of	  
osteoclasts	  and	  increasing	  their	  apoptosis.	  The	  potency	  and	  chemical	  affinity	  to	  bone	  
of	   bisphosphonates	   determines	   their	   effect	   to	   inhibit	   bone	   resorption	   and	   varies	  
greatly	  from	  compound	  to	  compound.	  
Bisphosphonates	   are	   available	   in	   oral	   and	   intravenous	   formulations,	   with	  
weekly,	  monthly	  and	  annual	  dosing	   schedules.	  They	  persist	   in	   the	  skeleton	   for	  many	  
months	   or	   years	   and	   their	   duration	   of	   action	   is	   prolonged,	   beyond	   the	   period	   of	  
administration.	   Bisphosphonates	   have	   been	   shown	   to	   reduce	   vertebral	   fracture	   risk	  
and	  increase	  BMD,	  whereas	  some	  have	  demonstrated	  reductions	  in	  non-­‐vertebral	  and	  
hip	  fracture	  risk	  as	  well.[97,	  152]	  
	  
• Alendronate	  	  -­‐	  has	  been	  reported	  to	  preserve	  bone	  mineral	  density,	  reduce	  
approximately	   by	   half	   the	   vertebral,	   wrist	   and	   hip	   fracture	   risk	   in	   women	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with	  prevalent	  vertebral	   fractures	  and	   to	  be	  well	   tolerated	   in	  women	  with	  
low	  bone	  mineral	  density,	  in	  large	  prospective	  studies.[165,	  166]	  	  
• Risedronate	   -­‐	   decreases	   the	   incidence	   of	   new	   vertebral	   and	   peripheral	  
fractures	  by	  the	  same	  extent	  as	  alendronate	  in	  women	  with	  low	  BMD	  and	  in	  
women	  with	  prevalent	  vertebral	  fractures.[167]	  
• Ibandronate	  -­‐	  is	  a	  potent	  nitrogen-­‐containing	  bisphosphonate	  available	  as	  a	  
once-­‐monthly	   oral	   formulation	   for	   the	   treatment	   and	   prevention	   of	  
osteoporosis.	   It	   has	   been	   showed	   that	   it	   can	   induced	   a	   rapid,	   pronounced	  
and	   persistent	   decrease	   in	   bone	   turnover,	   increase	   BMD	   and	   reduce	   the	  
incidence	   of	   vertebral	   fractures	   by	   at	   least	   50%.[168,	   169]	   It	   has	   been	  
reported	  that	  significantly	  more	  women	  with	  postmenopausal	  osteoporosis	  
preferred	   once-­‐monthly	   ibandronate	   therapy	   to	   once-­‐weekly	   alendronate	  
therapy.	  
• Zoledronic	   acid	   -­‐	   is	   a	   bisphosphonate	   which	   principal	   advantage	   is	   its	  
extended	   dosing	   interval,	   allowing	   a	   once-­‐a-­‐year	   administration.	   There	   is	  
evidence	  of	  a	  clinically	  significant	  effect	  on	  the	  increase	  in	  bone	  density	  and	  
reduce	   fracture	   risk	   in	   the	   hip,	   spine	   and	   total	   body	   in	   women	   with	  
osteoporosis.[170,	  171]	  
	  
Several	   apprehensions	   have	   been	   discussed	   such	   as	   the	   low	   oral	   absorption,	  
this	   is	   less	   than	  1	  percent	  of	   the	  dose	  and	  must	  be	   taken	  on	  an	  empty	   stomach	   for	  
maximal	  absorption	  with	  the	  patient	  sited	  upright.	  Particular	  side	  effects	  with	  systemic	  
repercussions	   have	   been	   reported	   included	   the	   gastrointestinal	   intolerability,	   ranging	  
from	  mild	  acid	  reflux	  to	  serious	  esophageal	  ulcers.	  Musculoskeletal	  pain	  is	  a	  	  significant	  
side	  effect,	  like	  hypocalcaemia,	  atrial	  fibrillation,	  among	  others.	  
Some	  possible	  side	  effects	  of	   the	  bisphosphonates	  have	  been	  raised,	  because	  
they	  are	  potent	  suppressors	  of	  bone	  resorption	  and	  such	  extreme	   inhibition	  of	  bone	  
remodeling	  may	   lead	   to	  an	  accumulation	  of	  microdamage,	  which	  might	   compromise	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Lately	  there	  have	  been	  long-­‐term	  safety	  concerns	  about	  bisphosphonates	  that	  
include	  a	  possible	  increased	  risk	  of	  atypical	  femoral	  fractures	  and	  osteonecrosis	  of	  the	  
jaw.	   It	   is	  possible	  that	  both	  are	  very	  rare	  adverse	  events	  and	  are	  time	  related.	   It	  has	  
been	  estimated	  that	  these	  risks	  in	  osteoporotic	  are	  1	  in	  50,000	  to	  1	  in	  150,000.	  These	  
events	  are	  more	  common	   in	  patients	  with	  cancer	  but	   these	  patients	  are	  given	  much	  
higher	   doses	   of	   bisphosphonates	   for	   metastatic	   bone	   disease	   as	   well	   as	   taking	  




Calcitonin	  is	  an	  endogenous	  polypeptide	  hormone	  that	  directly	  suppresses	  the	  
activity	   of	   osteoclasts	   and	   also	   inhibits	   their	   recruitment.	   Salmon	   calcitonin	   is	  
approximately	   40–50	   times	  more	  potent	   than	  human	   calcitonin,	   and	   the	  majority	  of	  
clinical	   trials	   have	   been	   performed	   with	   salmon	   calcitonin.[58]	   Calcitonin	   prevents	  
bone	  loss	  and	  vertebral	  fractures,	  but	  it	  has	  not	  been	  shown	  to	  reduce	  nonvertebral	  or	  
hip	   fractures.[177]	  Calcitonin	  as	   a	   short-­‐term	  effect	  on	  acute	  pain	   relief	   and	  may	  be	  
useful	   in	   the	   management	   of	   the	   pain	   associated	   with	   acute	   osteoporotic	  
fractures.[178]	   Calcitonin	   is	   approved	   in	   the	  United	   States	   for	   administration	   by	   the	  
subcutaneous,	   intramuscular,	   and	   intranasal	   routes.	   However	   some	   concerns	   were	  
reported	  about	  the	  use	  of	  a	  nasal	  spray	   formulation	  of	   the	  peptide	  hormone	  salmon	  
calcitonin	  can	  be	  associated	  with	  an	  increased	  risk	  of	  cancer.	  [111]	  
Since	   other	   medications	   with	   improved	   efficacy	   in	   fracture	   reduction	   are	  
available,	   and	   the	   downsides	   of	   repeated	   injections	   and	   the	   high	   costs	   of	   the	   nasal	  





Denosumab	   is	   a	   human	   monoclonal	   antibody	   that	   specifically	   binds	   RANKL,	  
blocks	  the	  binding	  of	  RANKL	  to	  RANK	  thereby	  reducing	  bone	  resorption	  and	  increasing	  
bone	  density.	  	  The	  FDA	  has	  approved	  the	  anti-­‐fracture	  efficacy	  of	  denosumab	  using	  60	  
LITERATURE	  OVERVIEW	  
	  
MODULATION	  OF	  THE	  BONE	  REGENERATION	  PROCESS	  IN	  SYSTEMIC	  IMPAIRED	  CONDITIONS	   81	  
mg	  subcutaneously	  every	  6	  months	   for	   treatment	  of	  osteoporosis.	  Nevertheless,	   it	   is	  
not	  yet	  approved	  for	  prevention	  (pending	  long-­‐term	  safety	  data).	  Denosumab	  is	  shown	  
to	   improve	   bone	   mineral	   density	   (BMD)	   in	   postmenopausal	   women	   with	   low	  
BMD.[111]	  
In	   the	   FREEDOM	   trial,	   7868	   postmenopausal	   women	   (60	   to	   90	   years	   of	   age)	  
with	  osteoporosis	  were	  randomly	  assigned	  to	  subcutaneous	  denosumab	  (60	  mg	  every	  
six	  months)	  or	  placebo	  for	  three	  years;	  denosumab	  increased	  BMD	  of	  the	  lumbar	  spine	  
and	   total	   hip	   compared	   with	   placebo)	   and	   significantly	   reduced	   the	   risk	   of	   new	  
vertebral	   fractures	   by	   68%,	   hip	   fractures	   by	   40%,	   and	   non-­‐vertebral	   fractures	   by	  
20%.[180]	  In	  FREEDOM	  extension	  trial	  of	  4550	  postmenopausal	  women,	  the	  FREEDOM	  
denosumab	  group	   is	   continued	  on	  3	  more	  years	  of	  denosumab	   for	  a	   total	  of	  6	  years	  
and	  women	  from	  the	  FREEDOM	  placebo	  group	  are	  given	  3	  years	  of	  denosumab.[181]	  
Lumbar	   spine	   and	   hip	   BMD	   increased	   significantly	   at	   the	   end	   of	   6	   years	   (15.2%	   and	  
7.2%	  respectively).	   In	  the	  cross	  over	  group	  lumbar	  spine	  and	  total	  hip	  BMD	  increased	  
by	   9.4%	   and	   4.8%	   respectively.	   The	   effects	   of	   denosumab	   on	   fracture	   risk	   are	  
particularly	  marked	  in	  patients	  at	  high	  fracture	  probability.	  	  
In	   the	   sixth	  year	  of	   the	  extension	   trial,	   six	   cases	  of	  osteonecrosis	  of	   jaw	  were	  
observed	  in	  the	  long-­‐term	  group.	  Atypical	  fracture	  was	  reported	  in	  one	  participant.	  The	  
most	   common	   side	   effects	   of	   denosumab	   include	   urinary	   and	   respiratory	   tracts	  
infections,	  cataracts,	  constipation,	  rashes	  and	  joint	  pain.	  [58,	  111]	  
Denosumab,	   by	   targeting	   the	   RANKL	   pathway,	   has	   a	   fundamentally	   different	  
mechanism	  of	  action	  from	  that	  of	  bisphosphonates.	  Denosumab	  prevents	  RANKL	  from	  
binding	   to	   its	   receptor,	   RANK,	   thereby	   inhibiting	   the	   development,	   activation,	   and	  
survival	   of	   osteoclasts.	   This	   is	   different	   from	   the	   mechanism	   of	   action	   of	  
bisphosphonates,	  which	  bind	  to	  bone	  mineral	  and	  probably	  inhibit	  osteoclast	  function	  
mainly	  by	  being	  taken	  up	  by	  osteoclasts	  at	  sites	  of	  bone	  resorption	  (Figure	  8).[182]	  
This	  may	   explain	   differences	   in	   the	   degree	   and	   rapidity	   of	   reduction	   of	   bone	  
resorption,	  their	  potential	  differential	  effects	  on	  trabecular	  and	  cortical	  bone,	  and	  the	  
reversibility	   of	   their	   actions.	   Denosumab	   has	   shown	   efficacy	   against	   vertebral,	  
nonvertebral,	  and	  hip	  fractures	  compared	  with	  placebo.[58,	  111]	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OPG was fused to the Fc portion of human immunoglobulin G1 (IgG1)
[13,56,57]. A third molecule, RANK-Fc was formed by fusing the
extracellular domain of RANK (amino acids 22–201) to the Fc portion
of IgG1 [59]. Later studies investigated RANKL inhibition using
denosumab, a fully human monoclonal antibody that targets RANKL
[60]. Denosumab is an immunoglobulin of the IgG2 subclass, and this
isotype is relatively inactive, eliciting effector functions [61]. In vitro
binding assays have shown high-afﬁnity binding of denosumab and
OPG to both soluble and membrane-bound forms of human RANKL
[62]. However, denosumab has several advantages over OPG-Fc or Fc-
OPG constructs. First, in terms of its selectivity, denosumab does not
bind to TRAIL (TNF-related apoptosis-inducing ligand) or to other TNF
family members including TNF-α, TNF-β, and CD40 ligand, whereas
TRAIL binding has been observed with OPG [62,63]. Second, due to its
molecular mass, its half life is prolonged compared to the Fc
constructs. Finally, neutralizing antibodies against OPG-Fc could
have neutralizing effects on both the drug and OPG, which would
not be expected with denosumab. At present, no neutralizing
antibodies have been identiﬁed with denosumab [64].
Denosumab prevents RANKL from binding to its receptor, RANK,
thereby inhibiting the development, activation, and survival of
osteoclasts. This is different from the mechanism of action of
bisphosphonates, which bind to bone mineral and probably inhibit
osteoclast function mainly by being taken up by osteoclasts at sites of
bone resorption (Fig. 4).
Effects on osteoclastogenesis
A major difference between denosumab and bisphosphonates on
osteoclasts is that bisphosphonates have to be internalized to act upon
cells, whereas denosumab acts in the extracellular milieu.
RANKL inhibition prevents the fusion of monocytes–macrophages
to become multinucleated osteoclasts, whereas long-term bispho-
sphonate treatment has been associated with an increase in the
number of osteoclasts, including giant, hypernucleated, detached
osteoclasts that undergo protracted apoptosis [65]. Inhibition of
osteoclast activity by bisphosphonates could trigger a feedback loop
that results in increased RANKL in the bone environment, which in
turn could help stimulate osteoclast precursors to fuse into multinu-
cleated osteoclasts. This hypothesis is supported by the evidence of
increased osteoclast numbers on bone surfaces in ovariectomized
huRANKL mice (see below) treated with alendronate, whereas
denosumab caused a nearly complete disappearance of osteoclasts
in this model [32]. Preliminary results of a study that used a rat
arthritis model to compare the effects of RANKL inhibition and
bisphosphonate treatment on serum and bone proteins further
indicate that RANKL inhibition using OPG treatment signiﬁcantly
reduced RANKL in bone, whereas zoledronic acid treatment caused a
two-fold increase in RANKL [66].
Other cell targets
Bone cells
Potential effects on osteoblasts
While data exist that OPG binds to membrane-bound RANKL on
osteoblasts, this does not apparently trigger intracellular signaling,
but may trigger internalization of the OPG/RANKL complex by a
clathrin-mediated mechanism followed by proteasomal degradation
[67]. Similarly, OPG exerts no direct effects on osteoblast survival, but
prevents TRAIL-induced apoptosis when added togetherwith TRAIL to
osteoblast-like cell cultures [68]. Cultured murine bone marrow
stromal cells exhibited enhanced osteoblastic differentiation when
treated with OPG [69], but the mechanisms of these effects have not
been elucidated. It is therefore unlikely that the moderate decrease of
osteoblast numbers per bone surface observed for instance in
huRANKL mice treated with denosumab [62] and/or the profound
decrease in bone forming indices observed with denosumab in
rodents and humans (see below) [32] might be explained by the
effects of RANKL antagonists directly on osteoblasts, but rather by
their marked inhibition of bone remodeling.
Very lowconcentrationsof bisphosphonates (as lowas10−11 mol/L)
have been shown to stimulate osteoblasts in vitro to release factors that
inhibit bone resorption by osteoclasts [70]. In contrast, others have
suggested that continuous exposure of osteoblasts to high-dose
bisphosphonates could inhibit osteoblast function and/or survival [71].
However, despite many studies, direct effects of bisphosphonates on
osteoblasts, either positive or negative, have been difﬁcult to demon-
strate in vivo using clinically relevant doses [39]. Similar to RANKL
inhibitors, most of the clinical effects of bisphosphonates on osteoblast
function, such as suppression of osteoblast-derived biochemical
markers, can be attributed to indirect effects on the remodeling cycle
caused by the reduction in bone resorption and consequent reduction in
bone formation (see section ‘Osteoblast–osteoclast coupling and
communication’ above).
Potential effects on osteocytes
Osteocytes, whichmake up over 90–95% of all bone cells in the adult
skeleton, are important cells for bone health. [72]. Due to their
distribution throughout the bone matrix and extensive interconnectiv-
ity, osteocytes are thought to play a major role in sensing mechanical
strain and orchestrating signals of resorption and formation [73].
Fig. 3. History of the development of RANKL antagonists.
Fig. 4. Osteoclast inhibition with denosumab vs bisphosphonates (BPs).

















Figure	  8	  –	  Osteoclast	  inhibition	  with	  denosumab	  vs.	  bisphosphonates	  (BPs).[182]	  
	  
           
B.	  Anabolic	  agents	  
	  
• Strontium	  ranelate	  	  
Strontium	  ranelate	  appears	  to	  both	  stimulate	  bone	  formation	  and	  inhibit	  bone	  
resorption.[183]	   It	   leads	   to	   the	  differentiation	  of	  pre-­‐osteoblast	   to	  osteoblast,	  which	  
increases	   the	   bone	   formation	   and	   also	   stimulates	   osteoblasts	   to	   secrete	  
osteoprotegerin	   leading	   to	   the	   decrease	   of	   bone	   resorption.	   The	   vertebral	   and	   hip	  
fractures	  decreases	  by	  about	  40%,	  in	  some	  studies.[183,	  184]	  
Strontium	  ranelate	  is	  an	  orally	  active	  drug	  recommended	  at	  a	  daily	  dose	  of	  2g,	  
between	  meals,	  due	  to	  its	  poor	  absorption	  when	  in	  presence	  of	  food.	  This	  drug	  is	  not	  
recommended	  for	  patients	  with	  severe	  renal	  impairment.	  The	  most	  common	  adverse	  
events	   are	   nausea	   and	   diarrhea,	   an	   increase	   in	   the	   incidence	   of	   venous 
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thromboembolism	   (VTE),	   and	   some	   cases	   of	   drug	   reaction	   with	   eosinophilia	   and	  




Is	  the	  name	  given	  to	  the	  human	  recombinant	  parathyroid	  hormone	  (PTH)	  that	  
has	   an	   identical	   sequence	   to	   the	   34	   N-­‐terminal	   amino	   acids	   (the	   biologically	   active	  
region)	   of	   the	   84-­‐amino	   acid	   human	   parathyroid	   hormone.	   Teriparatide	   increases	  
serum	   calcium	   by	   reducing	   renal	   excretion	   and	   mobilizing	   bone	   calcium	   through	  
increased	   osteoclastic	   resorption.	   It	   also	   indirectly	   increases	   intestinal	   calcium	  
absorption.	   Moreover,	   its	   effect	   on	   bone	   is	   also	   anabolic,	   since	   it	   increases	   bone	  
formation.[187]	   Reductions	   in	   vertebral	   fractures	   of	   around	   65%	  were	   reported	   and	  
significant	   reductions	   in	   all	   non-­‐vertebral	   fractures	   have	   been	   observed,	   although	   a	  
significant	   reduction	   in	   hip	   fracture	   has	   not	   yet	   been	   established.[188]	   The	  
recommended	  dose	   is	  20	  μg	  of	   teriparatide	  daily,	   given	  as	  a	   subcutaneous	   injection.	  
Beneficial	   effects	   on	   non-­‐vertebral	   fracture	   with	   teriparatide	   have	   been	   shown	   to	  
persist	  for	  up	  to	  30	  months	  after	  stopping	  the	  medication.[189]	  
The	   most	   common	   reported	   adverse	   events	   in	   patients	   treated	   with	  
teriparatide	  are	  nausea,	  pain	   in	  the	   limbs,	  headache	  and	  dizziness.	  Small	  and	  passing	  
elevations	  of	  serum	  calcium	  concentrations	  have	  been	  observed	  following	  the	  injection	  
teriparatide.	   	   The	  use	  of	  peptides	  of	   the	  PTH	   family	   is	   contra-­‐indicated	   in	   conditions	  
characterized	   by	   abnormally	   increased	   bone	   turnover	   (e.g.	   pre-­‐existing	  
hypercalcaemia;	  metabolic	   bone	  diseases	  other	   than	  primary	  osteoporosis,	   including	  
hyperparathyroidism	   and	   Paget's	   disease	   of	   the	   bone;	   unexplained	   elevation	   of	  
alkaline	  phosphatase;	  prior	  external	  beam	  or	  implant	  radiation	  therapy	  to	  the	  skeleton	  
or	  in	  patients	  with	  skeletal	  malignancies	  or	  bone	  metastasis).	  Severe	  renal	  impairment	  
is	   also	   a	   contraindication.	   Studies	   in	   rats	   have	   indicated	   an	   increased	   incidence	   of	  
osteosarcoma,	  with	   long-­‐term	  administration	  of	  very	  high	  doses	  of	   teriparatide	   from	  
the	   time	   of	  weaning.	   These	   findings	   have	   not	   been	   considered	   relevant	   for	   patients	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A	   comparative	   analysis	   of	   the	   efficacy	   on	   drug-­‐based	   fracture	   prevention	  
therapies	  is	  presented	  and	  safety	  of	  osteoporosis	  treatments	  in	  Table	  5.	  
	  
Table	   5	   -­‐	   Antifracture	   efficacy	   of	   the	   most	   frequently	   used	   treatments	   and	   safety	   of	  
postmenopausal	  osteoporosis.	  	  (+	  evidence;	  x	  no	  evidence;	  0-­‐no	  effects).	  Adapted	  from[94]	  
	  






Bisphosphonates	   	   	   	  
Osteonecrosis	  of	  the	  
jaw,	  subtrochanteric	  
femur	  fractures	  
.	  Alendronate	   Oral	   +	   +	   Oesophageal	  irritation	  
.	  Risedronate	   Oral	   +	   +	   Oesophageal	  irritation	  








potential	  renal	  toxic	  
effects	  
Raloxifene	   Oral	   +	   0	   Thromboembolic	  disease	  
Strontium	  
ranelate	   Oral	   +	   +	  
Thromboembolic	  





Teriparatide	   Subcutaneous	   +	   0	   Hypercalcaemia,	  nausea,	  diarrhea	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New	   compounds	   are	   in	   development	   and	   in	   advanced	   clinical	   trials,	   and	   the	  
number	   of	   available	   drugs	   will	   increase	   considerably	   in	   the	   coming	   years.	   Present	  
antiresorptive	   treatments	   are	   effective,	   but	   some	   are	   limited	   by	   side	   effects,	  
concurrent	   comorbidities,	   and	   inadequate	   long-­‐term	   compliance.	   Many	   of	   the	   new	  
drugs	  combine	  efficacy	  with	  convenient	  administration	  that	  might	  translate	  into	  better	  
adherence.	  Patients	  with	  severe	  osteoporosis	  may	  benefit	  from	  the	  sequential	  use	  of	  
one	   drug	   to	   stimulate	   bone	   formation	   in	   association	   with	   another	   to	   prevent	  
resorption.	  The	  effectiveness	  of	  such	  combinations	  has	  not	  been	  studied	  extensively,	  
and	   must	   be	   supervised	   by	   a	   physician	   who	   has	   experience	   of	   this	   method	   of	  
treatment.	  	  
Still,	  conventional	  antiresorptive	  such	  as	  amino	  bisphosphonates	  and	  denosumab	  can	  
profoundly	  suppress	  bone	  resorption	  and	  formation,	  which	  might	  contribute	  to	  the	  
pathogenesis	  of	  osteonecrosis	  of	  the	  jaw.	  Some	  of	  these	  issues	  are	  still	  under	  debate,	  
and	  long-­‐term	  clinical	  data	  are	  needed.	  
New	  therapies,	  as	   the	  odanacatib	  and	  saracatinib	   represent	  a	  distinct	  class	  of	  
antiresorptive	  that	  inhibit	  osteoclast	  activity	  rather	  than	  impairing	  osteoclast	  viability,	  
however	   if	   these	   compounds	   have	   an	   advantage	   over	   conventional	   antiresorptive	  
remains	   to	   be	   seen.[94,	   190]	   Calcilytic	   drugs	   and	   antagonist	   of	   Wnt	   inhibitors	   are	  
encouraging	  developments.[94]	  Moreover	  it	  is	  probable	  that	  new	  bisphosphonates	  will	  
emerge	  and,	  new	  forms	  of	  administration	  of	  parathyroid	  hormone	  (PTH)	  peptides	  are	  
being	   developed.[191,	   192]	   Another	   form	   of	   HRT	   is	   under	   development,	   comprising	  
the	  combination	  of	  estrogen	  with	  a	  SERM.	  	  
Although	   the	   ideal	   osteoporosis	   treatment	   has	   not	   yet	   been	   developed	   it	  
should	  take	  into	  account	  these	  parameters:	  
• Anti-­‐fracture	   efficacy	   at	   various	   skeletal	   sites,	   including	   spine,	   non-­‐vertebral	  
sites,	  and	  hip	  	  
• High	  safety	  margin,	  both	  skeletal	  and	  extra-­‐skeletal	  	  
• Mode	   of	   administration	   and	   treatment	   interval	   translate	   	  into	   patient’s	  
adherence	  	  
• Compatibility	  with	  drugs	  prescribed	  for	  other	  	  medical	  conditions	  	  
• Inexpensive	  cost.	  [94]	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ANIMAL	  MODELS	  OF	  OSTEOPOROSIS	  
	  
In	   vivo	   research	   reaching	   hand	   of	   animal	   models	   has	   been	   a	   preferred	  
experimental	  methodology	  since,	  by	  approximation,	  provides	  pertinent	  data	  gathering	  
regarding	  physiological	  and	  pathological	  conditions	  that	  could	  be	  of	  hand	  to	  establish	  
more	   effective	   clinical	   interventions.	   Accordingly,	   experimental	   in	   vivo	   research	  
establishes	  a	  bridge	  connection	  between	  in	  vitro	  experimentation	  and	  clinical	  trials.	  	  
Experimental	   animal	   models	   are	   essential	   to	   provide	   an	   adequate	  
approximation	   to	   translational	   applications	   and	   clinical	   settings.	   Accordingly,	   the	  
selection	  of	  the	  appropriate	   investigative	  design	  and	  animal	  model	  relies,	   in	  the	  very	  
end,	  in	  the	  therapeutic	  modality	  that	  is	  being	  tested.	  Furthermore,	  the	  selection	  of	  an	  
appropriate	  animal	  model	  relies	  on:	  1)	  appropriateness	  as	  an	  analog,	  2)	  transferability	  
of	   information,	   3)	   genetic	   uniformity	   of	   organisms	   where	   applicable,	   4)	   background	  
knowledge	   of	   biological	   properties,	   5)	   cost	   and	   availability,	   6)	   generalizability	   of	   the	  
results,	   7)	   ease	   and	   adaptability	   to	   experimental	   manipulation,	   8)	   ecological	  
considerations	  and	  9)	  ethical	  and	  societal	  implications.[113,	  193]	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A	   proper	   experimental	   animal	   model	   for	   the	   study	   of	   osteoporosis	   reduces	  
bioethics	   problematic	   and	   minimizes	   the	   limitations	   associated	   with	   studying	   the	  
disease	   in	  humans,	  namely	   time	  and	  behavioral	   variability	   among	   test	   subjects.[194]	  
Since	  1994,	  the	  United	  States	  Food	  and	  Drug	  Administration	  (FDA)	  requires	  data	  from	  
both	  the	  rat	  and	  a	  well	  validated	  large	  animal	  model	  for	  preclinical	  evaluation	  of	  new	  
experimental	  anti-­‐osteoporosis	  drug	  therapies.[195]	  
Animal	  models	  play	  a	   crucial	   role	   in	  osteoporosis	   -­‐	   they	  allow	   the	   research	  of	  
biological	   and	   biomechanical	   characteristics	   of	   bone	   metabolism/remodeling,	  
orthopedic	   implants	   placement,	   bone	   graft	   substitutes	   and	   prosthetic	   devices.	  
Experimental	  designs	  can	  be	  tested	  on	  large	  numbers	  of	  animals	  and	  maintained	  within	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a	  high	  confidence	  level	  of	  experimental	  control.[196]	  These	  models	  have	  the	  advantage	  
of	  skirting	  the	  elevated	  cost,	  long	  time	  frame	  and	  biosafety	  of	  the	  clinical	  testing.[197]	  	  
	  
Several	   mammalian	   species	   have	   been	   used	   in	   bone-­‐related	   fundamental,	  
feasibility	  and	  bioactive	  research,	  such	  as	  the	  mouse,	  rat,	  rabbit,	  sheep,	  dog,	  goat	  and,	  
less	  frequently,	  others	  such	  as	  nonhuman	  primates.	  	  
Some	   large	   animals	   could	   be	   used	   as	   models	   of	   osteoporosis,	   but	   the	   most	  
suitable	  are	  the	  dog,	  the	  pig,	  the	  sheep,	  and	  the	  nonhuman	  primates	  (Table	  6).[198]	  	  
The	  dog	  as	  a	  model	  for	  estrogen	  depletion	  was	  extensive	  reviewed.	  This	  model	  
offers	  numerous	  advantages.	  The	  most	  relevant	  feature	  is	  that	  dogs	  possess	  haversian	  
systems	  of	  cortical	  bone	  and	  internal	  bone	  remodeling	  of	  cortical	  and	  trabecular	  bone	  
similar	  to	  that	  of	  the	  human.[199]	  They	  are	  less	  expensive	  than	  the	  primate,	  and	  are	  in	  
general	  easier	   to	  work	  with.	  There	  are,	  however,	  disadvantages,	  available	  reports	  on	  
the	  nature	  of	  the	  skeletal	  response	  of	  the	  dog	  skeleton	  to	  ovariectomy	  are	  conflicting,	  
probably	   because	   these	   animals	   unlike	   humans	   and	   the	   primate	   models	   which	   are	  
polyestrous,	  dogs	  are	  diestrus,	  with	  ovulation	  occurring	  twice	  a	  year.	  	  The	  removal	  of	  
ovaries	   and	   uterus	   does	   not	   appear	   to	   be	   sufficient	   to	   create	   significant	   bone	   loss	  
showing	   that	   cessation	   of	   ovarian	   function	   in	   the	   dog	   does	   not	   predispose	   it	   to	  
osteoporosis	   as	   it	   does	   in	   the	   human.[200]	   Furthermore	   there	   is	   an	   emotional	  
attachment	   to	   the	   dog	   as	   "man's	   best	   friend"	   contributes	   to	   difficulty	   along	   with	  
housing	  regulations.	  
The	   pigs	   have	   also	   well-­‐developed	   Haversian	   systems	   as	   the	   dogs.	   The	   pigs	  
experience	   a	   continuous	   estrous	   cycle	   lasting	   about	   20	   days,	   in	   a	   way	   similar	   to	  
women.	  They	  are	  omnivorous	  and	  experimental	  serial	  biopsies	  can	  be	  easily	  obtained.	  	  
Miniature	  laboratory	  pigs	  are	  also	  available.	  However,	  there	  are	  some	  disadvantages,	  
information	  on	  ovariectomized	  pigs	  used	  for	  bone	  studies	  is	  limited,	  commercial	  farm	  
pigs	  are	  large	  in	  size	  and	  are	  difficult	  to	  manage	  and	  minipigs	  are	  quite	  expensive.[198,	  
201]	  
The	   sheep	   is	   a	   promising	   large	   animal	   model	   for	   bone	   and	   cardiovascular	  
systems.	   This	   is	   a	   seasonally	   polyestrous	   animal,	   experiencing	   several	   estrous	   cycles	  
during	   their	  breeding	   season.	  A	  7	  months	  old	   sheep	  has	  a	  well	  developed	  Haversian	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systems,	   an	  aged	   sheep	  display	  bone	   loss	  although	  has	  a	   lack	  of	  natural	  menopause	  
and	   a	   limitation	   of	   normal	   estrus	   cycles	   to	   fall	   and	   winter.	   The	   sheep	   is	   docile,	  
relatively	   inexpensive	   and	   available	   in	   large	   numbers.[198]	   Moreover,	   due	   to	   their	  
large	  body	  size,	  they	  require	  large	  spaces	  to	  be	  housed.	  Reviewing	  this	  topic,	  Oheim	  et	  
al.	   conclude	   that	   although	   different	   ewe	   models	   for	   osteoporosis	   have	   been	  
successfully	  established,	  a	  large	  animal	  model	  that	  perfectly	  mimics	  the	  human	  disease	  
is	  still	  to	  be	  found.[202]	  
Nonhuman	  primates	  include	  a	  wide	  range	  of	  diverse	  species,	  however	  only	  the	  
“man-­‐like	  monkeys”	   is	   used	   for	   studying	   human	   diseases.	   The	   Old	  World	  Monkeys,	  
such	   as	   rhesus	   are	   the	   most	   frequently	   used.	   The	   use	   of	   these	   animals	   is	   popular	  
because	   the	   FDA	   demands	   a	   large	   animal	   model	   data	   for	   the	   osteoporosis	  
therapeutics,	   in	  addition	   to	   the	  data	   from	  rodents,	  genetically	   they	  are	  very	  close	   to	  
humans	   and	   have	   menstrual	   cycles	   and	   a	   menopause	   similar	   to	   human	   females,	  
although	  their	  menopause	  occurs	  much	  later	  chronologically.[203]	  There	  are	  some	  of	  
them	  that	  sustain	  an	  upright	  body	  posture	  with	  a	  bone	  biomechanical	  loading	  pattern	  
similar	  to	  that	  of	  humans,	  they	  lose	  bone	  mass	  at	  an	  advanced	  age	  and	  their	  immune	  
system	   is	   similar	   to	   humans.	   The	   nonhuman	   primate	   is	   the	  most	   widely	   used	   large	  
animal	  model	  to	  evaluate	  the	  effects	  on	  bone	  of	  new	  drug	  entities,	  especially	  with	  the	  
increase	   in	   testing	   new	   biologic	   agents.[204]	   However,	   they	   also	   have	   certain	  
disadvantages	   because	   they	   must	   be	   ovariectomized	   to	   induce	   ovarian	   hormone	  
deficiency	   and	   bone	   loss	   of	   postmenopausal	   type.	   A	   large	   number	   of	   animals	   are	  
necessary	  to	  achieve	  adequate	  statistical	  significance	  and	  special	  facilities	  are	  required	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Table	   6	   -­‐	   Overview	   of	   initial	   practical	   aspects	   of	   animals	   commonly	   used	   for	   osteoporosis	  
research.	  
	  
Animal	   Cost	   Availability	   Handling	  
Life	  span	  
(years)	  
Social	  and	  ethical	  
issues	  
Rats	   Low	   Readily	   Easy	   2.5-­‐3	   Minimal	  
Dogs	   Moderate	   Readily	   With	  care	   10-­‐12	   Sensitive	  
Domestic	  
minipigs	  
Moderate	   Readily	  
Loud	  and	  noisy,	  
can	  be	  aggressive	  
10-­‐15	   Less	  critical	  
Sheep	   Moderate	   Readily	   Easy	   10-­‐15	   Less	  critical	  













Rats	  are	  considered	  the	  preferred	  animal	  model	  for	  studying	  the	  bone	  changes	  
associated	  with	  loss	  of	  reproductive	  function	  and	  has	  been	  the	  animal	  model	  of	  choice,	  
being	  selected	  for	  38%	  of	  bone	  repair-­‐related	  publications.[205]	  In	  fact,	  rat	  reports	  to	  
be	  of	  high	   level	   of	   experimental	   reproducibility	  due	   to	   the	  detailed	  definition	  of	   the	  
model	  in	  a	  biological,	  genetic	  and	  immunological	  point	  of	  view.[206]	  
The	   rat	   when	   compared	   to	   larger	   mammals,	   reports	   some	   limitations	   which	  
include	   a	   different	   loading	   pattern,	   a	   small	   blood	   volume	   for	   multiple	   biochemical	  
measurements,	  a	  reduced	  amount	  of	  total	  bone	  tissue	  available,	  minimal	  intra-­‐cortical	  
bone	   remodeling,	   and	   size-­‐related	   difficulties	   in	   the	   performance	   of	   surgical	  
procedures.[207]	   Moreover,	   a	   number	   of	   differences	   can	   be	   designated	   when	  
comparing	   rodent	  bone	   tissue	  with	   the	  one	  of	  humans:	   for	  example,	   the	  skeleton	  of	  
rodents	   continues	   to	   model	   during	   their	   life,	   and	   growth	   plates	   remain	   open	   until	  
adulthood;	  rodents	  report	   limited	  trabecular	  bone	  content	  and	  haversian	  remodeling	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does	   not	   occur,	   although	   cancellous	   remodeling	   is	   established;	   the	   rat	   skeleton	   has	  
proportionally	   less	   bone	   and	   a	   smaller	   contribution	   of	   cancellous	   bone	   to	   the	   total	  
bone	  mass.[208,	  209]	  
On	  the	  other	  hand,	  compared	  to	  large	  animal	  models,	  rodents	  are	  inexpensive	  
to	   purchase	   and	   maintain,	   are	   widely	   available,	   easy	   to	   manipulate,	   and	   report	  
minimal	  social	  concern.	  Rats	  have	  lamellar	  bone,	  cancellous	  bone	  remodeling,	  it	  is	  easy	  
to	   perform	   biomechanical	   tests	   on	   bones	   under	   standardized	   conditions	   and	   the	  
skeleton	   has	   any	   similarities	   with	   the	   human	   skeleton.[209]	   Additionally,	   they	   have	  
reproductive	   cycles	   resembling	   humans.	   The	   rat	   maintained	   continuously	   under	  
laboratory	   conditions	   will	   have	   estrus	   cycles	   (polyestrous)	   of	   4	   to	   5	   days	   duration.	  
Therefore,	  the	  rat	  skeleton	  will	  be	  affected	  by	  regular	  fluctuations	  in	  gonadal	  steroids.	  
This	  makes	  rats	  more	  sensitive	  to	  the	   loss	  of	  ovarian	  hormones	  compared	  to	  species	  
having	  only	  one	  estrus	  (monoestrus)	  cycle	  per	  year	  such	  as	  dog.[210]	  
Furthermore,	   if	   data	   that	   can	   be	   validated	   and	   that	   are	   trustworthy	   can	   be	  
acquired,	   animals	   placed	   at	   the	   lower	   end	   of	   the	   phylogenetic	   scale	   should	   be	  
preferably	  used	  –	   in	   this	  case;	   rodents	  are	  a	   first	  choice	  option	  over	   large	  mammals.	  
Due	  to	  their	  widespread	  utilization,	  much	  is	  known	  regarding	  the	  biological	  processes	  
associated	   with	   bone	   turnover,	   diet	   modifications	   and	   drug	   administration.	   A	   large	  
quantity	  of	  biological	  tools	  –	  such	  as	  PCR	  primers,	  microarrays,	  probes	  and	  antibodies	  
–	  is	  available	  and	  simplies	  the	  investigative	  process.	  Furthermore,	  the	  reduced	  lifespan	  
of	  these	  animals	  allows	  for	  the	  study	  of	  the	  influence	  of	  ageing	  in	  the	  bone	  metabolism	  
and	   regeneration	   processes;	   while	   the	   fast	   turnover	   of	   individuals	   and	   the	   rapid	  




Rat	  models	  of	  osteoporosis	  
	  
There	  are	  several	  methods	  to	  induce	  osteopenia	  and	  osteoporosis	  in	  the	  rat	  as	  
reported	   in	  Figure	  9.	   Immobilization,	  dietary	  manipulations,	  and	  hormonal	  deprivation	  
or	  administration	  are	  the	  methods	  of	  study	  that	  are	  usually	  chosen.	  The	  rate	  of	  loss	  of	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bone	  mass	  in	  male	  and	  female	  rats	  is	  highly	  dependent	  on	  the	  method	  used	  to	  induce	  
osteoporosis.	   All	   experimental	   osteoporosis	   protocols	   can	   be	   applied	   in	   skeletally	  
immature	   or	   mature	   rats.	   Although	   rats	   reach	   sexual	   maturity	   at	   the	   age	   of	   2.5	  

















Figure	  9	   -­‐	  Algorhythm	  for	  the	  selection	  of	  experimental	   interventions	  to	  induce	  osteopenia	  or	  
osteoporosis	  in	  the	  rat.[206]	  
	  
The	  ovariectomized	  (Ovx)	  rat	  is	  the	  most	  commonly	  used	  model	  for	  the	  study	  of	  
osteoporosis	   pathophysiology,	   diagnosis	   and	   therapy.[18]	   In	   this	   context,	   2	   different	  
animal	  types	  can	  be	  used:	  the	  aged	  rat	  and	  the	  mature	  rat.	  The	  mature	  rat	  is	  an	  animal	  
whose	  skeletal	  properties	  have	  been	  stabilized	  and	  no	  longer	  subject	  to	  age	  changes,	  
that	   is,	   similar	   to	   the	   skeletal	   characteristics	   of	   the	   women	   who	   are	   susceptible	   to	  
postmenopausal	   osteoporosis.	   The	   use	   of	   this	   type	   of	   rat	   brings	   with	   it	   sufficient	  
confidence	   that	   the	   bone	   changes	   observed	   after	   Ovx	   are	   really	   due	   to	   estrogen	  
deficiency	   and	   are	   not	   complicated	   by	   continued	   rapid	   bone	   growth	   as	   occurs	   in	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younger	  animals	  or	  by	  age-­‐related	  bone	   loss	  and	  diseases	  that	  can	  occur	   later	   in	   the	  
life	  of	  the	  rat.	  The	  aged	  rat	  is	  usually	  sacrificed	  several	  months	  after	  OVX	  to	  permit	  the	  
loss	  of	  a	  significant	  amount	  of	  bone.	  As	  a	  consequence,	  the	  aged	  rat	  is	  expensive	  and	  
its	  availability	  is	  limited,	  so	  that	  the	  less	  expensive	  and	  more	  easily	  available	  mature	  rat	  
is	  preferentially	  used.	  The	  mature	  rat	  is	  an	  approximately	  2,5	  months	  old	  and	  capable	  
of	   responding	   appropriately	   to	   the	   sex	   hormone	   deficiency	   induced	   by	   Ovx,	   whose	  
effects,	  in	  fact,	  become	  manifest	  in	  a	  month	  or	  less.[212]	  The	  bone	  changes	  that	  occur	  
in	  the	  two	  types	  of	  animals	  are	  similar.	  
The	   Ovx	   induced	   bone	   loss	   in	   the	   rat	   and	   postmenopausal	   bone	   loss	   share	  
many	  features	  such	  as;	  the	  increased	  rate	  of	  bone	  turnover	  with	  resorption	  exceeding	  
formation;	  Initial	  rapid	  phase	  of	  bone	  loss	  following	  by	  a	  much	  slower	  phase;	  superior	  
loss	   of	   cancellous	   than	   cortical	   bone;	   reduced	   intestinal	   absorption	   of	   calcium;	  
particular	  protection	  against	  bone	  loss	  by	  obesity;	  similar	  skeletal	  response	  to	  therapy	  
with	   estrogen,	   tamoxifen,	   bisphosphonates,	   parathyroid	   hormone,	   calcitonin,	   and	  
exercise.[213]	   	  
	  There	   is	   extensive	   literature	  on	   the	  histomorphometric	   changes,	   biochemical	  
markers,	  methodology	   for	  bone	  densitometry	   and	  evaluation	  of	  bone	   fragility	   in	   the	  
Ovx	   rat.[213-­‐215]	   The	   observation	   that	   acute	   ovarian	   hormone	   deficiency	   leads	   to	  
elevated	   cancellous	   bone	   turnover	   have	   led	   to	   the	   wide	   scale	   adoption	   of	   this	  
model.[214,	  216]	  The	  rat	   loses	  cancellous	  bone	  following	  the	  ovariectomy	  procedure	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Bone	  tissue	  is	  responsible	  for	  proper	  functional	  properties,	  such	  as	  mechanical	  
support	  and	  protection	  of	  the	  organs.	  Bone	  has	  the	  ability	  to	  regenerate	  in	  response	  to	  
injury	   and	   it’s	   continuously	   being	   remodeled,	   changing	   the	   equilibrium	   between	  
osteogenesis	   and	   resorption.	   Because	   the	   capacity	   of	   bone	   to	   regenerate	   and	   self-­‐
repair	   is	   limited	   to	   small	   fractures,	   therapeutic	   solutions	   need	   to	   be	   applied	   to	  
promote	  bone	  healing	  in	  case	  of	  defects	  of	  crucial	  size.	  
There	  are	  many	  bone	  diseases	  that	  can	  alter	  the	  function,	  such	  as	  bone	  loss	  to	  
removal	   of	   tumors,	   fractures	   and	   joint	   malfunction,	   cosmetic	   procedures	   and	  
degenerative	  disorders	  that	  affect	  many	  patients.	  	  
In	   order	   to	   improve	   the	   quality	   of	   life	   of	   a	   large	   amount	   of	   pacients	   who	  
otherwise	   had	   a	   limited	   and	   a	   painful	   life,	   	   orthopedic	  materials	   incluing	   grafts	   and	  
synthetic	  materials	  are	  available.	  
To	  date	  mainly	  transplantation	  of	  autogeneic	  and/or	  allogeneic	  bone	  grafts,	  or	  
implantation	   of	   graft	   materials	   with	   osteoconductive	   and	   osteoinductive	   properties	  
have	  been	  used	  in	  orthopedic	  applications.	  	  	  
Bone	  properties	  as	  a	  material	  have	  been	  extensively	  investigated	  and,	  although	  
depending	  of	  many	  factors	  like	  age	  and	  site,	  it	  is	  evident	  that	  its	  mechanical	  properties	  
are	  quite	  different	  from	  the	  ones	  of	  materials	  currently	  used	  as	  orthopedic	   implants.	  
Bone	   is	  much	  more	   complex	   than	   a	   simple	  material	   and	   bone	   substitute	   cannot	   be	  
restricted	   to	   a	   purely	  mechanical	   problem,	   leading	   to	  medium-­‐to-­‐long	   term	   implant	  
failure	   and	   substitution,	   especially	   in	  patients	  with	  poor	  bone	  quality,	   associated	   for	  
example	  with	  degenerative	  disorders.	  Although	  major	  advancements	  occurred	   in	   the	  
field	  of	  bone	  regenerative	  medicine,	  the	  current	  therapies,	  such	  bone	  grafts	  still	  have	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BIOMATERIALS	  
	  
Biomaterials	   is	   the	   definition	   of	   materials	   that	   are	   part	   of	   medical	   implants,	  
extracorporeal	   devices	   and	   disposables	   that	   have	   been	   used	   in	   medicine,	   surgery,	  
dentistry	   and	   veterinary	   medicine	   as	   well	   as	   in	   every	   aspect	   of	   patient	   health	  
care.[217]	  
The	  National	  Institutes	  of	  Health	  Consensus	  Development	  Conference	  defined	  a	  
biomaterial	   as	   “any	   substance	   (other	   than	   a	   drug)	   or	   combination	   of	   substances,	  
synthetic	  or	  natural	  in	  origin,	  which	  can	  be	  used	  for	  any	  period	  of	  time,	  as	  a	  whole	  or	  
as	   a	   part	   of	   a	   systemic	   which	   treats,	   augments,	   or	   replaces	   any	   tissue,	   organ	   or	  
function	   of	   the	   body”.[218]	   Biocompatibility	   is	   a	   common	   feature	   that	   all	   the	  
biomaterials	  need.	  Synthetic	  materials	  used	  in	  biomedical	  applications	  include	  metals	  
and	   alloys,	   polymers	   and	   ceramics	   among	   others.	   They	   present	   different	   structures	  
and	  properties	  therefore	  are	  used	  in	  different	  forms.	  The	  selection	  of	  a	  biomaterial	  is	  
based	   on	   the	   specific	   applications	   and	   founded	   in	   the	   physicochemical	   properties,	  
durability	  of	  the	  material,	  nature	  of	  the	  physiological	  environment	  of	  the	  organ/tissue	  
level,	   adverse	   effects	   in	   case	   of	   failure,	   cost,	   mechanical	   strength,	   stiffness,	   fatigue	  
endurance,	  wear	  resistance	  and	  dimensional	  stability.	  
	  
	  
GUIDED	  BONE	  REGENERATION	  (GBR)	  
The	   guided	   bone	   regeneration	   (GBR)	   is	   a	   surgical	   approach	   in	   order	   to	   attain	  
bone	  regeneration	  through	  the	  use	  of	  barrier	  membranes.[219]	  
The	   membranes	   should	   follow	   a	   series	   of	   criteria’s:	   biocompatibility,	   cell	  
occlusiveness,	   integration	   by	   the	   host	   tissues,	   clinical	   manageability,	   space	   making	  
function	  and	  limited	  susceptibility	  to	  complications.[220]	  
Further	   criteria’s	   should	   be	   achieved	   in	   the	   biodegradable	   and	   bioresorbable	  
membranes:	   the	   inflammatory	   response	   of	   the	   tissue	   to	   the	   resorption	   of	   the	  
membrane	  should	  be	   insignificant,	   reversible	  and	  be	  harmless	   to	   the	   regeneration	  of	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General	  Aspects	  
BIOCOMPABILITY	  
This	  is	  defined	  by	  the	  capacity	  of	  a	  material	  to	  function	  in	  a	  specific	  application	  
in	  the	  presence	  of	  an	  appropriate	  host	  response,	  and	  biocompatible	  materials	  should	  
offer	  safety	  to	  the	  patient.[222]	  All	  the	  medical	  devices	  should	  be	  biocompatibles.	  
These	   parameters	   are	   measure	   by	   the	   cytotoxicity,	   histocompatibility,	  
genotoxicity,	  mutagenicity	  and	  microbial	  effects.[222]	  
One	  parameter	  that	  must	  be	  taken	  into	  account	  is	  the	  fact	  that	  inert	  materials	  
often	   present	   a	   less	   complex	   safety	   situation	   than	   degrade	   materials,	   since	   those	  
release	  breakdown	  products	  into	  the	  surrounding	  host	  tissue	  that	  can	  result	  in	  a	  local	  
and	  systemic	  adverse	  reaction.[223]	  
	  
CELL	  OCLUSION	  
	  This	  principle	  was	   to	  exclude	  all	   the	  connective	   tissue	  cells	   that	   could	   fill	   the	  
space	   for	   the	   new	   bone.	   Tatakis	   et	   al.	   studied	   this	   concept	   thoroughly	   where	   the	  
exclusion	   of	   connective	   tissue	   and	   the	   dentogengival	   epithelium	   was	   proposed	   to	  
enable	  periodontal	  regeneration	  around	  the	  root	  surface.[224]	  
However,	  the	  awareness	  of	  total	  cell	  occlusion	  has	  been	  contested	  because	  of	  
the	   need	   of	   nutrients	   transfer	   across	   the	   membrane	   to	   a	   fruitful	   regeneration	  
process.[222]	   Zellin	   et	   al.	   and	   Wikesjo	   et	   al.	   claim	   a	   better	   outcome	   in	   bone	  
regeneration	  with	   the	   use	   of	  macroporous	  membranes	   than	   occlusive	   barrier.	   [225,	  
226]	  
	  
SPACE	  MAKING	  AND	  SPACE	  MAINTENCE	  
The	   space	   making	   capacity	   is	   define	   as	   the	   capacity	   to	   create	   and	   maintain	  
volume	   and	   geometry	   of	   space	   without	   collapsing	   allowing	   the	   bone	  
regeneration.[222]	  This	  feature	  is	  determined	  by	  the	  stiffness	  of	  the	  material.	  
	  The	  bioresorbable	  membranes	  due	  to	  the	  degradable	  materials	  often	  lose	  the	  
stiffness	  and	  begin	   to	   collapse;	  a	  way	   to	  overcome	   this	  problem	   is	   the	   simultaneous	  
use	  of	  supporting	  materials	  (bone	  grafts).[227,	  228]	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CLINICAL	  HANDLING	  
Membranes	   should	   be	   easy	   to	   handle	   to	   simplify	   the	   surgical	   procedure	   by	  
allowing	  to	  be	  trimmed,	  cut	  or	  shaped	  to	  fit	  and	  cover	  the	  bone	  defect.	  
Non-­‐resorbable	  membranes	  require	  screws	  and	  pins	  to	  sustain	  the	  shape	  [229,	  
230],	   while	   the	   bioresorbable	   membranes,	   especially	   the	   collagen,	   due	   to	   their	  
hydrophilicity	  adhere	  to	  the	  surrounding	  bone	  and	  grafting	  materials	  as	  soon	  as	  they	  
soaked	  with	  blood.[231]	  
	  
SUSCEPTIBILITY	  TO	  COMPLICATIONS	  	  
Non-­‐resorbable	  membranes	  have	  a	  higher	  risk	  of	  complications	  since	  they	  are	  
more	  likely	  to	  a	  premature	  exposure,	  leading	  to	  a	  wound	  infection.	  
Bioresorbable	   membranes	   are	   easier	   to	   handle	   and	   present	   lower	   risk	   of	  
exposure[232],	   although	   an	   inflammatory	   and	   foreign	   body	   reaction	   can	   be	  
encountered	  during	  the	  resorption	  period	  when	  synthetic	  materials	  are	  used.[233]	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TYPES	  OF	  MEMBRANES	  
	  
A.	  NON-­‐RESORBABLE	  MEMBRANES	  
	  
1. POLYTETRAFLUOROETHYLENE	  	  
The	   GBR	   technique	   was	   first	   introduced	   in	   1982	   and	   the	   expanded	  
polytetrafluoroethylene	   (e-­‐PTFE)	   membrane	   has	   been	   considered	   the	   gold	   standard	  
for	  barrier	  function	  materials.[234]	  
Expanded	   PTFE	   is	   a	   synthetic	   fluoropolymer	   that	   relies	   on	   an	   exceptionally	  
strong	   bond	   between	   carbon	   and	   fluorine	   for	   its	   nondegradable,	   biologically	   inert	  
properties.	  There	  is	  no	  known	  enzyme	  in	  the	  body	  capable	  of	  cleaving	  carbon-­‐fluorine	  
bonds	  polymer	  providing	  high	  stability	  in	  biological	  systems	  that	  resists	  breakdown	  by	  
host	  tissues	  and	  doesn’t	  stimulate	  immunologic	  reactions.[235,	  236]	  
This	   membrane	   is	   non-­‐resorbable,	   biocompatible	   and	   allows	   good	   coagulum	  
stability	  by	  covering	  the	  defect.[237]	  
However	   they	   have	   the	   disadvantage	   of	   a	   second	   surgery	   to	   remove	   the	  
bioinert	  membrane,	  which	  causes	  discomfort	  and	  increased	  the	  costs	  for	  the	  patient,	  
as	  long	  the	  risk	  of	  losing	  some	  of	  the	  regenerated	  bone	  due	  to	  the	  flap	  elevation.[238,	  
239]	   One	   of	   frequent	   complications	   reported	   is	   the	   exposure	   and	   subsequent	  
infection.[240-­‐243]	   These	   exposure	   can	   lead	   to	   a	   premature	   retrieval	   of	   the	  
membrane[244,	   245]	   and	   an	   impair	   bone	   regeneration	   is	   associated	   with	   this	  
complication,	  in	  a	  number	  of	  animals	  experiments	  [246-­‐248]	  and	  clinical	  studies.[249-­‐
252]	  
	  
2. TITANIUM	  REINFORCED	  ePTFE	  	  
When	   rehabilitating	   a	   large	   defect,	   conventional	   ePTFE	   membranes	   cannot	  
support	   and	   maintain	   the	   space	   unless	   they	   are	   filled	   with	   grafting	   materials.	   To	  
overcome	   this	   inconvenient	   the	   membranes	   have	   a	   double	   layer	   of	   ePTFE	   with	   a	  
titanium	   framework	   interposed,	   that	   provides	   a	   stable	   form.[253]	   Vertical	   ridge	  
augmentation	  demonstrated	  successful	  results	  with	  this	  membrane.[254,	  255]	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B.	  BIORESORBABLE	  MEMBRANES	  	  
	  
Since	  non-­‐resorbable	  membranes	  need	  a	  second	  surgical	  intervention	  for	  their	  
retrieval,	  this	  leads	  to	  patient	  morbidity	  and	  physiological	  stress,	  risk	  of	  tissue	  damage	  
and	   cost	   versus	   benefits,	   the	   clinicians	   and	   researchers	   encourage	   the	   use	   of	  
bioresorbable	  membranes.	  	  
Beside	   the	   advantage	   of	   the	   absence	   for	   a	   second	   surgery	   to	   remove	   the	  
membrane,	   the	   bioresorbable	   membranes	   offer	   a	   range	   of	   benefits	   that	   include	   a	  
simplified	   surgical	   procedure,	   decreased	   patient	   morbidity,	   improved	   soft	   tissue	  
healing	  and	  greatest	  cost-­‐effectiveness.	  [220,	  236,	  256]	  
On	   the	   other	   hand,	   the	   choice	   of	   the	   materials	   are	   critical	   since	   they	   have	  
distinctive	  features	  and	  biological	  effects,	  such	  as	  a	  different	  inflammatory	  reaction	  in	  
the	  tissue	  that	  vary	  from	  mild	  to	  severe.[257,	  258]	  These	  features	  guide	  the	  choice	  of	  
the	  membranes	  by	   the	   clinicians	  depending	  on	   the	   longevity	  of	   the	  barrier	   function,	  
tissue	  response	  and	  membrane	  breakdown.	  
	  
1. SYNTHETIC	  MEMBRANES	  	  
Synthetic	   polyester	   membranes	   are	   made	   from	   polyglycolides	   (PGAs),	  
polylactides	  (PLAs),	  copolymers,	  polydioxanones	  or	  trimethylene	  carbonates.[259,	  260]	  
These	   membranes	   have	   as	   advantage	   the	   capacity	   of	   been	   produce	   under	  
controlled	   conditions	   and	   produce	   in	   a	   large	   scale,	   unlike	   collagen	   membranes.	  
Another	   feature	   of	   these	   polymeres	   is	   the	   total	   biodegradation	   into	   carbon	   dioxide	  
and	  water	  by	  the	  Krebs	  cycle.[261]	  
The	  degradation	  of	  biodegradable	  polymers	   in	  vitro	  and	   in	  vivo	   is	  affected	  by	  
several	   factors,	   like	   their	   structure,	   chemical	   composition,	   molecular	   weight,	   shape,	  
processing	   conditions,	   sterilizing	   process,	   physicochemical	   factors	   and	  mechanism	  of	  
hydrolysis.[262,	  263]	   In	  maxillofacial	  and	  orthopedic	  surgery	  some	  of	   these	  polymers	  
had	  to	  be	  debrieded	  or	  removed	  since	  it	  triggered	  an	  inflammatory	  and	  foreign-­‐body	  
reaction.[233,	  264,	  265]	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Several	   studies	   tried	   to	  define	   the	   time	  of	   reabsorption	  of	   these	  membranes.	  
Robert	  et	  al.	  affirm	  that	  changing	  the	  polymer	  concentration,	  the	  membranes	  hold	  out	  
for	  4	  months.[266]	  Laurell	  	  et	  al.	  featured	  the	  timeline	  of	  reabsorption	  between	  6	  to	  12	  
months,	   and	   that	   the	   hydrolyses	   of	   the	  membrane	   caused	   little	   inflammation.[267]	  
Regardless	  that,	  many	  studies	  have	  the	  consensus	  in	  the	  time	  of	  reabsorption	  between	  
the	  6	  months.[268-­‐270]	  
Nowadays	  there	  are	  new	  polymers	  and	  copolymers	  being	  used,	  such	  as	  the	  poly	  
DTE-­‐carbonate	   that	   shows	   promising	   features	   since	   it	   induces	   low	   immunological	  
reaction	  and	  high	  ability	  to	  stimulate	  bone	  regeneration.[271]	  
	  
2. COLLAGEN	  MEMBRANES	  	  
The	  majority	  of	   the	  membranes	  are	   from	   type	   I	   collagen	  or	  a	   combination	  of	  
type	   I	   and	   III	   collagen.	   There	   source	   of	   collagen	   varies	   from	  bovine	   tendons,	   bovine	  
dermis,	  calf	  skin,	  porcine	  dermis	  among	  others.[272]	  
Collagen	   material	   appears	   to	   be	   an	   ideal	   choice	   for	   a	   bioresorbable	   GTR	  
(Guided	  Tissue	  Regeneration)	  or	  GBR	  barrier.	  Some	  of	  the	  advantages	  are:	  provides	  a	  
good	   hemostasis,	   chemotaxis	   for	   periodontal	   ligament	   fibroblasts	   and	   gingival	  
fibroblasts,	   weak	   immunogenicity,	   easy	   manipulation,	   a	   direct	   effect	   on	   bone	  
formation,	  and	  ability	  to	  augment	  tissue	  thickness.[273-­‐275]	  
The	   reabsorption	   of	   the	   collagen	   membranes	   occurs	   due	   to	   the	   action	   of	  
collagenases	  that	  cleave	  the	  collagen	  in	  two	  molecules	  which	  are	  denaturized	  at	  37°C	  
and	   decomposed	   into	   oligopeptides	   and	   aminoacids	   by	   the	   gelatinase	   and	  
proteinase.[237]	  
To	  prolong	  the	  barrier	  function	  of	  collagen	  membranes	  we	  can	  modify	  by	  cross-­‐
linked	   treatment.	   Several	   treatments	   have	   been	   used	   such	   as	   ultraviolet	   radiation,	  
glutaraldehyde,	   diphenyphosphoryl-­‐azide	   and	   hexamethylene	   diisocyanate.[276]	   The	  
most	   broadly	   used	   of	   these	   chemical	   cross-­‐linking	   techniques	   is	   the	   glutaraldehyde	  
technique,	   that	   reduces	   the	   inflammatory	   response	   and	   prevent	   degradation	   of	   the	  
membrane	  since	  30	  days,	  providing	  a	  prolonged	  presence	  of	  a	  mechanical	  barrier	  for	  
new	  bone	  formation.[277]	  Although	  some	  authors	  affirm	  that	  some	  cytotoxic	  residues	  
are	  left	  during	  the	  process.[278]	  
LITERATURE	  OVERVIEW	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  104	  
EVOLUTION®	  
	  
The	   membrane	   is	   obtained	   from	   mesenchymal	   tissue	   (heterologous	  
pericardium)	   and	   is	   completely	   resorbable.	   Its	   structure	   is	   made	   of	   dense	   collagen	  
fibers	  of	  high	  consistency	  and	  of	  high	  resistance	  that	  offer:	  	  the	  maximum	  adaptability	  
to	  bone	  tissue	  and	  soft	  tissues,	  an	  easy	  and	  secure	  suturability	  to	  nearby	  tissues,	  the	  
best	   membrane/bone	   and	   membrane/periosteum	   interface,	   stability	   and	   prolonged	  
protection	  of	  the	  underlying	  graft.	  
This	   membrane	   can	   be	   shaped	   with	   sterile	   scissors	   until	   the	   desired	   size	   is	  
reached;	   it	   must	   then	   be	   rehydrated	   with	   lukewarm	   physiological	   solution.	   Once	   it	  
acquires	  the	  desired	  plasticity,	  it	  must	  be	  adapted	  to	  the	  grafting	  site.	  	  The	  membrane	  
offers	  one	  smooth	  side	  and	  one	  micro-­‐rough	  side	  to	  improve	  the	  fitting	  to	  the	  tissues.	  
The	  rough	  side	  is	  faced	  to	  the	  bone	  to	  optimize	  integration	  and	  positioning.	  	  [279]	  
In	   case	   of	   accidental	   exposure,	   the	   dense	   collagen	   matrix	   of	   the	   membrane	  
protects	   the	   graft	   from	   infection.	   The	   membrane	   itself	   will	   also	   not	   be	   infected,	  
allowing	  second	  intention	  healing.	  
The	   average	   reported	   values	   are	   indicative	   and	   subject	   to	   a	   variability	   range	  
depending	  on	  the	  composition	  of	  the	  tissues	  of	  origin.	  
The	   estimated	   resorption	   time	   is	   about	   4	   months	   (standard	   thickness;	   0.5-­‐
0.7mm)	  and	  3	  months	   (fine	   thickness;	  0.3-­‐0.5mm),	  although	   the	   reported	  values	  are	  
estimates	   and	   purely	   indicative:	   these	   values	   can	   therefore	   vary	   depending	   on	   the	  
patient	  and	  grafting	  site.	  
The	   membranes	   have	   several	   clinical	   indications	   such	   as	   in	   oral	   surgery	   and	  
traumatology,	  implantology	  and	  periodontology.	  They	  have	  been	  used	  in	  lateral	  acess	  
in	   the	   sinus	   lift	   procedure	   to	   cover	   de	   antrostomy	   and	   protect	   the	   sinus	  membrane	  
from	  cutting	  risk	  due	  to	  graft	  pressure.[280,	  281]	  Many	  authors	  also	  described	  there	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BONE	  GRAFTS	  	  
	  
Bone	  graft	  is	  the	  second	  most	  employed	  transplantation	  tissue,	  being	  blood	  the	  
first.[284]	  Bone	  grafts	  are	  often	  necessary	  to	  provide	  support,	  fill	  voids,	  and	  enhance	  
biologic	  repair	  of	  skeletal	  defects.	  It	  is	  estimated	  that	  more	  than	  500.000	  bone	  grafting	  
procedures	   are	   performed	   annually,	   in	   the	   United	   States.[285]	   Bone	   grafting	  
procedures	   are	   broadly	   used	   in	   complicated	   fractures	   that	   fail	   to	   heal	   or	   severely	  
atrophied	  regions	  (like	  the	  mandibula	  after	  teeth	  extraction)	  that	  need	  augmentation.	  
In	  addition,	  they	  are	  often	  applied	  in	  the	  case	  of	  fractures	  with	  a	  high	  risk	  of	  nonunion,	  
when	  extensive	  regions	  of	  bone	  have	  been	  removed,	  and	  to	  ease	  fusion	  of	  bones	  after	  
extensive	   reconstructive	   procedures	   that	   are	   performed	   in	   orthopedic	   and	  
maxillofacial	  surgery.[207]	  
According	  to	  their	  origin,	  bone	  grafts	  can	  be	  classified	   in	  autogenic,	  when	  the	  
tissue	   is	   harvested	   from	   the	   same	   individual;	   allogenic,	   if	   the	   graft	   originates	   from	  
another	  individual	  of	  the	  same	  specie;	  xenogenic,	  if	  the	  graft	  is	  obtained	  from	  a	  donor	  
of	  another	  specie;	  and	  alloplastic,	  if	  it	  is	  a	  synthetic	  material.	  	  
The	   exact	   mechanisms	   by	   which	   bone	   graft	   incorporation	   occurs	   are	   not	  
completely	   understood,	   although	   several	   distinct	   bone	   formation	   mechanisms	   have	  
been	   determined.	   As	   so,	   osteoconduction	   is	   a	   property	   attributable	   to	   grafts	   that	  
allows	   deposition	   of	   bone	   tissue	   and	   subsequent	   integration	  within	   the	   surrounding	  
bone.	  Osteoinduction	  is	  the	  property	  of	  grafted	  materials	  that	  can	  induce	  surrounding	  
precursor	   cells	   to	   differentiate	   and	   produce	   new	   bone	   tissue.	   Osteogenesis	   is	   the	  
process	  by	  which	  vital	  osteoblasts	  originating	   from	  the	  bone	  graft	  contribute	   to	  new	  
bone	  growth.	  	  
	  
AUTOGENIC	  GRAFTS	  
These	   bone	   grafts	   are	   considered	   the	   gold	   standard	   application	   for	   bone	  
regenerative	   clinical	   applications,	   because	   they	   possess	   osteoconductive,	  
osteoinductive	   and	   osteogenic	   capabilities[207].	   The	   tissue	   is	   obtained	   from	   the	  
patient	   to	   himself.	   Nonetheless,	   autogenic	   grafts	   have	   significant	   limitations:	   the	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harvesting	   prolongs	   the	   time	  of	   the	   surgery;	   causes	   donor	   site	  morbidity	   (e.g.,	   pain,	  
blood	   loss	   and	   infections);	   may	   originate	   tissue	   in	   inadequate	   amount	   and/or	  
inappropriate	  form;	  may	  present	  limited	  mechanical	  strength	  for	  specific	  applications;	  
among	   others.[286]	   These	   limitations	   have	   prompted	   the	   increasing	   interest	   in	  
alternative	  grafts.	  	  
	  
ALLOGENIC	  GRAFTS	  
Allograft	  is	  an	  alternative	  and	  offers	  the	  same	  characteristics	  as	  autograft	  with	  
the	  exclusion	  of	  osteogenic	  cells.	  Bone	  allografts,	  by	  nature,	  are	  derived	  from	  different	  
human	  donors	  and	  may	  be	  cancellous,	  cortical,	  or	  a	  combination	  of	  both.[287]	  These	  
grafts	   are	   easily	   available,	   report	   predictable	   results	   and	   eliminate	   the	   need	   for	  
surgical	  harvesting	  of	   the	  graft	   tissue.	   	  Although	   they	  are	  an	  attractive	   source,	   there	  
are	   several	   problems	   encountered	   in	   their	   clinical	   use,	   including	   the	   risk	   of	   disease	  
transmission,	   immunological	   rejection,	   loss	   of	   biologic	   and	   mechanical	   properties	  
secondary	  to	  its	  processing,	  increased	  cost,	  and	  limited	  availability	  due	  to	  financial	  and	  
religious	   concerns.[288]	   Due	   to	   the	   potential	   risk	   of	   disease	   transmission	   allografts	  
undergo	   several	   treatments.	   The	   grafts	   are	   devitalized	   by	   freezing,	   and	   often	  
additional	   procedures	   like	   sterilization	   with	   ethylene	   oxide	   and/or	   high-­‐dosage	   of	   γ	  
irradiation	  are	  applied.	  These	  sterilization	  steps,	  however,	  can	  significantly	  reduce	  the	  
osteoinductivity	  of	  the	  grafts.[289]	  
A	   table	   comparing	   the	   main	   properties	   of	   autogenic	   and	   allogenic	   grafts	   is	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Table	  7	  –	  Comparative	  properties	  of	  bone	  grafts.[287]	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XENOGENIC	  GRAFTS	  
Bone	  xenografts	  for	  human	  application	  are	  essentially	  derived	  from	  pig,	  bovine	  
and	   equine	   origin,	   among	   others.	   This	   material	   is	   widely	   available	   and	   can	   be	  
combined	   with	   autologous	   material	   to	   augment	   graft	   quantity	   and	   control	   the	  
eventual	  resorption	  of	  the	  tissues.[290]	  Clinical	  outcomes	  are	  variable,	  with	  moderate	  
to	   good	   clinical	   results	   in	   some	   oral/maxillofacial	   applications.[291-­‐293]	   Biosafety	  




Synthetic	   bone	   grafts	   such	   as	   ceramics,	   polymers	   and	   composites	   have	  
different	   characteristics	   regarding	   biomechanical,	   biochemical	   and	   biological	  
properties.	   Specifically,	   they	   present	   a	   wide	   range	   of	   structural	   strength,	   rate	   of	  
resorption	   or	   replacement	   by	   host,	   mechanism	   of	   action,	   osteoinductive	   potential,	  
osteoconductive	  properties	  and	  handling	  capability.	  Some	  disadvantages	  of	  these	  graft	  
materials	  include	  cost,	  poor	  handling	  and	  variable	  resorbility.[285]	  	  
	  
	   	  
LITERATURE	  OVERVIEW	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  108	  
ORAL/MAXILLOFACIAL	  APPLICATIONS	  OF	  BONE	  GRAFTS	  	  
	  
With	   the	   advances	   in	   biomaterials	   and	   surgical	   techniques	   that	   allow	  
predictable	  bone	  regeneration,	  the	  needs	  of	  the	  patients	  for	  better	  oral	  rehabilitations	  
can	  be	  satisfied.	  Frequently,	  these	  patients	  have	  soft	  and	  hard	  tissue	  defects,	  resulting	  
from	   a	   variety	   of	   causes,	   such	   as	   infection,	   trauma,	   and	   tooth	   loss	   that	   causes	  
continuous	  resorption	  of	  the	  alveolar	  ridge.	  These	  defects	  create	  an	  anatomically	  less	  
favorable	  foundation	  for	  ideal	  implant	  placement.[296]	  
For	  prosthetic	  dental	  implant	  therapy,	  bone	  augmentation	  of	  the	  alveolar	  bone	  
through	   a	   variety	   of	   regenerative	   surgical	   procedures	   has	   become	   predictable.	  
Regenerative	   procedures	   are	   used	   for	   socket	   preservation,	   sinus	   augmentation,	   and	  
horizontal	  and	  vertical	  ridge	  augmentation.[297,	  298]	  
There	   are	   several	   techniques	   that	   allow	   a	   predictable	   bone	   regeneration	  
procedure	   in	   oral	   application,	   reaching	   hand	   of	   a	   wide	   range	   of	   bone	   grafts,	   from	  
autografts	  to	  alloplastic	  materials,	  xenografts	  or	  allografts.	  
Augmentation	   techniques	   can	   be	   realized	   by	   means	   of	   a	   local	   bone	   graft	  
(autograft)	   taken	   from:	   the	   symphysis	   area	   of	   the	   chin,	  maxillary	   tuberosity,	   cranial	  
vault	   (calvarium),	   iliac	   wing	   bone	   or	   by	   rib	   grafts,	   among	   others.	   Materials	   derived	  
from	   other	   individuals	   (allografts),	   from	   different	   species	   (xenografts)	   or	   even	   from	  
synthetic	  origin	  (alloplastic	  materials),	  have	  also	  been	  widely	  used.	  
These	   techniques	   are	   useful	   in	   trauma	   situations,	   forehead	   defects	   and	   oral	  
rehabilitations.[207]	  Another	  augmentation	  technique,	  which	  can	  be	  used	  in	  vertically	  
regeneration,	   is	   the	   distraction	   osteogenesis.[299]	   In	   the	   maxilla,	   another	   surgical	  
technique	   that	   allows	   bone	   augmentation	   is	   the	   sinus	   lift	   procedure.	   Reported	   used	  
materials	  include	  grafts	  from	  several	  origins,	  such	  as:	  autografts	  (iliac	  crest	  bone	  [300],	  
mandibular	   symphysis	   [301],	   maxillary	   tuberosity[301]),	   allografts	   (freeze-­‐dried	  
demineralized	  bone[302,	  303]),	  xenografts	  (Hydroxyapatite	  of	  bovine	  origin[304])	  and	  
alloplastic	  materials	   (Beta-­‐tricalcium	  phosphate	   (β-­‐TCP)[305]).	   In	  socket	  preservation,	  
different	  materials	  have	  also	  been	  reported	  to	  be	  used,	  such	  as:	  porcine	  bone	  [293],	  
Beta-­‐tricalcium	   phosphate	   (β-­‐TCP)	   [306],	   nanocrystalline	   hydroxyapatite	   paste	   [307],	  
Bio-­‐Oss	  Collagen®[308]	  among	  others.	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BIO-­‐OSS®	  
Bio-­‐oss®	   is	   an	   inorganic	   mineral	   product,	   of	   bovine	   origin,	   that	   is	   chemically	  
processed	  at	  low	  temperatures,	  in	  order	  to	  assure	  the	  extraction	  of	  the	  organic	  matter.	  
According	   to	   the	  manufacturers,	   the	   processing	   assures	   the	   complete	   removal	   of	   all	  
organic	   components	   from	   bovine	   bone,	   resulting	   in	   an	   almost	   unaltered	   natural	  
mineral	   structure.[309]	  Nonetheless,	   it	   has	  been	   reported	   the	  presence	  of	   a	  notable	  
content	  of	  organic	  waste	  that	  can	  be	  harmful	  to	  the	  biological	  response.[310,	  311]	  
Bio-­‐oss®	   presents	   physical	   and	   chemical	   characteristics	   similar	   to	   the	  mineral	  
matrix	  of	  human	  bone.[312]	  This	  material	  has	  a	  porous	  structure,	  with	  an	  average	  pore	  
size	   of	   100µm,	   that	   facilitates	   the	   proliferation	   of	   blood	   vessels	   and	   bone	   cells,	  
providing	   a	   three-­‐dimensional	   frame	   for	   the	   growth	   of	   new	   bone.[313]	   Due	   to	   the	  
crosslink	  of	  pores	  and	   small	   crystals,	   the	   inner	   surface	  of	  Bio-­‐oss®	   covers	  more	   than	  
90m2/g,	  which	  is	  a	  specific	  volume	  similar	  to	  the	  one	  of	  human	  cancellous	  bone.	  The	  
crosslinking	   of	   micro	   and	  macro	   pores	   also	   favors	   the	   stabilization	   of	   the	   clot.	   This	  
compound	  has	  a	  porosity	  of	  around	  60%	  and	  crystal	  size	  between	  10-­‐60nm.	  
Bio-­‐oss®	  is	  slowly	  resorbed	  and	  integrated	  into	  the	  natural	  remodeling	  process	  
of	   bone	   filling	   -­‐	   the	   requirements	   of	   an	   osteoconductive	   material.	   The	   mineral	  
component	  of	   the	  small	   crystals	  of	  hydroxyapatite,	  with	   less	  hydroxyl	   ions	  and	  more	  
carbon	   than	   the	   synthetic	   hydroxyapatite,	   seems	   to	   facilitate	   the	   process	   of	   natural	  
bone	  remodeling.[314]	  The	  proportion	  of	  calcium	  and	  phosphate	  is	  2:1,	  similar	  to	  the	  
one	  of	  human	  bone.	  
Bio-­‐oss®	  has	  been	  widely	  employed	  in	  clinical	  dentistry	  as	  a	  xenograft	  material	  
for	  implantation	  and	  sinus	  lift	  procedures.[236,	  315-­‐318]	  Ziztmann	  et	  al.	  affirmed	  that	  
the	  long-­‐term	  implant	  survival	  rate	  in	  Bio-­‐oss®	  grafet	  sites	  is	  similar	  to	  the	  survival	  rate	  
of	  implants	  placed	  in	  native	  bone	  (112	  implants,	  5	  years	  follow-­‐up).[318]	  	  Schekegel	  et	  
al.	   showed	   that	   after	   sinus	   floor	   augmentation	   with	   a	   mixture	   of	   Bio-­‐Oss®	   and	  
autologous	   bone,	   the	   percentage	   bone	   volume	  was	   preserved	   throughout	   the	   study	  
period,	  while	  the	  height	  of	  a	  purely	  autologous	  bone	  graft	  diminished	  markedly.[319]	  
Bio-­‐oss®,	  in	  maxillary	  sinus	  augmentation,	  was	  shown	  to	  not	  to	  interfere	  with	  normal	  
healing	   process	   and	   to	   promote	  new	  bone	   formation,	   as	   assessed	  by	   light,	   scanning	  
and	  transmission	  electron	  microscopy.[320]	  Hämmerle	  et	  al.,	  performed	  twelve	  lateral	  
LITERATURE	  OVERVIEW	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  110	  
ridge	  augmentations	  in	  patients,	  with	  Bio-­‐oss®	  and	  a	  commercial	  collagen	  membrane	  
to	   improve	   the	   alveolar	   ridge	   thickness,	   to	   implant	   therapy.	   The	   authors	   found	   that	  
this	   treatment	   is	   a	   valid	   option	   for	   horizontal	   bone	   augmentation	  with	   a	   decreased	  
morbidity.[235]	   Felice	   et	   al.,	   evaluated	   vertical	   ridge	   augmentation	   procedures	   and	  
compared	   the	   results	   using	   Bio-­‐oss®	   or	   bone	   blocs	   from	   the	   iliac	   crest.[321]	   The	  
authors	  established	  that	  both	  procedures	  achieved	  good	  results,	  but	  the	  use	  of	  bovine	  
blocs	  was	  less	  invasive.	  
There	   are	   several	   indications	   for	   the	   use	   of	   Bio-­‐oss®	   in	   dentistry	   such	   as:	  
horizontal	   augmentation,	   vertical	   augmentation,	   ridge	   reconstruction,	   ridge	  
preservation,	   sinus	   floor	   elevation	   and	   correction	   of	   intraosseous	   defects.	   	   These	  
procedures	   have	   been	   shown	   to	   be	   predictable,	   with	   good	   results	   and	   a	   valid	  
alternative	  to	  the	  use	  of	  other	  grafts.	  
	  
PUTTY®	  
Putty	   is	   an	   antigen-­‐free	   bone	   paste	   composed	   by	   a	   mix	   of	   cancellous	   and	  
cortical	   porcine	   bone,	   and	   the	   collagen	   tissue	   is	   preserved.	   It’s	   physical	   form	   as	   a	  
plastic	  consistency	  composed	  of	  	  80%	  micronized	  heterologous	  bone	  (granulometry	  ≤	  
300	  µm)	  and	  20%	  pure	  collagen	  gel.	  It	  is	  made	  with	  a	  particular	  process	  that	  provides	  
the	  product	  with	  special	  malleability	  and	  plasticity,	  making	  it	  easy	  to	  apply	  in	  sockets	  
and	   peri-­‐implant	   defects	   with	   walls.	   Thanks	   to	   its	   collagen	   component,	   the	   product	  
facilitates	   blood	   clotting	   and	   the	   subsequent	   invasion	   of	   repairing	   and	   regenerative	  
cells.	  This	  product	  has	  an	  average	  resorption	  time	  of	  less	  than	  4	  months.	  
This	  product	  as	  been	  applied	   in	   Implantology	  because	  of	   its	   versatile	  alveolar	  
filler	  aiming	  to	  preserve	  the	  crestal	  volume	  and	  in	  immediate	  post-­‐extraction	  implants	  
to	   facilited	  the	  primary	  stability.[322]	  Authors	  have	  described	   its	  use	   in	   treatment	  of	  
periimplantitis	   and	   in	   split	   crests.[323]	   In	   oral	   surgery	   its	   recommended	   to	   preserve	  
the	  dental	  extraction	  socket	  and	  bone	  defects	  in	  result	  of	  granulomas	  or	  dentigenous	  
cysts.[324]	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ANIMAL	  MODEL	  OF	  BONE	  REGENERATION
	  
Currently,	   several	   animal	  models	   are	  used	   to	  evaluate	   the	  bone	   regeneration	  
process,	   the	   bone–biomaterial	   interaction	   and	   the	   physiological	   or	   pathological	  
evidence	  of	   the	  modulation	  of	   the	  ossification	  pathway.	  Experimental	  models	  can	  be	  
classified	  as	  heterotopic	  or	  orthotopic,	  based	  on	   the	  vicinity	   to	   the	  autologous	  bone	  
tissue.	  Accordingly,	  the	  rat	  heterotopic	  model	  has	  been	  used	  successfully	  to	  show	  the	  
sequence	   of	   events	   involved	   in	   the	   ossification	   process	   and	   most	   common	  
implantation	   sites	   include	   the	   subcutaneous	   tissue	   or	   intramuscular	   anatomical	  
locations.[207]	   Alternatively,	   orthotopic	   models	   within	   intraosseous	   locations	   have	  
been	  used	   to	   evaluate	   the	  bone	   regeneration	  process	   in	   the	   repair	   of	   discontinuous	  
and	  weight-­‐bearing	  lesions.	  The	  selection	  of	  orthotopic	  models	  in	  bone	  research	  relies	  
broadly	  on	  one	  of	   the	  following	  options:	  calvarial,	   long	  bone	  or	  mandible	  segmental,	  
partial	  cortical	  and	  cancellous	  bone	  defects.[207]	  
	  
CALVARIAL	  DEFECT	  MODEL	  
	   	  
The	  calvarial	  model	  stands	  out	  as	  an	  adequate	  model	   for	  evaluating	  the	  bone	  
regeneration	   process,	   as	   well	   as	   the	   biocompatibility	   and	   adequacy	   of	   complex	  
materials	  and	  tissue	  engineering	  constructs	  aiming	  bone	  regeneration.	  
The	   calvarial	   model	   is	   very	   popular	   and	   appropriate	   for	   the	   following	  
reasons:[325-­‐327]	  	  
• The	   calvarial	   bone	   is	   a	   plate	   which	   allows	   the	   creation	   of	   a	   uniform	   circular	  
defect	  that	  enables	  convenient	  radiographical	  and	  histological	  analysis;	  	  
• Craniotomies	   are	  moderately	   easy	   to	  perform,	  have	   low	  morbidity	   rates,	   and	  
are	  highly	  reproducible	  if	  performed	  with	  a	  circular	  trephine;	  	  
• The	   calvarial	   bone	   has	   an	   adequate	   size	   for	   the	   surgical	   procedure	   and	  
specimen	  handling;	  	  
• No	  fixation	  is	  required	  because	  of	  the	  good	  support	  given	  by	  the	  dura	  and	  the	  
overlying	  skin;	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• The	  model	  has	  been	  thoroughly	  used	  and	  studied,	  and	  is	  well	  reproduced;	  	  
• calvaria,	   which	   develops	   from	   a	   membranous	   precursors,	   has	   a	   poor	   blood	  
supply	  and	  relatively	  little	  bone	  marrow;	  
• materials	   and	   tissue	   engineering	   constructs	   of	   all	   kinds	   can	   be	   tested	   in	   that	  
location,	   which	   is	   particularly	   well	   suited	   for	   assaying	   granular	   or	   paste-­‐like	  
materials;	  
• Laterally	  performed	  craniotomies	  have	  the	  advantage	  of	  allowing	  paired	  design	  
and	  minimized	  morbidity	  while	  avoiding	  accidental	  damage	  to	   the	  midsagittal	  
sinus.	  	  
	  
This	   model	   has	   been	   established	   in	   an	   extensive	   range	   of	   animal	   species	  
counting,	   mice,	   rats,	   rabbits,	   dogs,	   sheeps,	   goats,	   pigs	   and	   nonhuman	   primates,	  
although	  rats	  and	  rabbits	  are	  the	  most	  commonly	  used	  animals.	  	  
The	  selection	  of	  the	  calvarial	  model	  implies	  the	  determination	  of	  the	  size	  of	  the	  
defect.	   According	   to	   experimental	   design	   objectives	   and	   the	   regenerative	   behavior,	  
two	  types	  of	  defects	  can	  be	  surgically	  created:	  critical	  size	  and	  sub	  critical	  size	  defects,	  
which	  vary	  according	  to	  the	  animal	  species,	  gender,	  age,	  strain,	  anatomic	  site,	  shape,	  
size	  and	  micro-­‐mechanical	  environment.[326,	  327]	  
A	   critical	   size	   defect	   (CSD)	   by	   definition	  means	   that	   the	   defect	   will	   not	   heal	  
spontaneously	   during	   the	   expected	   lifetime	   of	   the	   animal.	   This	   is	   a	   essential	   quality	  
that	  permits	  to	  conclude	  that,	  in	  case	  of	  success,	  the	  therapy	  healed	  a	  defect	  instead	  
of	  only	  enhance	  its	  spontaneous	  repair.[207]	  
Critical	  size	  defects	  cannot	  rely	  on	  the	  physiological	  repair	  mechanisms	  of	  the	  
organism	   to	   fully	   heal	   the	   defect	  with	   bone	   tissue,	   and	   fibrous	   connective	   tissues	   is	  
broadly	  developed	  within	  the	  residual	  defect.[326,	  327]	  It	  has	  not	  been	  known	  why	  a	  
small	  defect	  can	  be	  repaired	  but	  a	  large	  defect	  cannot.	  Furthermore,	  little	  information	  
is	  available	  on	  how	  bone	  formation	  ceases	  during	  the	  repair	  of	  a	  critical	  size	  defect.	  A	  
variety	  of	  studies	  have	  looked	  into	  the	  repair	  of	  critical	  size	  bone	  defects	  with	  growth	  
factors,	  biomaterials,	  cell	  and	  tissue	  implantation,	  although	  the	  biological	  mechanism	  
that	  regulates	  the	  healing	  of	  bone	  defects	  has	  not	  been	  fully	  understood.[328]	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Bosch	  et	  al.,	  reported	  that	  the	  defects	  that	  satisfied	  the	  criteria	  for	  a	  critical	  size	  
in	  Wistar	   rats	   calvarial	   bone	  were	   full	   thickness	   5mm	   in	   diameter,	   since	   no	   signs	   of	  
spontaneous	   bone	   regeneration	   was	   verified	   12	   months	   after	   surgery,	   apart	   from	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MANDIBULAR	  BONE	  DEFECT	  
	  
There	   are	   many	   factors,	   which	   can	   alter	   the	   regeneration	   on	   the	   created	  
defects	   such	   as	   the	   anatomical	   location,	   cortical	   involvement,	   and	   the	   presence	   of	  
periosteum,	  dura,	  or	  both.	  The	  model	  of	  critical-­‐size	  calvarial	  defects	  have	  presented	  a	  
respectable	  bone	  remodeling,	  although	  Kaban	  &	  Glowacki	  describe	  the	  mandible	  as	  a	  
unique	  bone	   that	   is	   subjected	   to	  continuous	  motion	  and	  significant	  compressive	  and	  
shearing	  forces;	  therefore	  bone	  defects	  created	  in	  other	  craniofacial	  bones	  or	  in	  long	  
bones	  may	  not	  apply	  to	  the	  mandible.[332]	  	  
In	  the	  maxillofacial	  skeleton,	  a	  frequently	  used	  animal	  model	  is	  the	  mandibular	  
critical	  size	  defect	  in	  the	  rat.[332]	  This	  model	  consists	  of	  a	  circular	  through	  and	  through	  
defect	  of	  a	  diameter	  varying	  from	  4	  to	  7	  mm	  drilled	  into	  the	  mandibular	  ramus.[332]	  
The	   term	   critical	   size,	   as	   cited	   previously,	   implies	   that	   the	   defect	   will	   not	   heal	  
spontaneously,	   so	   that	   healing,	   if	   obtained,	   is	   caused	   by	   the	   experimental	  
intervention.[326,	   333]	   The	   rat	  mandibular	   defect	  model	   has	   been	   used	   to	   evaluate	  
bone	  regeneration	  of	  biomaterials	  and	  osteoconductive	  properties	  of	  membranes	  with	  
or	  without	  growth-­‐stimulatory	  factors.	  	  
The	   experimental	   mandibular	   model	   was	   based	   on	   Dahlin	   et	   al.	   article	   and	  
clearly	  illustrates	  the	  potential	  for	  bone	  regeneration.	  	  
This	  mandibular	  model	  is	  widely	  used	  and	  suitable	  for	  the	  following	  reasons:[219,	  334]	  
• The	  surgical	  procedures	  on	  the	  rat	  mandibular	  bone	  are	  relatively	  simple;	  
• Spontaneous	  healing	  would	  not	  occur	  in	  the	  control	  site;	  	  
• Observations	  can	  be	   focused	  on	  the	  healing	  process	  of	  bone,	  since	   there	  are	  
not	  any	  major	  nerves	  or	  blood	  vessels	  around	  the	  rat	  mandibular	  angles;	  
• The	  preparation	  of	  tissue	  specimen	  is	  easy;	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A.	  EXPERIMENTAL	  DESIGN	  
	  
This	  work,	  aiming	  to	  evaluate	  the	  bone	  regeneration	  process	   in	  a	  valid	  animal	  
model	   of	   the	   human	   condition	   of	   osteoporosis,	   was	   conducted	   during	   the	   period	  
between	  January	  2009	  and	  December	  2013.	  
The	   experimental	   design	   was	   divided	   in	   three	   phases:	   	   establishment	   and	  
characterization	   of	   an	   experimental	   osteoporotic	   model;	   the	   study	   of	   the	   calvarial	  
bone	  regeneration	  and	  the	  mandibular	  bone	  regeneration.	  The	  study	  was	  performed	  
under	  the	  authorization	  of	  the	  Direcção	  Geral	  de	  Veterinária	  for	  the	  project	  “Avaliação	  
do	  processo	  de	  regeneração	  em	  condições	  osteoporóticas”,	  according	  to	  the	  ordinance	  
nº	   49	   paragraph	   b).	   The	   technical	   standards	   of	   protection	   of	   experimental	   animals	  
were	   observed,	   according	   to	   the	   Portuguese	   (Decree	   No.	   1005/92)	   and	   European	  
(Directive	  2010/63)	  legislation.	  
	  
1.	  ESTABLISHMENT	  OF	  THE	  OSTEOPOROTIC	  MODEL	  
	  
Establishment	  and	   characterization	  of	   an	  experimental	  osteoporotic	  model	  82	  
adult	   female	   albino	  Wistar	   rats	   (Rattus	   norvegicus),	   7-­‐8	  weeks	   old,	   were	   used.	   At	   2	  
months	  of	   age,	   animals	  were	   randomly	  divided	   into	   two	  groups:	  Ovx	  and	  Sham.	  The	  
Ovx	  group	  of	  animals	  underwent	  a	  bilateral	  ovariectomy	  surgery	  while	  the	  Sham	  group	  
of	   animals	   was	   submitted	   to	   a	   control	   surgical	   procedure.	   Following	   ovariectomy	   or	  
sham	   surgery,	   the	   osteoporotic	   condition	  was	   assessed	   in	   all	   the	   animals	   by	   several	  
procedures.	  
Uterus,	   femur,	   tibiae,	   vertebra,	  maxilla,	   calvarial	   bone	   and	   the	   right	  mandible	  
were	  resected	  and	  adequately	  stored	  for	  posterior	  processment.	  	  
The	  uteri	  were	  dissected,	  collected	  and	  weighted	  in	  three	  time	  periods	  (month	  
3,	  5	  and	  8).	  	  
Blood	   was	   collected	   to	   address	   plasmatic	   parameters	   as	   the	   alkaline	  
phosphatase	  activity,	  calcium,	  phosphorous	  concentrations	  and	  estrogen	   levels	   in	   the	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three	   time	   points	   (month	   3,	   5	   and	   8).	   Albumin,	   Creatine	   kinase,	   Total	   protein	   and	  
Triglycerides,	   in	   Sham	   and	   Ovx	   animal	   groups,	   were	   evaluated	   in	   two	   time	   periods	  
(month	  3	  and	  5).	  	  
The	   resected	  bones	   such	  as	   the	   calvaria,	  mandible,	   tibiae,	   femur,	  maxilla	   and	  
vertebra	   were	   analyzed	   radiographically	   and	   these	   images	   were	   evaluated	   with	   an	  
image	   software	   program	   ImageJ®	   to	   evaluate	   the	   densitometric	   values	   in	   two	   time	  
periods	  (month	  3	  and	  5).	  	  
Proximal	   tibial	   bone	   specimens	   from	   both	   5	   and	   8	  months	   were	   scanned	   by	  
microcomputed	  tomography	  and	  microstructural	  measures	  included	  bone	  volume	  per	  
total	   volume	   (BV/TV),	   connective	   density	   (CD),	   trabecular	   number	   (Tb.N),	   trabecular	  
thickness	  (Tb.Th)	  and	  trabecular	  separation	  (Tb.Sp).	  
The	  femur	  and	  mandible	  were	  subject	  to	  biomechanical	  evaluation	  at	  month	  3.	  
Micro-­‐CT	   evaluation	   of	   the	   mandible	   and	   maxilla	   were	   performed	   in	   a	  
circunscrited	  area	  in	  the	  space	  between	  roots	  of	  the	  1st	  molar,	  at	  month	  3	  and	  5.	  
Harvested	  samples	  were	  evaluated	  by	  routine	  radiographic,	  micro-­‐tomography	  
and	  histological	  techniques,	  at	  the	  described	  time	  points	  (Figure	  10).	  
	  
STUDY	  DESIGN:	  
T1	  ––	  3	  month	  following	  ovariectomy	  (Ovx)	  and	  Sham	  operation	  (Sham)	  	  
T2	  ––	  5	  months	  following	  ovariectomy	  (Ovx)	  and	  Sham	  operation	  (Sham)	  	  






Figure	  10	  –	  Study	  timeline	  of	  the	  ovariectomy	  (Ovx)	  and	  Sham	  operation	  (Sham).	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2.	  ASSESSMENT	  OF	  THE	  CALVARIAL	  BONE	  REGENERATION	  
	  
In	   the	   calvarial	   bone	   regeneration	   assay,	   82	   adult	   female	   albino	   Wistar	   rats	  
(Rattus	   norvegicus),	   7-­‐8	   weeks	   old,	   were	   used.	   The	   animals	   used	   to	   within	   the	  
establishment	   and	   characterization	   of	   an	   experimental	   osteoporotic	   model	   were	  
simultaneously	   enrolled	   for	   the	   assessment	   of	   the	   calvarial	   bone	   regeneration.	  
Following	  2	  months	   (at	  4	  months	  of	  age),	  a	   single	  5mm	   in	  diameter	  bicortical	  defect	  
(CSD-­‐	   Critical	   Size	   Defect)	  was	   created	   in	   the	   skull	   (parietal	   bone)	   of	   Ovx	   and	   Sham	  
animals,	  previously	  to	  the	  implantation	  of	  Bio-­‐Oss®	  (Geistlich)	  .	  Defects	  left	  untreated	  
were	   used	   as	   negative	   controls.	   Animals	   were	   euthanized	   at	   1,	   3,	   and	   6	   months	  
following	   the	   craniotomy	   procedure	   (at	   3,	   5	   and	   8	   months	   after	   the	   ovariectomy	  
procedure	  i.e.,	  at	  5,	  7	  and	  10	  months	  of	  age	  respectively).	  	  
Harvested	  samples	  were	  evaluated	  by	  routine	  radiographic,	  micro-­‐tomography	  
and	  histological	  techniques,	  at	  the	  described	  time	  points	  (Figure	  11).	  
	  	  
STUDY	  DESIGN:	  
T1	  ––	  1	  month	  healing	  following	  craniotomy	  
T2	  ––	  3	  months	  healing	  following	  craniotomy	  	  








Figure	  11	  –	  Study	  timeline	  of	  the	  calvarial	  experiment.	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Figure	  12	  –	  Schematic	  representation	  of	  the	  number	  of	  animals	  used	  for	  experimentation.	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3.	   ASSESSMENT	   OF	   THE	   MANDIBULAR	   BONE	  
REGENERATION	  
	  
In	   the	   study	   for	   the	   mandibular	   bone	   regeneration,	   68	   adult	   female	   albino	  
Wistar	  rats	  (Rattus	  norvegicus),	  7-­‐8	  weeks	  old,	  were	  used.	  At	  2	  months	  of	  age,	  animals	  
were	   randomly	   divided	   into	   two	   groups:	   Ovx	   and	   Sham.	   The	   Ovx	   group	   of	   animals	  
underwent	   a	   bilateral	   ovariectomy	   surgery	   while	   the	   Sham	   group	   of	   animals	   was	  
submitted	   to	  a	  control	   surgical	  procedure.	  Following	  2	  months	   (at	  4	  months	  of	  age),	  
animals	  of	  each	  group	  were	  assigned	  to	  3	  sub-­‐groups:	  Membrane	  (M),	  Membrane	  and	  
Biomaterial	  (MB)	  and	  Control	  (C).	  	  
The	  animals	  were	  subject	  to	  a	  surgery	  of	  a	  4mm	  in	  diameter	  bicortical	  circular	  
defects	   on	   the	   right-­‐half	   ramus	   of	   the	  mandible	   of	   both	   Sham	   and	   Ovx	   animals,	   in	  
order	   to	   address	   the	  guided	  bone	   regeneration	  process.	   The	  membrane	  used	   in	   this	  
study	  was	   Evolution®	   (Osteobiol),	   and	   its	   composed	   by	   100%	  pericardium	  of	   equine	  
origin	   with	   a	   thickness	   of	   0,5-­‐0,7mm.	   The	   used	   biomaterial	   to	   assess	   bone	  
regeneration	   was	   Putty®	   (Osteobiol),	   a	   mix	   of	   80%	   of	   granulated	   cancellous	   and	  
cortical	  porcine	  bone	  with	  a	  granulometry	  ≤300µm	  and	  20%	  of	  collagen	  gel	  (type	  I	  and	  
III).	  
	  In	  the	  Membrane	  group	  (M),	  the	  membranes	  were	  applied	  with	  the	  rough	  side	  
faced	  to	  bone	  to	  optimize	  integration	  and	  positioning.	  The	  defect	  was	  covered	  with	  a	  
barrier	  membrane	   on	   the	   bucal	   and	   lingual	   side.	   In	   the	  Membrane	   and	   Biomaterial	  
group	   (MB)	   the	   defect	   was	   filled	  with	   the	   Putty®	   and	   the	  membrane	  was	   following	  
applied	   as	   in	   the	   M	   group.	   In	   the	   Control	   group	   the	   mandibular	   defect	   was	   left	  
untreated.	  The	  wound	  was	  closed	  in	  layers	  using	  4-­‐0	  resorble	  sutures	  (Vicryl	  Rapid	  4-­‐0,	  
Ethicon,	  Johnson	  &	  Johnson).	  
Animals	  were	  euthanized	  1	  and	  3	  months	  following	  the	  mandibular	  bone	  defect	  
procedure	   (at	   3	   and	   5	   months	   after	   ovariectomy,	   i.e	   at	   5	   and	   7	   months	   of	   age	  	  
respectively).	  	  
Harvested	  samples	  were	  evaluated	  by	  routine	  radiographic,	  micro-­‐tomography	  
and	  histological	  techniques,	  at	  the	  described	  time	  points	  (Figure	  13).	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STUDY	  DESIGN:	  
TE	  1	  –	  1	  month	  healing	  following	  mandibular	  bone	  defect	  








Figure	  13	  –	  Study	  timeline	  of	  the	  mandible	  experiment.	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Animals	  were	  randomized	  according	  to	  the	  following	  group	  organization:	  
	  






















Figure	  14	  –	  Schematic	  representation	  of	  the	  number	  of	  animals	  used	  for	  experimentation.	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B.	  ANIMAL	  CARE	  
	  
After	  assessing	  the	  general	  health	  of	  the	  animals,	  they	  were	  housed	  in	  groups,	  
in	   conventional	   type	   II	   cages,	   on	   a	   controlled	   environment	   of	   temperature	   and	  
humidity,	   in	  a	  12h	  light/dark	  cycle,	  for	  a	  quarantine	  period	  of	  two	  weeks.	  All	  animals	  
were	   clearly	   identified	  using	  nicks	  on	   the	  ears	   (Figure	   15).	  Dry	   feed	   (Mucedola	   S.R.L.®,	  
Italy)	  and	  water	  was	  supplied	  ad	  libitum.	  
During	   the	   experimental	   period	   animals	  were	   housed	   in	   similar	   conditions	   as	  
previously	  described.	  
	  
	  	   	  
Figure	  15	  –	  Animal	  identified	  using	  nicks	  on	  the	  ears.	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C.	  SURGICAL	  PROCEDURES	  
	  
1.	  ESTABLISHMENT	  OF	  OSTEOPOROTIC	  CONDITION	  
	  
• Surgical	  ovariectomy	  (Ovx)	  and	  Sham	  operation	  (Sham)	  
The	  animals	  assigned	  to	  ovariectomy	  were	  weighted	  and	  anesthetized	  by	  the	  
intraperitoneal	  (IP)	  injection	  of	  xylazine	  (10mg/kg)	  (Rompun®	  2%,	  Bayer)	  and	  ketamine	  
(90mg/kg)	  (Imalgene®	  1000,	  Merial)	  (Figures	  9).	  After	  assessment	  of	  the	  anesthetic	  
plane	  an	  IP	  injection	  of	  tramadol	  (10mg/Kg),	  for	  post-­‐operative	  analgesia	  was	  given,	  
and	  the	  skin	  around	  the	  back	  midline	  was	  shaved.	  Animals	  were	  following	  transferred	  
onto	  a	  heating	  pad	  (maintained	  at	  37	  ºC)	  in	  ventral	  recumbency	  and	  the	  operating	  field	  
















Figure	  17–	  Animal	  placement	  in	  ventral	  recumbency.	  The	  
red	  line	  indicates	  the	  incision	  site.	  
Figure	  16	  –	  Weighing	  of	  
the	  animals.	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A	   2-­‐3	   cm	   dorsal	  midline	   skin	   incision	  was	  made	   halfway	  between	   the	   caudal	  
edge	  of	  the	  ribcage	  and	  the	  base	  of	  the	  tail.	  (Figures	  20-­‐21).	  
	  A	  single	  incision	  of	  about	  15	  mm	  long	  was	  made	  into	  the	  muscle	  wall	  on	  both	  
the	  right	  and	  left	  sides	  approximately	  1/3	  of	  the	  distance	  between	  the	  spinal	  cord	  and	  











The	  ovaries	  are	  small	  organs,	  around	  0.5	  cm	  in	  diameter,	  with	  a	  pink-­‐red	  
irregular	  surface,	  connected	  to	  each	  oviduct,	  which	  then	  connects	  to	  the	  uterus	  (Figure	  
22).	  	  
Figure	  18	  –	  Pre-­‐operative	  preparation	  of	  the	  dorsal	  region	  
and	  disinfection	  of	  the	  dorsal	  area	  with	  iodopovidone.	  
Figure	  21	  –	  Incision	  of	  the	  muscular	  layers	  and	  exposure	  of	  
the	  abdominal	  cavity.	  
Figure	  20	  –	  Longitudinal	  incision	  of	  the	  skin	  with	  3	  cm.	  
Figure	  19	  –	  Incision	  of	  the	  skin.	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Figure	  22	  –	  Left	  –	  Anatomical	  representation	  of	  the	  ovaries	  and	  uterus	  following	  exposure	  of	  the	  




















Figure	  23	  –	  Uterus	  and	  its	  irrigation	  system.	  
Figure	  24	  –	  Placement	  of	  ligatures.	  	   Figure	  25	  –	  Placement	  of	  ligatures.	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The	  ovary	  and	  the	  oviduct	  were	  exteriorized	  through	  the	  muscle	  wall	  (Figures	  23-­‐
25).	  
The	  ovary,	   surrounded	  by	  a	   considerable	  amount	  of	   fat,	  was	   identified	   in	   the	  
cranial	  end	  of	  the	  uterus.	  The	  fat	  tissue	  was	  grasped	  and	  the	  ovary	  pulled	  out	  through	  
the	   incision.	   Ligatures	   were	   placed,	   with	   absorbable	   4-­‐0	   sutures	   (Vicryl	   Rapide®,	  
polyglatin	  910),	  around	  the	  uterine	  horns	  together	  with	  some	  fat	  tissue:	  one	  between	  
the	  ovary	   and	   the	  uterus	   and	   the	  other	  one	   in	   the	   cranial	   end,	  blocking	   the	  ovarian	  
artery	  just	  below	  the	  Fallopian	  tube.	  	  
	  Each	  ovary	  and	  part	  of	  the	  oviduct	  was	  removed	  with	  single	  cuts	  through	  the	  




















Figure	  26	  –	  Surgical	  removal	  of	  the	  ovary.	  	   Figure	  27	  –	  Assessment	  of	  hemostasis.	  	  
Figure	  28	  –	  Ovary	  removed.	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  After	   the	   removal	   of	   the	   two	   ovaries	   and	   inspection	   for	   hemorrhage,	   the	  
remaining	   tissue	  was	   replaced	   into	   the	   peritoneal	   cavity.	   The	  muscle	   tissue	   and	   skin	  
were	  sutured,	  with	  absorbable	  4-­‐0	  sutures	  (Vicryl	  Rapide®,	  polyglatin	  910),	  and	  a	  liquid	  
bandage	  was	  placed	  over	  the	  incision	   (Figures	  29-­‐32).	  After	  weighted,	  the	  animals	  were	  
placed	  into	  a	  heat	  recovering	  chamber,	  until	  full	  recovery	  from	  anesthesia.	  	  
The	   same	   procedure	   was	   performed	   to	   all	   animals	   assigned	   to	   the	   Sham	  
operated	   group,	   with	   the	   exception	   of	   placement	   of	   the	   ligatures	   and	   the	   ovaries	  
removal.	  	  
	  










	   	  
Figure	  30	  –	  Suture	  of	  the	  skin.	  Figure	  29–	  Suture	  of	  the	  muscle.	  
Figure	  32	  –	  Disinfection	  of	  the	  skin.	  Figure	  31	  –	  Suture	  of	  the	  skin.	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2.	  ESTABLISHMENT	  OF	  CALVARIAL	  DEFECT	  
	  
Surgical	   craniotomies	   were	   performed	   and	   aimed	   to	   establish	   a	   critical	   size	  
defect	   (CSD)	   with	   5	   mm	   in	   diameter,	   in	   which	   the	   biomaterial	   bone-­‐mediated	  
regeneration	   process	   was	   accessed.	   Both	   Ovx	   and	   Sham	   groups	   of	   animals	   where	  
submitted	  to	  craniotomy	  procedures.	  
Prior	   to	   the	   intervention,	   all	   animals	  were	  weighted	   and	   anesthetized	   by	   the	  
intraperitoneal	   (IP)	   injection	   of	   xylazine	   (10mg/kg)	   (Rompun®	   2%,	   Bayer)	   	   and	  
ketamine	   (90mg/kg)	   (Imalgene®	   1000,	   Merial)(Figures	   9).	   After	   assessment	   of	   the	  
anesthetic	   plane	   an	   IP	   injection	   of	   tramadol	   (10mg/Kg)	   (Tramal®,	   Pfizer),	   for	   post-­‐
operative	  analgesia	  was	  given.	  A	  subcutaneous	  injection	  of	  0,3-­‐0,4	  ml	  of	  1%	  lidocaine	  
(Lidocaina	   1%,	   Braun®),	   was	   conducted	   for	   enhanced	   local	   anesthesia.	   After	  
assessment	   of	   the	   anesthetic	   plane,	   the	   skin	   around	   the	   incision	   was	   shaved	   and	  
disinfected	  with	  iodopovidone	  solution	  (Fig.33-­‐34).	  
Animals	  were	  following	  transferred	  onto	  a	  heating	  pad	  (maintained	  at	  37	  ºC)	  in	  
ventral	  recumbency	  and	  the	  surgical	  field	  was	  placed	  (Figures	  35-­‐36).	  
	   	  
Figure	   34	   –	   Pre-­‐operative	   preparation	   of	   the	   calvarial	  
region	  -­‐	  tricotomy.	  	  
Figure	  33	  –	  Anesthetized	  animal	  in	  ventral	  recumbent.	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Following,	   a	  midline	   incision	   through	   the	   skin	   allowed	   access	   to	   the	   calvarial	  
bone.	  The	  skin	  was	  then	  reflected	  bilaterally	  and	  a	  midline	  periosteal	  incision	  (around	  
3	  cm	  long),	  allowed	  the	  division	  of	  the	  subcutaneous	  fascia	  and	  the	  bilateral	  reflection	  
of	  the	  periosteal	  flaps,	  following	  blunt	  dissection,	  to	  expose	  the	  calvarial	  bone	  surface	  












A	   trephine	   bur	   (external	   diameter	   of	   5mm,	   Komet®	   ref.050/5)	   was	   used	   to	  
establish	  one	  CSD,	  in	  the	  mid-­‐portion	  of	  each	  parietal	  bone	  (Figures	  39-­‐42).	  
Figure	  36	  –	  Surgical	  field	  placed.	  Figure	   35	   –	   The	   calvarial	   region	   was	   disinfected	   with	  
iodopovidone.	  
Figure	   38	   –	   Incision	   on	   the	   periosteum	   and	   exposure	   of	  
calvarial	  bone	  surface.	  
Figure	  37	  –	  Incision	  on	  the	  skin.	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The	  trephines	  were	  mounted	  on	  a	  low-­‐speed	  dental	  handpiece	  (WH®	  model	  WS	  
56E,	   Implantmed)	   and	   trephination	   was	   conducted	   with	   permanent	   irrigation	   with	  
sterile	  saline	  solution.	  Careful	  drilling	  aimed	  to	  prevent	  the	  damage	  the	  dura	  mater	  or	  
the	  underlying	  blood	  vessels	  and	  sinus.	  	  
CSD	   defects	   were	   then	   washed	   with	   saline	   solution	   and,	   according	   to	   the	  
protocol,	  left	  unfilled	  (negative	  control)	  or	  filled	  with	  Bio-­‐Oss®	  (with	  a	  granulometry	  of	  






















Figure	  39	  –	  Trephine	  bur	  with	  5mm	  of	  external	  diameter.	   Figure	  40	  –	  Trepanation	  of	  the	  calvaria.	  
Figure	  41	  –	  Sulcular	  definition	  of	  the	  CSD	  in	  the	  calvaria.	   Figure	  42	  –	  Defect	  of	  the	  calvaria	  achieve	  with	  the	  removal	  
of	  the	  bone.	  Note	  that	  the	  sinus	  is	  intact.	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The	  surgical	  wound	  was	  then	  closed	  in	  layers	  with	  4-­‐0	  resorbable	  suture	  (Vicryl	  
Rapide®,	   polyglatin	   910).	   Finally,	   the	   wound	   closed	   area	   was	   cleaned	   with	  












Following	   surgical	   intervention,	   the	   animals	   were	   given	   a	   subcutaneous	  
injection	  of	  sterile	  saline	  (10	  mL/kg/h	  of	  surgery).	  The	  rats	  were	  placed	  in	  soft-­‐bedded	  
plastic	   cages	   and	   housed	   individually	   after	   the	   procedure.	   Each	   animal	   received	   a	  
subcutaneous	   injection	   of	   tramadol	   (10	  mg/kg)	   (Tramal®,	   Pfizer)	   at	   12,	   24	   and	   36	   h	  
Figure	   43	   –	   Calvarial	   critical	   defect	   implanted	   with	   Bio-­‐
oss®.	  	  
Figure	  45	  –	  Suture	  of	  the	  skin.	  Figure	  44	  –	  Suture	  of	  the	  periosteum.	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after	  surgery	  for	  continued	  postoperative	  analgesia.	  Animals	  were	  given	  free	  access	  to	  
food	   and	   water	   and	   were	   monitored	   daily,	   in	   the	   postoperative	   period	   until	  
euthanasia,	   for	   any	   complications	   or	   abnormal	   behavior.	   Seven	   days	   following	  




The	  animals	  were	  euthanized	  at	  the	  determined	  timepoints	  (Figure	  11).	  Animals	  
were	   weighted	   and	   anesthetized	   by	   intraperitoneal	   injection	   of	   10mg/kg	   xylazine	  
(Rompun®	  2%,	  Bayer)	  and	  90mg/kg	  ketamine(Imalgene®	  1000,	  Merial)	  and	  euthanized	  
by	  exsanguination,	  following	  the	  assessment	  of	  the	  anesthetic	  plane.	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3.	  ESTABLISHMENT	  OF	  MANDIBULAR	  DEFECT	  
	  
The	  mandibular	  bone	  defects	  were	  performed	  and	  aimed	   to	  establish	  a	  bone	  
defect	   with	   4	   mm	   in	   diameter,	   aiming	   to	   evaluate	   the	   guided	   bone	   regeneration	  
process.	   Both	  Ovx	   and	   Sham	   groups	   of	   animals	  where	   submitted	   to	   the	  mandibular	  
bone	  defect	  procedures.	  
The	  animals	  were	  subject	  to	  a	  surgery	  to	  perform	  a	  bicortical	  circular	  defect	  on	  
the	  right-­‐half	  ramus	  of	  the	  mandible	  with	  a	  4	  mm	  in	  diameter.	  The	  membrane	  used	  in	  
this	  study	  was	  an	  Evolution®,	  composed	  by	  100%	  pericardium	  of	  equine	  origen	  with	  a	  
thickness	  of	  0,5-­‐0,7mm.	  The	  biomaterial	  to	  assess	  bone	  regeneration	  was	  Putty®,	  a	  mix	  
of	   cancellous	   and	   cortical	   porcine	   bone	  with	   a	   granulometry	   ≤300µm	   (80%)	   20%	   of	  
collagen	  gel	  (type	  I	  and	  III).	  
In	  the	  Membrane	  group	  (M),	  the	  membranes	  were	  applied	  with	  the	  rough	  side	  
faced	  to	  bone	  to	  optimize	  integration	  and	  positioning.	  The	  defect	  was	  covered	  with	  a	  
barrier	  membrane	   on	   the	   bucal	   and	   lingual	   side.	   In	   the	  Membrane	   and	   Biomaterial	  
group	  (MB)	  the	  defect	  was	  filled	  with	  the	  Putty®	  and	  the	  membrane	  was	  applied	  as	  in	  
the	  M	  group.	  In	  the	  Control	  group	  the	  mandibular	  defect	  was	  left	  untreated.	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Prior	   to	   the	   intervention,	   all	   animals	   were	   weighted	   and	   anesthetized	   using	  
intraperitoneal	  (IP)	  injection	  of	  xylazine	  (10mg/kg)	  (Rompun®	  2%,	  Bayer)	  and	  ketamine	  
(90mg/kg)	  (Imalgene®	  1000,	  Merial).	  An	  IP	   injection	  of	  tramadol	  (10mg/Kg)	  (Tramal®,	  
Pfizer)	  for	  post-­‐operative	  analgesia	  was	  given,	  and	  animals	  were	  then	  transferred	  onto	  
a	  heating	  pad,	  maintained	  at	  37	  ºC,	  in	  the	  operating	  field.	  A	  subcutaneous	  injection	  of	  
0,3-­‐0,4	  ml	  of	  1%	  lidocaine	  (Lidocaina	  1%,	  Braun®),	  was	  conducted	  for	  enhanced	   local	  
anesthesia.	  After	  assessment	  of	  the	  anesthetic	  plane,	  the	  skin	  around	  the	  incision	  was	  














Following,	  a	  submandibular	  skin	  incision	  (around	  2	  cm	  long)	  was	  made,	  which	  
incised	  the	  masseter	  muscle	  and	  periosteum.	  The	  skin	  and	  muscle	  was	  then	  reflected	  
bilaterally	  and	  following	  blunt	  dissection,	  the	  mandibular	  bone	  surface	  was	  exposed	  









Figure	   47	   –	   The	   mandibular	  
region	   was	   disinfected	   with	  
iodopovidone	   following	  
tricotomy.	  
Figure	   46	   –	   Pre-­‐operative	  
preparation	  of	   the	  mandibular	  
region.	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With	   a	   trephine	   bur	   (external	   diameter	   of	   4	   mm,	   Komet®	   ref.040/2.9),	   a	  











The	  trephines	  were	  mounted	  on	  a	  low-­‐speed	  dental	  handpiece	  (WH®	  model	  WS	  
56E,	   Implantmed)	   and	   trephination	   was	   conducted	   with	   permanent	   irrigation	   with	  
sterile	  saline	  solution.	  Careful	  drilling	  aimed	  to	  prevent	  the	  damage	  the	  submandibular	  
structures	  as	  the	  underlying	  blood	  vessels	  and	  nerves.	  	  
The	   mandibular	   bone	   defects	   were	   then	   washed	   with	   saline	   solution	   and,	  
according	  to	  the	  protocol,	  the	  negative	  control	  (C)	  was	  left	  unfilled,	  in	  the	  Membrane	  
Figure	  49	  –	  Incision	  on	  the	  skin.	  Figure	  48	  –	  Surgical	  field	  placed.	  
Figure	  51	  –	  Exposure	  of	  mandibular	  bone	  surface.	  Figure	  50	  –	  Incision	  on	  the	  muscle.	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group	   (M),	   the	  membranes	  were	   applied	   around	   the	  mandibular	   bone	  defect	   and	   in	  
the	  Membrane	  and	  Biomaterial	  group	  (MB)	  the	  defect	  was	  filled	  with	  the	  Putty®	  and	  

























Figure	  52	  –	  Trephine	  bur	  with	  4	  mm	  of	  external	  diameter.	  
Figure	  53	  –	  Establishment	  of	  the	  defect	  on	  the	  right	  
mandible.	  
Figure	  54	  –	  The	  membrane	  was	  placed	  on	  the	  lingual	  side	  
of	  the	  mandible.	  
Figure	  55	  –	  Mandibular	  bone	  defect	  implanted	  with	  
Putty®.	  	  
Figure	  56	  –	  The	  membrane	  placed	  around	  the	  mandibular	  
defect.	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The	   membrane	   was	   placed	   on	   the	   lingual	   and	   buccal	   side	   of	   the	   mandible,	  
surrounding	   the	   defect.	   A	   4-­‐0	   resorbable	   suture	   (Vicryl	   Rapide®,	   polyglatin	  910)	  was	  
placed	  around	  the	  membrane	  that	  allowed	  to	  secure	  it.	  	  
The	  muscular	  layer	  was	  then	  closed	  in	  layers	  with	  4-­‐0	  resorbable	  suture	  (Vicryl	  
Rapide®,	   polyglatin	   910)	   and	   the	   skin	   was	   closed	   with	   4-­‐0	   non-­‐resorbable	   suture	  
(Silkam®	  natural	  non-­‐absorbable	   suture	  made	  of	   silk).	   Finally,	   the	  wound	  closed	  area	  






















Figure	  59	  –	  Suture	  of	  the	  skin.	   Figure	  60	  –	  Disinfection	  of	  the	  surgical	  wound	  with	  
iodopovidone.	  
Figure	  58	  –	  Suture	  of	  the	  muscle	  layer.	  	  Figure	  57	  –	  Suture	  of	  the	  mandibular	  defect.	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Following	   surgical	   intervention,	   the	   animals	   were	   given	   a	   subcutaneous	  
injection	  of	  sterile	  saline	  (10	  mL/kg/h	  of	  surgery).	  The	  rats	  were	  placed	  in	  soft-­‐bedded	  
plastic	   cages	   and	   housed	   individually	   after	   the	   procedure.	   Each	   animal	   received	   a	  
subcutaneous	   injection	   of	   tramadol	   (10	  mg/kg)	   (Tramal®,	   Pfizer)	   at	   12,	   24	   and	   36	   h	  
after	  surgery	  for	  continued	  postoperative	  analgesia.	  Animals	  were	  given	  free	  access	  to	  
food	  and	  water	  and	  were	  monitored	  daily,	  in	  the	  postoperative	  period	  until	  euthanasia,	  
for	  any	  complications	  or	  abnormal	  behavior.	  Seven	  days	  following	  the	  mandibular	  bone	  




The	   animals	   were	   sacrificed	   after	   1	   and	   3	   months	   of	   the	   mandibular	   bone	  
defect	   procedure,	   according	   to	   the	   time	   line	   procedure	   (Figure	   13).	   Animals	   were	  
weighted	  and	  anesthetized	  by	  intraperitoneal	  injection	  of	  xylazine	  10mg/kg	  (Rompun®	  
2%,	   Bayer)	   and	   ketamine	   90mg/kg	   (Imalgene®	   1000,	   Merial)	   and	   euthanized	   by	  
exsanguination,	  following	  the	  assessment	  of	  the	  anesthetic	  plane.	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D.	  SAMPLE	  COLLECTION	  
	  
The	  animals	  from	  both	  bone	  regeneration	  experiments	  were	  subject	  to	  sample	  
and	  data	  collection	  to	  evaluate	  the	  osteoporotic	  condition	  as	  described	  below:	  
	  
BLOOD	  COLLECTION	  AND	  PLASMA	  SEPARATION	  
	  
Cardiac	  puncture	  aimed	  to	  collect	  blood	  for	  determination	  of	  plasmatic	  markers	  
of	  bone	  remodeling	  and	  estrogen	  levels.	  	  
Blood	   was	   collected	   into	   a	   heparinized	   tube	   previously	   to	   centrifugation.	  
Centrifugation	   protocol	   (5000	   rpm/15	   minutes	   at	   room	   temperature)	   aimed	   to	  
separate	  plasma	  from	  the	  cellular	  component	  of	  the	  blood	  (Figures	  61-­‐62).	  	  
	  
	   	  
Figure	  61	  –	  Collection	  of	  the	  blood	  from	  the	  left	  ventricle.	  	  
Figure	  62	  –	  Plasma	  separation	  by	  
centrifugation.	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NECROPSY	  
	  
Internal	  cavities	  were	  assessed	  for	  pathological	  organ	  alterations	  and	  presence	  
of	  abnormal	  fluids.	  Uterus,	  femur,	  tibiae,	  vertebra,	  maxilla,	  calvarial	  bone	  and	  the	  
mandible	  were	  resected	  and	  adequately	  stored	  for	  posterior	  processment.	  	  
	  
COLLECTION	  OF	  THE	  UTERUS	  
	  









	   	  
Figure	  63	  –	  Uterus	  from	  an	  Ovx	  group	  animal,	  at	  month	  6.	   Figure	  64	  –	  Uterus	  from	  a	  Sham	  group	  animal,	  at	  month	  6.	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COLLECTION	   OF	   BONES	   (FEMURS,	   TIBIAS,	   MAXILLA,	  
MANDIBLE,	  CALVARIA	  AND	  VERTEBRAE)	  
	  
Femur,	   tibiae,	   maxilla,	   left	   mandible,	   rigth	   mandible,	   calvarial	   and	   vertebrae	  
were	   removed,	   cleaned	   for	   soft-­‐tissue	   and	   stored	   at	   4oC	   in	   buffered	   natural	  
formaldehyde	   10%	   to	   adress	   evaluation	   by	   x-­‐ray,	  Micro-­‐CT	   and	   histological	   analysis	  
(Figures	  65–75).	  
Some	  of	  the	  femurs	  and	  mandibles	  were	  forthwith	  stored	  at	  -­‐80°C,	  to	  perform	  




















Figure	  66	  –	  View	  of	  the	  tibiae.	  Figure	  65	  –	  View	  of	  the	  femur.	  
Figure	  67	  –	  Palatine	  view	  of	  the	  maxilla.	   Figure	  68	  –View	  of	  the	  calvaria.	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Figure	  69	  –	  Top	  view	  of	  the	  calvaria	  bone	  of	  the	  CSD	  
without	  Bio-­‐oss®.	  
Figure	  70	  –	  Calvarial	  bone	  block	  of	  the	  CSD	  without	  Bio-­‐
oss®.	  
Figure	  73	  –	  Buccal	  view	  of	  the	  rigth	  mandible.	   Figure	  74	  –	  Lingual	  view	  of	  the	  rigth	  mandible.	  
Figure	  71	  –	  Top	  view	  of	  the	  calvaria	  bone	  of	  the	  CSD	  with	  
Bio-­‐oss®.	  
Figure	  72	  –	  Calvarial	  bone	  block	  of	  the	  CSD	  with	  Bio-­‐oss®.	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Figure	  75	  –	  View	  of	  the	  left	  mandible,	  without	  
intervention.	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E.	  DATA	  COLLECTION	  
	  





The	  attained	  plasma	  was	  pipetted	  and	  stored	  at	  -­‐80	  ºC	  until	  the	  determination	  
of	   plasmatic	   parameters.	   Alkaline	   phosphatase	   activity,	   calcium,	   phosphorous	   ,	  
albumin,	   total	   protein,	   triglycerides	   and	   creatine	   cinase	   concentrations	   were	  
determined	   in	   an	   autoanalyzer	   (PRESTIGE	   24i,	   Cormay)	   and	   estrogen	   levels	   were	  
assessed	   by	   an	   ELISA	   kit	   (Mouse/Rat	   Estradiol	   (E2)	   ELISA	   Kit	   –	   Calbriotech,	   USA)	   –	  
Sensitivity	  <3pg/mL.	  
	  
X-­‐RAY	  DENSITOMETRIC	  ANALYSIS	  OF	  THE	  BONES	  
	  
The	   resected	  bones	   such	  as	   the	   calvaria,	  mandible,	   tibiae,	   femur,	  maxilla	   and	  
vertebra	  were	  analyzed	  radiographically.	  
Imaging	   protocol	   and	   computer	   image	   analysis	   was	   achieved	   with	   a	   RVG	  
intraoral	   sensor	   (KODAK®	   RVG	   5100,	   USA)	   and	   processed	   with	   software	   KODAK®	  
Dental	   Imaging	   Software	   6.8.6.0.	   As	   a	   source	   of	   X-­‐ray,	   a	   conventional	   X-­‐ray	   tube	  
(Trophy,	  type	  708,	  long	  cone,	  8mA,	  70kV)	  was	  used.	  The	  relative	  position	  of	  the	  sensor	  
and	   exposure	   time	  was	   constant	   for	   all	   specimens	   (film-­‐focus	   distance	   of	   20cm	   and	  
exposure	  time	  of	  0.2seg).	  	  
These	  images	  were	  evaluated	  with	  an	  image	  software	  program	  ImageJ®.	  This	  	  is	  
a	  	  Java-­‐based	  image	  processing	  program	  developed	  at	  the	  National	  Institutes	  of	  Health	  
that	   allows	  processing	  of	   	  digital	   images.	   [336,	   337]	   This	   software	   can	   calculate	   area	  
and	  pixel	   value	   statistics	   in	   determined	   regions	  of	   interest	   (ROIs)	   and	   create	  density	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histograms	  and	  line	  profile	  plots.	  The	  density	  or	  gray	  scale	  calibration	  measured	  is	  also	  
available	  and	  brightness	  values	  of	  images	  are	  calculated,	  that	  allow	  us	  to	  retrived	  the	  
intensity	  statistics	  (Mean,	  Modal,	  Median,	  Min.	  &	  Max.	  Gray	  Value,	  Standard	  Deviation	  
and	   Integrated	  Density)	   that	  were	   performed	  on	   the	   definied	   ROI	   for	   each	   bone,	   to	  
assess	   the	   bone	   regeneration	  process	   in	   the	   calvaria	   and	  mandible	   and	   to	   adress	   te	  










For	   the	  densitometric	   analysis,	   regions	  of	   interest	   (ROIs)	  were	  defined.	   These	  
regions	   for	   the	  assessment	  of	   tibiae,	   femur,	  maxilla,	  mandible,	  calvarial	  and	  vertebra	  
bones,	  were	   established	   as	   seen	   in	   the	   images	   to	   evaluate	   the	   densitometric	   values	  
(Figures	  78-­‐83).	  	  
Intensity	   of	   signal	  was	   evaluated	   in	  unprocessed	  TIFF	   files	   and	  normalized	  by	  
the	  intensity	  of	  aluminium	  references.	  	  
	  
	   	  
Figure	  76	  -­‐	  Placement	  of	  the	  bones	  for	  x-­‐ray	  
collection.	  
Figure	  77	  –	  X-­‐ray	  acquirement.	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Figure	  78	  –	  ROI	  of	  the	  tibiae.	   Figure	  79	  –	  ROI	  of	  the	  femur.	  
Figure	  80	  –	  ROI	  of	  the	  vertebra.	   Figure	  81	  –	  ROI	  of	  the	  calvaria.	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Figure	  82	  –	  ROI	  of	  the	  maxilla.	  Interradicular	  space	  in	  the	  2nd	  molar.	  
Figure	  83	  –	  ROI	  of	  the	  mandible.	  Interradicular	  space	  in	  thedistal	  root	  	  of	  the	  1st	  
molar.	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MICRO-­‐CT	  ANALYSIS	  	  OF	  THE	  TIBIAE	  
	  
Proximal	   tibial	   bone	   specimens	   from	   both	   8	   months	   Sham	   and	   Ovx	   animals	  
were	  scanned	  by	  microcomputed	  tomography	  (μCT).	  The	  μCT	  was	  performed	  using	  a	  
desktop	  scanner	  (μCT	  35;	  Scanco	  Medical,	  Bruttisellen,	  Switzerland)	  with	  a	  voxel	  size	  of	  
12	   mm,	   an	   X-­‐ray	   tube	   voltage	   of	   70	   kVp,	   current	   intensity	   of	   114	   mA,	   and	   an	  
integration	   time	   of	   600	   ms.	   A	   volume	   of	   interest	   was	   manually	   drawn	   on	   each	  
specimen	   to	   include	   the	   trabecular	   structure	   of	   the	   proximal	   tibia.	   Structural	  
evaluation	   was	   carried	   out	   using	   the	   version	   6.0	   of	   the	   Scanco	   Medical	   software.	  
Microstructural	  measures	  included	  bone	  volume	  per	  total	  volume	  (BV/TV),	  connective	  
density	   (CD),	   trabecular	   number	   (Tb.N),	   trabecular	   thickness	   (Tb.Th)	   and	   trabecular	  
separation	  (Tb.Sp).	  The	  computation	  of	  these	  structural	  measures	  has	  previously	  been	  




The	  femur	  and	  mandible	  were	  subject	  to	  biomechanical	  evaluation	  by	  using	  an	  
Instron	  1186	  Materials	  Testing	  System	   (Instron	  Corp.)	  and	  a	   JJ	   Instruments	   force	  cell	  
with	  5000N.	  Force	  records	  were	  collected	  using	  LabView	  2.0	  data	  acquisition	  software	  
(National	  Instruments).	  
The	  femurs	  and	  mandible	  were	  stored	  at	  -­‐80°C.	  The	  samples	  were	  defrosted	  to	  
room	  temperature,	  before	  the	  analysis.	  These	  were	  kept	  moist	  during	  the	  preparation	  
and	  testing	  using	  physiological	  saline	  solution.	  The	  maximum	  load	  (N),	  ultimate	  stress	  
(mpa)	  and	  young´s	  module	   (gpa)	  were	  evaluated,	  on	   the	  diaphysis	  of	   the	   femur	  and	  
mandible	   from	  each	  group.	  Both	  groups	  Sham	  and	  Ovx	  were	  assessed	  at	  month	  3	  of	  
the	  osteoporotic	  condition.	  Each	   femur	  were	  placed	  on	   two	  supports	   spaced	  12	  mm	  
apart,	   and	   load	   was	   applied	   to	   the	   bone	   midway	   between	   the	   supports	   at	   a	  
deformation	  rate	  of	  1	  mm/minute	  until	  failure.	  The	  femurs	  were	  positioned	  such	  that	  
bending	  occurred	  about	  the	  medial-­‐lateral	  axis.	  	  
	  
MATERIALS	  AND	  METHODS	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  152	  
2.	   CHARACTERIZATION	   OF	   THE	   CALVARIAL	   AND	  
MANDIBULAR	  BONE	  REGENERATION	  MODELS	  	  
X-­‐RAY	  DENSITOMETRIC	  ANALYSIS	  	  
	  
The	  resected	  bones	  of	  the	  calvaria	  of	  the	  CSD	  calvarial	  bone	  regeneration	  and	  
the	   rigth	   mandible	   with	   the	   bone	   regeneration	   procedure	   were	   analyzed	  
radiographically.	  
Imaging	   protocol	   and	   computer	   image	   analysis	   was	   achieved	   with	   a	   RVG	  
intraoral	   sensor	   (KODAK®	   RVG	   5100,	   USA)	   and	   processed	   with	   software	   KODAK®.	  
These	   images	   were	   evaluated	   with	   an	   image	   software	   program	   ImageJ®	   as	   seen	  
previously	  in	  the	  protocol	  for	  evaluation	  of	  the	  osteoporotic	  condition.	  
In	  the	  assessment	  of	  the	  bone	  regeneration	  of	  CSD	  of	  the	  calvarial	  bone	  defect,	  
circular	  ROIs	  with	  5	  mm	  in	  diameter	  were	  established,	  as	  the	  original	  bone	  defect,	  as	  
seen	  in	  the	  image	  (Figure	  84).	  To	  assess	  the	  bone	  regeneration	  of	  CSD	  of	  the	  mandibular	  
bone	   defect,	   circular	   ROIs	   with	   4	  mm	   in	   diameter	   were	   established,	   as	   the	   original	  
bone	   defect,	   as	   seen	   in	   the	   image	   (Figure	   85).	   Intensity	   of	   signal	   was	   evaluated	   in	  
unprocessed	  TIFF	  files	  and	  normalized	  by	  the	  intensity	  of	  aluminium	  	  or	  gutta-­‐percha	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Figure	  84	  –	  ROI	  of	  the	  CSD	  of	  the	  calvaria.	  
Figure	  85	  –	  ROI	  of	  the	  mandible.	  Circular	  region	  with	  4mm	  of	  diameter	  such	  as	  the	  
original	  bone	  defect.	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MICRO-­‐CT	  ANALYSIS	  	  	  
	  
Micro-­‐CT	   imaging	  of	   the	  calvarias	   from	  both	  6	  months	  Sham	  and	  Ovx	  animals	  
were	  performed.	  The	  mandibles	  were	  evaluated	  at	  month	  1	  and	  3,	  both	  the	  Sham	  and	  
Ovx	  animals.	  The	  μCT	  was	  performed	  with	  a	  desktop	  scanner	  (μCT	  35;	  Scanco	  Medical,	  
Bruttisellen,	  Switzerland)	  with	  a	  voxel	  size	  of	  12	  mm,	  an	  X-­‐ray	  tube	  voltage	  of	  70	  kVp,	  
current	  intensity	  of	  114	  mA,	  and	  an	  integration	  time	  of	  600	  ms.	  The	  volume	  of	  interest	  
(VOI)	  was	  manually	   selected	   involving	   the	  area	  of	   the	  defect.	  Quantification	  of	  bone	  
volume	  was	  performed	  using	  MicroView	  software	  (GE	  Healthcare).	  
	  
HISTOLOGIC	  ANALYSIS	  	  
	  
The	   area	   of	   the	   original	   surgical	   defect	   and	   the	   surrounding	   tissues	   were	  
removed	   in	   one	   piece.	   In	   the	   cut	   of	   the	   calvaria	   and	   mandible,	   a	   bone	   saw	   with	  
mechanical	   cooling	  was	  used,	  ensuring	   the	   integrity	  of	  all	  margins	  of	   the	  defects.	  All	  
the	   specimens	  were	   prepared	   for	   non-­‐decalcified	   histological	   study,	   according	   to	   an	  
established	  protocol.[339]	  
Briefly,	  the	  blocks	  were	  fixed	  in	  10%	  neutral	  formalin,	  pH	  7.4.	  After	  the	  fixation	  
period,	   the	   process	   of	   continuous	   agitation	   in	   a	   dehydration	   and	   infiltration	   system	  
(Exakt	   510)	   was	   established.	   The	   samples	   were	   immersed	   in	   a	   growing	   series	   of	  
ethanol	  concentrations	  followed	  by	  the	  infiltration	  in	  growing	  series	  of	  methacrylate	  in	  







	   Figure	  86	  –	  Dehydration	  &	  Infiltration	  System	  (Exakt	  510).	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The	  subsequent	  stage	  was	   to	  embed	  the	  samples	   in	  a	   resin	   (EXAKT	  Technovit	  
7200	  VLC	  Embedding	  media)	  and	  its	  photopolimerization	  in	  a	  light	  polymerization	  unit	  










After	   the	   polymerization,	   the	   blocs	   were	   set	   up	   in	   an	  	  
acrylic	  sheet	  (50x100x1,	  5	  mm)	  with	  a	  specific	  methacrylate	  resin	  (Technovit	  4000).	  	  
	  This	  allowed	  the	  blocks	  to	  maintain	  with	  parallel	  surfaces,	   including	  the	  areas	  









The	  samples	  were	  cut	  in	  a	  microtome	  for	  hard	  tissues	  (Exakt	  310	  CP).	  This	  is	  a	  
precision	  cutting	  system	  with	  regulator	  speed	  and	   irrigation,	  using	  a	  band	  saw	   (Figure	  
90).	   Following,	   the	   samples	   were	   grinded	   in	   a	   polishing	   turntable,	   with	   adjustable	  
speed	  and	  permanent	  irrigation	  (Exakt	  400	  CS)	  (Figure	  91).	  The	  control	  of	  the	  thickness	  
Figure	  87	  –	  Light	  Polymerization	  Unit	  (EXAKT	  520)	  and	  
embedding	  media	  (Technovit	  7200	  VLC).	  
Figure	  89	  –	  Cut	  of	  the	  block	  with	  the	  
sample.	  
Figure	  88	  –	  Block	  with	  the	  sample	  of	  the	  
mandibles.	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was	  carried	  out	  at	  a	  constant	  weight	  of	  50	  grams.	  The	  slides	  were	  prepared	  in	  the	  final	  
sandwich	   technique	   using	   a	   light-­‐cured	   resin	   (Technovit	   7210	   VLC)	   as	   glue	   between	  
layers.	  The	  final	  thickness	  of	  around	  50	  µm	  was	  obtained	  by	  cutting	  with	  a	  saw	  band,	  
followed	  by	  polishing	  with	  calibrated	  disks,	  decreasing	  in	  grain	  size.	  The	  final	  thickness	  










The	  sections	  were	  stained	  with	  Toluidine	  blue	  for	  analysis	  by	  light	  microscope	  
Oympus®	  CX31	  with	  DP-­‐25	  Camera	  (Imaging	  Software	  Cell^B)	  (Fig.	  92)	  and	  by	  











Figure	  90	  –	  EXAKT	  310	  CP.	   Figure	  91	  –	  EXAKT	  400	  CS.	  
Figure	  93–	  Olympus®	  CX31	  
with	  DP-­‐25	  Camera.	  
Figure	  92	  –	  Nikon®	  SMZ800.	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HISTOMORPHOMETRIC	  ANALYSIS	  	  
	  
The	   most	   central	   portion	   of	   each	   defect	   of	   the	   calvarial	   bone	   defect	   and	  
mandibular	  bone	  defect	  from	  both	  groups,	  Sham	  and	  Ovx,	  at	  all	  the	  time	  points	  of	  the	  
study,	  were	  identified	  and	  subjected	  to	  histomorphometric	  analysis.	  The	  sections	  were	  
viewed	   and	   evaluated	   for	   new	   bone	   formation	   by	   two	   calibrated	   and	   blinded	  
examiners	  using	  a	  light	  microscope,	  for	  high	  magnifications.	  
Histomorphometric	   analyses	   were	   performed	   with	   appropriate	   software	  
(Image-­‐Pro	  Plus®	  (version	  6.0.0.260),	  Media	  Cybernetics,	  Berkshire,	  UK)	  which	  allowed	  
calibrated	  calculation	  of	  the	  area	  of	  tissue	  sections.	  	  
The	   total	   bone	   area,	   newly	   formed	   bone	   area,	   and	   bone	   substitute	  
(biomaterial)	  area	  were	  manually	  delimited.	  Following,	  bone	  volume	  per	  tissue	  volume	  
(BV/TV;	  i.e.	  the	  percentage	  of	  newly	  formed	  bone	  in	  the	  region	  of	  interest)	  and	  bone	  
substitute	  volume	  per	  tissue	  volume	  (BSV/TV;	  i.e.	  the	  percentage	  of	  bone	  substitute	  in	  
the	  region	  of	  interest)	  were	  determined.	  
	  
QUANTITATIVE	  REAL-­‐TIME	  PCR	  EVALUATION	  
	  
Regenerating	   bone	   samples	  were	   harvested	   from	   calvarial	   tissue,	   at	  month	   6	  
following	  the	  craniotomy	  from	  both	  groups	  Sham	  and	  Ovx.	  These	  sections	  enclosed	  a	  
bone	  volume	  exceeding	  the	  defect	  region	  by	  2mm.	  The	  samples	  were	  frozen	  in	  liquid	  
nitrogen	  and	  grinded	  to	  powder	   in	  a	  mortar.	  Following,	   total	  RNA	  was	   isolated	  using	  
the	   TRIzol	   reagent	   (Invitrogen,	   Germany)	   according	   to	   the	   manufacturer's	   protocol.	  
The	  concentration	  of	  the	  total	  RNA	  was	  determined	  using	  a	  spectrophotometer.	  cDNA	  
was	   synthesized	   from	   0.5	   μg	   of	   total	   RNA	   using	   a	   commercial	   first-­‐strand	   cDNA	  
synthesis	   kit	   (QIAGEN,	   Germany).	   Reverse	   transcription	   PCR	   was	   performed	   in	  
triplicate	  for	  each	  sample,	  using	  primers	  specific	  for	  amplification	  of	  rat	  alpha-­‐1	  type	  I	  
collagen	  (Col	  I),	  osteocalcin	  (OC),	  Runt-­‐related	  transcription	  factor	  2	  (RUNX2),	  estrogen	  
receptor-­‐alpha	   (ER-­‐a),	   estrogen	   receptor-­‐beta	   (ER-­‐b)	   and	   peroxisome	   proliferator-­‐
activated	   receptor	   gamma	   (PPAR-­‐g)	   genes.	   Sequences	   of	   the	   used	   primers	   are	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presented	   in	   Table	   8.	   Real-­‐time	   PCR	   reactions	  were	   performed	   using	   SYBRGreen	   in	   a	  
7900HT	  Fast	  Real-­‐Time	  PCR	  System	  (Applied	  Biosystems).	  To	  discriminate	  specific	  from	  
nonspecific	   PCR	   products,	   a	   melting	   curve	   was	   obtained	   at	   the	   end	   of	   each	   run.	  
Glyceraldehyde	   3-­‐phosphate	   dehydrogenase	   (GAPDH)	  mRNA	   was	   used	   to	   normalize	  
the	  data	  and	  to	  determine	  the	  relative	  expression	  of	  the	  target	  genes.	  
	  
Table	  8	  –	  Sequence	  of	  the	  PCR	  primers	  for	  amplification	  of	  expressed	  genes.	  	  
SEQUENCES	  OF	  PRIMERS	  
Col 1a1 F TCCTTGTGTAATTGTGTTGC	  
Col 1a1 R GGGATAAAAACTGCTTTGTG	  
OC F ATGCCACTGCGTATTGGTTGA	  
OC R TCCGCTAGCTCGTCACAATTG	  
Runx2 F CGAAATGCCTCTGCTGTTAT	  
Runx2 R TTCTGTCTGTGCCTTCTTGG	  
ER-alpha F TGCGCAAGTGTTACGAAGTGG	  
ER-alpha R TTCGGCCTTCCAAGTCATCTC	  
ER-beta F AAAAACTCACCGTCGAGCCTT	  
ER-beta R GCTGAATACTCATGGCGGTTG	  
PPAR-γ F TGTGGACCTCTCTGTGATGG	  
PPAR-γ R CATTGGGTCAGCTCTTGTGA	  
GAPDH F GTGAGGTGACCGCATCTTCT	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F.	  DATA	  STATISTICAL	  ANALYSIS	  
	  
All	  the	  data	  were	  collected	  and	  stored	  in	  a	  database	  created	  in	  Excel®	  software.	  
Subsequently,	   analyses	   were	   performed	   using	   the	   statistical	   analysis	   program	  
SPSS	  ®	  v.16.0	  (Statistical	  Package	  for	  the	  Social	  Sciences)	  and	  a	  significance	  level	  of	  5%	  
was	  considered	  (p<0.05).	  
For	   descriptive	   analyses,	   summary	   statistics	   were	   applied	   as	   appropriate.	  
Continuous	   variables	   were	   described	   by	   measures	   of	   central	   tendency	   (mean)	   and	  
dispersion	   (standard	   deviation).	   Continuous	   variables	   were	   also	   represented	   by	   box-­‐
plot	   graphs.	   Hypotheses	   on	   the	   distribution	   of	   continuous	   variables	   between	   two	  
independent	   samples	   were	   tested	   using	   the	   Student	   t-­‐test	   or	   a	   non-­‐parametric	   test	  
(Mann-­‐Whitney),	  when	  appropriate.	  Normality	  distribution	  of	  variables	  was	  tested	  by	  
the	  Shapiro-­‐Wilk	  test.	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In	   order	   to	   establish	   the	   characterization	   of	   the	   osteoporotic	   condition	   we	  
addressed	  the	  animals	  from	  the	  calvarial	  experiment,	  since	  they	  were	  observed	  for	  a	  
longer	   period	   than	   in	   the	   experiment	   evaluating	   the	   mandibular	   regeneration.	   The	  
time	   points	   analyzed	   in	   the	   results	   refer	   to	   the	   time	   following	   the	   ovariectomy	  
procedure,	  i.e.	  the	  rats	  at	  2	  months	  of	  age	  underwent	  sham	  or	  ovariectomy	  procedure;	  
the	  TE1	  corresponds	  to	  3	  months	   following	  ovariectomy	  or	  sham	  procedure;	   the	  TE2	  
corresponds	   to	   5	   months	   following	   ovariectomy	   or	   sham	   procedure	   and	   TE3	  
corresponds	   to	   8	   months	   following	   ovariectomy	   or	   sham	   procedure	   (see	   the	  
matherials	  and	  methods).	  	  
All	  the	  animals	  survived	  both	  surgical	  procedures	  without	  the	  development	  of	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1.	  ANIMAL’S	  WEIGHT	  	  
	  
From	  the	  observation	  of	  the	  weight	  of	  the	  animals,	  it	  was	  possible	  to	  perceive	  
that	  at	  all	  times,	  the	  animals	  that	  underwent	  the	  ovariectomy	  procedure	  presented	  a	  
mean	  weight	   higher	   than	   the	   animals	   that	   underwent	   the	   sham	  procedure	   (Table	   9).	  
These	  results	  were	  evaluated	  at	  the	  three	  time	  points	  (month	  3,	  5	  and	  8)	  and	  in	  all	  the	  
time	  points	  the	  weight	  of	  the	  Ovx	  animals	  were	  significantly	  higher	  than	  that	  of	  Sham	  
animals	  (p<0.05).	  	  
	  
Table	  9	  –	  Comparison	  of	  weight	  of	  animals	  between	  the	  two	  groups	  under	  study	  of	  the	  critical	  
size	  defects	  (CSD):	  animals	  submitted	  to	  ovariectomy	  (Ovx)	  and	  Sham	  animals.	  
Time	  following	  
surgery	  
Weight	  of	  animals	  
Sham	   Ovx	  
	   Mean	  (g)	   sd	  (g)	   Mean	  (g)	   sd	  (g)	  
Month	  3	   252.71	   37.498	   377.57*	   38.449	  
Month	  5	   297.03	   27.210	   420.43*	   45.232	  
Month	  8	   396.29	   28.439	   450.14*	   51.874	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test,	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2.	  UTERI	  CHARACTERIZATION	  
	  
Ovariectomy	  was	  confirmed	  by	  observation	  of	  an	  atrophic	  uterus	  and	  failure	  to	  

























Figure	  94	  –	  Uterus	  from	  Ovx	  animal	  at	  month	  3.	   Figure	  95	  –	  Uterus	  from	  Sham	  animal	  at	  month	  3.	  
Figure	  96	  –	  Uterus	  from	  Ovx	  animal	  at	  month	  8.	   Figure	  97	  –	  Uterus	  from	  Sham	  animal	  at	  month	  8.	  Note	  the	  
presence	  of	  the	  ovaries.	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The	  weight	  of	  the	  animal	  uterus	  at	  all	  time	  points	  of	  evaluation	  (month	  3,	  5	  and	  
8)	  of	  those	  which	  underwent	  the	  ovariectomy	  procedure	  (Ovx)	  was	  significantly	  lower	  
than	  for	  the	  Sham	  group	  (Table	  10).	  These	  results	  were	  significantly	  higher	  than	  that	  of	  




Table	   10	   –	  Comparison	   of	   weight	   of	   uterus	   between	   the	   two	   groups	   under	   study	   of	   the	   critical	   size	  
defects	  (CSD):	  animals	  submitted	  to	  ovariectomy	  (Ovx)	  and	  Sham	  animals.	  
Time	  following	  
surgery	  
Weight	  of	  uterus	  
Sham	   Ovx	  
	   Mean	  (g)	   sd	  (g)	   Mean	  (g)	   sd	  (g)	  
Month	  3	   0.492	   0.093	   0.080*	   0.050	  
Month	  5	   0.550	   0.097	   0.087*	   0.065	  
Month	  8	   0.574	   0.081	   0.088*	   0.067	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test,	  
*	  p<0.05	  Vs.	  Sham	  group.;	  sd:	  standard	  deviation	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3.	  PLASMA	  LEVELS	  
	  
Blood	   was	   collected	   to	   address	   plasmatic	   parameters	   as	   the	   alkaline	  
phosphatase	  activity,	  calcium,	  phosphorous	  concentrations	  and	  estrogen	  levels	  in	  the	  
three	   time	   points	   (month	   3,	   5	   and	   8).	   Albumin,	   Creatine	   kinase,	   Total	   protein	   and	  
Triglycerides,	   in	   Sham	   and	   Ovx	   animal	   groups,	   were	   evaluated	   in	   two	   time	   periods	  
(month	  3	  and	  5).	  	  
In	  the	  Figure	  98	  the	  estradiol	  levels	  (pg/mL),	  measured	  at	  month	  3,	  5	  and	  8,	  for	  
both	  animals’	  groups:	  Ovx	  and	  Sham	  are	  presented.	   In	  Sham	  animals,	  mean	  estradiol	  
levels	  were	  kept	  around	  20pg/mL	  over	   time,	  but	   in	   the	  Ovx	  animals,	   levels	  were	   too	  
low	   to	   be	   detected	   by	   the	   used	   measurement	   methods.	   In	   the	   Figure	   98	   the	   mean	  
plasma	  values	  of	  alkaline	  phosphatase	  activity	  (ALP),	  calcium	  (Ca)	  and	  phosphorous	  (P),	  
in	   Sham	   and	   Ovx	   animal	   groups,	   in	   three	   time	   periods	   (month	   3,	   5	   and	   8)	   are	  






















In	  the	  Figure	  99	  the	  mean	  plasma	  values	  of	  albumin	  (ALB),	  Creatine	  kinase	  (CK),	  
Total	  protein	  (TP)	  and	  Triglycerides	  (TG),	  in	  Sham	  and	  Ovx	  animal	  groups,	  in	  two	  time	  
periods	  (month	  3	  and	  5),	  are	  presented.	  No	  significant	  differences	  were	  verified	  in	  ALB	  
and	  CK	   in	  both	  timepoints.	  There	  are	  statistically	  significant	  differences	   in	  PT	  and	  TG	  
plasma	   concentrations	   groups.	   In	   the	  evaluation	  of	   the	   total	   protein	   in	   the	  month	  3	  
there	  are	  significant	  differences	  between	  the	  Sham	  and	  Ovx	  group.	  In	  the	  evaluation	  of	  
the	  Triglycerides	   levels	   in	   the	  month	  3	   there	  are	   significant	  differences	  between	   the	  




Figure	   98	   –	   Graphic	   representation	   of	   the	   comparison	   of	   the	   levels	   of	   Estradiol(pg/mL),	   ALP	   (U/L),	   Calcium	  
(mg/dL)	  and	  Phosphorous	  (mg/dL)	  of	  Sham	  and	  Ovx	  animals,	  over	  time.	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Figure	   99	   –	   Graphic	   representation	   of	   the	   comparison	   of	   the	   levels	   of	   Albumin	   (g/dl),	   Total	   protein	   (TP),	  
Triglycerides	   (TG)	   and	   Creatine	   kinase	   (CK),	   	   plasma	   concentrations	   by	   Sham	   and	   OVX	   groups,	   over	   time.	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4.	  EVALUATION	  OF	  TIBIAE	  
	  
The	  tibiae	  were	  studied	  to	  examine	  and	  analyze	  whether	  differences	  between	  the	  
animals	   from	   the	   Sham	   and	  Ovx	   group	   existed.	   To	   this,	   x-­‐ray	   images	  were	   obtained	  	  
and	  a	  densitometric	  analysis	  was	  performed.	  Micro-­‐CT	  images	  of	  the	  tibiae	  were	  also	  
taken,	   that	   allowed	   us	   to	   examine	   microstructural	   parameters	   of	   the	   trabecular	  
structure.	  We	  also	  performed	  biomechanical	  tests	  and	  histological	  analysis	  	  to	  disclose,	  




I.	  X-­‐RAY	  OF	  ANIMALS’	  TIBIAE	  
	  
Radiological	   evaluation	   of	   the	   tibias	   X-­‐rays	   reveal	   a	   well-­‐marked	   difference	  
between	   the	   structure	   of	   tibiae	   between	   the	   Sham	   and	   Ovx	   groups.	   This	   was	   of	  
particular	   relevant	   at	   the	   month	   8	   of	   evaluation	   (Figures	   100-­‐103).	   A	   substantial	  
reduction	  of	  the	  trabecular	  structure	  in	  the	  Ovx	  group	  needs	  also	  to	  be	  highlighted.	  	  
Densitometric	   evaluations	   were	   performed	   using	   the	   ImageJ®	   software.	  
Densitometric	   results	   are	   shown	   in	  Table	   11.	   The	  Ovx	  group	   reported	   lower	   values	  at	  
month	   5	   and	   8	   compared	   to	   the	   Sham	   group,	   but	   significant	   differences	   were	   only	  
attained	   at	   the	  month	   8	   of	   evaluation.	   In	   both	   groups,	   a	  markedly	   decrease	   of	   the	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Figures	  100A	  and	  100B	  –Radiographic	  image	  of	  left	  tibia	  of	  Sham	  animal,	  month	  5,	  A:	  
lateral	  view	  and	  B:	  anteroposterior	  view.	  
	  	  A	   	  	  B	  
	  	  A	   	  	  B	  
Figures	  101A	  and	  101B	  –	  Radiographic	  image	  of	  left	  tibia	  of	  Ovx	  animal,	  month	  5.	  A:	  
lateral	  view	  and	  B:	  anteroposterior	  view.	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   Figures	  103A	  and	  103B	  –	  Radiographic	  image	  of	  left	  tibia	  of	  Ovx	  animal,	  month	  8.	  A:	  
lateral	  view	  and	  B:	  anteroposterior	  view.	  
Figures	  102A	  and	  102B	  –	  Radiographic	  image	  of	  left	  tibia	  of	  Sham	  animal,	  month	  8.	  A:	  
anteroposterior	  view	  and	  B:	  lateral	  view.	  
	  	  A	   	  	  B	  
	  	  A	   	  	  B	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A	  progressive	  loss	  of	  trabecular	  structure	  was	  determined	  in	  which	  regards	  the	  Ovx	  
group,	  from	  month	  5	  to	  month	  8.	  In	  the	  Sham	  group,	  the	  decrease	  was	  not	  significant,	  
as	  we	  can	  observe	  in	  the	  Table	  11.	  
	  
Table	  11	  –	  Densitometry	  of	  tibiae	  of	  Sham	  and	  Ovx	  animals,	  over	  time.	  
Time	  following	  surgery	  
Densitometry	  (AU)	  
Sham	   Ovx	  
	   Mean	   sd	   Mean	   sd	  
Tibiae	  Month	  5	   1335.25	   123.43	   1267.50	   51.07	  
Tibiae	  Month	  8	   1200.91	   95.47	   900.00*	   132.90	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group;	  sd:	  standard	  deviation;	  AU:	  arbitrary	  unit	  
	  
In	  Figures	  104-­‐105	  is	  presented	  the	  graphical	  distribution	  of	  the	  densitometry	  












	   Figure	  104	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  tibiae	  at	  month	  5	  of	  
Sham	  and	  Ovx	  groups.	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Figure	  105	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  tibiae	  at	  month	  8	  of	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II.	  MICRO-­‐CT	  OF	  TIBIAE	  
	  
The	  3D	  rendering	  of	  the	  high	  resolution	  microtomographies	  of	  8	  months	  time	  point	  
from	   Sham	   and	  Ovx	   animals	   shows	   the	   analyzed	   volume	   of	   interest	   in	   the	   proximal	  
tibia.	   This	   exam	   revealed,	   as	   compared	   to	   Sham	   controls,	   a	   thinner	   trabecular	  
organization,	   with	   decreased	   interconnectivity	   and	   increased	   separation,	   in	   Ovx	  
animals	  (Figure	  106).	  	  
	  
	   	  
Figure	  106	  –	  Representative	  3D	  renderings	  of	  8	  months	  time	  point,	  showing	  the	  analyzed	  volume	  of	  interest	  in	  the	  
proximal	  tibia.	  Scale	  bar	  represents	  1	  mm	  A:	  Sham	  animal;	  B:	  Ovx	  animal.	  
A	   B	  
RESULTS	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  178	  
Morphological	   analyses	   were	   confirmed	   by	   the	   quantification	   of	   the	  
microstructural	  parameters	  that	  revealed	  a	  marked	  reduction	  in	  the	  Bone	  volume	  per	  
total	   volume	   (BV/TV),	   Connective	   density	   (CD),	   Trabecular	   thickness	   (Tb.Th),	   and	  
Trabecular	   number	   (Tb.N)	   and	   an	   increased	   Trabecular	   separation	   (Tb.Sp)	   in	   Ovx	  
animals	  (Table	  12).	  	  
	  
Table	  12	  –	  Microstructural	  parameters	  of	  the	  trabecular	  structure	  of	  the	  proximal	  tibia	  in	  Sham	  




	   BV/TV	  (sd)	   CD	  (sd)	   Tb.N	  (sd)	   Tb.Th	  (sd)	   Tb.Sp	  (sd)	   Density	  (sd)	  
5	  Months	  
Sham	   0.49	  (0.081)	   317.2	  (40.6)	   7.36	  (0.56)	   0.081	  (0.002)	   0.116	  (0.03)	   903.6	  (9.3)	  
Ovx	   0.17	  (0.052)*	   89.2	  (7.9)*	   1.89	  (0.28)*	   0.071	  (0.003)	   0.538	  (0.06)	  *	   828.5	  (8.5)	  *	  
8	  Months	  
Sham	   0.54	  (0.051)	   300.4	  (34.5)	   8.07	  (0.65)	   0.090	  (0.003)	   0.100	  (0.06)	   883.5	  (8.5)	  
Ovx	   0.18	  (0.043)	  *	   33.7	  (8.4)	  *	   1.89	  (0.32)	  *	   0.092	  (0.003)	   0.545	  (0.07)	  *	   836.2	  (9.5)	  *	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation,	  BT/TV:	  bone	  volume	  per	  total	  volume,	  CD:	  connective	  density,	  Tb.N:	  	  trabecular	  number,	  
Tb.Th:	  trabecular	  thickness,	  Tb.Sp:	  trabecular	  separation.	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III.	  BIOMECHANIMAL	  TEST	  OF	  TIBIAE	  
	  
The	   biomechanical	   parameters	   of	   the	   tibiae	   were	   evaluated	   at	   month	   3	   of	   the	  
osteoporotic	   condition.	   By	   the	   observation	   of	   the	   results	   the	   Ultimate	   stress	   and	  
Young´s	   module	   parameters	   were	   significant	   different	   between	   the	   two	   groups	   in	  
evaluation,	   the	   Sham	   and	   Ovx	   animals.	   The	   Ultimate	   stress	   and	   Young´s	   module	  
present	  higher	  values	  in	  the	  Sham	  animals.	  The	  maximum	  load	  parameter	  is	  higher	  in	  
the	  Ovx	  animals	  although	  without	  a	  significant	  difference.	  
	  
Table	  13	  –	  Biomechanical	  parameters	  of	  the	  proximal	  tibia	  in	  Sham	  and	  Ovx	  animals	  at	  month	  
3.	  
	   Maximum	  Load	  (N)	   sd	  
Ultimate	  stress	  
(Mpa)	   sd	  
Young's	  
module	  (GPa)	   sd	  
Sham	   49.62	   6.15	   349.05	   143	   5.02	   1.74	  
Ovx	   57.37	   9.41	   264.26*	   49.58	   3.43*	   1.78	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	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IV.	  HISTOLOGY	  
	  
The	  histologic	   sections	  of	   the	   tibiae	  at	  month	  8,	   allows	  us	   to	  observe	   in	   the	  Ovx	  
group	   a	   loss	   in	   the	   number	   of	   trabecular	   stuctures	   and	   a	   thinner	   thickness	   of	   these	  




	   	  
Figure	  107	  –	  View	  of	  the	  proximal	  tibia	  with	  a	  magnification	  of	  40x	  of	  
the	  Sham	  animal	  at	  month	  8.	  Toluidine	  blue	  staining.	  
Figure	  108	  –	  View	  of	  the	  proximal	  tibia	  with	  a	  magnification	  of	  40x	  of	  
the	  Ovx	  animal	  at	  month	  8.	  Toluidine	  blue	  staining.	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5.	  EVALUATION	  OF	  THE	  FEMUR	  	  
The	   x-­‐ray	   images	  were	   obtained	   and	   a	   densitometric	   analyzes	  was	   performed	   in	  
order	   to	   realized	   if	   there	  were	  differences	  between	   the	   animals	   from	   the	   Sham	  and	  
Ovx	  group.	  3	  point	  bending	  tests	  were	  conducted	  to	  measure	   femur’s	  biomechanical	  
properties	   and	   histological	   analysis	   was	   conducted	   to	   adress	   the	   microstructure	  





Radiological	   evaluation	   of	   the	   femurs	   X-­‐rays	   reveal	   a	   well-­‐marked	   difference	  
between	  the	  structure	  of	  femur	  between	  the	  Sham	  and	  Ovx	  groups,	  with	  a	  substantial	  
reduction	  of	  the	  trabecular	  structure	  in	  the	  Ovx	  group	  (Figures	  109-­‐113).	  
Densitometric	  evaluations	  were	  performed	  as	  previously	  described.	  Densitometric	  
results	  are	  shown	  in	  Table	  13.	  The	  Ovx	  group	  reported	  lower	  values	  at	  month	  3	  and	  5	  
compared	   to	   the	   Sham	   group,	   and	  were	   significant	   differences	   at	   both	   times	   of	   the	  
evaluation.	   In	   both	   groups,	   a	   markedly	   decrease	   of	   the	   densitometry	   values	   was	  







































Figure	  109	  –	  Femur	  from	  Sham	  animal	  at	  
month	  3.	  
Figure	  110	  –	  Femur	  from	  Ovx	  animal	  at	  
month	  3.	  
	  Figure	  111	  –	  Femur	  from	  Sham	  animal	  at	  
month	  5.	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Table	  13	  –	  Densitometry	  of	  femurs	  of	  Sham	  and	  Ovx	  animals,	  over	  time.	  
Time	  following	  surgery	  
Densitometry	  (AU)	  
Sham	   Ovx	  
	   Mean	   sd	   Mean	   sd	  
Femur	  Month	  3	   3159.23	   417.10	   2777.33	  *	   389.40	  
Femur	  Month	  5	   2975.71	   389.17	   2398.81	  *	   266.58	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation:	  AU:	  arbitrary	  unit	  
 
In	  Figures	  113-­‐114	  is	  presented	  the	  graphical	  distribution	  of	  the	  densitometry	  






Figure	  113	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	   femurs	  at	  month	  3	  











	    
Figure	  114	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  femurs	  at	  month	  5	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II.	  BIOMECHANICAL	  TEST	  OF	  FEMUR	  
	  
The	   biomechanical	   parameters	   of	   the	   femur	   were	   evaluated	   at	   month	   3	   of	   the	  
osteoporotic	   condition.	   By	   the	   observation	   of	   the	   results	   the	   Ultimate	   stress	  
parameter	  was	   lower	   in	   the	  Ovx	   group	   and	  was	   significant	   different	   than	   the	   Sham	  
group.	   The	  Maximum	   load	   and	   Young´s	   module	   present	   higher	   values	   in	   the	   Sham	  
animals,	  although	  without	  a	  significant	  difference,	  between	  the	  two	  groups.	  
	  
	  






Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test.	  
*p<0.05	  Vs.	  Sham	  group	  ,	  sd:	  standard	  deviation	  
	  
	   	  









Sham	   92.66	   9.09	   100.07	   7.44	   1.92	   0.19	  
Ovx	   91.7	   5.53	   86.75*	   6.38	   1.48	   0.26	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III.	  HISTOLOGY	  
	   	   	  
A	  loss	  of	  trabecular	  structure	  was	  observed	  in	  the	  histologic	  sections	  of	  the	  femur	  
at	   month	   3	   of	   the	   osteoporotic	   condition	   in	   the	   Ovx	   group.	   It	   is	   of	   relevance	   the	  








	  	   	  
Figure	  115	  –	  View	  of	  the	  femur	  with	  a	  magnification	  of	  10x	  of	  the	  Sham	  
animal	  at	  month	  8.	  Toluidine	  blue	  staining.	  
Figure	  116	  –	  View	  of	  the	  femur	  with	  a	  magnification	  of	  10x	  of	  the	  Ovx	  
animal	  at	  month	  8.	  Toluidine	  blue	  staining.	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6.	  	  EVALUATION	  OF	  THE	  CALVARIA	  
	  
X-­‐ray	   images	   of	   the	   calvaria	   were	   taken	   to	   evaluate	   the	   differences	   on	   mineral	  
density	  of	  the	  bone,	  between	  the	  Sham	  and	  Ovx	  animals.	  Densitometric	  evaluations	  of	  




Radiological	   evaluation	   of	   the	   calvaria	   X-­‐rays	   show	   a	   variance	   between	   the	  
structure	  of	  calvaria	  between	  the	  Sham	  and	  Ovx	  groups,	  with	  a	  slight	  reduction	  of	  the	  






	   	  
Figure	  117	  –	  Calvaria	  from	  Sham	  animal	  at	  
month	  3.	  


















Densitometric	   evaluations	   of	   the	   calvarial	  were	   performed	   using	   the	   ImageJ®	  
software	  at	  month	  3	  and	  5.	  Densitometric	  results	  are	  shown	  in	  Table	  15.	  The	  Ovx	  group	  




Table	  15	  –	  Densitometry	  analyses	  of	  calvarial	  bones	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  
5.	  
Time	  following	  surgery	  
Densitometry	  (AU)	  
Sham	   Ovx	  
	   Mean	   sd	   Mean	   sd	  
Calvaria	  Month	  3	   612.01	   98.36	   517.69*	   107.25	  
Calvaria	  Month	  5	   568.27	   72.35	   438.08	   61.39	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation:	  AU:	  arbitrary	  unit	  
 
Figure	  119	  –	  Calvaria	  from	  Sham	  animal	  at	  
month	  5.	  













	    
Figure	  121	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  calvarial	  bone	  at	  
month	  3	  of	  Sham	  and	  Ovx	  group.	  
Figure	  122	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  calvarial	  bone	  at	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7.	  EVALUATION	  OF	  THE	  VERTEBRA	  
	  
X-­‐ray	  images	  of	  the	  vertebra	  were	  taken	  to	  evaluate	  mineral	  density	  differences	  
between	  the	  Sham	  and	  Ovx	  animals.	  Densitometric	  evaluations	  of	  the	  vertebral	  were	  
performed	  using	  the	  ImageJ®	  software	  at	  month	  3	  and	  5.	  	  
	  
I.	  X-­‐RAY	  
A	  progressive	  loss	  of	  trabecular	  structure	  was	  significantly	  determined	  in	  which	  
regards	  the	  Ovx	  group,	  at	  month	  5.	  Radiological	  evaluation	  of	  the	  vertebras	  revealed	  a	  
well-­‐marked	  difference	  between	  the	  structure	  of	  vertebra	  between	  the	  Sham	  and	  Ovx	  

















Figure	  123	  –	  Vertebra	  from	  Sham	  animal	  
at	  month	  3.	  
Figure	  124–	  Vertebra	  from	  Ovx	  animal	  
at	  month	  3.	  
Figure	  126	  –	  Vertebra	  from	  Ovx	  animal	  
at	  month	  5.	  
Figure	  125	  –	  Vertebra	  from	  Sham	  animal	  
at	  month	  5.	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The	  Ovx	  group	  reported	  lower	  values	  at	  the	  densitometric	  analysis,	  at	  month	  3	  
and	  5	  compared	  to	  the	  Sham	  group,	  but	  significant	  differences	  were	  only	  attained	  at	  
the	  month	  5	  of	  evaluation.	   In	  both	  groups,	  a	  markedly	  decrease	  of	   the	  densitometry	  
values	  was	  observed	  between	  the	  two	  evaluation	  points.	  
	  
	  
Table	  16	  –	  Densitometry	  analyses	  of	  vertebras	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  5.	  







Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation:	  AU:	  arbitrary	  unit	  
	   	  
Time	  following	  surgery	  
Densitometry	  (AU)	  
Sham	   Ovx	  
	   Mean	   sd	   Mean	   sd	  
Vertebra	  Month	  3	   3705.58	   619.73	   2236.67	  *	   337.89	  
Vertebra	  Month	  5	   3543.85	   924.28	   1955.25	  *	   414.47	  
Figure	  127	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  vertebras	  









	    
Figure	  128	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  vertebras	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8.	  EVALIATION	  OF	  THE	  MAXILLA	  	  
X-­‐ray	   images	   of	   the	   maxilla	   were	   taken	   to	   compare	   the	   mineral	   density	  
between	   the	   Sham	   and	   Ovx	   animals.	   Densitometric	   evaluations	   of	   the	  maxilla	   were	  
then	  performed	  using	  the	  ImageJ®	  software	  at	  month	  3	  and	  5.	  Micro-­‐CT	  images	  of	  the	  
maxilla	  were	  also	  acquired,	  that	  allowed	  us	  to	  examine	  microstructural	  parameters	  of	  
the	  trabecular	  structure	  within	  the	  interradicular	  area	  of	  the	  1st	  molar.	  
	  
I.	  X-­‐RAY	  
Radiological	  evaluation	  of	   the	  maxilla	  X-­‐rays	   shows	  a	   slight	  variation	  between	  
the	  radiopacity	  of	   the	  maxilla	  bone	  between	  the	  Sham	  and	  Ovx	  groups,	  with	  a	  slight	  
dissimilarity	   in	  the	  reduction	  of	  the	  trabecular	  structure	  when	  observed	  between	  the	  










	   	  
Figure	  129	  –	  Maxilla	  from	  Sham	  animal	  at	  month	  3.	   Figure	  130	  –	  Maxilla	  from	  Ovx	  animal	  at	  month	  3.	  
Figure	  131	  –	  Maxilla	  from	  Sham	  animal	  at	  month	  5.	   Figure	  132	  –	  Maxilla	  from	  Ovx	  animal	  at	  month	  5.	  
RESULTS	  
	  
SARA	  FILIPA	  DE	  OLIVEIRA	  DURÃO	  194	  
Densitometric	   evaluations	   of	   the	   maxilla	   were	   performed	   using	   the	   ImageJ®	  
software	  at	  month	  3	  and	  5.	  Densitometric	  results	  are	  shown	  in	  Table	  17.	  At	  month	  3	  no	  
significant	   differences	   were	   found	   between	   groups.	   The	   Ovx	   group	   reported	   lower	  




Table	  17	  –	  Densitometry	  analyses	  of	  maxilla	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  5.	   	  
Time	  following	  surgery	  
Densitometry	  (AU)	  
Sham	   Ovx	  
	   Mean	   sd	   Mean	   sd	  
Maxilla	  Month	  3	   1289.23	   186.79	   1306.00	   361.97	  
Maxilla	  Month	  5	   1520.00	   514.91	   1217.75	   261.01	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation:	  AU:	  arbitrary	  unit	  
	   	  
RESULTS	  
	  
MODULATION	  OF	  THE	  BONE	  REGENERATION	  PROCESS	  IN	  SYSTEMIC	  IMPAIRED	  CONDITIONS	   195	  
	  
	   	  
Figure	  133	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  maxilla	  at	  
month	  3	  of	  Sham	  and	  Ovx	  group.	  	  
Figure	  134	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  maxilla	  at	  
month	  5	  of	  Sham	  and	  Ovx	  group.	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II.	  MICRO-­‐CT	  
	  
Micro-­‐CT	  evaluation	  was	  performed	  in	  a	  circunscrited	  area	  in	  the	  space	  
between	  roots	  of	  the	  1st	  molar,	  of	  the	  maxilla,	  at	  month	  3	  of	  the	  study,	  and	  reported	  a	  
significant	  decrease	  in	  the	  number	  of	  trabecular	  structures	  in	  the	  Ovx	  animals	  (Figures	  


















	   	  
Figure	  138	  –	  Maxilla	  from	  Ovx	  animal	  at	  month	  3.	  Figure	  137	  –	  Maxilla	  from	  Ovx	  animal	  at	  month	  3.	  
Figure	  136	  –	  Maxilla	  from	  Sham	  animal	  at	  month	  3.	  Figure	  135	  –	  Maxilla	  from	  Sham	  animal	  at	  month	  3.	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A	  microstructural	  analysis	  of	  the	  maxilla	  was	  performed	  at	  month	  3	  and	  5	  in	  
both	  groups.	  The	  parameter	  bone	  volume	  per	  tissue	  volume	  (BV/TV),	  was	  higher	  in	  the	  
Sham	  animals	  in	  both	  time	  of	  the	  evaluation,	  month	  3	  and	  5.	  These	  values	  were	  only	  
significant	  different	  on	  month	  5.	  The	  connective	  density	  (CD)	  was	  lower	  in	  the	  Sham	  
animals	  in	  both	  the	  times	  of	  the	  evaluation,	  month	  3	  and	  5,	  without	  significant	  
differences.	  The	  trabecular	  number	  (Tb.N)	  and	  trabecular	  thickness	  (Tb.Th)	  had	  
elevated	  values	  in	  the	  Sham	  group	  in	  both	  the	  evaluation	  time	  points,	  but	  only	  the	  
trabecular	  thickness	  (Tb.Th)	  had	  significant	  differences.	  The	  trabecular	  separation	  
(Tb.Sp)	  was	  higher	  in	  the	  Ovx	  animals	  in	  both	  time	  points	  of	  evaluation,	  with	  significant	  
differences	  in	  both	  times	  of	  evaluation,	  month	  3	  and	  5.	  The	  density	  was	  higher	  in	  the	  
Sham	  animals	  in	  both	  time	  points	  of	  evaluation,	  with	  significant	  differences	  in	  the	  
month	  5	  of	  evaluation.	  
	  
Table	  18	  –Microstructural	  analysis	  of	  maxilla	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  5.	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation,	  BT/TV:	  bone	  volume	  per	  tissue	  volume,	  CD:	  connective	  density,	  Tb.N:	  	  trabecular	  number,	  
Tb.Th:	  trabecular	  thickness,	  Tb.Sp:	  trabecular	  separation	  
	   	  
Time	  
following	  
surgery	   	  
BV/TV	  (sd)	   CD	  (sd)	   Tb.N	  (sd)	   Tb.Th	  (sd)	   Tb.Sp	  (sd)	   Density	  (sd)	  
Month	  3	  
Sham	   0.88	  (0.078)	   43.5	  (8.94)	  
5.72	  
(0.48)	   0.255	  (0.02)	   0.121	  (0.02)	   1081.7	  (13.2)	  
Ovx	   0.79	  (0.054)	   69	  (15.43)	   5.15	  (0.54)	   0.232	  (0.03)	   0.156	  (0.03)*	   1055.2	  (11.5)	  
Month	  5	  
Sham	   0.88	  (0.067)	   36.7	  (10.4)	  
5.32	  
(0.53)	   0.297	  (0.06)	   0.145	  (0.07)	   973.2	  (10.5)	  
Ovx	   0.75	  (0.035)*	   51.2	  (8.54)	  
4.87	  
(0.68)	   0.255	  (0.04)*	   0.159	  (0.05)*	   816.3	  (13.7)*	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9.	  EVALUATION	  OF	  THE	  MANDIBLE	  
	  
X-­‐ray	  images	  of	  the	  mandible	  were	  taken	  to	  address	  the	  differences	  regarding	  
the	  mineral	  density	  between	  the	  Sham	  and	  Ovx	  animals.	  Densitometric	  evaluations	  
were	  then	  performed	  using	  the	  ImageJ®	  software	  at	  month	  3	  and	  5.	  Micro-­‐CT	  images	  
of	  the	  mandibles	  were	  also	  taken,	  that	  allowed	  us	  to	  examine	  microstructural	  
parameters	  of	  the	  trabecular	  structure.	  We	  performed	  biomechanical	  tests	  to	  measure	  
among	  other	  values	  of	  maximum	  stress	  between	  the	  Sham	  and	  Ovx	  animals.	  
	  
I.	  X-­‐RAY	  
Radiological	  evaluation	  of	  the	  mandible	  shows	  a	  variance	  between	  the	  
radiopacity	  of	  the	  mandibular	  bone	  between	  the	  Sham	  and	  Ovx	  groups,	  with	  a	  slighty	  
reduction	  of	  the	  trabecular	  structure	  when	  observed	  in	  the	  alveolar	  bone	  between	  the	  














Figure	  139	  –	  Mandible	  from	  Sham	  animal	  at	  
month	  3.	  
Figure	  140	  –	  Mandible	  from	  Ovx	  animal	  at	  
month	  3.	  
Figure	  141	  –	  Mandible	  from	  Sham	  animal	  at	  
month	  5.	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Densitometric	  evaluations	  of	  the	  mandible	  were	  performed	  using	  the	  ImageJ®	  
software	  at	  month	  3	  and	  5.	  Densitometric	  results	  are	  shown	  in	  Table	  19.	  The	  Ovx	  group	  
reported	  slightly	  lower	  values	  in	  all	  time	  points	  of	  evaluation,	  and	  no	  significant	  
differences	  were	  observed.	  
	  
Table	  19	  –Densitometry	  analyses	  of	  the	  mandible	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  5.	  
Time	  following	  surgery	  
Densitometry	  (AU)	  
Sham	   Ovx	  
	   Mean	   sd	   Mean	   sd	  
Mandible	  Month	  3	   6794.96	   915.39	   6618.03	   814.90	  
Mandible	  Month	  5	   7080.86	   705.64	   6661.85	   762.98	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  





	    
Figure	  143	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  mandible	  
at	  month	  3	  of	  Sham	  and	  Ovx	  group.	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Figure	  144	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  mandible	  
at	  month	  5	  of	  Sham	  and	  Ovx	  group.	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II.	  MICRO	  CT	  OF	  MANDIBLE	  
	  
Micro-­‐CT	  evaluation	  was	  performed	  in	  a	  circunscrited	  area	  in	  the	  space	  
between	  roots	  of	  the	  1st	  molar,	  of	  the	  mandible,	  and	  at	  month	  3	  of	  the	  study,	  reported	  
a	  significant	  decrease	  in	  the	  number	  of	  trabecular	  structures	  in	  the	  Ovx	  animals	  (Figures	  





















	   Figure	  147	  –	  Mandible	  from	  Ovx	  animal	  at	  month	  
3.	  
Figure	  145	  –	  Mandible	  from	  Sham	  animal	  at	  
month	  3.	  
Figure	  146	  –	  Mandible	  from	  Sham	  animal	  at	  
month	  3.	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A	  microstructural	  analysis	  of	  the	  mandible	  was	  performed	  at	  month	  3	  and	  5	  in	  
both	  groups.	  The	  parameter	  bone	  volume	  per	  tissue	  volume	  (BV/TV)	  was	  higher	  in	  the	  
Sham	   animals	   in	   both	   time	   of	   the	   evaluation,	   month	   3	   and	   5.	   These	   values	   were	  
significant	  different	  on	  both	  time	  points	  of	  evaluation.	  The	  connective	  density	  (CD)	  was	  
higher	   in	   the	   Sham	   animals	   at	   month	   3,	   but	   lower	   in	   month	   5,	   with	   significant	  
differences	   in	   this	   time	  point.	  The	  trabecular	  number	   (Tb.N)	  and	  trabecular	   thickness	  
(Tb.Th)	  had	  elevated	  values	  in	  the	  sham	  group	  on	  month	  3.	  On	  month	  5	  the	  trabecular	  
number	   (Tb.N)	   was	   lower	   in	   the	   Sham	   animals	   and	   the	   trabecular	   thickness	   (Tb.Th)	  
higher.	   None	   of	   these	   values	   presented	   significant	   differences.	   The	   trabecular	  
separation	   (Tb.Sp)	  was	   higher	   in	   the	   Ovx	   animals	   in	   both	   time	   points	   of	   evaluation,	  
with	  significant	  differences	  at	  month	  5.	  The	  density	  was	  higher	  in	  the	  Sham	  animals	  in	  
both	  time	  points	  of	  evaluation,	  without	  significant	  differences	  in	  both	  months.	  
	  
	  
Table	  20	  –Microstructural	  analyses	  of	  mandible	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  3	  and	  5.	  
Time	  
following	  
surgery	   	  
BV/TV	  (sd)	   CD	  (sd)	   Tb.N	  (sd)	   Tb.Th	  (sd)	   Tb.Sp	  (sd)	   Density	  (sd)	  
Month	  3	  
Sham	   0.79	  (0.072)	   26.2	  (2.8)	   4.67	  (0.41)	   0.26	  (0.03)	   0.157	  (0.05)	   1035.5	  (13.2)	  
Ovx	   0.65	  (0.062)*	   25.3	  (3.1)	   4.14	  (0.38)	   0.248	  (0.03)	   0.197	  (0.04)	   1021.2	  (14.5)	  
Month	  5	  
Sham	   0.83	  (0.061)	   17.2	  (1.7)	   3.94	  (0.65)	   0.28	  (0.03)	   0.129	  (0.06)	   926.7	  (13.4)	  
Ovx	   0.68	  (0.054)*	   24.7	  (2.7)*	   4.67	  (0.32)	   0.276	  (0.04)	   0.147	  (0.03)*	   897.3	  (16.7)	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs.	  Sham	  group,	  
sd:	  standard	  deviation,	  BT/TV:	  bone	  volume	  per	  tissue	  volume,	  CD:	  connective	  density,	  Tb.N:	  	  trabecular	  number,	  
Tb.Th:	  trabecular	  thickness,	  Tb.Sp:	  trabecular	  separation	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III.	  BIOMECHANIMAL	  TEST	  OF	  MANDIBLE	  
	  
The	  biomechanical	  parameters	  of	  the	  mandible	  were	  evaluated	  at	  month	  3	  of	  
the	  osteoporotic	  condition.	  The	  Ultimate	  stress	  parameter	  was	  lower	  in	  the	  Ovx	  group	  
with	   a	   score	   of	   27.5	  Mpa	   (sd=4.5),	   comparing	  with	   the	   Sham	   group	  with	   38.9	  Mpa	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  B. EVALUATION	  OF	  THE	  CALVARIAL	  BONE	  DEFECT	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In	  order	  to	  address	  the	  biomaterial-­‐mediated	  bone	  regeneration	  process	  in	  a	  bone	  
not	   submitted	   to	  biomechanical	   loading,	   a	   critical	   size	  defect	  was	  established	  within	  
the	   calvarial	   bone	   and	   implanted	   with	   a	   xenograft	   The	   time	   points	   analyzed	   in	   the	  
results	  refer	  to	  the	  time	  following	  the	  calvarial	  bone	  defect,	  i.e	  	  the	  rats	  at	  2	  months	  of	  
age	  underwent	  the	  sham	  or	  ovariectomy	  procedure;	  the	  TE1	  corresponds	  to	  1	  month	  
of	   healing	   following	   the	   craniotomy	   and	   3	   months	   following	   ovariectomy	   or	   sham	  
procedure;	  	  the	  TE2	  corresponds	  to	  3	  months	  of	  healing	  following	  the	  craniotomy	  and	  
5	  months	  following	  ovariectomy	  or	  sham	  procedure	  and	  TE3	  corresponds	  to	  6	  months	  
of	   healing	   following	   the	   craniotomy	   and	   8	   months	   following	   ovariectomy	   or	   sham	  
procedure	  (Figure	  149).	  






	   	  
	  
	  
Figure	  149	  –	  Study	  timeline	  of	  the	  craniotomy	  procedure.	  
	  
ANIMALS	  EUTHANASIA:	  
TE1	  –	  Time	  of	  experiment	  1	  –	  1	  month	  healing	  following	  craniotomy	  (month	  3	  after	  
ovariectomy	  procedure)	  
TE2	  –	  Time	  of	  experiment	  2	  –	  3	  months	  healing	  following	  craniotomy	  (month	  5	  after	  
ovariectomy	  procedure)	  
TE3	  –	  Time	  of	  experiment	  3	  –	  6	  months	  healing	  following	  craniotomy	  (month	  8	  after	  
ovariectomy	  procedure)	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1.	  MACROSCOPIC	  EVALUATION	  
	  
In	   the	   CSD	   filled	   with	   Bio-­‐oss®,	   it	   is	   established	   that	   the	   vast	   majority	   of	   the	  
biomaterial	   was	   well	   contained	   within	   the	   defect,	   apart	   from	   sporadic	   finding	   of	  
granules	   outside	   the	   delimited	   defect	   area.	  Moreover,	   the	   vast	  majority	   of	   granules	  
seemed	  not	  to	  have	  been	  resorpted,	  even	  after	  month	  6	  of	  implantation,	  both	  in	  Sham	  
and	  Ovx	  animals	  (Figures	  150-­‐155).	  	  
The	   unfilled	   defects	   (negative	   control	   group)	   remained	   open	   with	   reduced	  
evidence	  of	  new	  bone	  formation,	   throughout	  the	  evaluation	  period,	  both	   in	  Ovx	  and	  


















Figure	  150	  –	  Sham	  calvarial	  CSD	  
with	  Bio-­‐oss®,	  at	  month	  1.	  
Figure	  151	  –	  Ovx	  calvarial	  CSD	  
with	  Bio-­‐oss®,	  at	  month	  1.	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Figure	  152	  –	  Sham	  calvarial	  CSD	  
with	  Bio-­‐oss®,	  at	  month	  3.	  
Figure	  153	  –	  Ovx	  calvarial	  CSD	  
with	  Bio-­‐oss®,	  at	  month	  3.	  
Figure	  154	  –	  Sham	  calvarial	  CSD	  
with	  Bio-­‐oss®,	  at	  month	  6.	  
Figure	  155	  –	  Ovx	  calvarial	  CSD	  
with	  Bio-­‐oss®,	  at	  month	  6.	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Figure	  156	  –	  Sham	  calvarial	  CSD	  
without	  Bio-­‐oss®,	  at	  month	  6.	  
Figure	  157	  –	  Ovx	  calvarial	  CSD	  
without	  Bio-­‐oss®,	  at	  month	  6.	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2.	  X-­‐RAY	  EVALUATION	  
	  
By	   the	   evaluation	   of	   the	   X-­‐rays	   it	   is	   recognizable	   that	   the	   Bio-­‐oss®	   granules	   are	  
present	   in	   all	   of	   the	   seeded	   CSD.	   No	   evidence	   of	   biomaterial	   resorption	  was	   found,	  
nonetheless	   the	   vast	   majority	   of	   the	   graft	   material	   was	   confined	   to	   the	   calvarial	  
defects.	  Apparently,	  new	  bone	  formation	  area	  is	  limited	  to	  the	  margin	  of	  the	  defect,	  in	  
both	  Ovx	  and	  Sham	  groups	  (Figures	  158-­‐163).	  	  

















	   	  
Figure	  158	  –	  Radiographic	  image	  of	  
Sham	  CSD	  filled	  with	  Bio-­‐Oss®,	  1	  
month	  following	  craniotomy.	  
Figure	  159	  –	  Radiographic	  image	  of	  
Ovx	  CSD	  filled	  with	  Bio-­‐Oss®,	  1	  
month	  following	  craniotomy.	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Figure	  160	  –	  Radiographic	  image	  of	  
Sham	  CSD	  filled	  with	  Bio-­‐Oss®,	  3	  
months	  following	  craniotomy.	  
Figure	  161	  –	  Radiographic	  image	  of	  
Ovx	  CSD	  filled	  with	  Bio-­‐Oss®,	  3	  
months	  following	  craniotomy.	  
Figure	  162	  –	  Radiographic	  image	  of	  
Sham	  CSD	  filled	  with	  Bio-­‐Oss®,	  6	  
months	  following	  craniotomy.	  
Figure	  163	  –	  Radiographic	  image	  of	  
Ovx	  CSD	  filled	  with	  Bio-­‐Oss®,	  6	  
months	  following	  craniotomy.	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CALVARIAL	  CRITICAL	  DEFECTS	  –	  NEGATIVE	  	  CONTROL	  GROUP	  
	  


















The	   X-­‐rays	   analysis	   reveals	   that	   the	   unfilled	   defects	   (negative	   control	   group)	  
remained	   open,	   with	   residual	   evidence	   of	   new	   bone	   formation,	   throughout	   the	  






Figure	  165	  –	  Ovx	  5mm	  Month	  6	  control.	  Figure	  164	  –	  Sham	  5mm	  Month	  6	  control.	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3.	  MICRO-­‐	  CT	  OF	  CALVARIAL	  
	  
Micro-­‐tomographic	  analysis	  was	  conducted	  for	  samples	  of	  Sham	  and	  Ovx	  animals,	  
6	   months	   following	   craniotomy	   and	   biomaterial	   implantation.	   Due	   to	   density	  
differences	   and	   the	   high	   resolution	   acquisition,	   biomaterial	   granules	   with	   high	  
radiopacity	  (bright	  white)	  could	  be	  easily	  differentiated	  from	  old	  bone	  and	  from	  newly	  
regenerated	  bone	  tissue	   (light	  grey).	  Overall,	   the	  amount	  of	  newly	   formed	  bone	  was	  
relatively	   low,	  at	   the	  assayed	   time	  point,	   in	  both	  experimental	  groups.	  At	   the	  defect	  
margin,	   a	   centripetal	   growth	   of	   the	   newly	   formed	   radiopaque	   tissue	   could	   be	  
identified	  at	  the	  sagittal	  view,	   in	  both	  Sham	  and	  Ovx	  samples	   (Figure	  166).	  Evidence	  of	  
newly	   formed	  bone	   could	  be	  depicted	   in	   light	   grey,	   throughout	   and	   in	   close	   contact	  
with	  the	  interspersed	  granular	  material.	  In	  the	  assessed	  Sham	  samples	  an	  evidence	  of	  
a	  higher	  bone	   formation	  could	  be	  verified	  by	   the	  presence	  of	  denser	  areas	  of	  newly	  















Figure	  166	  –	  Micro-­‐Ct	  of	  the	  Ovx	  and	  Sham	  CSD	  filled	  with	  Bio-­‐oss®,	  at	  month	  6,	  
sagittal	  view.	  Scale	  bar	  represents	  400µm.	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In	   the	   axial	   view	   (Figure	   167),	   it	   is	   observable	   that	   the	   granules	   of	   Bio-­‐oss®	   are	  
uniformly	   distributed	   within	   the	   defect.	   In	   the	   Sham	   defect	   we	   can	   observe	   an	  
increased	   area	   of	   newly	   formed	   bone	   tissue	   (arrows),	   at	   the	   margin	   of	   the	   defect,	  
comparing	   to	   the	   Ovx	   group	   of	   animals.	   Some	   Bio-­‐oss®	   granules	   seem	   to	   be	  

















Details	  of	  the	  bone	  regeneration	  process	  in	  the	  vicinity	  of	  the	  defect	  margin	  were	  
disclosed	   by	   the	   axial	   view	   (Figure	   168).	   In	   Sham	   animals,	   an	   increased	   bone	   tissue	  
regeneration	  could	  be	  branded,	  as	  evidenced	  by	  the	  greater	  amount	  of	  newly	  formed	  
mineralized	  tissue	  engulfing	  the	  implanted	  granules	  (dotted	  rectangle),	  and	  increased	  
amount	  of	  newly	  formed	  bone	  within	  the	  implanted	  granules	  surface	  (triangles).	  In	  Ovx	  
animals,	  the	  evidence	  of	  newly	  formed	  mineralized	  tissue	  was	  far	   less	  scarce	  with	  no	  
signs	  of	  biomaterial	  engulfment	  and	  reduced	  amount	  of	  formed	  tissue	  on	  biomaterial	  
surface	  (triangles).	  
Figure	  167	  –	  Micro-­‐Ct	  of	  the	  Sham	  (A)	  and	  Ovx	  (B)	  CSD	  filled	  with	  Bio-­‐oss®,	  at	  month	  6,	  axial	  view.	  
Sham	   Ovx	  
	  RESULTS	  
	  





















Quantitative	   analysis	   of	   the	   BV	   within	   the	   assayed	   TV	   (BV/TV),	   considering	  
segmentation	   based	   on	   the	   grey	   scale	   value,	   was	   used	   to	   determine	   the	   bone	  
formation	  process.	  At	   the	  assayed	   time	  points,	   values	  were	   found	   to	  be	  consistently	  
lower	   in	   the	  Ovx	   group,	   as	   comparing	   to	   the	   time	  matched	   Sham	   group	   (Figure	   169).	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Figure	  169	  –	  Graphic	  representantion	  of	  the	  bone	  volume	  per	  tissue	  volume	  
(BV/TV),	  of	  the	  calvarial	  bone	  defects	  at	  month	  1,	  3	  and	  6,	  of	  Sham	  and	  Ovx	  group.	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4.	  HISTOLOGY	  
	  
Histological	  sections	  were	  analyzed	  and	  scored	  to	  address	  the	  tissue	  response	  
at	  the	  bone–material	  interface	  and	  the	  tissue	  ingrowth	  within	  the	  grafted	  defects.	  Due	  
to	   the	   slow	   regenerative	  process	   verified	   throughout	   the	  dimension	  of	   the	  defect,	   a	  
special	  focus	  was	  set	  at	  the	  defect	  margins.	  	  
	  




At	   1	   month	   following	   craniotomy,	   at	   the	   defect	   margin,	   it	   was	   verified	   the	  
typical	  formation	  of	  a	  cone	  with	  the	  vertex	  oriented	  toward	  the	  center	  of	  the	  defect,	  in	  
which	  the	  centripetal	  tissue	  growth	  was	  attained.	  Osteogenic	  activity	  is	  observed	  with	  
a	  pattern	  of	   intramembranous	  ossification,	   especially	   along	   the	  margins	  of	   the	  bone	  
defect,	   for	   both	   Sham	   and	   Ovx	   animals.	   The	   biomaterial	   granules	   seem	   to	   be	  
interspaced	  by	  fibrous	  tissue	  in	  the	  vast	  majority	  of	  the	  sample.	  In	  the	  close	  vicinity	  to	  
the	  defect	  margin,	  some	  Bio-­‐oss®	  granules	  seem	  to	  be	  partially	  surrounded	  by	  a	  thin	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Figure	  171	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  Bio-­‐oss®,	  at	  month	  1.	  100x	  
magnification.	  Toluidine	  blue	  staining.1	  –	  Bio-­‐oss®;	  2	  –	  Old	  bone;	  3-­‐	  New	  bone;	  4-­‐	  Connective	  
tissue;	  5-­‐	  New	  blood	  vessels.	  
Figure	  170	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  Bio-­‐oss®,	  at	  month	  1.	  40x	  


































Figure	  173	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  Bio-­‐oss®,	  at	  month	  1.	  100x	  
magnification.	  Toluidine	  blue	  staining.1	  –	  Bio-­‐oss®;	  2	  –	  Old	  bone;	  3-­‐	  New	  bone;	  4-­‐	  Connective	  
tissue.	  
Figure	  172	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  Bio-­‐oss®,	  at	  month	  1.	  40x	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MONTH	  3	  
	  
At	  3	  months	  osteogenic	  activity	  is	  visualized	  at	  the	  margins	  of	  the	  defect,	  with	  
the	  characteristic	  cone	  formation	  in	  both	  Ovx	  and	  Sham	  samples	  (Figures	  174-­‐178).	  In	  the	  
representative	  images	  of	  the	  Sham	  group	  of	  animals,	  there	  is	  also	  a	  significant	  amount	  
of	   newly	   formed	   bone	   tissue	   without	   contact	   with	   biomaterial	   particles,	   and	  
apparently	   unrelated	   to	   the	   spatial	   top,	   bottom,	   outer	   and	   median	   of	   the	   defect	  
margin	   (Figures	   174-­‐176).	   In	   both	   Ovx	   and	   Sham	   samples,	   the	  majority	   of	   biomaterial	  
granules	   seem	   to	   be	   interspaced	   by	   fibrous	   tissue,	   nonetheless,	   some	   Bio-­‐oss®	  










	   	  
Figure	   174	   –	   Representative	   image	   of	   the	   Sham	   CSD	   filled	   with	   Bio-­‐oss®,	   at	   month	   3.	   40x	  


























	   	  
Figure	  176	   –	  Representative	   image	  of	   the	   Sham	  CSD	   filled	  with	   Bio-­‐oss®,	   at	  month	  3.	  100x	  
magnification.	  Toluidine	  blue	  staining.	  1	  –	  Bio-­‐oss®;	  2	  –	  Fibrous	  tissue;	  3-­‐	  New	  bone.	  
Figure	  175	   –	  Representative	   image	  of	   the	   Sham	  CSD	   filled	  with	   Bio-­‐oss®,	   at	  month	  3.	  100x	  


























	   	  
Figure	   177	   –	   Representative	   image	   of	   the	   Ovx	   CSD	   filled	   with	   Bio-­‐oss®,	   at	   month	   3.	   40x	  
magnification.	  Toluidine	  blue	   staining.	  1	  –	  Bio-­‐oss®;	  2	  –	  Old	  bone;	  3-­‐	  New	  bone;	  4-­‐	   Fibrous	  
tissue.	  
Figure	   178	   –	   Representative	   image	   of	   the	   Ovx	   CSD	   filled	   with	   Bio-­‐oss®,	   at	   month	   3.	   100x	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MONTH	  6	  
	  
At	  month	  6	  of	  evaluation,	  a	  significant	  amount	  of	  bone	  formation	  was	  visualized	  
at	  the	  margins	  of	  the	  defect,	  either	  in	  Sham	  and	  Ovx	  animals	  (Figures	  179-­‐183).	  	  In	  Sham	  
animals,	  it	  is	  evident	  the	  inclusion	  of	  biomaterial	  granules	  into	  the	  newly	  formed	  bone	  
at	   the	  margin	   of	   the	   defect.	   In	   the	   Figures	   179-­‐180,	   it	   was	   evident	   the	   engulfment	   of	  
biomaterial	   granules	   into	   the	   newly	   formed	   bone	   at	   the	   margin	   of	   the	   defect	   a	  
biomaterial	  granule	  fully	  surrounded	  and	  enclosed	  by	  new	  bone	  is	  presented.	  	  
In	   Ovx	   samples,	   significant	   newly	   formed	   bone	   tissue	   is	   visualized	   in	   close	  
association	   with	   marginal	   Bio-­‐oss®	   granules,	   but	   no	   evidence	   of	   biomaterial	  
entrapment	  by	  the	  regenerative	  process	   is	  seen.	  Nevertheless,	  both	  in	  Ovx	  and	  Sham	  
animals,	  most	   of	   the	   space	   between	   the	   biomaterial	   granules	   seemed	   to	   be	   fulfilled	  











Figure	   179	   –	   Representative	   image	   of	   the	   Sham	   CSD	   filled	   with	   Bio-­‐oss®,	   at	   month	   6.	   40x	  



























	   	  
Figure	   181	   –	   Representative	   image	   of	   the	   Ovx	   CSD	   filled	   with	   Bio-­‐oss®,	   at	   month	   6.	   40x	  
magnification.	  Toluidine	  blue	  staining.	  1	  –	  Bio-­‐oss®;	  2	  –	  Old	  bone;	  3-­‐	  New	  bone.	  
Figure	  180	   –	  Representative	   image	  of	   the	   Sham	  CSD	   filled	  with	   Bio-­‐oss®,	   at	  month	  6.	  100x	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Figure	   183	   –	   Representative	   image	   of	   the	   Ovx	   CSD	   filled	   with	   Bio-­‐oss®,	   at	   month	   6.	   100x	  
magnification.	  Toluidine	  blue	  staining.	  1-­‐Bio-­‐oss®;	  2-­‐	  New	  bone;	  3-­‐	  Fibrous	  tissue.	  
3	  
Figure	   182	   –	   Representative	   image	   of	   the	   Sham	  CSD	   filled	  with	   Bio-­‐oss®,	   at	   month	   6.	   40x	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CALVARIAL	  CRITICAL	  DEFECTS	  –NEGATIVE	  	  CONTROL	  GROUP	  
	  
In	   the	   defects	   left	   unfilled,	   after	   6	   months	   of	   healing,	   reduced	   new	   bone	  
formation	  was	  attained.	  Osteogenic	  activity	  was	  minimal	  and	  limited	  to	  the	  margins	  of	  
the	  defects,	   both	   in	   Sham	  and	  Ovx	   groups	   (Figures	   184-­‐185).	  No	   significant	  differences	  










	   	  
Figure	  184	  –	  Representative	  image	  of	  the	  Sham	  animal,	  at	  month	  6.	  100x	  
magnification.	  Toluidine	  blue	  staining.	  1	  –	  Old	  bone;	  2	  -­‐	  New	  bone.	  	  
Figure	  185	  –	  Representative	  image	  of	  the	  Ovx	  animal,	  at	  month	  6.	  100x	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5.	  HISTOMORPHOMETRIC	  ANALYSIS	  
	  
In	   order	   to	   validate	   the	   qualitative	   histologic	   findings	   by	   a	   quantitative	  
approach,	  the	  relative	  amount	  of	  the	  newly	  formed	  bone	  was	  determined.	  The	  bone	  
volume	   per	   tissue	   volume	   (BV/TV)	   was	   lower	   in	   Ovx	   animals,	   comparing	   to	   Sham	  
animals,	  throughout	  the	  experimental	  period.	  Significant	  differences	  were	  attained	  at	  
the	  month	  3	  and	  6	   following	  the	  craniotomy	  procedure.	  The	  bone	  substitute	  volume	  
per	  tissue	  volume	  (BSV/TV)	  was	  also	  calculated	  and	  no	  significant	  differences	  between	  
experimental	  groups	  were	  found,	  at	  any	  assayed	  time	  point	  (Table	  21).	  	  	  	  	  
Table	  21	   –	  Morphometric	   analysis	  of	  histological	   samples.	  Histomorphometric	   analysis	  of	   the	  





BV/TV	   BSV/TV	  







Month	  1	   4,98	  (3,78)	   2,35	  (1,67)	   68,56	  (8,21)	   70,45	  (6,54)	  
Month	  3	   18,35	  (5,78)	   13,67	  (7,65)*	   63,56	  (6,78)	   69,54	  (5,43)	  
Month	  6	   28,45	  (7,89)	   16,56	  (8,76)*	   61,45	  (3,56)	   63,32	  (5,43)	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  
*p<0.05	  Vs	  Sham	  group;	  sd:	  standard	  deviation,	  BV/TV:	  bone	  volume	  per	  tissue	  volume,	  BSV/TV:	  bone	  substitute	  
volume	  per	  tissue	  volume.	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6.	   QUANTITATIVE	   PCR	   ANALYSIS	   OF	   GENE	   EXPRESSION	  
DURING	  BONE	  HEALING	  
	  
Quantitative	  real-­‐time	  PCR	  was	  employed	  for	  quantifying	  bone	  healing	  related	  
gene	  expression	  at	  mRNA	   level.	  Transcriptional	  regulation	  of	  gene	  expression	   is	  a	  key	  
mechanism	  controlling	  cellular	  differentiation	  and	  function	  in	  all	  cell	  types.	  Osteoblasts	  
differentiate	   from	   mesenchymal	   precursor	   cells	   and	   then	   produce	   the	   bonespecific	  
extracellular	  matrix.	  
Its	  use	  can	  be	  pertinent,	  since	  the	  dysregulation	  of	  estrogen	  receptors	  could	  be	  
involved	  in	  the	  underlying	  mechanism	  responsible	  for	  osteoporotic	  bone	  healing	  after	  
estrogen	   depletion	   among	   other	   factors.	   The	   Col1,	   osteocalcin	   and	   RUNX	   2	   mRNA	  
expression	   are	   associated	   with	   bone	   formation,	   as	   the	   ER-­‐	   alpha.[340]	   Runx2	   plays	  
crucial	   role	   as	   a	   transcriptional	   activator	   of	   osteoblast	   differentiation	   and	   the	   serum	  
osteocalcin	  is	  a	  sensitive	  and	  specific	  marker	  of	  osteoblastic	  activity	  and	  its	  serum	  level	  
thus	  reflects	  the	  rate	  of	  bone	  formation.[341]	  
The	   PPAR-­‐gamma	   is	   a	   master	   regulator	   of	   the	   adipogenic	   differentiation,	   its	  
expression	   as	   the	   expression	   of	   ER-­‐beta	   can	   be	   related	   with	   diminished	   bone	  
formation.	  [342]	  
The	  expressions	  of	  osteoblast-­‐specific	   genes	  Col	   I,	  OC	  and	  RUNX	  2,	   as	  well	   as	  
ER-­‐alpha,	   ER-­‐beta	   and	   PPAR-­‐gamma	   genes,	   in	   the	   regenerating	   calvarial	   bone	   tissue	  
following	  6	  months	  of	  graft	  implantation	  are	  expressed	  in	  Figure	  186.	  	  
The	  expression	  of	  osteoblastic	  specific	  markers	  was	  significantly	  higher	  in	  Sham	  
animals	   rather	   than	   in	   ovariectomized	   rats.	   ER-­‐alpha	   mRNA	   expression	   levels	   were	  
significantly	  lower	  in	  the	  regenerating	  tissue	  of	  Ovx	  animals,	  whereas	  the	  expression	  of	  
ER-­‐beta	   was	   significantly	   higher	   in	   Ovx	   rats,	   as	   comparing	   to	   Sham	   animals.	   PPAR-­‐
gamma	   expression	   was	   significantly	   higher	   in	   Ovx	   animals,	   comparing	   to	   Sham	  
controls.	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*	  
Figure	  186	  –	  Graphic	  representation	  of	  Collagen	  type	  I	  (Col	  I),	  Runt-­‐related	  transcription	  factor	  2	  (RUNX2),	  
peroxisome	   proliferator-­‐activated	   receptor	   gamma	   (PPAR-­‐γ),	   estrogen	   receptor-­‐beta,	   estrogen	   receptor-­‐
alpha	   and	   osteocalcin	   (OC)	   expression	   between	   the	   Sham	   and	   Ovx	   group	   ate	   month	   6	   following	   the	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In	  order	  to	  address	  the	  guided	  bone	  regeneration	  process	  biomaterial-­‐mediated	  
in	   a	   bone	   submitted	   to	   biomechanical	   loading,	   a	   critical	   size	   defect	   was	   established	  
within	  the	  mandibular	  bone	  and	  implanted	  with	  a	  xenograft	  and	  a	  collagen	  membrane.	  
The	   ovariectomized	   rat	   model	   was	   selected	   and	   the	   bicortical	   critical	   sized	  
defect	   was	   established	   in	   the	   mandible	   right	   angle.	   Three	   groups	   were	   formed	  
Membrane	   (M),	   Membrane	   and	   Biomaterial	   (MB)	   and	   Control	   (C)	   group.	   In	   the	  
Membrane	   group	   (M),	   the	  membranes	  were	   applied	   and	   the	   defect	  was	   covered	  on	  
the	   bucal	   and	   lingual	   side.	   In	   the	  Membrane	   and	  Biomaterial	   group	   (MB)	   the	   defect	  
was	   filled	  with	   the	  Putty®	  and	   the	  membrane	  was	  applied	  as	   in	   the	  M	  group.	   In	   the	  
Control	  group	  the	  mandibular	  defect	  was	  left	  untreated.	  These	  groups	  were	  performed	  
in	  the	  Sham	  and	  Ovx	  animals,	  as	  described	  in	  the	  Material	  and	  Methods	  chapter.	  
The	   time	   points	   analyzed	   in	   the	   results	   refer	   to	   the	   time	   following	   the	  
mandibular	  bone	  defect	  (see	  in	  the	  Material	  and	  Methods).	  The	  TE1	  corresponds	  to	  1	  
month	   of	   healing	   following	   the	   mandibular	   bone	   defect	   and	   3	   months	   following	  
ovariectomy	   or	   sham	   procedure	   and	   the	   TE2	   corresponds	   to	   3	   months	   of	   healing	  
following	   the	  mandibular	   bone	   defect	   and	   5	  months	   following	   ovariectomy	   or	   sham	  
procedure.	  
All	   the	   animals	   survived	   the	   surgical	   procedures	  without	   the	   development	   of	  
major	  post-­‐operative	  complications.	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1.	  MACROSCOPIC	  EVALUATION	  
	  
In	   the	  macroscopic	  evaluation	  of	   the	  mandibles	   in	  which	  the	  bone	  defect	  was	  
filled,	   the	   Evolution®	  membranes	   that	   surrounded	   the	   defects	  were	   visible.	   The	   CSD	  
filled	  with	  Putty®	  and	  surrounded	  by	  the	  membrane	  Evolution®,	  allowed	  us	  to	  establish	  
that	  the	  biomaterial	  was	  well	  contained	  within	  the	  defect	  (Figures	  187-­‐188).	  The	  integrity	  
observed	   macroscopically	   of	   bone	   regeneration	   procedure	   suggests	   that	   the	  
membrane	  was	  not	  completely	  resorbed	  in	  the	  two	  time	  points	  of	  evaluation.	  
The	   unfilled	   defects	   (negative	   control	   group)	   remained	   open	   with	   reduced	  
evidence	  of	  new	  bone	   formation,	   throughout	   the	  evaluation	  period,	  both	   in	  Ovx	  and	  













	   	  
Figure	  188	  –	  Right	  mandible,	  CSD	  with	  Putty®	  and	  
Evolution®	  membrane,	  lingual	  view.	  
Figure	   187	  –	   Right	  mandible,	   CSD	  with	  Putty®	  and	  
Evolution®	  membrane,	  buccal	  view.	  
Figure	   190	   –	   Left	   mandible,	   lingual	   view	   without	  
bone	  defect.	  
Figure	   189	   –	   Right	  mandible,	   CSD	   control	   (without	  
biomaterial	  and	  membrane)	  buccal	  view.	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2.	  X-­‐RAY	  EVALUATION	  
	  
The	   evaluation	   of	   the	  mandibular	   X-­‐rays	   allow	   us	   to	   perceive	   the	   incomplete	  
bone	  regeneration	  process,	  by	  detecting	  the	  margins	  of	  the	  original	  defect	  on	  the	  right	  
angle	  of	   the	  mandible,	  with	  a	   radiopaque	   image	  around	   the	  edges	   in	   all	   the	   groups.	  
The	   biomaterial	   is	   not	   perceptible	   assuming	   that	   this	   one	   as	   benn	   reabsorved.	   The	  
Control	  group,	  with	   the	  defect	   left	  untreated,	   showed	  clearly	   the	  original	  defect	  as	  a	  
radiolucent	  image,	  in	  both	  groups	  Sham	  and	  Ovx,	  assuming	  an	  absence	  of	  intense	  bone	  
regeneration	  (Figures	  191-­‐192).	  
Centripetal	  growth	  of	  the	  newly	  formed	  radiopaque	  tissue	  could	  be	  observed	  in	  
the	   margins	   of	   the	   original	   defect	   in	   the	   M	   (membrane)	   and	   MB	   (membrane	   and	  
biomaterial)	  group.	  
The	  M	  group	   in	   the	   Sham	  animals,	   presents	   a	  more	   radiopaque	   image	   in	   the	  
defect	   when	   compared	  with	   the	   Ovx	   animals	   (Figures	   193-­‐194).	  On	   the	  MB	   group	   the	  
Sham	  animals	  present,	  as	  above,	  a	  more	  radiopaque	   image	  when	  compared	  with	  the	  
Ovx	  animals	  (Figures	  195-­‐196).	  
Apparently,	  new	  bone	  formation	  area	  is	  limited	  to	  the	  margin	  of	  the	  defect,	  in	  
both	  Ovx	  and	  Sham	  groups	  (Figures	  193-­‐196).	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Figure	   193	   –	  Mandibular	   CSD	  M	   group,	   Sham	   animal	   at	  
month	  1.	  
Figure	   194	   –	   Mandibular	   CSD	   M	   group,	   Ovx	   animal	   at	  
month	  1.	  
Figure	  191	  –	  Mandibular	  CSD	  control	  group	  Sham	  animal	  
at	  month	  1.	  




MODULATION	  OF	  THE	  BONE	  REGENERATION	  PROCESS	  IN	  SYSTEMIC	  IMPAIRED	  CONDITIONS	   237	  













The	  evaluation	  of	  the	  mandibular	  bone	  defect	  with	  a	  high	  magnification,	  allow	  
us	   to	   calculate	   the	   bone	   density	   by	   the	   radiopacity	   in	   the	   x-­‐ray.	   Densitometric	  
evaluations	   were	   performed	   using	   the	   ImageJ®	   software.	   Densitometric	   results	   are	  
shown	  in	  Table	  22.	  The	  Ovx	  group	  reported	  lower	  values	  compared	  to	  the	  Sham	  group	  in	  
both	  the	  groups	  (M	  and	  MB),	  but	  no	  significant	  differences	  were	  attained.	  Between	  all	  
groups	  of	  evaluation,	  the	  Sham	  animals	  with	  the	  membrane	  and	  biomaterial	  reported	  a	  







Figure	  195	   –	  Mandibular	  CSD	  MB	  group,	   Sham	  animal	  at	  
month	  1.	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Table	  22	  –	  Densitometry	  of	  mandibular	  bone	  defects	  of	  Sham	  and	  Ovx	  animals,	  at	  1	  month.	  
	   	   Densitometry	  
	   	   Mean	  (AU)	   sd	  (AU)	   p	  
Membrane	  
Sham	   3166.67	   1266.107	  
0.234	  
Ovx	   2119.57	   1655.640	  
Membrane	  and	  biomaterial	  
Sham	   3761.67	   338.078	  
0.094	  
Ovx	   2914.29	   1026.367	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test	  between	  the	  Sham	  and	  Ovx	  group.	  
sd:	  standard	  deviation;	  Au:	  Arbitrary	  unit	  
	  
	   	  
Figure	  197	  –	  High	  magnification	  of	  the	  mandibular	  defect.	  A	  –	  Sham	  animal	  M	  group;	  B	  –	  Ovx	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In	  Figure	  198	  is	  presented	  the	  graphical	  distribution	  of	  the	  densitometry	  values	  of	  
mandibular	  bone	  defects	  in	  the	  Membrane	  group	  and	  the	  Membrane	  and	  biomaterial	  










	    
Figure	  198	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  mandibular	  bone	  defect	  with	  the	  Membrane	  	  (A)	  and	  Membrane	  
and	  Biomaterial	  (B),	  at	  month	  1	  of	  Sham	  and	  Ovx	  groups.	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   B	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MONTH	  3	  
	  
By	  the	  evaluation	  of	  the	  mandibular	  X-­‐rays	  at	  month	  3	  it	  is	  possible	  to	  observe	  
the	   center	   of	   the	   original	   defect	  with	   a	   radiolucent	   image,	   on	   the	   right	   angle	   of	   the	  
mandible,	  revealing	  the	  absence	  of	  complete	  regeneration.	  The	  M	  group	   in	  the	  sham	  
animals	  presents	  a	  more	  radiopaque	  image	  in	  the	  defect	  when	  compared	  with	  the	  M	  
group	  Ovx	  animals	  (Figures	  199-­‐200).	  The	  centripetal	  regeneration	  is	  observed	  presenting	  
a	  more	   radiopaque	   image	   in	   the	   borders	   of	   the	   defect.	   On	   the	  MB	   group	   the	   sham	  
animals	   as	   above	   presents	   a	   more	   radiopaque	   image	   when	   compared	   with	   the	   ovx	  
group	   (Figures	   201-­‐202).	  A	   substantial	   reduction	   of	   the	   trabecular	   structure	   in	   the	  Ovx	  
group	  needs	  also	  to	  be	  highlighted,	  noticeable	  on	  the	  angle	  of	  the	  mandible.	  
	  












	   	  
Figure	   200	   –	   Mandibular	   CSD	   with	   an	   Evolution®	  
membrane,	  Ovx	  animal	  at	  month	  3.	  
Figure	   199	   –	   Mandibular	   CSD	   with	   an	   Evolution®	  
membrane,	  Sham	  animal	  at	  month	  3.	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The	  evaluation	  of	  the	  mandibular	  bone	  defect	  with	  a	  high	  magnification,	  allow	  
us	   to	   calculate	   the	   bone	   density	   by	   the	   radiopacity	   in	   the	   x-­‐ray.	   Densitometric	  
evaluations	   were	   performed	   using	   the	   ImageJ®	   software.	   Densitometric	   results	   are	  
shown	  in	  Table	  23.	  The	  Ovx	  group	  reported	  lower	  values	  compared	  to	  the	  Sham	  group	  in	  
both	  the	  groups	  (M	  and	  MB).	  As	  noted	  earlier	  in	  the	  month	  1,	  the	  sham	  animals	  in	  the	  
MB	  group,	  presents	  the	  highest	  value	  for	  the	  densitometric	  analysis,	  when	  compared	  
with	  all	  groups.	  In	  the	  M	  group	  significant	  differences	  were	  attained	  between	  the	  sham	  
and	   Ovx	   animals,	   as	   the	   sham	   animals	   show	   higher	   values	   in	   the	   densitometric	  
analysis.	  The	  Ovx	  animals	  in	  the	  MB	  group	  attained	  lower	  values	  when	  compared	  with	  
the	  sham	  animals,	  but	  no	  significant	  differences	  were	  noticed.	   In	  both	  groups	  M	  and	  
MB	  in	  the	  sham	  and	  Ovx	  animals,	  a	  markedly	  increase	  of	  the	  densitometry	  values	  was	  
observed	  between	  the	  two	  evaluation	  points.	  
	  
Figure	   201	   –	   Mandibular	   CSD	   with	   an	   Evolution®	  
membrane	  and	  Putty®	  Sham	  animal	  at	  month	  3.	  
Figure	  202	  –	  Mandibular	  CSD	  with	  an	  Evolution®	  
membrane	  and	  Putty®	  Ovx	  animal	  at	  month	  3.	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Table	  23	  –	  Densitometry	  of	  mandibular	  bone	  defects	  of	  Sham	  and	  Ovx	  animals,	  at	  3	  month.	  
Densitometry	   	   Mean	  (AU)	   sd	  (AU)	   p	  
Membrane	  
Sham	   3955	   976	  
0,281	  
Ovx	   3558	   511	  
Membrane	  and	  biomaterial	  
Sham	   4773	   470	  
0,003	  
Ovx	   3883*	   253*	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test	  between	  the	  Sham	  and	  Ovx	  group.	  
*p<0.05	  Vs.	  Sham	  group;sd:	  standard	  deviation;	  Au:	  Arbitrary	  unit	  
	  
	  
Figure	  203	  –	  High	  magnification	  of	  the	  mandibular	  defect.	  A	  –	  Sham	  animal	  M	  group;	  B	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In	  Figure	  204	  is	  presented	  the	  graphical	  distribution	  of	  the	  densitometry	  values	  of	  
mandibular	  bone	  defects	  in	  the	  Membrane	  group	  and	  the	  Membrane	  and	  biomaterial	  






 	  	  
 
 	  
	   	  
Figure	  204	  –	  Box	  plot	  of	  the	  densitometry	  values	  of	  the	  mandibular	  bone	  defect	  with	  the	  Membrane	   	  (A)	  and	  Membrane	  
and	  Biomaterial	  (B),	  at	  month	  3	  of	  Sham	  and	  Ovx	  groups.	  *p<0.05	  Vs.	  Sham	  group.	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3.	  MICRO-­‐CT	  
	  
Micro-­‐tomographic	   analysis	   was	   conducted	   for	   samples	   of	   Sham	   and	   Ovx	  
animals,	  1	  and	  3	  months	  following	  the	  mandibular	  bone	  defect	  and	  with	  implantation	  
of	  biomaterial	  and	  a	  membrane	  of	  biomaterial	  implantation,	  depending	  on	  the	  group;	  
Membrane	   (M)	   or	   Membrane	   and	   Biomaterial	   (MB).	   Due	   to	   the	   capacity	   to	  
differentiate	   between	   mineralized	   tissue	   density,	   a	   different	   color	   is	   presented	  
differentiating	  the	  highly	  mineralized	  tissue	  (light	  pink)	  from	  the	  less	  mineralized	  tissue	  
(dark	  pink),	  within	  the	  created	  CSD.	  Overall,	  the	  defect	  was	  not	  closed	  in	  any	  essayed	  
experimental	  situation,	  at	  the	  assayed	  time	  point,	  in	  both	  experimental	  groups.	  At	  the	  
defect	  margin,	   a	   centripetal	   growth	  of	   the	  newly	   formed	   radiopaque	   tissue	   could	  be	  
identified	  at	  the	  axial	  view,	  in	  both	  Sham	  and	  Ovx	  samples	  (Figures	  205-­‐208).	  	  
In	  all	  the	  images	  was	  not	  possible	  to	  distinguish	  the	  bone	  from	  the	  biomaterial.	  
The	   radiographic	   densities	   of	   the	   bone	   and	   biomaterial	   are	   similar,	   precluding	   the	  
possibility	   of	   discriminate	   the	   new	   bone	   formation	   from	   the	   biomaterial.	   This	   also	  
justifies	  the	  small	  granules	  that	  are	  observed	  around	  the	  defect	  which	  must	  correspond	  
to	  a	  portion	  of	  the	  biomaterial.	  The	  biomaterial	   is	  expected	  to	  be	  gradually	  resorbed,	  
since	  the	  defect	  is	  no	  longer	  completely	  filled	  as	  observed	  in	  Figure	  207.	  
In	  the	  Membrane	  group,	  in	  Sham	  animals,	  we	  can	  observe	  an	  increased	  area	  of	  
newly	   formed	  bone	  tissue	   (pink	  and	  grey),	  at	   the	  margin	  of	   the	  defect,	  comparing	  to	  
the	  Ovx	  animals	  also	  implanted	  with	  the	  membrane	  alone	  (Figures	  205-­‐206).	  
In	  the	  Membrane	  and	  Biomaterial	  group,	  Sham	  animals,	  increased	  bone	  tissue	  
regeneration	  could	  be	  branded,	  as	  evidenced	  by	  the	  greater	  amount	  of	  newly	  formed	  
mineralized	  tissue	  in	  light	  and	  dark	  pink.	  In	  Ovx	  animals,	  the	  evidence	  of	  newly	  formed	  
mineralized	  tissue	  was	  far	  less	  scarce	  within	  the	  defect	  (Figures	  207-­‐208).	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Figure	  205	  –	  Mandible	  from	  Sham	  animal	  treated	  with	  a	  Membrane	  at	  month	  1.	  
Figure	  206	  –	  Mandible	  from	  Ovx	  animal	  treated	  with	  a	  Membrane	  at	  month	  1.	  
Figure	  207	  –	  Mandible	  from	  Sham	  animal	  treated	  with	  a	  Membrane	  and	  biomaterial	  at	  month	  1.	  
Figure	  208	  –	  Mandible	  from	  Ovx	  animal	  treated	  with	  a	  Membrane	  and	  Biomaterial	  at	  month	  1.	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The	  mineralized	  tissue	  volume	  was	  attained	  in	  the	  samples	  of	  all	  the	  groups	  in	  
the	   two	   timepoints	   of	   evaluation.	   In	   the	  month	   1,	   Sham	   animals	   of	   the	  MB	   groups	  
present	   the	  highets	  values	   for	  bone	  volume,	   followed	  by	   the	  Sham	  animals	  of	   the	  M	  
group	  and	  by	  the	  Ovx	  animals	  of	   the	  MB	  group	  and	  finally	   the	  Ovx	  animals	  of	   the	  M	  
group.	  	  
At	  month	  3	  as	  observed	  previously,	  Sham	  animals	  in	  the	  MB	  group	  present	  the	  
highets	  values	  of	  bone	  volume.	  Between	  the	  Sham	  and	  Ovx	  animals	  in	  the	  M	  and	  MB	  
groups,	   the	   sham	   animals	   continually	   show	   higher	   values	   than	   the	   Ovx	   animals.	  




Table	  24	  –Microstructural	  analyses	  of	  mandibular	  defect	  in	  the	  Membrane	  (M)	  and	  Membrane	  
and	  Biomaterial	  (MB)	  groups	  of	  Sham	  and	  Ovx	  animals,	  at	  month	  1	  and	  3.	  
	   	   	   MTV	   sd	  
Month	  1	  
Membrane	  
Sham	   1.785	   0.035	  
Ovx	   0.965	   0.013	  
Membrane	  and	  Biomaterial	  
Sham	   1.990	   0.028	  
Ovx	   1.280	   0.056	  
Month	  3	  
Membrane	  
Sham	   3.061	   0.067	  
Ovx	   1.675	   0.152	  
Membrane	  and	  Biomaterial	  
Sham	   3.661	   0.140	  
Ovx	   2.775	   0.141	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test	  between	  the	  Sham	  and	  Ovx	  group.	  
*p<0.05	  Vs	  Sham	  group,;	  sd:	  standard	  deviation;	  MTV:	  mineralized	  tissue	  volume.	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4.	  HISTOLOGY	  
	  
Histological	  sections	  were	  analysed	  and	  scored	  to	  address	   the	  tissue	  response	  
at	   the	   bone–material	   interface	   and	   the	   tissue	   ingrowth	   within	   the	   grafted	   defects.	  
Throughout	  the	  analysis,	  a	  special	  focus	  was	  set	  at	  the	  defect	  margins.	  	  
	  
MONTH	  1	  :	  MEMBRANE	  
	  
At	   1	   month	   following	   the	   mandibular	   surgery,	   at	   the	   defect	   margin,	   it	   was	  
verified	  the	  typical	  formation	  of	  a	  cone	  with	  the	  vertex	  oriented	  toward	  the	  center	  of	  
the	  defect,	   in	  which	  the	  centripetal	  tissue	  growth	  was	  attained.	  Osteogenic	  activity	   is	  
observed	  with	  a	  pattern	  of	  intramembranous	  ossification,	  especially	  along	  the	  margins	  
of	  the	  bone	  defect,	  for	  both	  Sham	  and	  Ovx	  animals.	  The	  new	  bone	  was	  interspaced	  by	  
fibrous	   tissue	   in	   the	   vast	   majority	   of	   the	   sample.	   In	   the	   close	   vicinity	   to	   the	   defect	  
margin,	  a	  small	  part	  of	  newly	  formed	  bone	  tissue	   is	  observed,	  both	   in	  Ovx	  and	  Sham	  
samples	  (Figures	  209-­‐213).	  
The	  Sham	  animals	  in	  the	  Membrane	  group	  display	  in	  the	  peripheral	  zone	  of	  the	  
central	   area	  of	   the	  defect	   the	   residual	   fibers	  of	   the	   collagen	  membrane,	   finding	   that	  
this	  was	  not	  completely	  resorbed.	  When	  comparing	  the	  sham	  and	  Ovx	  animals,	  we	  can	  
observe	   a	   more	   developed	   and	   compact	   trabecular	   new	   bone	   on	   the	   limits	   of	   the	  
original	   defect	   in	   the	   Sham	   animals,	   than	   in	   the	   Ovx	   animals,	   with	   a	   thinner	   bone	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Figure	  209	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  
at	  month	  1.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  Old	  bone;	  3	  –	  
Connective	  tissue;	  4-­‐	  Bone	  marrow.	  
3	  
Figure	  210	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  
at	  month	   1.	   100x	  magnification.	   Toluidine	   blue	   staining.	   1	   –	  New	   bone;	   2-­‐	   Connective	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Figure	  211	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  at	  
month	   1.	   40x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone;	   2	   –	   Old	   bone;	   3-­‐	  
Connective	  tissue.	  
Figure	  212	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  at	  
month	   1.	   100x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone	   (mature);	   2-­‐	  


























MONTH	  1	  :	  MEMBRANE	  	  AND	  BIOMATERIAL	  
	  
At	  month	  1,	  osteogenic	  activity	   is	  visualized	  at	  the	  margins	  of	  the	  defect,	  with	  
the	   characteristic	   cone	   formation	   in	   both	  Ovx	   and	   Sham	   samples	   (Figures	   214-­‐220)..	   In	  
the	   representative	   images	   of	   the	   Sham	   animals	   in	   the	   Membrane	   and	   Biomaterial	  
group,	  there	  is	  a	  significant	  amount	  of	  newly	  formed	  bone	  tissue	  when	  compared	  with	  
Ovx	  animals.	  The	  Membrane	  and	  Biomaterial	  group	  display	  a	  larger	  area	  of	  new	  bone	  
formation	   when	   compared	   with	   animals	   of	   the	   Membrane	   group,	   at	   the	   same	  
timepoint.	  	  
The	   Sham	  and	  Ovx	   animals	   display	   residual	   fibers	   of	   the	   collagen	  membrane,	  
finding	  that	  this	  was	  not	  completely	  resorbed.	  Although	  no	  biomaterial	  is	  perceptible,	  
we	  assume	  that	   it	  has	  been	  reabsorbed	   in	  a	  cell-­‐mediated	  process.	  When	  comparing	  
the	  Sham	  and	  Ovx	  animals,	  we	  can	  observe	  a	  more	  developed	  and	  compact	  trabecular	  
new	  bone	  on	   the	   limitis	   of	   the	   original	   defect	   in	   the	   Sham	  animals,	   than	   in	   the	  Ovx	  
animals,	  with	  a	  thinner	  bone	  trabaculae	  (Figures	  214-­‐220).	  
Figure	  213	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  at	  
month	  1.	  1000x	  magnification.	  Toluidine	  blue	   staining.	  1	  –	  New	  bone	  (mature);	  2-­‐	  New	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Figure	  214	  –	  Representative	   image	  of	  the	  Sham	  CSD	  filled	  with	  Putty®	  and	  a	  Membrane	  
Evolution®,	  at	  month	  1.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  Old	  
bone;	  3-­‐	  Connective	  tissue;	  4-­‐	  Masseter	  muscle	  layer;	  5	  –	  Bone	  marrow.	  
Figure	   215	   –	   Representative	   image	   of	   the	   Sham	   CSD	   filled	   with	   Putty®	   a	   Membrane	  
Evolution®,	  at	  month	  1.	  100x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	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Figure	   216	   –	   Representative	   image	   of	   the	   Sham	   CSD	   filled	   with	   Putty®	   a	   Membrane	  
Evolution®,	   at	  month	   1.	   100x	  magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone;	   2-­‐	  




Figure	   217	   –	   Representative	   image	   of	   the	   Sham	   CSD	   filled	   with	   Putty®	   a	   Membrane	  
Evolution®,	   at	  month	   1.	   400x	  magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone;	   2-­‐	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Figure	   218	   –	   Representative	   image	   of	   the	  Ovx	   CSD	   filled	  with	   Putty®	   and	   a	  Membrane	  
Evolution®,	  at	  month	  1.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  Old	  
bone;	   3-­‐	   Connective	   tissue;	   4-­‐	   Masseter	   muscle	   layer;	   5-­‐	   Remnants	   of	   the	   residual	  
membrane.	  
Figure	   219	   –	   Representative	   image	   of	   the	   Ovx	   CSD	   filled	   with	   Putty®	   a	   Membrane	  
Evolution®,	  at	  month	  1.	  100x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  
Old	  bone;	  3-­‐	  Connective	  tissue.	  
4	  
3	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MONTH	  3	  :	  MEMBRANE	  
	  
At	  month	  3	  of	  evaluation,	  a	  significant	  amount	  of	  bone	  formation	  was	  visualized	  
at	  the	  margins	  of	  the	  defect,	  either	  in	  Sham	  and	  Ovx	  animals	  in	  the	  Membrane	  group	  
(Figures	   221-­‐226).	   	   In	   Sham	   animals,	   it	   is	   evident	   the	   residual	   fibers	   of	   the	   collagen	  
membrane	  on	   the	  peripheral	   zone	  of	   the	  central	   area	  of	   the	  defect.	   The	  area	  of	   the	  
new	   bone	   is	   superior	   when	   compared	   with	   month	   1	   of	   evaluation,	   with	   new	   bone	  
mature	   in	   the	  center	  of	   the	  defect	  and	  new	   trabeculae	  beeing	   formed	   (Figure	   221).	   In	  
Ovx	  samples,	   significant	  newly	   formed	  bone	  tissue	   is	  visualized	  when	  compared	  with	  
month	  1,	  but	  with	  a	  smaller	  area	  when	  matched	  with	  the	  Sham	  animals,	  presenting	  a	  
thinner	  bone	  trabaculae	  and	  a	  wider	  bone	  marrow	  (Figures	  221-­‐226).	  
	  
	  
Figure	   220	   –	   Representative	   image	   of	   the	  Ovx	   CSD	   filled	  with	   Putty®	   and	   a	  Membrane	  
Evolution®,	  at	  month	  3.	  400x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  














	   	  
Figure	  221	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  
at	  month	  3.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –New	  bone;	  2	  –	  Old	  bone;	  3-­‐	  
Masseter	  muscle	  layer;	  4-­‐	  Remnants	  of	  the	  residual	  Evolution®	  membrane.	  
Figure	  222	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  
at	  month	  3.	  100x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone	  (immature);	  2	  –	  

































Figure	  224	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  at	  
month	  3.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –New	  bone;	  2	  –	  Old	  bone.	  
Figure	  223	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  
at	  month	  3.	  100x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone	  immature;	  2	  –	  





































Figure	  225	  –	  Representative	  image	  of	  the	  Sham	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  
at	  month	  3.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone	  immature;	  2	  –	  New	  
bone	  mature;	  3-­‐	  Old	  bone.	  
Figure	  226	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  a	  Membrane	  Evolution®,	  at	  
month	  3.	  400x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone	   immature;	  2	  –	  New	  
bone	  mature;	  3-­‐	  Osteocytes.	  
4	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MONTH	  3	  :	  MEMBRANE	  AND	  BIOMATERIAL	  
	  
At	   month	   3	   of	   evaluation,	   a	   significant	   amount	   of	   new	   bone	   formation	   was	  
perceived	   at	   the	   margins	   of	   the	   defect,	   either	   in	   Sham	   and	   Ovx	   animals	   in	   the	  
Membrane	  and	  Biomaterial	  group	  (Figures	  227	  e	  231).	  In	  Sham	  and	  Ovx	  animals,	  it	  is	  clear	  
the	   residual	   fibers	  of	   the	  collagen	  membrane,	  and	  with	  a	  higher	  magnification	   (Figure	  
233).	   In	  the	  Sham	  animals	  the	  area	  of	  the	  new	  bone	   is	  superior	  when	  compared	  with	  
month	   1	   of	   evaluation,	  with	   new	   bone	  mature	   in	   the	   center	   of	   the	   defect	   and	   new	  
trabeculae	   beeing	   formed.	   In	   Ovx	   samples,	   significant	   newly	   formed	   bone	   tissue	   is	  
visualized	  when	  compared	  with	  month	  1,	  but	  with	  a	  smaller	  area	  when	  matched	  with	  


















Figure	  227	  –	  Representative	   image	  of	  the	  Sham	  CSD	  filled	  with	  Putty®	  and	  a	  Membrane	  
Evolution®,	  at	  month	  3.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  Old	  




































Figure	  228	  –	  Representative	   image	  of	  the	  Sham	  CSD	  filled	  with	  Putty®	  and	  a	  Membrane	  
Evolution®,	   at	   month	   3.	   100x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone	  







Figure	  229	  –	  Representative	   image	  of	  the	  Sham	  CSD	  filled	  with	  Putty®	  and	  a	  Membrane	  
Evolution®,	   at	   month	   3.	   100x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone	  






































Figure	  231	  –	  Representative	  image	  of	  the	  Ovx	  CSD	  filled	  with	  Putty®	  and	  a	  Membrane	  
Evolution®,	  at	  month	  3.	  40x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  New	  bone;	  2	  –	  Old	  






Figure	  230	  –	  Representative	   image	  of	  the	  Sham	  CSD	  filled	  with	  Putty®	  and	  a	  Membrane	  
Evolution®,	   at	   month	   3.	   400x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone	  
immature;	   2	   –	   New	   bone	  mature;	   3-­‐Old	   bone;	   4-­‐	   Bone	   marrow;	   5	   –	   Osteoblasts;	   6	   –	  






































Figure	   232	   –	   Representative	   image	   of	   the	  Ovx	   CSD	   filled	  with	   Putty®	   and	   a	  Membrane	  
Evolution®,	   at	   month	   3.	   100x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   New	   bone	  
immature;	  2	  –	  New	  bone	  mature.	  
1	  
2	  
Figure	   233	   –	   Representative	   image	   of	   the	  Ovx	   CSD	   filled	  with	   Putty®	   and	   a	  Membrane	  
Evolution®,	  at	  month	  3.	  100x	  magnification.	  Toluidine	  blue	  staining.	  1	  –	  Remnants	  of	  the	  





















	   	  
Figure	   234	   –	   Representative	   image	   of	   the	  Ovx	   CSD	   filled	  with	   Putty®	   and	   a	  Membrane	  
Evolution®,	   at	   month	   3.	   1000x	   magnification.	   Toluidine	   blue	   staining.	   1	   –	   Residual	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5.	  HISTOMORPHOMETRIC	  ANALYSIS	  
	  
In	   order	   to	   validate	   the	   qualitative	   histologic	   findings	   by	   a	   quantitative	  
approach,	  the	  relative	  amount	  of	  the	  newly	  formed	  bone	  was	  determined.	  At	  month	  1	  
and	  3	  of	  evaluation	  the	  bone	  volume	  (BV)	  was	  lower	  in	  Ovx	  animals	  in	  the	  M	  and	  MB	  
group,	   comparing	   to	   Sham	   animals,	   throughout	   the	   experimental	   period.	   Significant	  
differences	  were	  attained	  at	  the	  month	  1	  and	  3	  following	  the	  mandibular	  bone	  defect	  
procedure.	  The	  bone	  volume	  was	  higher	   in	   the	  MB	  group	   in	   sham	  animals	  at	  month	  
and	  3,	  comparing	  to	  all	  groups	  in	  the	  timepoint	  of	  evaluation	  (Table	  25).	  	  	  	  	  
	  
Table	   25	   –	   Morphometric	   analysis	   of	   histological	   samples.	   Histomorphometric	   analysis	   of	   the	   bone	  





Regenerated	  area	   	   BV	  (%)	   sd	  	   p	  
Month	  1	  
Membrane	  
Sham	   38.0	   5.8	  
0.005	  
Ovx	   28.0*	   4.1	  
Membrane	  and	  biomaterial	  
Sham	   39.9	   4.8	  
0.001	  
Ovx	   29.25*	   4.8	  
Month	  3	  
Membrane	  
Sham	   59.0	   2.3	  
<0.001	  
Ovx	   43.8*	   4.1	  
Membrane	  and	  biomaterial	  
Sham	   63.4	   9.0	  
0.011	  
Ovx	   51.6*	   4.7	  
Comparisons	  performed	  by	  the	  Mann-­‐Whitney	  test:	  



















Figure	  236	  –	  Box	  plot	  of	  the	  Regenerated	  area	  (%)	  values	  of	  the	  mandibular	  bone	  defect	  with	  the	  Membrane	  	  
(A)	  and	  Membrane	  and	  Biomaterial	  (B),	  at	  month	  3	  of	  Sham	  and	  Ovx	  groups.	  *p<0.05	  Vs.	  Sham	  group.	  
Figure	  235	  –	  Box	  plot	  of	  the	  Regenerated	  area	  (%)	  values	  of	  the	  mandibular	  bone	  defect	  with	  the	  Membrane	  	  
(A)	  and	  Membrane	  and	  Biomaterial	  (B),	  at	  month	  1	  of	  Sham	  and	  Ovx	  groups.	  *p<0.05	  Vs.	  Sham	  group.	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Osteoporosis	   is	  a	  major	  health	  problem	  worldwide;	  approximately	  200	  million	  
women	   have	   osteoporosis.	   Although	   the	   likelihood	   of	   developing	   osteoporosis	  
currently	   is	   greatest	   in	   North	   America	   and	   Europe,	   it	   will	   increase	   in	   developing	  
countries	   as	   population	   longevity	   in	   these	   countries	   continues	   to	   increase.[108]	  This	  
disease	   reports	   a	   gradual	   deterioration	   of	   the	   bone	   mineral	   content	   over	   time,	   a	  
process	   that	   can	   significantly	   enhance	   the	   risk	   of	   bone	   fracture.[343]	   Despite	   the	  
acknowledged	  alterations	  in	  the	  osteoporotic	  bone,	  the	  regeneration	  process	  is	  far	  less	  
understood	  in	  this	  systemically	  affected	  circumstance,	  especially	  in	  a	  process	  mediated	  
by	  biomaterials	  implantation.	  This	  is	  of	  the	  highest	  importance	  since	  fractures	  related	  
to	  osteoporosis	  often	  cannot	  be	  readily	  repaired	  by	  a	  self-­‐healing	  approach,	  and	  thus	  
the	  use	  of	  degradable	  or	  nondegradable	  biomaterials	  is	  required.[344-­‐346]	  
A	   proper	   experimental	   animal	   model	   for	   the	   study	   of	   osteoporosis	   reduces	  
bioethics	   problematic	   and	   minimizes	   the	   limitations	   associated	   with	   studying	   the	  
disease	   in	  humans,	   namely	   time	  and	  behavioral	   variability	   among	   test	   subjects.[194]	  
There	   is	  a	   range	  of	  animals	   that	  allows	  us	   to	  study	  the	  osteoporotic	  model,	  although	  
the	   rat,	  especially	   the	  ovariectomized	  model,	  provides	  a	  wide	  assortment	  of	  benefits	  
when	  compared	  with	  other	  models.	  	  Numerous	  studies	  showed	  that	  this	  model	  offers	  a	  
similar	   characteristics	   as	   the	   postmenopausal	   bone	   loss;	   i.e.,	   Increased	   rate	   of	   bone	  
turnover	  with	  resorption	  exceeding	  formation;	  initial	  rapid	  phase	  of	  bone	  loss	  following	  
by	   a	   much	   slower	   phase;	   greater	   loss	   of	   cancellous	   than	   cortical	   bone;	   decreased	  
intestinal	  absorption	  of	  calcium;	  some	  protection	  against	  bone	  loss	  by	  obesity;	  similar	  
skeletal	   response	   to	   therapy	  with	   estrogen,	   tamoxifen,	   bisphosphonates,	   parathyroid	  
hormone,	  calcitonin,	  and	  exercise.[206,	  213,	  214,	  347]	  
	  
Accordingly,	   this	   work	   aimed	   to	   establish	   and	   characterize	   the	   representative	  
model	  of	  the	  human	  osteoporotic	  condition	  –	  the	  ovariectomized	  rad	  model.	  Moreover	  
we	   aimed	   to	   address	   the	   bone	   regeneration	   process,	   either	  mediated	   or	   not	   by	   the	  
presence	   of	   biomaterials,	   in	   a	  model	  without	   biomechanical	   load	  –	   the	   critical	   sized	  
calvarial	   model;	   and	   the	   guided	   bone	   regeneration	   process	   by	   the	   presence	   of	  
biomaterials	  in	  a	  model	  with	  biomechanical	  load	  –	  the	  mandibular	  critical	  sized	  defect.	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There	   is	   extensive	   literature	   studying	   the	   Ovx	   rat	   in	   which	   regards	   to	   bone	  
histomorphometric	   changes,	   biochemical	   markers	   and	   biomechanical	   changes.	   In	  
accordance,	   following	  ovariectomy	  a	  rapid	   loss	  of	  cancellous	  bone	  mass	  and	  strength	  
occurs,	  which	  then	  proceeds,	  in	  a	  less	  rapid	  rate	  and	  in	  a	  site-­‐specific	  fashion,	  to	  reach	  
steady	  state	  phase	  of	  bone	  mass	  with	  an	   increase	   in	  the	  rate	  of	  bone	  turnover.	  [213-­‐
215,	  348]	  Wronski	  et	  al.	  revealed	  osteopenia	  in	  ovariectomized	  female	  rats,	  as	  early	  as	  
14	  days	  after	  the	  ovariectomy.[349]	  
In	  the	  present	  study,	  the	  expected	  biochemical	  and	  structural	  responses	  of	  the	  
Ovx	   rat	   model	   were	   demonstrated.	   The	   ovariectomy	   procedure	   was	   confirmed	   by	  
failure	  to	  detect	  ovarian	  tissue	  and	  observation	  of	  an	  atrophic	  uterus	  in	  the	  Ovx	  group,	  
at	   the	  necropsy.	  Moreover,	  significant	  differences	  were	  attained	  regarding	  the	  weight	  
of	  the	  uterus	  in	  Sham	  and	  Ovx	  animals,	  at	  all	  time	  points.	  Substantiating	  the	  efficacy	  of	  
the	   ovarian	   ablation,	   plasmatic	   levels	   of	   estradiol	   were	   shown	   to	   be	   below	   the	  
detection	   limit	   of	   the	   test	   used	   for	   the	   animals	   in	   the	   Ovx	   group,	   while	   in	   Sham	  
animals,	  estradiol	  levels	  were	  kept	  broadly	  constant,	  around	  20pg/mL,	  throughout	  the	  
study	  period,	  which	  is	  in	  accordance	  with	  the	  published	  data	  on	  ovariectomy-­‐induced	  
experimental	  osteoporosis.[350,	  351]	  
Results	   showed	   that	   Ovx	   animals	   presented	   an	   increased	   body	   weight,	  
comparing	  to	  the	  group	  of	  Sham	  animals.	  This	  is	  in	  accordance	  with	  literature	  reports	  
substantiating	  an	   increased	  hyperphagia	  and	  augmented	  body	  weight	  associated	  with	  
the	   ovariectomy-­‐mediated	   disruption	   of	   the	   normal	   hypothalamic-­‐pituitary-­‐gonadal	  
(HPG)	  axis	  cycling,	   in	  adult	   female	  rats.[352,	  353]	   It	  has	  been	  shown	  that	  the	  ovarian	  
inhibition	   of	   feeding	   involves	   two	   specific	   components:	   one,	   related	   with	   the	   tonic	  
inhibition	   that	   is	   revealed	   by	   the	   increased	   basal	   level	   of	   food	   intake;	   and	   other,	  
associated	  with	  the	  phasic	  or	  cyclic	  inhibition	  that	  is	  revealed	  by	  the	  decrease	  in	  food	  
intake	  during	  estrus	   in	   intact	   female	  rats,	  which	   is	  naturally	  absent	   in	  ovariectomized	  
animals.[354,	   355]	   Additionally,	   it	   has	   been	   demonstrated	   that	   a	   cyclic,	   near-­‐
physiological	  pattern	  of	  plasma	  estradiol	  treatment	  is	  sufficient	  to	  restore	  the	  HPG	  axis	  
cycling	  and	  maintain	  normal	  levels	  of	  body	  weight,	  spontaneous	  feeding	  patterns,	  and	  
total	  food	  intake,	  in	  Ovx	  rats.[356]	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Serum	   levels	  of	   the	  ALP	  activity	  were	  slightly	  higher	   in	  our	  study,	  but	  with	  no	  
statistically	  significantly	  differences	  between	  the	  two	  experimental	  groups,	  throughout	  
the	   experimental	   period.	   Similar	   changes	   were	   observed	   by	   other	   authors	   were	   the	  
serum	   ALP	   levels	   were	   increased	   in	   osteoporosis	   and	   other	   bone	   metabolic	  
disorders.[357]	   Serum	   levels	   of	   Ca	   and	   P,	   were	   shown	   not	   to	   differ	   significantly	  
between	   the	   two	   experimental	   groups,	   throughout	   the	   experimental	   period.	   The	  
unchanged	  levels	  of	  serum	  calcium	  and	  phosphorus	  in	  Sham	  and	  OVX	  group	  indicated	  
that	   homeostatic	  mechanisms	  were	   able	   to	  maintain	   serum	   levels	   of	   these	  minerals	  
despite	  ovariectomy.[358,	  359]	  
Plasma	   values	   of	   Albumin	   (ALB),	   Creatine	   kinase	   (CK),	   Total	   Protein	   (TP)	   and	  
Triglycerides	   (TG),	   in	   Sham	   and	  Ovx	   animals	   at	  months	   3	   and	   5,	  were	   evaluated.	  No	  
significant	   differences	   were	   verified	   in	   ALB	   and	   CK	   in	   both	   time	   points.	   There	   are	  
statistically	  significant	  differences	  in	  plasma	  values	  of	  TP	  and	  TG	  plasma	  concentrations	  
at	  month	  3	  of	  evaluation.	  The	  levels	  of	  TP	  and	  TG	  were	  lower	  on	  the	  Ovx	  groups.	  	  The	  
lower	  values	  of	  TG	  complies	  to	  other	  studies	  that	  revealed	  that	  Ovx-­‐induced	  estrogen	  
deficiency	  caused	  prominent	  changes	  in	  lipid	  metabolism	  with	  a	  significant	  elevation	  in	  
the	  polyunsatured	  fatty	  acids	  levels	  and	  depletion	  of	  saturated	  fatty	  acids	  and	  TG.	  They	  
also	   observed	   concurrent	   elevation	   of	   lipid	   b-­‐oxidation	   products	   (3-­‐HB	   and	  
acetoacetate)	   in	   the	   plasma	   of	   Ovx	   rats.[360]	   The	   marked	   decrease	   in	   plasma	  
triglycerides	  observed	  here	  also	  agreed	  well	  with	  previous	  findings	  of	  reduced	  hepatic	  
TG	  secretion	  in	  Ovx	  rats.[361]	  	  
Skeletal	  alterations	  were	  also	  observed	  in	  animals	  submitted	  to	  the	  ovariectomy	  
procedure.	  Image	  analysis	  of	  left	  tibia	  X-­‐rays	  revealed	  a	  decreased	  trabecular	  structure	  
in	  Ovx	  animals,	  specially	  focused	  in	  the	  proximal	  metaphysis,	  both	  at	  month	  5	  (animals	  
with	   7	  months	   of	   age)	   and	  month	   8	   (animals	   with	   10	  months	   of	   age)	   of	   the	   study.	  
Moreover,	   conventional	   radiographic	   bone	   densitometry	   was	   conducted	   at	   a	   ROI	  
involving	  the	  proximal	  epiphysis,	  metaphysis	  and	  part	  of	  the	  diaphysis,	  and	  revealed	  an	  
increased	  intensity	  for	  Sham	  animals,	  which	  attained	  significance	  at	  month	  8	  (animals	  
with	  10	  months	  of	  age).	  Conventional	  radiographic	  bone	  density	  has	  been	  shown	  to	  be	  
a	  valid	  technique	  to	  address	  the	  bone	  mineral	  density	  (BMD)	  loss,	  reflecting	  the	  status	  
of	  the	  crystalline	  component	  of	  bone.[362]	  This	  technique	  has	  been	  shown	  to	  correlate	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strongly	  with	  quantitative	  computed	  tomography	  (qCT),	   in	  the	  assessment	  of	  BMD	  of	  
human	  cadaveric	  femurs.[362]	  It	  has	  also	  been	  used	  to	  detect	  osteopenia	  in	  the	  tibia	  of	  
young	  ovariectomized	  rats.[363]	  
Attained	   tibial	   differences	   between	  Ovx	   and	   Sham	   animals	   are	   in	   accordance	  
with	  data	  reported	  from	  the	  literature.	  As	  so,	  ovariectomized	  rats	  have	  been	  shown	  to	  
be	   characterized	   by	   osteopenia	   and	   histomorphometric	   indices	   of	   increased	   bone	  
turnover,	  at	  the	  proximal	  tibia,	  2.5	  months	  following	  ovariectomy.[347]	   Increasing	  the	  
period	   of	   assessment	   regarding	   the	   effect	   of	   ovariectomy	   over	   the	   tibial	   bone,	   a	  
biphasic	  pattern	  of	  cancellous	  bone	  loss	  was	  observed	  in	  the	  proximal	  metaphysis:	  an	  
initial	   rapid	   phase	   of	   bone	   loss	   was	   verified	   until	   around	   3	   months	   following	  
ovariectomy,	  and	  was	  followed	  by	  a	  period	  of	  relative	  stabilization	  of	  cancellous	  bone	  
volume,	  at	  the	  markedly	  osteopenic	  level	  of	  5-­‐7%,	  until	  approximately	  12	  months.[214]	  
Both	   phases	   of	   ovariectomized-­‐dependent	   bone	   loss	  were	   associated	  with	   increased	  
bone	   turnover.	   In	   Sham	   animals,	   cancellous	   bone	   volume	   of	   the	   tibial	   methaphysis	  
remained	   relatively	   constant	   at	   25-­‐30%,	   out	   to	   12	   months	   of	   age.[214]	   Female	   rat	  
ovariectomy	   has	   also	   been	   shown	   to	   cause	   deterioration	   of	   the	   three-­‐dimensional	  
trabecular	  microstructure,	  notably	  structure	  model	   index	  and	  connectivity	  density,	  as	  
assessed	   by	  microtomography	   of	   the	   proximal	   tibia,	   9	  months	   following	   the	   surgical	  
ablation	  of	  the	  ovaries.[364]	  These	  data	  are	  in	  agreement	  with	  our	  work	  that	  revealed	  
a	  marked	  reduction	  in	  the	  BV/TV,	  CD,	  Tb.Th,	  and	  Tb.N	  and	  an	  increased	  Tb.Sp,	   in	  Ovx	  
animals	   in	  month	  5	  and	  8	  after	   the	  ovariectomy	  procedure	  when	  compared	  with	   the	  
Sham	  animals.	  In	  fact,	  microtomography	  and	  DXA	  have	  been	  shown	  to	  detect	  bone	  loss	  
earlier	   than	   bone	   histomorphometry,	   in	   the	   tibia	   assessment	   of	   a	   rat	   model	   of	  
osteoporosis.[365]	  Accordingly,	  a	  decrease	  in	  the	  total	  BMD	  and	  trabecular	  BMD	  of	  the	  
tibia	  of	  the	  Ovx	  rat	  has	  been	  reported	  by	  several	  authors.[366,	  367]	  Whit	  the	  decrease	  
of	   these	   parameters,	   the	   biomechanical	   strength	   ends	   up	   to	   be	   inferior	   in	   the	   Ovx	  
animals,	  as	  showed	  in	  our	  work	  by	  the	  values	  of	  the	  biomechanical	  tests	  at	  the	  tibia.	  
Some	   studies	   assert	   that	   the	   biomechanical	   tests	   at	   long	   bones	   provide	   maximum	  
information	   as	   they	   are	   composed	   of	   pure	   cortical	   bone	   and	   they	   are	   covered	   by	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The	   biomechanical	   parameters	   of	   the	   femur	   in	   our	   study	   were	   evaluated	   at	  
month	  3	  of	  the	  osteoporotic	  condition	  and	  we	  attained	  a	  significant	  difference	   in	  the	  
ultimate	   stress	   between	   the	   Ovx	   and	   sham	   animals,	   enabling	   the	   susceptibility	   of	  
fractures	   the	   femurs	   in	   an	   osteoporotic	   condition.	   Available	   data	   in	   the	   literature	  
substantiate	   these	   findings.	   Ovariectomy	   has	   been	   shown	   to	   promote	   periosteal	  
modeling	  and	  induce	  endocortical	  and	  cancellous	  femoral	  bone	  remodeling,	  with	  a	  net	  
loss	  of	  bone	  mass	  due	  to	  excess	  bone	  resorption.[368]	  Bagi	  et	  al.	  observed	  in	  the	  Ovx-­‐
induced	  an	  increase	  resorption	  resulted	  in	  reduced	  trabecular	  number,	  thickness,	  and	  
endocortico-­‐trabecular	   connectivity	   at	   the	   proximal	   femur,	   3	   months	   following	   Ovx	  
procedure	   in	   female	   rats.[368]	  Moreover,	   significant	   reduction	   in	   femoral	   trabecular	  
BMD	  was	  observed	  in	  vivo,	  by	  qCT,	  at	  6	  and	  14	  weeks	  following	  ovariectomy,	  in	  a	  study	  
of	  Breu	   et	   al.[369]	  Cortical	   femoral	   thickness	   in	  Ovx	   rats	   has	   also	  been	   shown	   to	  be	  
reduced	  because	  of	  the	  high	  endocortical	  resorption,	  which,	   in	  addition	  to	  cancellous	  
bone	  resorption,	  resulted	  in	  fewer	  endocortico-­‐trabecular	  connections.[370]	  Giavaresi	  
et	   al.	   also	   observed	   a	   decrease	   in	   the	   mechanical	   results	   of	   Ovx	   animals	   when	  
compared	   to	   sham	   animals,	   with	   a	   significantly	   decrease	   in	   the	   maximum	   load	  
assessed	  on	  the	  femur	  of	  Ovx	  animals,	  affirming	  that	  important	  changes	  in	  the	  femoral	  
shaft	  mechanical	  competence	  arise	  in	  adult	  rat	  4	  months	  after	  ovariectomy.	  [371]	  
Alternatively,	   the	   ovariectomy	  of	   young	   skeletally	   immature	   animals	  may	   also	  
lead	   to	   site-­‐specific	   bone	   loss,	   particularly	   focused	   on	   trabecular	   component,	   while	  
cortical	  bone	  seems	  to	  respond	  differently	   to	  estrogen	  deficiency	  attained	  during	  the	  
skeletal	  growth.	  For	  instance,	  increased	  cortical	  density,	  bone	  mass,	  and	  bone	  size	  were	  
verified	  in	  the	  femur.	  [372]	  In	  the	  study	  a	  significant	  trabecular	  bone	  loss	  was	  observed	  
in	  the	  vertebras	  measured	  by	  the	  densitometry	  technique	  on	  the	  x-­‐rays,	  in	  accordance	  
with	  some	  studies.[373]	  These	  differences	  were	  significant	  and	  attained	  in	  the	  month	  3	  
and	   5	   of	   our	   study.	   Wronski	   et	   al.	   observed	   the	   osteopenic	   changes	   of	   vertebral	  
ovariectomized	   rats	   and	   following	   180	   days	   after	   the	   surgery	   the	   cancellous	   bone	  
volume	  was	  decreased	  to	  30-­‐35%.	  [373]	  Toolan	  et	  al.	  observed	  a	  significant	  reduction	  
in	  the	  stiffness	  and	  ultimate	  load	  of	  L6	  and	  the	  area	  fraction	  of	  trabecular	  bone	  of	  L5,	  
in	  ovariectomized	  rats.[374]	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Bone	   loss	   and	   a	   reduced	   mineral	   density	   were	   verified	   in	   the	   cranio-­‐maxilo-­‐
facial	   complex,	   namely	   at	   the	  mandible	   and	   calvarial	   bone	   of	   young	   ovariectomized	  
female	  rats.[375,	  376]	   In	  our	  work	  we	  found	  a	  significant	  decreased	   in	  the	  density	  of	  
calvarial	  bones	  at	  month	  3	  and	  5	   in	   the	  Ovx	  animals	  when	  compared	  with	   the	  Sham	  
animals,	  by	  the	  densitometry	  evaluation	  of	  the	  x-­‐rays.	  	  	  	  
In	  the	  present	  study,	  we	  found	  the	  density	  and	  trabecular	  bone	  decrease	  of	  the	  
molar	   region	   of	   the	  mandible	   and	  maxilla	   in	   Ovx	   rats,	  manly	   in	   the	  month	   5	   in	   the	  
maxilla.	  Although	  the	  mechanism	  of	   the	   low	  susceptibility	  of	   the	  molar	   region	  of	   the	  
mandible	  to	  estrogen	  deficient	  condition	  is	  not	  clear,	  it	  is	  likely	  that	  mechanical	  stress	  
derived	   from	   functional	   occlusion	   is	   preventing	   the	   bone	   loss	   in	   this	   pathological	  
condition.	   Elovic	   et	   al.	   have	   clearly	   demonstrated	   that	   maxillary	   molar	   extraction	  
together	  with	  ovariectomy	  causes	  more	  bone	  loss	  in	  the	  mandible	  than	  maxillary	  molar	  
extraction	   alone,	   [377,	   378]	   which	   funds	   this	   theory.	   	   Yang	   et	   al.	   investigated	   the	  
oestrogen	   deficiency	   on	   the	   rat	   mandible	   and	   tibial	   microarchitecture	   after	  
ovariectomy,	  and	  reported	  alterations	  of	  the	  trabecular	  bone	  both	  in	  the	  mandible	  and	  
the	   tibia	  within	  16	  weeks.	  They	  also	   realized	   that	   the	  size	  of	  marrow	  spaces	  and	   the	  
shape	  of	  the	  trabeculae	  in	  the	  mandible	  correlate	  with	  the	  osteoporotic	  changes	  in	  the	  
long	  bones.[379]	  
Tanaka	  et	  al.	  studied	  the	  effects	  of	  ovariectomy	  on	  trabecular	  structures	  of	  rat	  
alveolar	   bone	   and	   observed	   a	   significant	   decrease	   of	   bone	   mass	   in	   the	   alveolar	  
interradicular	   septum	   of	   the	   rat	   first	  molar.	   The	  microtrabecular	   stiffness	   was	   lower	  
when	   compared	   with	   the	   sham	   animals	   and	   revealed	   a	   thinner	   distal	   alveolar	  
bone.[380]	  These	  same	  authors	  found	  in	  another	  study	  a	  consistent	  bone	  loss	  in	  manly	  
in	  the	  posterior	  region	  of	  the	  mandibular	  condyle	  of	  ovariectomized	  rats.[381]	  
The	  rat	  mandibular	  cortical	  bone	  as	  been	  studied	  by	  Fu	  et	  al.	  using	  spectroscopy	  
and	   a	   multivariate	   analysis,	   they	   observed	   the	   mandibles	   at	   2,	   4	   and	   8	   months	  
following	   the	  ovariectomy	  and	  noticed	  a	   significant	   redution	   in	   the	  mineral-­‐to-­‐matrix	  
ratio	  in	  the	  mandibular	  cortical	  bone	  after	  Ovx.[382]	  
The	  biomechanical	  test	  in	  our	  study	  of	  the	  mandible	  shows	  that	  the	  Ovx-­‐group	  
presents	  a	  lower	  threshold	  of	  the	  ultimate	  stress	  when	  compared	  with	  the	  sham	  group	  
(27,5Mpa	  Vs.	  38,9Mpa).	  The	  biomechanical	  property	  of	   the	  mandible	   in	  osteoporotic	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conditions	   is	   an	   understudied	   subject.	  However	   the	   rat	  mandibular	   cortical	   bone	   as	  
been	  studied	  by	  Fu	  et	  al.	  using	  spectroscopy	  and	  a	  multivariate	  analysis,	  they	  observed	  
the	  mandibles	  at	  2,	  4	  and	  8	  months	  following	  the	  ovariectomy	  and	  noticed	  a	  significant	  
reduction	  in	  the	  mineral-­‐to-­‐matrix	  ratio	  in	  the	  mandibular	  cortical	  bone	  after	  Ovx.[382]	  
Elovic	  et	  al.	  studied	  the	  effect	  of	  the	  ovariectomized	  rat	  in	  the	  bone	  fraction	  of	  
the	   rat	  mandible;	   they	  performed	  a	   test	   in	   three-­‐point	   bending	   to	   evaluate	   the	   load	  
failure,	  stiffness	  and	  bone	  area	  fraction	  between	  Ovx	  and	  Sham	  rats	  within	  the	  day	  14,	  
114	  and	  200	  following	  the	  post-­‐Ovx.	  The	  ovariectomy	  led	  to	  an	  increase	  in	  failure	  load	  
(15%)	  and	  stiffness	  (28%)	  of	  the	  mandible	  of	  Ovx	  rats	  in	  the	  114	  day	  of	  evaluation.	  In	  
the	  200	  day	  of	  evaluation	  a	  decreased	  of	  8%	  in	  bone	  area	  fraction	  of	  the	  mandible	  was	  
assessed.	  	  The	  stiffness	  (20%)	  and	  bone	  area	  fraction	  (7%)	  of	  the	  mandible	  decreased	  
in	  the	  Ovx	  rats	  at	  day	  200	  when	  compared	  with	  the	  Ovx	  rats	  at	  day	  114.	  The	  increase	  in	  
structural	   properties	   of	   the	   mandible	   may	   be	   a	   consequence	   of	   an	   increase	   in	  
masticatory	  function	  as	  it	  has	  been	  reported	  that	  Ovx	  rats	  eat	  approximately	  10%	  more	  
than	   sham	   controls.[383]	   These	   theory	   is	   in	   accordance	   with	   other	   authors	   that	  
affirmed	   that	   the	   normal	   (hard)	   diet	   may	   limited	   the	   negative	   effects	   of	   oestrogen	  
deficiency	  on	  mandibular	  architecture	  four	  months	  after	  ovariectomy.[384]	  
These	   findings	   are	   in	   accordance	  with	   several	   studies	   like	   Comelekoglu	   et	   al.	  
that	  investigate	  the	  effect	  of	  ovariectomy	  on	  rat	  femur	  biomechanical	  parameters.	  They	  
observed	  an	  Ultimate	  stress	  decreased	  21%	  in	  Ovx	  rats	  and	  the	  cortical	  thickness	  was	  
significantly	   decreased	   in	   Ovx	   rats	  when	   compared	  with	   the	   controls.	   They	   affirmed	  
that	  the	  femur	  biomechanical	  parameters	  are	  decreased	  in	  osteoporosis.[385]	  Peng	  et	  
al.	  evaluated	  the	  maximal	  load	  of	  the	  femoral	  neck	  and	  the	  tibia	  in	  three	  different	  rat	  
models	  of	  experimental	  osteoporosis	  and	  found	  a	  significant	  decrease	  in	  the	  Ovx	  rats	  in	  
both	  bones	   in	  evaluation.	   [386]	  He	  affirmed	   that	  mechanical	   strength	  of	   the	   femoral	  
neck	  was	  a	  sensitive	  indicator	  of	  bone	  loss	  associated	  with	  Ovx.	  [386]	  	  
In	  this	  study,	  in	  order	  to	  evaluate	  the	  bone	  regeneration	  process	  in	  osteoporotic	  
conditions	  and	  to	  address	  the	  biomaterial-­‐mediated	  bone	  regeneration	  and	  the	  bone-­‐
biomaterial	   interaction,	  a	  CSD	   (5	  mm	   in	  diameter)	   filled	  with	  a	  commercial	  xenograft	  
(Bio-­‐oss®)	  with	  proven	  clinical	  success	  was	  accomplished,	  on	  the	  calvaria	  of	  both	  Ovx	  
and	  Sham	  animals.	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Regarding	   the	   analysis	   of	   the	   regeneration	   process,	   radiographic,	   micro-­‐
tomographic,	   histological	   methodologies	   and	   quantitative	   PCR	   analysis	   expression	  
were	  used.	  Radiological	  observation	   revealed	   the	  validity	  of	   the	  5	  mm	  CSD,	   in	  which	  
negative	   controls	  –	  defects	   left	   unfilled	  –	  were	  unable	   to	   regenerate	   throughout	   the	  
duration	   of	   the	   study.	   In	   fact	   only	   residual	   new	   bone	   formation	  was	   verified	   on	   the	  
margins	  of	  the	  defects,	  as	  stated	  for	  the	  definition	  of	  critical	  size	  defect.[331]	  Defects	  
filled	   with	   Bio-­‐oss®	   revealed	   the	   integrity	   of	   the	   biomaterials’	   granules	   within	   the	  
defect	  margin.	   Regions	   of	   interest	   (ROIs)	   for	   both	  microtomographic	   and	   histological	  
analysis	  were	   set	  manually.	  Nonetheless,	   giving	   the	   high	   feasibility	   and	   resolution	   of	  
the	  used	   analytical	   tools,	  manual	   selection	   allowed	   the	   fine	   tuning	  of	   ROIs,	   since	  no	  
fixed	  anatomical	  landmarks	  could	  be	  of	  use	  to	  delimit	  standardized	  ROIs	  in	  relation	  to	  
the	  healing	  bone	  defect.	  
Micro-­‐tomographic	   analysis	   of	   the	   implanted	   CSD	   defects,	   in	   a	   longitudinal	  
view,	   showed	   an	   increased	   bone	   formation	   at	   the	   margin	   of	   the	   defect,	   in	   Sham	  
animals,	  compared	  to	  Ovx	  animals,	  at	  month	  6	  –	  animals	  with	  10	  months	  of	  age.	  The	  
axial	  view	  analysis	  of	  the	  defect	  area	  also	  revealed	  an	   increased	  new	  bone	  formation	  
zone,	   at	   the	  margin	   of	   the	   defect,	   in	   Sham	  animals.	   There	  were	   no	   evident	   areas	   of	  
biomaterial	  resorption,	  neither	  zones	  of	  new	  bone	  formation	  apart	  from	  the	  continuity	  
with	   the	   defect	  margin.	   Histological	   analysis	   revealed	   an	   increased	   amount	   of	   bone	  
formation	  throughout	  the	  assayed	  time	  points	  of	  the	  study	  –	  1	  month,	  3	  months	  and	  6	  
months,	   both	   for	   Sham	   and	   Ovx	   animals.	  When	   the	   two	   groups	  were	   compared,	   at	  
each	  time	  point,	  the	  process	  of	  new	  bone	  formation	  was	  more	  evident	  within	  animals	  
of	  Sham	  group,	  either	  in	  which	  regards	  the	  bone	  formation	  at	  the	  defects	  margin,	  and	  
the	  new	  bone	  formation	  at	  the	  biomaterial	  granules’	  border.	  Even	  so,	  the	  vast	  majority	  
of	   the	   space	   between	   Bio-­‐oss®	   granules	   was	   occupied	   by	   fibrous	   tissue,	   at	   all	   time	  
points.	  	  
In	   this	   study,	   Bio-­‐oss®,	   a	   bovine-­‐derived	   xenograft	   material	   which	   has	   found	  
clinical	   success	   in	   several	  bone	   regenerative	  applications,	  namely	   in	   those	  associated	  
with	   the	   cranio-­‐maxilofacial	   area	   (e.g.,	   dental	   implant	   placement	   and	   sinus	   lift	  
procedures),	  was	  used.[235,	  236,	  315,	  321]	  In	  this	  particular	  experimental	  setting,	  Bio-­‐
oss®	  allowed	  only	  a	  modest	  process	  of	  bone	  regeneration,	  at	  the	  border	  of	   individual	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granules,	   both	   in	   Sham	   and	   Ovx	   animals,	   throughout	   the	   assayed	   time	   points.	  
Literature	   reports	  of	   the	  use	  of	  Bio-­‐oss®	   in	   the	  assessment	  of	   the	  bone	   regeneration	  
process,	  in	  rats,	  present	  data	  which	  is	  in	  accordance	  with	  the	  attained	  results.	  Slotte	  et	  
al.	  showed	  that	  following	  the	  implantation	  of	  non-­‐permeable	  silicone	  domes	  filled	  with	  
Bio-­‐oss®	   in	   rat	   calvaria,	   significantly	   less	   augmented	   bone	   was	   found,	   comparing	   to	  
control	  –	  in	  which	  the	  domes	  were	  left	  empty	  –	  8	  weeks	  post-­‐surgically.[387]	  A	  similar	  
experimental	  design,	  in	  which	  Teflon®	  capsules	  were	  filled	  with	  Bio-­‐oss®	  or	  left	  unfilled	  
(control),	   analysis	   was	   used	   to	   address	   bone	   augmentation	   in	   the	   surface	   of	   the	  
mandibular	   ramus	   of	   rats.	   Following	   2	   and	   4	   months	   post-­‐operatively,	   the	   mean	  
volume	  of	  the	  newly	  formed	  bone	  was	  significantly	  increased	  in	  the	  control	  versus	  the	  
Bio-­‐oss®	   group.[388]	   The	   same	   authors	   used	   this	   methodology	   to	   evaluate	   the	  
mandibular	   bone	   formation,	   one	   year	   following	   the	   implantation	   of	   the	   Teflon®	  
capsules,	  filled	  or	  not	  with	  Bio-­‐oss®.	  The	  mean	  volume	  of	  newly	  formed	  bone	  occupied	  
only	   23%	   of	   the	   total	   space	   in	   the	   animals	   grafted	   with	   Bio-­‐oss®,	   while	   in	   control	  
animals,	   the	   mean	   volume	   increased	   to	   around	   88%.[389]	   This	   research	   group	   also	  
addressed	   the	   mandibular	   bone	   regeneration,	   with	   the	   same	   experimental	  
methodology,	  with	  a	  re-­‐entry	  surgery,	  one	  year	  following	  capsule	  implantation.	  In	  this	  
second	   surgical	   intervention,	   capsules	  were	   removed	   and	   animals	  were	   immediately	  
sacrificed	  (baseline),	  or	  euthanized	  at	  3	  or	  6	  months	  following	  re-­‐entry	  surgery.	  Newly	  
formed	  bone	  within	  the	  capsule	  reached	  between	  92	  to	  94%	  at	  the	  control,	  and	  20	  to	  
23%	  within	  the	  Bio-­‐oss®	  group,	  throughout	  the	  assayed	  time	  points.[390]	  Bio-­‐oss®	  was	  
also	   evaluated	   in	   the	   bone	   formation	   process	   in	   the	   rat	   mandibular	   ramus,	   in	  
association	  with	  enamel	  matrix	  proteins	  (EMP),	  in	  filled	  polytetrafluoroethylene	  (PTFE)	  
capsules.[391]	  It	  was	  shown	  that	  neither	  the	  application	  of	  EMP,	  or	  the	  use	  of	  Bio-­‐oss®,	  
or	  even	  the	  combination	  of	  both,	  resulted	  in	  the	  enhancement	  of	  the	  bone	  formation,	  
comparing	  to	  control	  –	  unfilled	  capsules	  –	  either	  at	  2	  months	  or	  4	  months,	   following	  
implantation.[391]	  	  
On	   another	   report,	   the	   effect	   of	   Bio-­‐oss®,	   associated	   with	   enamel	   matrix	  
proteins	   (EMP),	   or	   a	   resorbable	   collagen	   membrane	   was	   evaluated	   in	   a	   5mm	   CSD	  
established	  on	   the	   rat	  calvaria.[392]	   It	  was	  shown	  that	   the	  predictability	  of	   the	  bone	  
formation	   was	   essentially	   dependent	   on	   the	   presence	   or	   absence	   of	   the	   barrier	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membrane	   alone,	   and	   that	   the	   combined	   use	   of	   Bio-­‐oss®	   and/or	   EMP	   did	   not	  
significantly	  increase	  the	  potential	  for	  complete	  healing	  of	  the	  defect.[392]	  
In	   the	  appraised	  works,	   the	  newly	   formed	  bone	  was	  always	   in	  continuity	  with	  
the	  host	  bone	  and	  extended	  only	  a	  limited	  distance	  from	  the	  pre-­‐existing	  bone	  surface.	  
In	  the	  reports	  addressing	  the	  capsule	  model,	   in	  the	  remaining	  volume	  of	  the	  capsule,	  
granules	   were	   embedded	   in	   fibrovascular	   connective	   tissue.	   This	   pattern	   of	  
regeneration/repair,	   also	   verified	   in	   this	   study,	   has	   been	   observed	   following	   the	  
grafting	  procedure	  of	  Bio-­‐oss®	  in	  various	  types	  of	  bone	  defects,	  either	  regarding	  in	  vivo	  
research	  or	   clinical	   application.[387-­‐391,	  393-­‐395]	  New	  bone	   formation	  mediated	  by	  
Bio-­‐oss®	   seems	   to	   be	   confined	   to	   the	   neighborhood	   of	   the	   host	   bone,	   even	   in	   long	  
periods	  of	  healing.	  Nonetheless,	   the	  bone	   tissue	   formed	   in	  association	  with	  Bio-­‐oss®	  
seems	  to	  be	  biologically	  and	  biomechanically	   stable	  on	  a	   long-­‐term	  basis,	  which	  may	  
substantiate	   the	   reported	   long-­‐term	   clinical	   success	  of	   implant	  placement	   associated	  
with	   Bio-­‐oss®	   grafting.[318,	   396,	   397]	   This	   is	   in	   line	   with	   the	   published	   in	   vivo	  
experimental	   reports	   that	   failed	   to	   detect	   a	   reduction	  of	   the	   amount	   of	   grafted	  Bio-­‐
oss®	   over	   time[398,	   399]	   and	   to	   the	   finding	   of	   large	   amounts	   of	   unresorbed	   graft	  
granules	  44	  months[400]	  and	  6	  years[401]	  following	  clinical	  implantation.	  	  	  	  	  
In	   our	   study,	   the	   combined	   analyze	   of	   the	   bone	   regeneration	   in	   osteoporotic	  
conditions,	  either	  in	  which	  regards	  CSD	  implanted	  with	  Bio-­‐oss®,	  revealed	  an	  impaired	  
biological	  process	  of	  new	  bone	  formation	  in	  Ovx	  animals,	  compared	  to	  Sham	  animals.	  
Literature	   reports	  have	   shown	   that	  osteoporosis	  modified	  bone	  cell	  proliferation	  and	  
functional	   activity,	   cell	   reactivity	   to	   local	   factors,	   and	   the	   availability	   and	   number	   of	  
progenitor	   cells.[1,	   402,	   403]	   These	   biological	   differences,	   in	   association	   with	  
differences	  in	  biomechanical	  and	  micro-­‐architectural	  bone	  properties,	  may	  be	  involved	  
in	   the	   etiology	   of	   the	   impairment	   of	   the	   bone	   regeneration	   process.	   Although	   some	  
biological	   highlights	   have	   been	   acknowledged	   for	   the	   bone	   regeneration	   process	   in	  
osteoporotic	   conditions,	   limited	   data	   is	   available	   regarding	   the	   study	   of	   orthopedic	  
biomaterials	  behavior	   following	   implantation	   in	  osteoporotic	  bone.	  Kin	  et	  al.	   showed	  
that	  ovariectomy	  may	  act	  as	  a	  negative	  factor	  for	  new	  bone	  formation,	  as	  assessed	  in	  
rat	   calvarial	   CSD	   implanted	  with	   a	  mixture	   of	   tooth	   ash	   and	   plaster	   of	   Paris.	   Data	   is	  
presented	   for	   1,	   2	   and	   4	   months	   following	   ovariectomy	   procedure.[404]	   Fini	   et	   al.	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studied	   the	   effect	   of	   osteopenia	   on	   the	   osteointegration	   of	   biomaterials	   in	   rats	   and	  
displayed	   the	   detrimental	   effects	   of	   the	   osteopenic	   condition,	   due	   to	   estrogen	  
deficiency,	   on	   osteointegration	   of	   titanium,	   zirconia	   and	   a	   bioglass	   (AP40).[367]	   The	  
biological	   behavior	   of	   synthetic	   hydroxyapatite	   was	   also	   addressed	   in	   the	   femoral	  
condyle	  of	  Ovx	  and	  Sham	  rats	  and	  a	  significant	  decrease	  in	  the	  osteointegration	  of	  the	  
material	   was	   attained	   in	   Ovx	   animals.[405]	   Interestingly,	   Hayashi	   et	   al.	   found	   no	  
significant	  differences	  between	  the	  affinity	  index	  (the	  length	  of	  bone	  directly	  apposed	  
to	  the	  implant/the	  total	  length	  of	  the	  bone-­‐implant	  interface	  ×100%)	  of	  tibia	  implanted	  
hydroxyapatite	  cylinders	  in	  Sham,	  Ovx	  or	  Ovx	  plus	  neurectomized	  rats,	  at	  2	  or	  6	  months	  
following	  implantation.[406]	  
Most	   recently,	   an	   experimental	   report	   aimed	   to	   address	   the	   effect	   of	  
ovariectomy	  in	  the	  consolidation	  of	  implanted	  methyl	  methacrylate	  capsules	  filled	  with	  
Bio-­‐oss®,	  in	  rat	  calvaria.	  The	  rate	  of	  new	  bone	  formation	  was	  similar	  in	  Ovx	  and	  control	  
animals	   –	   not	   submitted	   to	   Sham	   surgery	   –	   both	   at	   4	   and	   8	   weeks	   following	  
implantation.	   In	   both	   groups,	   the	   amount	   of	   new	   bone	   formation	   was	   low	   and	  
insufficient	  for	  quantification	  by	  microtomography.[407]	  	  
In	  both	  Sham	  and	  Ovx	  animals,	  with	  the	  used	  experimental	  design	  –	  a	  grafted	  
critical	  size	  defect	  –	  the	  bone	  regeneration	  process	  was	  found	  to	  be	  slow-­‐paced,	  even	  
following	  6	  months	  of	  healing,	  and	  broadly	  distributed	  within	  the	  close	  vicinity	  of	  the	  
margin	   of	   the	   defect.	   Grafted	   critical	   size	   defects	  must	   rely	   on	   the	   osteoconductive,	  
osteoinductive	  or	  osteogenic	  capabilities	  of	  the	  implanted	  constructs	  to	  achieve	  tissue	  
regeneration	   and,	   in	   the	   absence	   of	   potent	   osteoinductive	   or	   osteogenic	   stimuli,	  
broadly	   fail	   to	   output	   a	   significant	   tissue	   regeneration.[329]	  Thus,	   in	   this	  model,	   the	  
use	  of	  a	  bone	  biocompatible	  xenograft,	  which	   is	  endowed	  with	  only	  osteoconductive	  
properties,	  might	  determine	  a	  slow	  bone	  healing	  process.	  	  This	  seems	  to	  be	  particularly	  
relevant	  in	  bones	  with	  high	  cortical	  content	  (such	  as	  the	  calvaria),	  in	  which	  the	  healing	  
seems	  to	  be	  slower	  than	  in	  bones	  with	  high	  trabecular	  content	  (e.g.	  tibia).[408]	  
Apart	   from	   the	   observed	   slow-­‐paced	   bone	   regenerative	   process,	   qualitative	  
data	   from	   microtomographic	   and	   histological	   analysis,	   as	   well	   as	   acquired	  
histomorphometric	   data	   revealed	   reduced	   bone	   regeneration	   in	   osteoporotic	  
conditions,	  being	  significant	  differences	  attained	  at	  3	  and	  6	  months	  healing	  time.	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Some	   previous	   literature	   reports	   have	   addressed	   the	   biomaterial-­‐mediated	  
bone	   regeneration	   in	   osteoporotic	   conditions	   in	   sub-­‐critical	   size	   models,	   outputting	  
distinct	   results.	  On	  one	  hand,	   some	  experimental	   studies	   failed	   to	   identify	   significant	  
differences	  between	  the	  biomaterial-­‐mediated	  bone	  formation	  process	  in	  osteoporotic	  
conditions,	  as	  compared	  to	  sham	  controls	  [409-­‐411].	  Some	  other	  authors	  substantiate	  
the	   impaired	   biomaterial-­‐mediated	   bone	   regeneration	   process	   in	   osteoporotic	  
conditions	  [412-­‐414].	  Attained	  variances	  in	  the	  available	  literature	  might	  be,	  at	  least	  in	  
part,	   justified	   by	   differences	   in	   the	   experimental	   design.	   Distinct	   animal	   models,	  
methodologies	   for	   the	   induction	   of	   the	   osteoporotic	   condition,	   biomaterials,	   bone	  
defects	   and	   evaluation	   periods	   were	   used	   and	   thus,	   the	   establishment	   of	   direct	  
correlations	  between	  studies	  is	  difficult.	  	  
Despite	  these	  substantiations,	  biological	  evidence	  seems	  to	  sustain	  an	  impaired	  
regenerative	   potential	   of	   the	   osteoporotic	   bone.	   In	   our	  model,	   we	   found	   an	   altered	  
pattern	  of	  osteoblast-­‐related	  gene	  expression	  in	  the	  regenerating	  calvarial	  bone	  tissue	  
of	   Ovx	   animals,	   i.e.,	   Col	   I,	   OC	   and	   RUNX2	   mRNA	   expression	   were	   significantly	  
decreased,	  as	  comparing	   to	  control.	  While	   the	  gene	  expression	  pattern	  has	  not	  been	  
previously	   evaluated	   in	   the	   biomaterial-­‐mediated	   regenerating	   osteoporotic	   bone,	  
previously	  reports	  addressing	  the	  osteogenic	  differentiation	  of	  mesenchymal	  stem	  cells	  
(MSCs)	  derived	   from	  osteoporotic	  environments	   revealed	  significant	  alterations	   [415-­‐
417].	   Indicated	   differences	   set	   ground	   on	   intrinsic	   deficiencies	   in	   the	   self-­‐renewal	  
capability	   and	   differentiation	   potential	   of	   the	   osteoporotic	   stem	   cells,	   particularly	  
nourishing	  a	  down-­‐regulation	  of	  specific	  osteogenic-­‐related	  markers,	  thus	  sustaining	  an	  
impaired	  function	  of	  MSCs	  in	  the	  osteogenic	  differentiation	  pathway	  [415-­‐417].	  	  
The	   expression	   of	   estrogen	   receptors	   was	   also	   found	   to	   differ	   in	   the	  
regenerating	  bone	  of	  Ovx	  and	  Sham	  animals.	  ER-­‐alpha	  expression	  was	  reduced	  in	  the	  
ovariectomized	  rat	  regenerating	  tissue,	  while	  the	  expression	  of	  ER-­‐beta	  was	  increased.	  
This	  pattern	  of	  expression	  was	  found	  to	  occur	  in	  the	  non-­‐regenerating	  bone	  of	  the	  Ovx	  
rat	  [418],	  as	  well	  as	  on	  the	  healing	  of	  drilled	  femoral	  defects	  on	  the	  Ovx	  mice	  [419].	  ER-­‐
alpha	   activation	   is	   known	   to	   induce	   the	   intramembranous	   and	   endochondral	  
ossification	   processes	   in	   rodent’s	   femur,	   and	   to	   promote	   the	   bone	   formation	   at	   the	  
periosteal	   surface	   of	   the	   cortex	   and	   the	   prevention	   of	   the	   resorption	   at	   the	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endocortical	  surface	   [420].	  Likewise,	  signaling	  through	  the	  ER-­‐beta	  receptor	  seems	  to	  
inhibit	   both	   intramembranous	   and	   endochondral	   ossification	   processes	   in	   a	   gene	  
knock-­‐out	  model	  [421],	  and	  to	  retard	  periosteal	  bone	  formation	  and	  suppress	  gain	   in	  
bone	  size	  and	  bone	  strength	  [422].	  This	  altered	  expression	  of	  estrogen	  receptors	  may	  
though	  contribute	  to	  the	  altered	  bone	  regenerative	  potential	  of	  the	  osteoporotic	  bone.	  	  
We	  also	  verified	  an	  increased	  expression	  of	  PPAR-­‐gamma,	  a	  master	  regulator	  of	  
the	   adipogenic	   differentiation,	   in	   the	   regenerating	   bone	   of	  Ovx	   animals.	   It	   has	   been	  
proposed	   that	   the	   bone	   marrow	   fat	   content	   is	   increased	   during	   the	   osteoporotic	  
development	   [342].	   Furthermore,	  mesenchymal	   stem	  cells	  derived	   from	  osteoporotic	  
conditions	   revealed	   an	   increased	   adipogenic	   potential,	   as	   shown	   by	   the	   higher	  
expression	  of	  PPAR-­‐gamma	  and	   inactivation	  of	  osteogenic	   transcription	   factors	   [423].	  
This	  fact	  seems	  to	  disrupt	  the	  normal	  osteogenic	  equilibrium	  and	  favor	  the	  adipogenic	  
differentiation	  of	  recruited	  mesenchymal	  stem	  cells,	  within	  the	  bone	  milieu	  [424].	  The	  
increased	  adipogenesis,	  either	  in	  terms	  of	  cell	  number	  and/or	  cellular	  function,	  seems	  
to	  further	  increase	  osteoblasts	  apoptosis,	  as	  well	  as	  to	  promote	  osteoclast	  recruitment,	  
activation	  and	  function,	  resulting	  in	  a	  net	  increase	  of	  the	  bone	  resorption	  process	  [425,	  
426].	  	  
In	  this	  study,	  in	  order	  to	  evaluate	  the	  bone	  regeneration	  process	  in	  the	  presence	  
of	   functional	   biomechanical	   loading	   in	   osteoporotic	   conditions,	   and	   to	   address	   the	  
guided	  bone	  regeneration	  process,	  a	  CSD	  (4	  mm	  in	  diameter)	  filled	  with	  a	  commercial	  
xenograft	   (Putty®)	  and	  surrounded	  by	  a	  with	  saleable	  membrane	  (Evolution®)	  proven	  
clinical	  success	  was	  accomplished,	  on	  the	  mandible	  of	  both	  Ovx	  and	  Sham	  animals.	  	  
Regarding	   the	   analysis	   of	   the	   regeneration	   process,	   radiographic,	   micro-­‐
tomographic	   and	   histological	   methodologies	   were	   used.	   Radiological	   observation	  
revealed	  the	  validity	  of	  the	  4	  mm	  CSD,	  in	  which	  negative	  controls	  –	  defects	  left	  unfilled	  
–	  were	  unable	  to	  regenerate	  throughout	  the	  duration	  of	  the	  study.	  This	  methodology	  is	  
consistent	  with	  that	  described	  by	  Schmitz	  and	  Hollinger,	  a	  circular	  through	  and	  through	  
defect	  of	  a	  diameter	  varying	  from	  4	  to	  7	  mm	  drilled	  into	  the	  mandibular	  ramus.[326]	  In	  
fact	  only	   residual	  new	  bone	  formation	  was	  verified	  on	  the	  margins	  of	   the	  defects,	  as	  
stated	  for	  the	  definition	  of	  critical	  size	  defect.	  [326,	  333]	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The	  rat	  mandibular	  defect	  model	  has	  been	  used	  to	  evaluate	  bone	  regeneration	  
of	  biomaterials	  and	  osteoconductive	  properties	  of	  membranes	  with	  or	  without	  growth-­‐
stimulatory	   factors	   and	   permits	   the	   evaluation	  of	   the	   response	   to	   related	   to	   clinical	  
applications	  of	  the	  implanted	  material.	  [427-­‐431]	  
Kaban	   et	   al.	   define	   the	   mandible	   as	   a	   distinctive	   bone	   that	   is	   subjected	   to	  
continuous	   motion	   and	   significant	   compressive	   and	   shearing	   forces;	   therefore	   bone	  
defects	   created	   in	   other	   craniofacial	   bones	   or	   in	   long	   bones	   may	   not	   apply	   to	   the	  
mandible,	   given	   the	   functional	   biomechanical	   loading	   submitted	   to	   this	   bone.	  
Considering	  the	  increase	  in	  the	  life	  expectancy	  of	  humans,	  this	  experimental	  model	  is	  
of	  clinical	  interest	  for	  the	  relevance	  of	  bone	  repair	  in	  the	  craniofacial	  region	  in	  cases	  of	  
osteoporosis.[332]	  
Defects	  covered	  with	  the	  membrane	  Evolution®	  (M)	  and	  the	  defects	  filled	  with	  
Putty®	  and	  covered	  with	  the	  membrane	  Evolution®	  (MB)	   in	  a	  macroscopic	  evaluation	  
revealed	  the	  integrity	  of	  coating	  of	  the	  defects	  in	  both	  time	  points	  of	  evaluation.	  	  The	  
original	  defect	  of	  the	  animals	  in	  the	  control	  group	  in	  both	  sham	  and	  Ovx	  animals	  were	  
invaginated	  by	  the	  masseter	  muscle,	  impairing	  the	  diameter	  of	  the	  original	  defect	  in	  all	  
time	  points	  of	  evaluation.	  	  	  
The	   x-­‐ray	   evaluation	   at	   month	   1	   –	   animals	   with	   5	   months	   of	   age,	   allows	   to	  
observe	  an	  increased	  area	  in	  the	  margins	  of	  the	  original	  defect	  in	  Sham	  animals	  when	  
compared	   with	   the	   Ovx	   animals,	   both	   in	   the	   M	   group	   and	   the	   MB	   group.	   The	  
densitometry	  analysis	  of	   the	  mandibular	  bone	  defects	  demonstrated	  that	   the	  defects	  
were	  more	   closed	   in	   the	   Sham	   animals,	   in	   the	   group	  MB,	  when	   compared	  with	   the	  
other	  groups.	  The	  Ovx	  animals	  in	  both	  groups	  presented	  lower	  values	  of	  regeneration.	  
Although	  no	  significant	  differences	  were	  achieved.	  At	  month	  3	  –	  animals	  with	  7	  months	  
of	  age,	   the	   results	  are	   in	  accordance	  with	   the	  ones	  observed	  at	  month	  1,	  but	  with	  a	  
significant	   difference	   in	   the	   M	   group	   between	   the	   Sham	   animals	   with	   a	   higher	  
densitometric	  values,	  comparing	  with	  the	  Ovx	  animals.	  
Micro-­‐tomographic	  analysis	  of	  the	  implanted	  CSD	  defects	  shows	  the	  apposition	  
of	  the	  bone	  in	  the	  defect	  margin,	  a	  centripetal	  growth	  of	  the	  newly	  formed	  radiopaque	  
tissue	   could	   be	   identified,	   in	   both	   Sham	   and	  Ovx	   samples	   in	  M	   and	  MB	   groups.	   An	  
increased	  bone	  formation	  was	  observed	  at	  the	  margin	  of	  the	  defect,	  in	  Sham	  animals,	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compared	  to	  Ovx	  animals,	  at	  month	  1,	  in	  the	  M	  group.	  In	  the	  MB	  group,	  at	  month	  1,	  in	  
the	  center	  and	  proximity	  of	  the	  defect	  we	  can	  observe	  some	  spots	  distributed	  in	  and	  
around	   the	   defect	   that	   correspond	   to	   the	   biomaterial.	   The	   membrane	   was	   not	  
observed	  in	  the	  micro-­‐Ct	  images.	  The	  Sham	  animals	  in	  the	  MB	  group	  reveal	  increased	  
bone	  regeneration	   in	   the	  margins	  of	   the	  defect	  when	  compared	  with	   the	  Ovx	  group.	  
Regions	  of	  interest	  (ROIs)	  for	  both	  microtomographic	  and	  histological	  analysis	  were	  set	  
manually,	  which	  may	  be	  a	  source	  of	  errors/bias	  throughout	  data	  analysis.	  Nonetheless,	  
giving	  the	  high	  feasibility	  and	  resolution	  of	  the	  used	  analytical	  tools,	  manual	  selection	  
allowed	  the	  fine	  tuning	  of	  ROIs,	  since	  no	  fixed	  anatomical	  landmarks	  could	  be	  of	  use	  to	  
delimit	  standardized	  ROIs	  in	  relation	  to	  the	  healing	  bone	  defect.	  	  	  
Quantitative	  analysis	  of	  the	  amount	  of	  bone	  formed	   in	  rat	  mandibular	  defects	  
covered	  by	  the	  M	  and	  the	  MB	  showed	  that	  significant	  new	  bone	  was	  formed,	  without	  
statistically	  significant	  differences	  between	  the	  animals	  and	  groups.	  At	  month	  1	  the	  M	  
group	   in	   the	   sham	  animals	   presented	  a	  Bone	  Volume	   (BV)	  of	   1.785,	   that	  was	  higher	  
than	  the	  0.965	  BV	  of	   the	  Ovx	  animals.	  The	  MB	  group	   in	   the	  sham	  animals	  presented	  
the	   highest	   values	   of	   BV	  with	   1.990,	   compared	   to	   the	   1.280	   of	   the	   Ovx	   animals.	   At	  
month	  3	  the	  same	  tendency	  was	  followed	  as	  observed	  at	  month	  1,	  with	  an	  increased	  
BV	  in	  all	  groups	  evaluated,	  showing	  the	  sham	  animals	  with	  a	  superior	  volume	  of	  bone,	  
in	  M	  and	  MB	  group.	  	  
Histological	   analysis	   revealed	   an	   increased	   amount	   of	   bone	   formation	  
throughout	   the	   assayed	   time	  points	   of	   the	   study	  –	  1	  month	   and	  3	  months,	   both	   for	  
Sham	   and	   Ovx	   animals.	   The	   graft	   biomaterial	   wasn’t	   noticeable	   in	   the	   histological	  
specims,	  the	  Putty®,	  a	  mix	  of	  80%	  of	  granulated	  cancellous	  and	  cortical	  porcine	  bone	  
with	  a	  granulometry	  ≤300µm	  and	  20%	  of	  collagen	  gel,	  could	  be	   imperceptible	  due	  to	  
his	   low	   granulometry.	   	   The	   Evolution®	   membrane,	   is	   a	   collagen	   membrane	   derived	  
100%	  pericardium	  of	  equine	  origin	  with	  a	  thickness	  of	  0,5-­‐0,7mm.	  This	  one	  is	  observed	  
by	  residual	  debris	  that	  leaves	  in	  the	  margins	  of	  the	  defect.	  The	  tissue	  response	  to	  the	  
collagen	   membrane	   was	   characterized	   by	   a	   slighter	   reaction,	   possibly	   due	   to	   its	  
resemblance	   to	   native	   collagen.	   The	   degradation	   profile	   is	   characterized	   by	   a	  
macrophage	   and	   polymorphonuclear	   leukocyte	   associated	   degradation	   as	  well	   as	   an	  
enzymatic	  degradation	  profile.	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At	  month	  1	  and	  month	  3	  of	  observation,	  the	  Sham	  group	  when	  compared	  with	  
the	  Ovx	  group	  manifested	  a	  higher	  bone	  regeneration	  process	  in	  both	  experimental	  M	  
and	   MB	   groups.	   The	   animals	   of	   month	   1	   of	   evaluation	   are	   in	   accordance	   with	   the	  
results	   obtained	   previously	   in	   the	  microtomographic	   analysis.	   	   The	  MB	   group	   in	   the	  
sham	   animals	   at	   month	   1	   and	   3	   attained	   the	   higher	   values	   in	   the	   morphometric	  
analysis	  of	  the	  histological	  samples,	  followed	  by	  the	  M	  group	  in	  the	  sham	  animals	  and	  
the	  MB	  group	  of	  the	  Ovx	  animals	  and	  at	  last	  the	  M	  group	  in	  the	  Ovx	  animals.	  
When	   the	   two	   groups	   (M	   and	   MB)	   within	   the	   sham	   and	   Ovx	   animals	   were	  
compared,	  at	  each	  time	  point,	   the	  process	  of	  new	  bone	  formation	  was	  more	  evident	  
within	  animals	  of	  Sham	  group	  in	  regards	  of	  the	  bone	  formation	  at	  the	  defects	  margin.	  
Even	  so,	  the	  vast	  majority	  of	  the	  space	  between	  the	  immature	  bone	  was	  occupied	  by	  
connective	  fibrous	  tissue,	  at	  all	  time	  points.	  	  
The	  bone	  regeneration	  process	  applied	  in	  this	  experimental	  study	  was	  based	  on	  
the	  guided	  bone	  regeneration	  (GBR)	  that	  has	  proven	  to	  be	  a	  predictable	  procedure	  for	  
many	   techniques	   namely	   in	   the	   augmentation	   of	   alveolar	   ridges	   prior	   to	   implant	  
dentistry.[220]	   Several	   studies	   have	   proven	   the	   expected	   results	   in	   these	   techniques	  
using	  a	  resorbable	  collagen	  membrane	  like	  the	  one	  used	  in	  our	  study.	  The	  collagen	  is	  a	  
material	   with	   several	   advantages	   such	   as	   hemostatic	   function,	   allowance	   of	   early	  
wound	   stabilization,	   chemotactic	   properties	   and	  enabling	  nutrient	   transfer,	   therefore	  
being	  a	  membrane	  of	  choice	  for	  most	  GBR	  procedures.[432]	  Leeuwen	  et	  al.	  evaluated	  
the	  difference	  between	  the	   regeneration	  process	  using	   three	   types	  of	  membranes	   to	  
cover	  a	  circular	  CSD	  of	  5mm	  in	  the	  left	  mandibular	  angle	  in	  Sprague-­‐Dawley	  rats.	  The	  
defects	   were	   evaluated	   by	   micro-­‐radiography,	   micro-­‐computed	   tomography	   and	  
histological	   analysis	   at	   all	   time	   points	   (2,	   4	   and	   12	   weeks).	   They	   evaluated	   a	  
ply(trimethylene	   carbonate),	   collagen	   and	   an	   expanded	   polytetrafluoroethylene	  
membrane.	  They	  observed	  that	  the	  control	  group	  that	  was	  left	  uncovered	  didn’t	  show	  
new	   bone	   formation,	   at	   all	   time	   points.	   The	   groups	   treated	   with	   a	   membrane	  
presented	   substantial	   bone	   healing	   that	   increased	   progressively	   until	   the	   12	   weeks,	  
although	   no	   statically	   significant	   differences	   were	   attained	   between	   the	   groups,	  
verifying	  that	  all	  were	  well	  suited	  for	  use	  in	  guided	  bone	  regeneration.[433]	  The	  use	  of	  
bioresorbable	   membranes	   in	   the	   mandibular	   bone	   defect	   was	   assessed	   by	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Kostopoulos	  et	  al.	  to	  perceive	  the	  difference	  between	  the	  guided	  bone	  regeneration	  in	  
contrast	  with	  a	  control	  group	  without	  a	  barrier.	  They	  observed	  an	  incrising	  bone	  filling	  
in	   the	   group	  with	   an	   occlusive	   bioresorbable	  membrane	  whereas	   in	   the	   control	   site	  
only	   35%	   of	   the	   defect	   was	   filled	   with	   bone	   and	   observed	   a	   ingowth	   of	   muscular,	  
glandular	  and	  connective	  tissue	  in	  the	  defect,	  showing	  	  the	  importance	  of	  an	  occlusive	  
bioresorbable	  membrane	  excluding	  the	  surrounding	  soft	  tissues	  from	  the	  wound.[434]	  
The	   Evolution®	  membrane	   used	   in	   our	   experimental	   study	   has	   found	   clinical	  
success	  in	  several	  bone	  regenerative	  applications,	  namely	  in	  those	  associated	  with	  the	  
cranio-­‐maxilofacial	   area	   (e.g.,	   dental	   implant	   placement	   and	   sinus	   lift	   procedures).	  
Pagliani	  et	  al.	  in	  a	  multicenter	  case	  series	  studies	  used	  the	  Evolution®	  membrane	  with	  a	  
porcine	  bone	  substitute	   for	  augmentation	  of	   the	  alveolar	  crest	  or	   the	  maxillary	   sinus	  
floor	   augmentation	   prior	   to	   implant	   placement,	   as	   the	   histological	   results	   of	   the	  
samples	  retrieved	  5	  or	  7	  months	  after	  the	  surgical	  intervention	  reveals	  a	  good	  clinical	  
results	   with	   bone	   condensation	   properties	   and	   the	   material	   proved	   to	   be	   resorbed	  
with	  time.[435]	  Scarano	  et	  al.	  also	  used	  the	  Evolution®	  membrane	  with	  a	  porcine	  bone	  
graft	  in	  sinus	  augmentation	  procedures,	  with	  a	  5-­‐year	  retrospective	  clinical	  evaluation	  
presenting	   a	   92%	   survival	   rate	   on	   the	   implants	   placed	   on	   the	   grafted	   bone.[436]	  
Additional	   studies	   similarly	   used	   the	   Evolution®	   membrane	   for	   maxillary	   sinus	  
procedures.[281]	  This	  membrane	  has	  been	  use	  also	   for	   crestal	   ridge	  preservation	   for	  
posterior	   placement	   of	   implants.	   Covani	   et	   al.	   used	   these	   membranes	   with	   porcine	  
bone	  xenograft	  on	  post	  extraction	  sites	  and	  filled	  them.	  After	  4	  months	  of	  the	  surgery	  
clinical	   and	   histological	   observations	   showed	   new	   bone	   formation	   with	   satisfactory	  
healing	  without	  any	  signs	  of	  complications,	  providing	  the	  opportunity	  to	  place	  implants	  
for	  future	  prosthetic	  rehabilitations.	  [437]	  
The	  membrane	   is	  useful	   to	  allow	  the	  space	  maintenance,	  although	  the	  use	  of	  
bone	  grafts	  materials	  prevents	  in	  situ	  membranes	  from	  collapsing	  into	  the	  defect,	  thus	  
making	   it	   more	   suitable	   to	   bridge	   defects.	   Some	   authors	   refer	   that	   some	   of	   these	  
biodegradable	  membranes	  are	  primarily	  designed	   for	  periodontal	   regeneration,	   so	   to	  
aid	   the	  membrane	  adaptation	   to	   the	  defect,	  a	  soft	  configuration	  has	  been	  applied	   in	  
the	   fabrication	  of	   the	  membrane.	  Accordingly,	   these	  characteristic	  are	  not	   ideally	   for	  
bone	  regenerative	  purposes,	  in	  the	  specific	  application	  of	  the	  developed	  experimental	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model,	  the	  membranes	  may	  not	  be	  able	  to	  resist	  the	  forces	  from	  the	  elevating	  muscles	  
in	   the	   angulus	   region	   of	   the	   rat	   mandible,	   loosing	   their	   mechanical	   strength	   and,	  
therefore,	  their	  space	  maintaining	  properties.[430]	  Therefore	  the	  collagen	  membrane	  
is	  best	  used	  in	  combination	  with	  grafting	  materials.[438-­‐440]	  	  
The	   lower	   values	   attained	   in	   the	   Membrane	   group	   in	   both	   sham	   and	   Ovx	  
animals	   when	   compared	   with	   the	   Membrane	   and	   Biomaterial	   group,	   could	   be	  
explained	   by	   this	   disadvantage	   of	   the	   collagen	   membranes	   used	   alone	   in	   locations	  
subjected	  to	  forces,	  like	  the	  mandible.	  
The	   graft	   biomaterial	   used	   in	   this	   study	   was	   the	   Putty®	   a	   mix	   of	   80%	   of	  
granulated	  cancellous	  and	  cortical	  porcine	  bone	  with	  a	  granulometry	  ≤300µm	  and	  20%	  
of	  collagen	  gel.	  This	  is	  a	  biomaterial	  that	  proved	  its	  effect	  and	  has	  been	  clinically	  used.	  	  
Nannmark	  et	  al.,	  evaluated	  the	  different	  collagen	  ratios	  on	  the	  bone	  tissue	  response	  to	  
collagenated	  porcine	  bone	  grafts.	  They	  produced	  a	  bone	  defect	  in	  the	  maxilla	  of	  rabbits	  
and	  filled	  with	  Putty®	  or	  Gel40®	  and,	  after	  8	  weeks,	  observed	  by	  x-­‐ray	  and	  histological	  
evaluation.	  They	  concluded	  that	  cortical	  porcine	  bone	  with	  different	  ratios	  of	  collagen	  
exhibits	  good	  biocompatibility	  and	  osteoconductive	  properties.	  In	  this	  model,	  the	  two	  
materials	   were	   equally,	  with	   respect	   to	   both	   bone	   formation	   and	   resorption,	   which	  
started	  at	  the	  endpoint	  at	  8	  weeks.[441]	  	  
This	  biomaterial	  has	  been	  used	  as	  a	  filler	  for	  post	  extraction	  sockets	  to	  preserve	  
ridge	  volume.	  One	  example	  is	  the	  clinical	  evaluation	  of	  Arcuri	  et	  al.	  that	  inserted,	  in	  the	  
residual	   socket,	   the	  Putty®	   graft	   and	   three	  months	   later	   a	  bone	  biopsy	  was	   taken	   to	  
evaluate	  the	  bone	  regeneration	  process.	  The	  histological	  investigation	  of	  the	  graft	  site	  
in	  all	  the	  samples	  examined	  showed	  complete	  resorption	  of	  the	  heterologous	  material	  
and	  its	  substitution	  with	  bone	  tissue	  for	  the	  whole	  extension	  of	  the	  sample	  collected.	  
No	   traces	   of	   the	   particulate	   previously	   inserted	  were	   found.	   They	   conclude	   that	   the	  
biomaterial	   shows	   exceptional	   malleability	   and	   plasticity,	   thanks	   to	   its	   structural	  
characteristics,	  which	  makes	   it	  easy	   to	  apply,	   favoring	   its	  osteoconductive	  properties.	  
[324]	  Although,	  the	  biomaterial	  has	  yet	  few	  studies	   in	  animal	  model.	   In	  our	  study	  we	  
also	   observed,	   in	   histological	   examination,	   the	   absence	   of	   the	   biomaterial	   particles	  
allowing	  us	  to	  foresee	  the	  total	  resorption	  of	  the	  biomaterial.	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The	  literature	  in	  guided	  bone	  regeneration	  in	  osteoporotic	  conditions	  in	  the	  rat	  
mandibular	  model	  is	  scarce.	  Arisawa	  et	  al.	  investigated	  the	  bone	  promotion	  in	  4	  mm	  in	  
diameter	   in	   surgical	   defects	   in	   the	   mandible	   angle	   in	   normal	   and	   ovariectomized	  
female	   rats	   treated	  with	   calcitonin	   and	   a	  polytetrafluoroethylene	  barrier.	  The	   female	  
rats	   were	   divided	   in	   four	   groups:	   control	   (C),	   control	   treated	   with	   calcitonin	   (CM),	  
ovariectomized	   control	   (OV)	   and	   ovariectomized	   treated	   with	   calcitonin	   (OVM);	  
assessed	   in	  day	  3,	  7,	  14,	  21	  e	  28	  days	  after	  surgery.	  Groups	  CM	  and	  C	  showed	  higher	  
levels	   of	   bone	   formation	   after	   7	   days	   compared	   with	   the	   OV	   and	   OVM	   groups.	   A	  
significant	   difference	   was	   observed	   between	   group	   C	   and	   Ov	   at	   3-­‐14	   days.	   The	   OV	  
group	  presented	  slower	  bone	  regeneration	  of	  the	  surgical	  bone	  defect	  when	  compared	  
with	   the	   C	   group.	   Synthetic	   salmon	   calcitonin	   accelerated	   bone	   regeneration	   in	   the	  
defect	  in	  osteoporotic	  animals	  treated	  with	  calcitonin	  when	  compared	  with	  the	  control	  
group.[442]	   	  Jardini	  et	  al.	  evaluated	  the	   influence	  of	  osteopenia	   induced	  by	  the	  bone	  
repairing	  of	  the	  receptor	  site/autogenous	  bone	  graft	  block	  interface	  either	  associated	  
with	  or	  without	  PTFE-­‐e	  membrane	  through	  the	  analysis	  of	  the	  trabecular	  bone	  volume.	  
The	  rats	  were	  submitted	  to	  parietal	  bone	  graft	  whitch	  was	  fixed	  to	  the	   lateral	  wall	  of	  
the	  left	  mandibular	  ramus,	  with	  our	  without	  covering	  by	  the	  membrane.	  They	  assessed	  
the	   process	   of	   the	   graft	   intervention	   with	   the	   receptor	   site	   and	   state	   that	   it	   was	  
negatively	   affected	   by	   the	   induced	   osteopenia	   presence	   and	   that	   the	   presence	   or	  
absence	  of	  the	  membrane	  did	  not	  interfere	  in	  the	  integration	  process.[443]	  
	  
	  
Overall,	   and	   taking	   into	   account,	   the	   stated	   biological	   hindrances	   associated	  
with	  the	  osteoporotic	  state	  and	  the	  data	  trend	  substantiating	  the	  impaired	  biomaterial-­‐
mediated	   bone	   regeneration	   process	   in	   osteoporotic	   conditions,	   new	   therapeutic	  
approaches	  ought	  to	  be	  developed	  in	  order	  to	  find	  optimized	  clinical	  interventions	  for	  
the	   treatment	   of	   osteoporotic-­‐mediated	   problems.	   The	   controlled	   release	   of	  
bisphosphonates	  from	  bioceramic	  materials	  has	  been	  considered[444,	  445],	  as	  well	  as	  
the	   delivery	   of	   osteogenic	   factors[446]	   or	   even	   the	   development	   of	   smart	  
biomaterials.[447]	  Nonetheless,	   effective	   and	   predictable	   therapies	   are	   far	   from	   the	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application	   in	   the	   clinical	   scenario	   and	   urge	   to	   mitigate	   the	   personal,	   social	   and	  
economic	  cost	  of	  osteoporosis-­‐mediated	  complications.	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Osteoporosis	   is	   a	   prevalent	   disease	   and	   a	   major	   worldwide	   health	   problem	  
reporting	   a	   high	   rate	   of	   mortality	   and	   morbidity.	   It	   is	   a	   pathological	   condition	  
characterized	  by	  changes	   in	  the	  microarchitecture	  of	  the	  bone	  tissue	  and	  a	   low	  bone	  
mass,	   which	   converge	   to	   compromise	   bone	   strength	   and	   increase	   the	   risk	   of	   bone	  
fracture.	   Bone	   regeneration	   process,	   in	   osteoporotic	   conditions,	   may	   be	   somewhat	  
limited	   mainly	   due	   to	   a	   decrease	   of	   new	   bone	   formation,	   nonetheless	   specific	  
mechanisms	  have	  not	  been	  stated.	  	  
In	  this	  work,	  the	  bone	  regeneration	  process	  was	  evaluated	  in	  an	  animal	  model	  
representative	  of	  the	  human	  osteoporotic	  condition.	  Bone	  regeneration	  was	  addressed	  
in	   the	   presence	   of	   Bio-­‐oss®,	   in	   calvarial	   critical	   size	   defects	   (CSD),	   and	   guided	   bone	  
regeneration	   process	   was	   evaluated,	   in	   the	   mandibular	   CSD	   in	   the	   presence	   of	   a	  
membrane	  and	  membrane	  or	  biomaterial.	  	  
The	   rat	   ovariectomized	   model	   proved	   to	   be	   a	   valid	   system	   for	   osteoporosis-­‐
related	  research,	  reporting	  significant	  metabolic	  (i.e.,	   increased	  body	  weight,	  absence	  
of	   estradiol	   production	   and	   evidence	   of	   uterus	   atrophy)	   and	   bone	   alterations	   (i.e.,	  
altered	  tibial	  and	  femoral	  microarchitectural	  organization	  and	  cortical	  thickness),	  highly	  
relatable	  to	  the	  clinical	  post-­‐menopausal	  osteoporotic	  state.	  The	  biomaterial-­‐mediated	  
bone	   regeneration	   of	   CSD	   also	   seemed	   to	   be	   enhanced	   in	   Sham	   animals.	   Bio-­‐oss®	  
allowed	   only	   modest	   new	   bone	   formation,	   either	   in	   Sham	   and	   Ovx	   animals,	  
nonetheless	   this	  process	  was	   significantly	  higher	   in	  animals	  of	   the	  Sham	  group.	   	  The	  
guided	   bone	   regeneration	   process	   assessed	   in	   the	   mandibular	   defect	   was	   also	  
enhanced	   in	  the	  Sham	  animals	  in	  the	  Membrane	  (M)	  and	  Membrane	  and	  Biomaterial	  
(MB)	   group,	   with	   enhance	   outcomes	   in	   the	  MB	   group.	   The	   Ovx	   animals	   reported	   a	  
minor	  regeneration	  process	  in	  both	  groups	  comparing	  to	  the	  Sham	  animals.	  
The	   stated	   biological	   hindrances,	   verified	   in	   bone	   regeneration	   process	   in	  
osteoporotic	  conditions,	  justify	  that	  care	  should	  be	  taken	  on	  pre-­‐operative	  preparation	  
of	   osteoporotic	   patients	   undergoing	   bone-­‐related	   interventions,	   and	   that	   a	   selective	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